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Abstract 
 
Hepatitis C virus (HCV) is a major cause of chronic liver disease, leading to hepatic 
steatosis, fibrosis, cirrhosis and hepatocellular carcinoma.  
A vaccine is currently not available, while the standard of care is effective in only 50% 
of treated patients. The first specific anti-HCV drugs have been recently approved, and 
new classes of targeted agents are under clinical trials/investigation. Nevertheless, 
improved treatment strategies are needed, in order to bypass the rapid emergence of 
resistance.  
All the viral non-structural proteins are a possible target for the identification of novel 
and selective antivirals. Among them, the NS3 helicase is still underexploited, with no 
known inhibitor under pre-clinical or clinical development. This enzyme plays a crucial 
role in the virus life cycle: it catalyses the separation of double-stranded RNA strands, 
which is necessary for genome amplification and translation. Due to its essential 
function, the NS3 helicase was chosen as a target for the identification of new, specific 
anti-HCV compounds. 
Different computer-aided techniques were employed to identify potential small-
molecule inhibitors of the enzyme. Two structure-based virtual screenings of 
commercially available compounds were performed on the main nucleic acid binding 
site. A series of candidate inhibitors was evaluated in the HCV replicon assay, yielding 
two primary hits with low µM activity.  
Secondly, the model of the one known inhibitor co-crystallised with the enzyme was 
used as a starting point for a shape-comparison screening of small molecule libraries. A 
new series of compounds was selected and evaluated for anti-HCV activity, and one of 
them was found to inhibit the viral replication at a low µM concentration. 
Several new derivatives of the initial hits were synthesised, belonging to four main 
structural families: bis-aromatic piperazine derivatives, symmetrical phenylendiamine 
compounds, differently substituted thieno-pyrimidines, and triphenyl-pyrrolone 
analogues. 
Inhibition of HCV replication in the replicon assay was evaluated for the new 
compounds prepared and several structures showed a range of activity from low-µM to 
nM. 
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1.1 Hepatitis C virus 
 
Hepatitis C virus (HCV) is one of the major causes of chronic liver disease, and affects 
approximately 170 million people worldwide.1 
This blood-borne infection becomes chronic in 60-85% of patients and leads to the 
development of hepatic steatosis, fibrosis, cirrhosis and hepatocellular carcinoma.2-3 
The virus tropism involves both hepatic and lymphatic systems, and chronic infection is 
therefore associated also to extrahepatic diseases and malignancies such as 
cryoglobulinemia, lymphoma and thyroid cancer.4 
 
Figure 1.1: HCV prevalence5 
 
Patients are generally asymptomatic before development of cirrhosis; the infection is 
often underdiagnosed, leading people unaware of their disease to spread the virus by 
body fluids, and causing the loss of treatment opportunities.4 
HCV modifies the intracellular environment to promote its replication and long-term 
persistence within the liver. Moreover, it has developed a multi-factorial immune 
evasion capacity, characterised by disruption of signalling pathways that control innate 
antiviral responses, evasion of IFN-mediated responses, retardation and impairment of 
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T-cell responses.6 
A vaccine against the virus is currently not available and treatment options are still 
limited. The standard of care is a combination of pegylated interferon (pegIFN) and 
ribavirin, a therapy that is not specific for HCV and efficient in 50% of treated patients, 
with many associated side effects.7 In May 2011 the FDA approved the use of the first 
two specific HCV NS3/NS4A inhibitors, telaprevir and boceprevir, to treat patients not 
responding to the standard of care, in association with interferon and ribavirin.8 
Even if new classes of specific targeted antiviral agents, whose action is mainly directed 
against the viral non-structural proteins NS5B polymerase and NS3/4A protease, have 
entered clinical trials, there is still need for improved treatment strategies, which might 
lead to the cure of all infected patients with an equal effectiveness against all HCV 
genotypes. A reason for this requirement is the high error rate of the viral RNA-
dependent RNA polymerase, which leads to rapid development of drug-resistant viral 
strains in response to new antiviral administration.9 
 
Figure 1.2: HCV genotype distribution 
 
1.1.1 HCV genome organisation 
 
HCV is an enveloped RNA virus that belongs to the Flaviviridae family, and is the 
unique member of the Hepacivirus genus.10 The viral single-stranded, positive-sense, 
9.6 kb RNA contains an open reading frame (ORF) that encodes a unique polyprotein 
precursor of about 3000 residues, and is flanked by an untranslated region (UTR) at 
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both  5’  and  3’   termini.11 The polyprotein is translated under the control of an internal 
ribosomal entry site (IRES) within  the  5’-UTR, and is subsequently cleaved by cellular 
and viral proteases into four structural proteins (core, E1, E2 and p7) and six non-
structural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B).12 
 
Figure 1.3: Polyprotein precursor encoded in the HCV (+)ssRNA genome13 
 
HCV genome is characterised by a high level of genetic variability: it is divided into 
eleven main genotypes that differ by 31-34% of nucleotide sequences.14 Moreover, due 
to the high error rate of the RNA-dependent RNA polymerase (RdRp) function carried 
by the NS5B protein, HCV is present in a same infected individual as a population of 
different but closely related variants identified as quasispecies.9 
 
1.1.2 Viral proteins 
 
The four structural proteins, cleaved from the N-terminus of the polyproteic precursor, 
are the core protein, the E1 and E2 envelope proteins, and a small hydrophobic 
polypeptide, p7. The core protein is believed to form the viral nucleocapsid and shows a 
high level of conservation among different HCV strains.15 The E1 and E2 proteins are 
necessary components for viral entry,16 while the p7 hydrophobic polypeptide is 
essential for infectious virions production in vivo.17-18 
The six non-structural proteins (NS) are responsible for polyprotein processing, viral 
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RNA replication and production of infectious virions; they form a multicomponent 
RNA replication complex that carries out its functions within virus-induced modified 
subdomains of the ER, referred to as membranous web.19 
The NS2 protein is an auto-protease which catalyses the cleavage of the polyproteic 
precursor on the level of the NS2/NS3.20 
The NS3-4A complex is a bifunctional molecule; the N-terminal region is a serine 
protease, non-covalently bound to the NS4A cofactor, which processes the non-
structural proteins.21 The C-terminal portion of NS3 shows a helicase-ATPase domain, 
whose main function is to unwind double-stranded RNA substrates in the direction  3’-to 
-5’.22 
NS4B is responsible for membrane association: its function leads to the formation of a 
specialised membrane compartment, the membranous web, where viral RNA replication 
is believed to take place.19, 23 
NS5A is a phosphoprotein whose function is not completely clear, but it is believed to 
influence replication efficiency.24 
The NS5B protein shows a conserved sequence motif that characterises viral RNA-
dependent RNA polymerases.25 
 
1.1.3 Viral life cycle 
 
Infectious HCV particles circulate in the host serum in association with low-density 
lipoproteins and very-low-density lipoproteins, forming the so-called lipoviroparticles.26 
Putative HCV receptors have been identified in CD81, SR-BI, the LDL receptor (LDL-
R), claudin-1 (CLDN1) and occludin (OCLN), none of which characterises exclusively 
liver cells.27 
 
Chapter 1: Introduction 
 
6 
 
 
 
Figure 1.4: HCV life cycle12 
 
After receptor-mediated endocytosis, fusion and uncoating events lead to the release of 
the viral RNA into the host cell cytoplasm. The viral genome undergoes then translation 
and replication processes by the non-structural protein replication complex.28-29 
The uncapped viral RNA molecules are translated by a cap-independent IRES-mediated 
process: the translational product of HCV genome is a large polyprotein precursor 
processed by cellular and viral proteases into the mature viral proteins.30 
The structural proteins are processed by host peptidases on the level of the junctions 
core/E1, E1/E2, E2/p7, p7/NS2.31 HCV non-structural proteins are processed into their 
mature forms by two viral proteases: NS2 cystein protease catalyses the cleavage 
between NS2 and NS3, while the remaining junctions NS3/4A, NS5A/5B, NS4A/4B 
and NS4B/5B are cleaved by the NS3 serine protease.32 
HCV genome replication begins with the synthesis of a complementary negative-strand 
RNA using the positive-strand genomic RNA as a template. The negative-strand RNA 
is subsequently used as template for the production and amplification of positive-strand 
RNA. Both these steps are catalysed by the NS5B RdRp.29 
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Mature HCV virions consist of a nucleocapsid surrounded by an outer envelope formed 
by a lipid membrane and envelope proteins.33 Nucleocapsid assembly requires 
oligomerisation of the capsid protein and encapsidation of viral genomic RNA.34 
Once the nucleocapsid is formed in the cell cytoplasm, it acquires an envelope by 
budding into the ER lumen, and is released by the Golgi apparatus through 
exocytosis.35-37 
 
1.1.4 Current treatment 
 
The standard of care to treat chronic HCV infection is a combination of pegylated 
interferon alpha (peg-IFN-) and ribavirin, both non-specific for HCV. In addition to 
this treatment, two selective inhibitors of NS3/4A protease, telaprevir and boceprevir, 
have been approved by the FDA in May 2011 for use in combination with peg-IFN and 
ribavirin.8 
Interferon alpha is a natural cytokine produced by leucocytes that allows recognition of 
viral antigens by the immune system and activates natural killer cells and macrophages. 
This protein is used as a broad-spectrum antiviral to boost the host immune system 
against pathogen organisms. Many adverse effects are related to its administration, 
including depression, autoimmune diseases, nausea, fever, chills, headache, muscle 
pain, leukopenia and thrombocytopenia.38-39 
Ribavirin (figure 1.5) is a synthetic nucleoside analogue that exerts activity against a 
broad spectrum of both RNA and DNA viruses.40 
 
O
OHHO
HO
N
NN
NH2O
ribavirin  
 
Figure 1.5: Chemical structure of the broad-spectrum antiviral ribavirin 
 
Ribavirin has multiple general mechanisms of action, and in the case of HCV its activity 
seems to be due to the induction of abnormal viral mutagenesis, that overcomes the 
threshold of error catastrophe, along with the up-regulation of genes involved in IFN 
Chapter 1: Introduction 
 
8 
 
signalling.41 
Efficacy of treatment with ribavirin in combination with pegylated interferon alpha is 
genotype-specific, with genotype 1 and 4 being more resistant than genotypes 2 and 3: 
viral eradication or a sustained virological response (undetectable HCV RNA six 
months after the end of treatment) is achieved in 75-85% of cases for genotypes 2 and 3, 
and in 55% of cases for genotypes 1 and 4.42 The main adverse effect introduced by the 
addition of ribavirin to therapy with interferon is haemolytic anaemia.43 
The significant side effects of the combination treatment, along with its high costs and 
its limited cross-efficacy against the different viral genotypes, cause the requirement of 
new, specific anti-HCV agents with a broad spectrum of efficacy across genotypes, 
reduced adverse effects and unlikeness to develop resistant viral mutants.44 
Standard treatment has been improved with the approval of the first specific anti-HCV 
agents, telaprevir (Incivek, Vertex)45 and boceprevir (Victrelis, Merck)46. They both are 
NS3/NS4A protease inhibitors, and have been demonstrated to significantly increase a 
sustained viral response in not-responding patients with genotype 1, in combination 
with peg-interferon-alpha and ribavirin. 
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Figure 1.6: Chemical structures of telaprevir and boceprevir 
 
These first-generation direct antiviral agents (DAAs) cannot eradicate HCV infection 
alone, due to rapid development of resistant viral strains. The two drugs are related to 
different toxicity profiles: for telaprevir the main associated adverse effect is rash, while 
boceprevir is related to anaemia, dysgeusia and headache.47 
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1.1.5 New treatments under development 
 
Along with novel types of interferons, several new classes of selective antiviral agents 
are at different stages of development: the main targets involved are viral NS3/4A 
protease, NS5B polymerase, binding of NS4B protein to RNA and multifunctional 
NS5A protein. 
Due to the high frequency of mutations that characterises HCV genome and to the fast 
selection of resistant mutants, a successful therapy with small molecule inhibitors would 
require the use of a cocktail of antiviral compounds directed against different targets, in 
order to set a barrier to resistance to multiple separate simultaneous mutations.48 
 
 
Figure 1.7: HCV inhibitors competitive landscape5 
 
NS3/4A protease inhibitors 
Several selective inhibitors of NS3/4A protease are at different stages of preclinical and 
clinical studies: the main candidates in clinical development are summarised in table 
1.1. 
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Name Company Phase IC50(nM) 
ACH-2684 Achillion II  
ABT-450 Abbott/Enanta III  
ACH-1625 (Sovaprevir) Achillion II  
GS-9451 Gilead II  
RG7227 (Danoprevir) Intermune/Genentech II  
MK-5172 Merck II  
MK-8742 Merck II  
Vaniprevir (MK-7009) Merck III 0.06-1.4 
BI-201335 Boehringer Ingelheim III  
TMC435 Medivir/Tibotec III 13 
BMS-650032 (Asunaprevir) Bristol-Myers Squibb III 0.2-0.4 
 
Table 1.1: protease inhibitors in clinical development as of June 2013; IC50, 50% inhibitory concentration 
in biochemical assays of protease 
 
All protease inhibitors show rapid emergence of viral resistance and significant adverse 
effects such as severe rash and anaemia, characteristics that make not possible their use 
as monotherapies.49 
 
NS5B polymerase inhibitors 
NS5B inhibitors are at various stages of preclinical and clinical trials.50 These antiviral 
agents can be classified in nucleosides, targeting the active site of the enzyme, and non-
nucleosides, targeting one of the several allosteric sites, and interfering with the 
enzymatic activity by an induced conformational change. Phase II and III studies 
include nucleoside and non-nucleoside analogues, as shown in table 1.2. 
 
Name Class Company Phase Replicon EC50 (nM) 
MK-3281 NNI Merck I  
ABT-333 NNI Abbott III 2-7 
ANA-598 NNI Anadys II 0.5-52 
IDX184 Nuc Idenix II  
RG7128 (Mericitabine) Nuc Genentech III 610 
VX-135 (ALS-2200)  Nuc Vertex/Alios II  
GS-7977 Nuc Gilead III  
TMC647055 NNI Tibotec/Janssen II  
 
Table 1.2: polymerase inhibitors in clinical development; NNI, non-nucleosides; Nuc, nucleosides 
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NS4B multifunctional protein inhibitors 
The NS4B protein is involved in membranous web formation, interaction with other 
non-structural proteins in the replication complex, GTP hydrolysis and RNA binding, 
all essential roles for viral replication.51-52 
Clemizole hydrochloride, a H1 histamine receptor antagonist widely used as an 
antipruritic, has been found to inhibit NS4B interaction  with   the  3’   terminus  of  HCV 
negative-strand RNA, and has shown a strong synergistic effect in vitro with both 
bocepevir and telaprevir: phase I studies are ongoing, while other small molecule 
inhibitors are in preclinical development.53-54 
 
 
 
Figure 1.8: Chemical structure of clemizole hydrochloride 
 
NS5A protein inhibitors 
Extensive high-throughput screening studies for the identification of HCV replication 
inhibitors led to the discovery of BMS-790052 (Daclatasvir), which inhibits viral 
replication at picomolar concentrations and shows a resistance profile addressing its 
action to NS5A. Synergistic effects were demonstrated with IFN, NS3 inhibitors and 
NS5B inhibitors, and phase III clinical trials in individuals with genotype 1 infection are 
now under the way.55 
Other NS5A inhibitors in clinical development include ABT-267 (Phase III), GS-5885 
(Phase III) and PPI688 (Phase II).56 
 
 
 
Figure 1.9: Chemical structure of the NS5A inhibitor BMS-790052 
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Other candidates in preclinical and clinical development 
Other therapeutic strategies in preclinical and clinical trials include inhibitors of p7 
polypeptide such as amiloride analogues,57 cyclophilin inhibitors such as cyclosporine 
A analogues (Alisporivir or Debio 025 is in Phase III, and SCY-635, in Phase II 
studies),58 modulators of the host innate immune response like Nitazoxanide (Phase II 
studies in combination with pegIFN and ribavirin),59 already approved in the USA for 
the treatment of specific parasitic gastroenteritides, and modulators of the adaptive 
immune response.60 
 
 
 
Figure 1.10: Chemical structure of immune-modulator Nitazoxanide 
 
Approaches in early development 
Several new approaches are at early stages of study, including the possibility to rupture 
HCV virions,61 interference with host lipid metabolism,62 inhibition of translation 
initiation,63 and the possibility to achieve a therapeutic vaccination.64 
 
1.1.6 Alternative strategies 
 
In order to allow oral multitherapies to avoid IFN use and its adverse effects, to have a 
broad spectrum across genotypes, and to prevent the emergence of viral resistance, 
targeting different steps of the viral replication with a cocktail of inhibitors is an 
essential requisite; this goal could be achieved through the exploration of still 
underexploited viral targets, such as the NS2 protease and the NS3 helicase, which still 
lack any drug candidate in advanced stages of development. 
 
1.1.7 Experimental techniques 
 
HCV is difficult to grow in laboratory environment and the only non-human animal that 
the virus can infect is the chimpanzee.65 The first HCV molecular clones were isolated 
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from infected blood in 1989,66 while the first clones to infect chimpanzees were 
obtained in 1997,67 and the study of HCV replication in cultured cells, referred to as 
replicon systems, was possible from 1999.68 The first replicons used recombinant clones 
that could associate sequences encoding HCV non-structural proteins with a gene 
encoding a drug-resistant marker, allowing the selection of cells possessing viral RNA 
autonomous for its replication.68 These systems improved with the identification of 
adaptive viral mutations that allow a more efficient HCV replication in hepatocytes, 
more permissive cell lines and replicons containing the full-length HCV genome.69-71 
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1.2 HCV NS3 helicase 
 
The NS3 helicase is one of the most underexploited targets in the search for HCV 
replication inhibitors. The enzyme main actions are duplex RNA separation and 
displacement of proteins bound to nucleic acids, reactions that are permitted by ATP 
hydrolysis.72-74 
This enzyme is formed by three domains and occupies the C-terminal portion of the 
NS3 protein. It presents multiple ligand-binding regions, the main ones being an ATP 
binding site in the cleft separating domain 1 from domain 2, a single-stranded nucleic 
acid binding site at the interface of the three main domains, and a second single-
stranded RNA binding site located within the cleft that separates the helicase from the 
protease portion of NS3.75 
 
 
 
Figure 1.11a: Protease and helicase portions of the NS3 protein 
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Figure 1.11b: NS3 helicase domains and binding sites 
 
A functional NS3 helicase is essential for viral RNA replication in cells, and HCV with 
a defective NS3 ATPase function is not infective: evidence validates the NS3 helicase 
as target to inhibit HCV replication.76-77 
 
1.2.1 Roles in HCV replication 
 
For their successful replication, Flaviviruses synthesise negative-stranded RNA from 
genomic positive-stranded RNA, subsequently using the newly-synthesised RNA as a 
template for the synthesis and the amplification of several copies of positive-stranded 
RNA genome, which is finally assembled into viral particles. As an intermediate of 
nucleic acid synthesis, double-stranded RNA sequences are formed between the 
complementary positive and negative strands, requiring the intervention of the helicase 
unwinding activity in order to separate RNA strands and terminate viral proliferation, 
by assisting RNA–dependent RNA replication with a tracking movement along RNA, in 
correspondence of ss-ds RNA junctions. The unwinding process is unidirectional with 
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respect to the template strand, moving exclusively in the 3’  to  5’  direction.78-79 
By inhibiting the helicase, not only the viral replication cycle could be arrested, but a 
cellular response against the presence of unnatural double-stranded RNA within the cell 
could be induced.80 
 
1.2.2 Structure, motifs and binding clefts 
 
HCV NS3 helicase is classified as a DExH/D-box motor protein, belonging to the 
superfamily 2 (SF2) helicases: all enzymes of this family share a nucleic acid 
remodelling capacity, promoted by ATP hydrolysis, and move in a unidirectional way 
along a single-stranded nucleic acid, that is identified as the tracking strand.81-82 
The enzyme has three structural domains, three-dimensionally arranged in the shape of 
a Y. Domains 1 and 2, known as RecA-like domains, show significant structural 
similarities with all other helicases, and form a molecular motor that allows the protein 
to move along nucleic acids. In particular, it is believed that ATP binding and 
hydrolysis regulate domain 2 conformational changes, that lead to the movement of the 
protein along RNA.83 
 
ATP binding site 
The ATP binding cleft has been identified at the interface between the two RecA-like 
motor domains, 1 and 2. Domain 1 shows a phosphate binding loop known as P-loop, 
motif I or Walker A motif, and a Mg2+ co-factor binding loop, motif II or Walker B 
motif. ATP is bound to this region via a conserved lysine (Lys210) in the P-loop and an 
acidic residue (Asp290 in HCV NS3) that interacts with the divalent metal cation 
cofactor.84 
 
Main nucleic acid binding site 
The RNA tracking-strand along which the NS3 helicase moves is located on the cleft 
separating the two RecA-like motor domains from domain 3.85 
Among the key residues within this site are Val432 and Trp501, which act like 
bookends between the nucleic acid bases and are critical for unwinding reaction and 
viral replication.86 Another important residue is Glu493 (domain 3), that needs 
protonation for helicase optimal activity: it is conserved in all HCV genotypes, and is 
characterised by a high pKa value of approximately 7, becoming protonated when the 
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pH falls to the optimum level for the enzyme, at 6.5.87 This unusual electrostatic profile 
is believed to help deriving the driving force for helicase movements along RNA. The 
residue protonation would help attract the nucleic acid in the binding cleft, while 
following deprotonation as the pH increases the RNA would be repelled, helping the 
translocation of the protein along the RNA strand.87 
The nucleic acid is held in this site by an arginine clamp focused on Arg393, that is 
proved to rotate in consequence of ATP binding and hydrolysis, allowing the protein to 
translocate.88 
 
1.2.3 Mechanism of action 
 
The structural mechanism by which the NS3 helicase translocates along RNA remains 
unclear. Nevertheless, the publication of two series of crystal structures where NS3 is 
bound to a labelled DNA oligonucleotide (PDB IDs 3KQH, 3KQK, 3KQL, 3KQN, 
3KQU)89 and a labelled RNA oligonucleotide (PDB IDs 3O8B, 3O8C, 3O8D and 
3O8R),90 provides insights into the positional changes of nucleic acid and protein during 
a discrete step of ATP hydrolytic cycle. 
ssRNA is bound within the enzyme in an extended conformation, and shows 
interactions with all three helicase domains. Prior to ATP binding, the enzyme is bound 
to the nucleic acid substrate in a high RNA-affinity   ‘open’   conformation,   with   five  
RNA residues bound between the conserved bookends, Val432 and Trp501. Trp501 in 
particular, which belongs to domain 3, anchors the nucleic acid residue to the protein by 
a stacking  interaction  with  the  base  of  the  last  nucleotide  at  the  3’  end  of  RNA. 
Most specific NS3-RNA interactions consist of hydrogen bonds between polar protein 
atoms and phosphoryl oxygens of the RNA backbone. These interactions are given by 
backbone NH groups of protein residues Lys371, Arg393, Val232, Gly255, and the 
polar side chains of Thr411, Thr416 and Thr 269. The only additional contact between 
NS3 and a RNA base is a solvent-exposed hydrogen bond between the side chain of 
Asn556 and the base of the last  5’-terminal residue included in the binding cleft of the 
ATP-free protein conformation. 
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Figure 1.12: RNA binding pocket and interactions within the 3O8C crystal structure 
 
The two series of crystal structures show the three-dimensional conformations of the 
NS3 helicase in its apo form (3O8B), in complex with an RNA or DNA nucleic acid 
substrate (3O8C, 3KQH and 3KQK), in a ternary ground-state complex with an 
oligonucleotide substrate and an ATP-mimicking residue of ADPBeF3 (3O8D, 3O8R, 
3KQN and 3KQU), and finally in a ternary transition-state complex with a hydrolysed 
ADP-mimicking residue of ADPAlF4 (3KQL).89-90 
The ternary complex structures reveal that domain 1 and domain 2 undergo a 
remarkable conformational change upon ADPBeF3 binding, with domain 2 pivoting 
towards domain 1 in the enzyme ternary complex  ‘closed’  conformation. The number of 
contacts between NS3 and ssRNA or ssDNA is reduced in the nucleotide-bound state; 
Thr416 is shifted away from the binding cleft causing the disruption of a hydrogen bond 
with the phosphodiester backbone of the nucleic acid. The interaction between NS3 and 
the  5’-end of bound oligonucleotide is weakened, and the ternary complex shows four 
bases stacked in the nucleic acid binding cleft.91 
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Figure 1.13: ATP-induced changes in RNA binding90 
 
Following ATP hydrolysis and ADP release, conformational changes allow the 
movement of the protein of one base along the oligonucleotide in the direction  3’  to  5’.  
Domains 1 and 2 relax back into the enzyme open conformation, accompanied by the 
re-exposition of Thr416 to the binding cleft and the restoration of its original 
interaction, with  a  shift  of  one  base  towards  the  5’ direction. In its open conformation, 
the NS3 helicase shows high affinity for the nucleic acid substrate and pulls an 
additional nucleotide into the binding cleft,  resulting  in  the  3’-5’  directed  movement  of  
domain 2 along the phosphodiester backbone of the tracking strand. Evidence supports a 
mechanism of action in which ATPase activity allows the protein to cycle between 
nucleotide-free high affinity and nucleotide-bound low-affinity conformational states: 
the enzyme grabs and releases the nucleic acid tracking-strand in correspondence of 
single-stranded/double-stranded RNA junctions.92 Moreover, a pair of threonine 
residues, Thr269 in domain 1 and Thr411 in domain 2, interact with the phosphodiester 
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backbone in both the nucleotide-bound and the nucleotide-free states, acting as pincers 
to grip the nucleic acid backbone.93 Site-directed mutational studies confirm that 
replacing either Thr269 or Thr411 with alanine binding to nucleic acids is reduced and 
helicase activity is lost.94 
 
 
Figure 1.14: Representation of NS3 movements along a RNA tracking strand102 
 
1.2.4 HCV helicase inhibitors 
 
Existing helicase inhibitors can be classified into four main categories, on the basis of 
their mechanism of action: compounds that inhibit helicase activity by interfering with 
ATP binding, competitive inhibitors of RNA binding, polynucleotide chain intercalators 
and compounds binding to unknown sites. 
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Compounds that interfere with ATP binding 
To date, only one small molecule has been directly proven to inhibit the helicase by 
occupying the ATP-binding site: the dye soluble blue HT (compound 1, figure 1.15), 
that directly interacts with Lys210 (domain 1), essential for ATP hydrolysis.95 From its 
structure, compound 2 was derived: it shows inhibition of helicase activity (IC50 10 M) 
and a good inhibition of HCV replication in replicon (EC50 2.7 M), but it is associated 
with cytotoxicity (CC50 10 M).96 
 
 
 
Figure 1.15: Chemical structures of compounds 1 and 2 
 
Nucleotides and derivatives are believed to competitively occupy the ATP-binding site 
(figure 1.16): this is the case for ribavirin   5’-triphosphate (RTP, IC50 180 M) and 
ribavirin  5’-diphosphate (RDP, IC50 250 M), that demonstrate good ATPase inhibition 
but are weak inhibitors of unwinding activity.97 Other nucleoside or base-analogue 
inhibitors are dichloro(ribofuranosyl) benzotriazole DRBT (IC50 1.5 M) and 
tetrabromo-benzotriazole TBBT (IC50 20 M), that both inhibit as well HCV RNA 
replication in cells.98 
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Figure 1.16: Chemical structures of RTP, RDP, DRBT and TBBT 
 
Another category of compounds shown to inhibit HCV helicase-catalysed reactions in 
vitro are ring-expanded  ‘fat’  nucleosides  such  as  compound 3 (IC50 5.5 M).99 
 
 
 
Figure 1.17: Chemical structure of compound 3 
 
Finally, the natural sesterterpene manoalide, isolated from marine sponge extracts, has 
been shown to inhibit HCV NS3 helicase activity (IC50 15 M), by both inhibiting 
ssRNA binding and ATPase activity (IC50 70 M).100 
 
 
 
Figure 1.18: Chemical structure of manoalide 
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Competitive inhibitors of RNA binding 
A small number of compounds are known to inhibit HCV helicase by acting on the 
known RNA binding cleft. Small molecule inhibitors include symmetrical 
aminophenylbenzimidazole and piperidinylbenzimidazole derivatives such as (BIP)2B 
(figure 1.19) and compounds 4-6 (figure 1.20), patented by ViroPharma in 1997, the 
most active of which being compounds 4 (IC50 0.7 M) and 5a-e (IC50 0.7 M).101 
 
 
 
Figure 1.19: Chemical structure and activity of (BIP)2B 
 
 
 
Figure 1.20: Chemical structure and activity of compounds 4-6 
 
Another series of symmetrical inhibitors has been recently reported, with the most 
active compounds being DB2 and DB11 (IC50 0.7 M), both sharing the presence of a 
dimeric benzimidazole system (figure 1.21).102 
 
 
 
Figure 1.21: Chemical structure and activity of DB2 and DB11 
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Structure optimisation of the nucleotide-mimicking inhibitor QU663 (IC50 0.75 M) has 
led to the identification of more potent derivatives, the most effective in enzymatic 
assays being compound 7 (IC50 20 nM) (figure 1.22).103-104 
 
 
 
Figure 1.22: Chemical structures of QU663 and compound 7 
 
Finally, a 14 amino acid-long peptide inhibitor, p14, has proven to inhibit both helicase-
catalysed DNA unwinding (IC50 200 nM) and replication of HCV replicons in cells 
(EC50 83 M). This peptide shows basic characteristic that could suggest both a 
potential activity of sequestration of the nucleic acid substrate and binding in 
correspondence of the P-loop in domain 1, twisting along it and occupying the RNA-
binding cleft surrounding Trp501.105-106 
 
Compounds that inhibit unwinding by intercalating the polynucleotide chain 
DNA and RNA duplexes are stabilised by the presence of a bound or intercalated agent, 
increasing the energy required for duplex unwinding: as a consequence, intercalating 
compounds become potential helicase inhibitors.107 
The two anthracyclines epirubicin and nogalamycin show a good activity profile against 
HCV helicase unwinding reaction, with IC50 values of 0.75 M and 0.1 M 
respectively.108 Both are associated with a high cytotoxicity and weak penetration into 
cells, their potential as antiviral agents is limited and the identification of less toxic and 
more selective derivatives is required. 
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Figure 1.23: Structures of intercalating agents epirubicin and nogalamycin 
 
Compounds binding to unknown sites 
A small number of compounds have been found to inhibit HCV helicase activity with a 
binding mechanism that has not been clarified so far. 
This group includes a series of tropolone derivatives, the most potent being 3,7-
dibromo-5-morpholinomethyltropolone DBMTr, that shows an IC50 value of 17.6 M 
and is not related to high cytotoxicity (figure 1.24).109 
 
 
 
Figure 1.24: Structure of DBMTr 
 
Some acridone compounds have been identified as potential HCV helicase-inhibitors, 
with two of the most potent derivatives, compounds 8 and 9 in figure 1.25, showing 
IC50 values of respectively 9 and 4 M. Interestingly, these compounds also inhibit 
HCV replication in replicon systems, with EC50 values of approximately 10 M, and are 
not cytotoxic.110 
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Figure 1.25: Structures of compounds 8 and 9 
 
Application of a de novo drug design approach to the structure of HCV NS3 helicase led 
to the identification of potent inhibitor compound 10 (figure 1.26), which shows activity 
in both enzymatic (IC50 0.26 M) and replicon assay (EC50 9 M), but is relatively toxic 
to cells (CC50 30 M).111 
 
 
 
Figure 1.26: Structure of compound 10 
 
Finally, from the isolation of different components of the yellow dyes thioflavine S and 
primuline, a new series of compounds was found to show both helicase unwinding and 
viral replication inhibition potential, with the most active compound being P4 (IC50 0.9 
+/- 0.4 M, ~45% HCV inhibition at 10 M) (figure 1.27).112 
 
 
 
Figure 1.27: Structure of P4 
 
From a first series of synthetically modified analogues of the dyes components, 
compound 11 was found as the most potent (IC50 2.6+/- 1 M, 54+/- 10% HCV 
replication inhibition at 10 M).112 
 
Chapter 1: Introduction 
 
27 
 
 
 
Figure 1.28: Structure of compound 11 
 
1.2.5 HCV helicase assays 
 
A variety of assays are available to monitor HCV-catalysed DNA or RNA unwinding 
activity, in order to test the ability of small molecules to inhibit this reaction. The most 
recent and widely used techniques are based on helicase substrates labelled with 
fluorescent moieties. In a first generation assay, one nucleic acid strand is labelled on 
the   5’-end with a fuorescent probe annealed to a complementary strand with a 
quenching  molecule   at   the  3’-end, and the increase of fluorescence as the substrate is 
incubated with HCV helicase is measured: it will be proportional to the amount of DNA 
or RNA unwound.113-114 In a new generation assays, dual-labelled single stranded 
nucleic acid moieties that can form stem loop structures are used: one end of these 
moieties, called molecular beacons, is attached to a fluorescent molecule, while the 
other end is linked to a quencher. Molecular beacons are annealed to a complementary 
DNA or RNA oligonucleotide to form helicase substrates and, once incubated with the 
enzyme and upon strand separation, the stem-loop structure, or intramolecular hairpin, 
is irreversibly formed, and fluorescence is quenched as a consequence. The measured 
decrease in fluorescence will be proportional to the amount of substrate unwound.115-116 
Despite the abundance of structural information available, only few specific inhibitors 
of the enzyme have been reported so far: this might be due to the fact that high 
throughput screenings yield few hits.116 The reason for such a low success rate could 
rely on the nature of the assays: the measurement of strand separation upon helicase 
activity is relatively complex, and inhibitors could act through different mechanisms, 
which might involve required cofactors not included in the assay. Moreover, the protein 
conformational changes during the monitoring of its motor action in the assays could 
interfere with the identification of potential inhibitors. Furthermore, fluorescent 
compounds or compounds that absorb the light emitted by fluorescent probes can 
interfere with the assay and give false leads or skipped hit compounds, while the results 
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of these assays have been proven to be difficult to reproduce.112, 117 
These limitations in the enzymatic assay could be an explanation for the lack of specific 
helicase inhibitors identified so far. 
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1.3 Molecular modelling 
 
Molecular modelling techniques are widely used in pharmaceutical research. 
Most drugs are effective due to specific interactions with a biological target: many of 
them have significant shape complementarity with their binding site, and can form 
hydrogen bonds with the target, while some targets have hydrophobic pockets where the 
ligand can place a hydrophobic group with the right size. In a drug discovery 
programme, the first step is usually to identify hit molecules, and then to produce lead 
series. Finding novel lead series among chemical compounds can be hard, and it 
becomes often necessary to identify subsets of potential ligands for a given target with 
the aid of computational techniques, that can be applied also for lead optimisation and 
identification of structure-activity relationships among series of compounds. Computer-
aided techniques can be used to speed up different steps of drug discovery and 
optimisation processes. 
On the basis of how the system energy is calculated, algorithms used in molecular 
modelling calculations belong to three main categories: programs to perform ab initio 
quantum mechanics, programs for semi-empirical quantum mechanics and programs for 
molecular mechanics.118-119 
 
1.3.1 Molecular mechanics: empirical force field models 
 
Molecular mechanics or force field methods ignore the electronic motions and calculate 
the energy of a system as a function of the nuclear positions only; they can be used for 
calculations on systems containing large numbers of atoms. Their principal limitation is 
that it is not possible to calculate properties that depend on electronic distribution.120 
Molecular mechanics can be interpreted in terms of a four-component ensemble of the 
intra- and inter-molecular forces within the system: energetic penalties associated with 
the deviation of bonds and angles from their equilibrium values (stretching and 
bending), energetic changes that follow bond rotations (torsional terms), interactions 
between non-bonded parts of the system (electrostatic and Van der Waals interactions). 
To these four basic elements, additional terms can be added in more sophisticated 
elaborations; force fields used in molecular modelling are mainly designed to reproduce 
certain structural properties and are therefore parameterised accordingly.121 
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These methods are empirical: there is not an absolute correct form for them, and many 
share a similar structure that usually tends to conform to the interactions present in a 
system, and is often the result of a compromise between accuracy and computational 
efficiency. 
A common concept to most force fields is atom type: the atom type for each atom in the 
system is necessary to be assigned, and it contains not only the atomic number but also 
its hybridisation state and sometimes the local environment. Often atom types reflect the 
neighbouring environment and can be extensive for some atoms, making the force field 
they are included suitable for different categories of molecules: for example, MMFF94 
is a force field widely used for small molecules,122 while AMBER force fields are 
commonly used for proteins and nucleic acids. 123 
 
1.3.2 Energy minimisation 
 
Except for the simplest systems, potential energy tends to be a complicated 
multidimensional function of the system coordinates. The way in which energy varies 
with the coordinates of the atoms in a system is usually referred to as potential energy 
surface.124 In molecular modelling, the interest is mainly in minimum points of the 
energy surface: minimum energy arrangements of atoms correspond to stable states of 
the system, and any movement away from a minimum gives a configuration with a 
higher energy level. 
 
 
Figure 1.29: Example of one-dimension energy surface. Minimisation algorithms move downhill to the 
closest minimum 
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In order to identify those geometries of a system that correspond to minimum points on 
the energy surface, minimisation algorithms are commonly used: such methods go 
downhill on the energy surface to locate the nearest minimum for a given system.125 
These analyses are almost always used in molecular modelling and related techniques 
like conformational search procedures, to prepare a system for other types of 
calculation, in order to identify and avoid any unfavourable interaction in the system 
initial configuration. 
 
1.3.3 Conformational analysis 
 
Physical-chemical and biological properties of a molecule can dramatically depend on 
the three-dimensional structures, or conformations, that it can adopt: a conformational 
analysis is the evaluation of the conformations of a molecule and their influence on its 
properties.126 The different conformations of a molecule are identified as the 
arrangements of its atoms that can be interconverted by rotation about single bonds. The 
purpose of a conformational analysis is to identify the preferred conformations of a 
molecule, which determine its chemical and biological behaviour. These conformations 
usually correspond to minimum points on the energy surface: energy minimisation plays 
therefore an important part in conformational analysis. 
 
 
Figure 1.30: Potential energy diagram for cyclohexane conformations 
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1.3.4 Database searching 
 
Substructure searching is the simplest way to identify compounds of interest. Many 
databases of chemical compounds can be used as a research source, and some of them 
are of public access. A quick way to find all the molecules in a database that contain 
specific required features is a two-dimensional substructure search.127 Nevertheless, 
biological targets recognise three-dimensional stereoelectronic features of a molecule, 
and to search for compounds that satisfy the chemical and geometrical requirements of a 
given target a three-dimensional database searching method is required. One method 
that can be used also when detailed information about the target structure is not 
available is a pharmacophoric model, which indicates the key characteristics of a set of 
active molecules.128 
 
1.3.5 3D Pharmacophores and conformational databases 
 
Typical features of a pharmacophore are hydrogen-bond donors and acceptors, 
positively and negatively charged groups, and hydrophobic regions, which can be all 
referred to as pharmacophoric groups: they can be seen as an extension of the concept 
of bioisosteres. A three-dimensional pharmacophore embodies the spatial relationship 
between these groups, generally expressed in terms of distance ranges, angles and 
planes.128 
Once a pharmacophore has been developed, it can be used to find other active 
molecules. The key point to create a good pharmacophoric model is to deduce which 
features are required for activity, and to determine conformations in which 
pharmacophoric groups are in the same relative position. Pharmacophores are often 
expressed in terms of location constraints, which are points in the space surrounded by a 
spherical region: a molecule must be able to place the relevant features within the 
appropriate spheres. The presence of the receptor can also be included in terms of 
exclusion spheres, which indicate regions where the ligand is not permitted to position 
any of its parts. 
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Figure 1.31: Example of pharmacophoric model based on the 3KQN crystal structure 
 
In a three-dimensional database search the three-dimensional structures of the 
molecules to screen need to be considered: for most of them a well-defined crystal 
structure is not available, therefore structure generation programs are often used to 
perform a conformational analysis, in order to find low-energy conformations for the 
compounds to analyse. In order to take conformational flexibility into account during a 
database search, many conformations, not only the lowest-energy one, are usually 
stored for each input structure. 
 
1.3.6 Molecular docking 
 
In the search for new drug-like entities, it is often useful to have a prediction of the 
potential binding mode of a set of chemical compounds to the biological target of 
interest. The aim of molecular docking is to predict the structure of the intermolecular 
complex formed between two or more molecules, thus suggesting the binding modes of 
ligands to the biological target. Docking algorithms usually generate a large number of 
possible conformations, each of which needs to be scored in order to identify the most 
interesting ones. The docking problem is the generation and evaluation of potential 
structures for intermolecular complexes. It involves many degrees of freedom: six 
degrees of translational and rotational freedom of one molecule relative to the other, and 
the conformational degree of freedom of each molecule itself.129 
Most methods to perform conformationally flexible docking include the conformational 
degrees of freedom of the ligand only, while the receptor is assumed to be rigid.  
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In order to take into account both ligand and receptor conformational space, the most 
common solution is to perform a molecular dynamics simulation of the ligand-receptor 
complex. Nevertheless, such calculations are computationally highly demanding, and 
are practically useful only to refine structures produced by other docking methods, since 
they do not explore the range of possible binding modes, except for very small and 
mobile ligands.  
 
1.3.7 Scoring functions 
 
Most docking algorithms generate a large number of possible solutions: some of these 
can be immediately rejected because of high-energy clashes with the protein, but the 
remaining ones have to be assessed with mathematical functions, the scoring functions, 
used to identify the docked orientation that corresponds to the most probable structure 
of an intermolecular complex. When docking a database of compounds, the scoring 
function should not only identify the best docking mode of a given ligand, but also 
allow the ranking of one ligand relative to another.  
Many scoring functions approximate the binding free energy for the ligand to the 
receptor, dividing it in different components that reflect the various contributions to 
binding:130 
 
 ΔGbind  =  ΔGsolvent  +  ΔGconf  +  ΔGint  +  ΔGrot+  ΔGt/r  +  ΔGvib 
 
ΔGsolvent  is  the  contribution  due  to  solvent  effects,  ΔGconf  arises  from  conformational 
changes in the protein and the  ligand,  ΔGint  is  the  free  energy variation due to specific 
protein-ligand   interactions,   ΔGrot   is   the   free   energy   loss   associated with freezing 
internal  rotations  of  the  protein  and  the  ligand,  most  due  to  entropic  contribution,  ΔGt/r 
corresponds to the loss in translational and rotational free energy due to the association 
of  the  two  structures  to  give  a  single  body,  and  ΔGvib  is the free energy variation due to 
changes in vibrational modes.  
Many scoring functions also consider the relationship between binding free energy and 
a series of parameters like hydrogen bonding, ionic and lipophilic interactions, 
introducing also specific penalty scores that account for large deviations from the ideal 
geometry of each type of interaction. These parameters are derived from multiple linear 
regression analyses of experimental binding data on protein-ligand complexes. One 
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limitation is that they are derived from ligands that bind very tightly to their receptors, 
while docking is usually used to identify ligands of modest potency from a large 
database. For this and other reasons, comparing the results of different scoring functions 
shows better results than the use of a single scoring function: this approach is referred to 
as consensus scoring.131, 132 
 
1.3.8 Drug discovery strategies 
 
When facing a new biological target or searching for a better treatment for a certain 
pathology, molecular modelling techniques can provide a variety of useful tools to 
obtain hit compounds and lead molecules. 
Two different approaches can be adopted: attention can be focused on the molecular 
target, if known, or on the chemical structure of known ligands. 
If the starting point is the biological target, the first question to be asked is whether its 
crystal structure has been experimentally determined or not. If the target structure is 
available, a structure-based virtual screening or a structure-based drug design study can 
be performed.133 
Structure-based virtual screenings (SBVS) usually start with a database search, in order 
to find already known compounds that can fit the binding site or show particular 
features for binding to the protein. This initial phase is often followed by molecular 
docking analyses, which allow to evaluate the binding free energy associated with each 
ligand-target complex. The same approach can be applied if a crystal structure is not 
available for the given target, starting from its amino acid sequence and creating a 
homology model on the basis of the 3D structures of homologous proteins. A different 
strategy is to search for new structures to interact within the target binding site: in this 
case, a structure-based de novo design (SBDD, structure-based drug design) method can 
be used. 
If the structure of one or more active ligands is known, a ligand-based drug design or a 
ligand-based virtual screening study can be performed. In ligand-based drug design the 
starting point is the ligand structure(s), from which new compounds are derived on the 
basis of similarity and pharmacophore concepts, or of QSAR, quantitative structure-
activity relationship, analyses.134 
In ligand-based virtual screening the structures of known ligands are taken as the 
starting point to perform database searching such as 2D similarity and pharmacophore 
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matching. Virtual screening studies based on the structure of known active ligands are 
proven to give better results, in terms of activity, than screenings based on the target 
structure.135 
Once a series of hit compounds has been determined, the next step is lead optimisation, 
whose aim is to find chemical modifications to the hit structures that can improve their 
activity or chemical-physical properties.135 This study can be performed on the basis of 
the target structure, in structure-based lead optimisation, or on the basis of the ligand 
structure, in ligand-based lead optimisation. 
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1.4 Project aims 
 
Due to the essential role of a functional NS3 helicase for HCV replication, and the lack 
of selective inhibitors under development as drug candidates, this enzyme was chosen 
as a target for the identification of viral replication inhibitors, through the potential 
interference with its biological activity on the level of the known RNA binding cleft. 
This purpose will be pursued with the application of different molecular modelling 
techniques to the study of the enzyme and its known inhibitors structures, in order to 
identify and synthesise small molecule compounds as potential antiviral agents. 
All selected compounds will be evaluated for their activity against the viral replication 
in HCV replicon assays, and their biological evaluation will be considered to direct 
further studies. 
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2.1 Structure-based Virtual Screening 
 
Given the abundance of crystal structure information available for the HCV NS3 
helicase, different structure-based in silico evaluations were performed to identify 
potential inhibitors of this enzyme. 
A recent series of HCV NS3 helicase structures in complex with a single-stranded DNA 
substrate was used for all the studies carried out.1 Among the five ssDNA-NS3 helicase 
complexes, two were chosen for their high resolution and their conformational 
characteristics, representative respectively of the low-affinity closed conformation 
(PDB ID 3KQN) and the high-affinity open conformation of the complex (PDB ID 
3KQH).1 
The target site selected was the known nucleic acid binding cleft, in order to inhibit 
natural substrate binding. Due to the essential role demonstrated for Thr269, Arg393, 
Thr411 and Trp501, the aim was to identify compounds likely to bind the region 
including these residues, situated approximately at the interface between the enzyme 
main domains 1, 2 and 3.2 
The highest-resolution crystal structure of the NS3 helicase complex with a ssDNA 
substrate in the closed conformation corresponds to PDB ID 3KQN (2.05 Å). An ATP-
mimicking residue, ADP-BeF3, is present in the ATP binding pocket, domain 2 is 
shifted towards domain 1 and four nucleotide residues are spanned between the two 
bookends, Val432 and Trp501. In this low-affinity conformation of the enzyme the 
three main domains are close together, and the target residues are all located within a 
narrow space. In particular, a possible interaction with both Trp501 (domain 3) and 
Arg393 (domain 2) was evaluated in the search for inhibitors, to ideally block the 
enzyme in the closed conformation. 
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Figure 2.1: 3KQN crystal structure 
 
2.1.1 Database conformational search and pharmacophoric filter 
 
The site defined by the position of Trp501 and Arg393 in the 3KQN crystal structure 
was used to perform a structure-based virtual screening (SBVS) of small molecule 
libraries: the SPECS database was chosen for this search,3 and pre-screened with a 
pharmacophoric filter. The approximately 450000 structures available were downloaded 
and analysed with MOE 2010.10 conformational search tool; 500 low-energy 
conformations were kept for each input molecule.4 
The main interactions between the target residues and the co-crystallised substrate were 
considered to build the pharmacophoric query, and the selection was restricted to five 
features. A hydrophobic/aromatic group to interact with Trp501 (F1:Hyd|Aro in figure 
2.2) and a hydrogen-bond acceptor or anion group to interact with Gly255 and Thr269 
(F2:Acc|Ani) were kept as essential elements, while a H-bond donor to target Asp296 
(F3:Don), a H-bond donor and acceptor to interact with Thr298 and Ser297 
(F4:Acc&Don) and a hydrogen-bond acceptor to target Arg393 (F5:Acc) were added as 
alternative features, requiring a partial match of four elements. 
 
Chapter 2: Piperazines 
 
54 
 
 
 
Figure 2.2: 3KQN-based pharmacophoric model 
 
Exclusion volumes corresponding to the protein occupational space were added, and the 
model was used to screen the conformational database of the SPECS compounds, 
obtaining approximately 3000 molecules matching the search criteria. 
 
2.1.2 Molecular docking and consensus scoring 
 
The 3000 hit structures were evaluated within the RNA binding site with a docking 
analysis, to predict which of them could best fit the target pocket. Three different 
docking programs were used in parallel; they were chosen for their validated ability to 
predict binding capacities of different compounds against different target structures:5 
Glide,6 FlexX7 and Plants.8 One conformational database of docked poses was obtained 
for each algorithm, while the next step was the evaluation of the docking results to 
select those structures assessed as the best to bind the target pocket. 
Each docking program evaluates the output poses by applying its own scoring function, 
assigning an internal score to each generated conformation. Nevertheless, the use of a 
single scoring function is not recommended in virtual screening,9 since for their own 
definition different scoring functions typically give different importance, for the binding 
free energy calculation, to diverse aspects, that may or may not be the most significant 
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to evaluate the effective binding potential of a specific compound. To overcome these 
limitations, a combination of multiple scoring functions was used to evaluate the 
docking results.10 The three docking outputs were re-scored with the scoring functions 
implemented in each docking program: Glide XP, Plants ChemPLP and FlexX scoring 
function, all belonging to the most widely used and best validated scoring algorithms.11-
12 
Prior to the application of the rescoring procedure, all docking solutions were 
minimised within the RNA binding site of the 3KQN structure: the Glide Refinement 
tool was used to perform such conformational smoothing. Once refined, the three 
conformational databases deriving from docking were rescored with the three scoring 
functions, and the results belonging to a same docking output were combined together 
for each docked pose. A consensus scoring function was elaborated to equally give the 
same importance to the three scoring algorithms, and to select the structures belonging 
to the best 25% according to all functions at the same time (Chapter 6.1). 
The selected poses were visually inspected in the context of the 3KQN target site in 
MOE 2010.10,4 in order to identify a small number of candidates to purchase and test 
against HCV replication in the replicon assay.13 The main criterion that guided the 
identification of potential NS3 inhibitors was the interaction with Trp501 and Arg393, 
and with the surrounding residues important for nucleic acid binding. 
A final selection of fourteen molecules was made (Appendix I). Among them, 
compound 12 (figure 2.3) showed a good activity profile, without relevant toxicity 
against cells: its EC50 value for HCV replication inhibition was 8 M, with a CC50 
greater than 90 M. Due to these results, its structure was chosen as the starting point 
for the synthesis of a series of new derivatives. 
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Figure 2.3: structure and predicted binding mode for compound 12 
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2.2 Synthesis of symmetrical piperazines 
 
Compound 12 has a symmetrical structure, with a central piperazine ring and two 
aliphatic linkers connected by a sulfonamide group to two equal aromatic systems 
(figure 2.4).  
 
 
 
Figure 2.4: Structure and features of compound 12 
 
The first modifications designed included different aromatic substitutions, linker chain 
variations and disruption of the molecule symmetry. 
 
2.2.1 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))diaryl sulfonamides 
(12, 30-36) 
 
A first series of new derivatives was designed to explore the effect of the aromatic 
substituent on the original structure, by varying the substitutions on the phenyl rings 
while keeping the central piperazine nucleus and the three-carbon saturated linker. 
Some commercially available aromatic sulfonyl chlorides (13-20) were chosen as 
starting materials to obtain piperazine derivatives 12, 30-36 according to a two-step 
synthetic pathway (scheme 2.1). 
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Starting Sulfonyl 
Chloride 
Ar 
Bromide 
intermediate 
Yield % Product Yield % 
13 4-Chlorophenyl 22 94 12 64 
14 Phenyl 23 97 30 64 
15 4-Methylphenyl 24 89 31 68 
16 4-Methoxyphenyl 25 86 32 60 
17 4-Nitrophenyl 26 73 33 43 
18 3,4-Dimethoxyphenyl 27 61 34 65 
19 2,5-Dimethoxyphenyl 28 70 35 71 
20 2-Naphthyl 29 89 36 79 
 
Scheme 2.1: Pathway for the synthesis of compounds 12, 30-36 
 
Synthesis of N-(3-bromopropyl)arylsulfonamides (22-29) 
Intermediates 22-29 were obtained with a nucleophilic displacement by the amine group 
of 3-bromopropylamine on the electrophilic site of the sulfonylchloride.14 In order to 
avoid a self-reaction between two molecules of the nucleophile, the amine group of 3-
bromopropylamine hydrobromide (21) was slowly released by the dropwise addition of 
the base, triethylamine, at 0C, to favour the reaction towards the sulfonylchloride. 
 
Synthesis of N,N’-(3,3’-(piperazine-1,4-diyl)bis(propane-3,1-diyl))diaryl 
sulfonamides (12, 30-36) 
Compound 12 and its derivatives 30-36 were obtained with a second nucleophilic 
substitution, with the displacement of the bromide leaving group of intermediates 22-29 
by the two secondary amine groups of piperazine, thus obtaining the final symmetrical 
derivatives. 
Two good methods in terms of yield (approximately 60% after purification) were 
identified for the synthesis of compound 12: the first consisted of stirring the two 
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reagents with triethylamine in THF for 48 h,15 the second using NaHCO3/ethanol as 
base/solvent system, and refluxing the reaction mixture for 24 h.16 Due to the shorter 
time required by the second procedure, it was generally adopted for the preparation of 
all remaining compounds of this series.  
 
2.2.2 N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl)) diaryl sulfonamides (46-
53) 
 
A second series of derivatives was planned to modify, along with the aromatic 
substituent, the length of the aliphatic linker, by shortening it from a three-carbon to a 
two-carbon saturated chain, while maintaining the symmetry of the molecule with the 
central piperazine ring. The previous two-step reaction strategy was applied (scheme 
2.2). 
 
 
Starting Sulfonyl 
Chloride 
Ar 
Bromide 
intermediate 
Yield % Product 
Yield 
% 
13 4-Chlorophenyl 38 87 46 45 
14 Phenyl 39 80 47 52 
15 4-Methylphenyl 40 83 48 89 
16 4-Methoxyphenyl 41 75 49 78 
17 4-Nitrophenyl 42 65 50 63 
18 3,4-Dimethoxyphenyl 43 83 51 74 
19 2,5-Dimethoxyphenyl 44 81 52 77 
20 2-Naphthyl 45 87 53 82 
 
Scheme 2.2: Pathway for the synthesis of compounds 46-53 
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Synthesis of N-(2-bromoethyl)arylsulfonamides (38-45) 
The same nucleophilic displacement strategy adopted for compounds 22-29 was 
followed for the synthesis of compounds 38-45, using 2-bromoethylamine 
hydrobromide (37) to obtain a two-carbon linker, to be subsequently functionalised by 
piperazine secondary amine groups. 
Synthesis of N,N’-(2,2’-(piperazine-1,4-diyl)bis(ethane-2,1-diyl))diaryl 
sulfonamides (46-53) 
Final symmetrical piperazine derivatives with a shorter linker 46-53 were prepared in 
the system NaHCO3/ethanol under reflux for 24 h, to allow the nucleophilic 
displacement by piperazine secondary amine groups on the level of the alkyl bromide 
leaving group. 
 
2.2.3 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))diaryl 
sulfonamides (74-80) 
 
A third series of derivatives was designed to rigidify the three-carbon linker and study 
the importance of the two positive charges/H-bond acceptors of the piperazine amine 
groups. For this reason, it was planned to insert an amide group in correspondence of 
piperazine nitrogen atoms, obtaining an oxypropylic linker in the symmetrical structure: 
to achieve this result, the scaffold of -alanine (54) was chosen as the new linker, and 
inserted in the two-step synthetic pathway shown in scheme 2.3. 
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Starting Sulfonyl 
Chloride 
Ar 
Acid 
intermediate 
Yield % Product 
Yield 
% 
13 4-Chlorophenyl 55 64 62 41 
14 Phenyl 56 52 63 57 
16 4-Methoxyphenyl 57 72 64 46 
17 4-Nitrophenyl 58 51 65 35 
18 3,4-Dimethoxyphenyl 59 58 66 47 
19 2,5-Dimethoxyphenyl 60 64 67 52 
20 2-Naphthyl 61 61 68 54 
 
Scheme 2.3: Pathway for the synthesis of compounds 62-68 
 
Synthesis of 3-arylsulfonylamine propionic acids (55-61) 
Intermediate acids 55-61 were obtained through a nucleophilic substitution by -alanine 
(54) amine group on the level of the sulfonyl chloride, according to procedures reported 
for glycine.17 By following the reaction with monitoring of the pH to maintain basic 
conditions with 1M NaOH, the corresponding carboxylates were obtained, while the 
free acids were subsequently precipitated out by acidification of the reaction mixture. 
 
Synthesis of N,N’-(3,3’-(piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))diaryl 
sulfonamides (62-68) 
Final symmetrical amide derivatives 62-68 were obtained with a coupling reaction 
between propionic acids 55-61 and piperazine, using TBTU as coupling agent.18 
TBTU, O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium tetrafluoroborate, belongs 
to a family of coupling agents called uronium compounds, used for efficient amide bond 
formation under mild reaction conditions. Uronium reagents, like most coupling agents, 
are used to enhance the electrophilic characteristic of the carbonyl carbon towards 
nucleophilic substitution, by the formation of a highly reactive intermediate ester.19 
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This type of reaction can be carried out efficiently at r.t. for a few hours or overnight. 
 
2.2.4 N-(3-(Piperidin-1-yl)propyl)arylsulfonamides (69, 70) 
 
Aiming to evaluate the role of the length and the symmetry of the molecule, two shorter 
unsymmetrical derivatives were obtained by reacting intermediates 22 and 29 with 
piperidine. This was used to replace the piperazine central core with a single 
nucleophilic substitution by piperidine secondary amine on the alkyl bromide leaving 
group (scheme 2.4). 
 
 
Bromide intermediate Ar Product Yield % 
22 4-Chlorophenyl 69 75 
29 2-Naphthyl 70 71 
 
Scheme 2.4: Synthesis of compounds 69 and 70 
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2.2.5 N,N’-(4,4’-(Piperazine-1,4-diyl)bis(butane-4,1-diyl))bis(4 
chlorobenzenesulfonamide) (73) 
 
Several attempts were made in order to synthesise one symmetrical derivative with a 
longer aliphatic linker of four carbons. The first strategy designed for the preparation of 
the desired analogue, compound 73, is shown in scheme 2.5. 
 
 
Scheme 2.5: First strategy for the synthesis of compound 73 
 
The two-step synthetic pathway started with the formation of intermediate 72, 4-chloro-
benzenesulfonic acid 4-(4-chloro-benzenesulfonylamine)-butyl ester, through a double 
nucleophilic displacement on 4-chlorobenzenesulfonyl chloride (13) by both the amine 
and the hydroxyl groups of 4-aminebutanol (71), following procedures previously 
reported for tosyl chloride.20 This intermediate was isolated and reacted with piperazine 
in THF and triethylamine at r.t., in order to displace the good leaving group of the 
sulfonate ester with the two amine groups of piperazine. The desired reaction did not 
proceed at r.t., and only starting material 72 was isolated after 48 h. The reaction 
mixture was then heated under reflux for 24 h, and even though the formation of a new 
species was observed by T.L.C, it was not possible to purify the new compound via 
column chromatography or recrystallisation. 
To overcome purification difficulties, a second synthetic strategy, shown in scheme 2.6, 
was attempted. 
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Scheme 2.6: Second strategy designed for the synthesis of compound 73 
 
The amine group of 4-aminebutanol was first substituted with 4-chlorobenzenesulfonyl 
chloride to give compound 74, 4-chloro-N-(4-hydroxy-butyl)-benzenesulfonamide. 
Next a good leaving group was created on the free hydroxy function in 74 by 
conversion to mesylate ester, through a nucleophilic displacement on mesyl chloride. 
Intermediate 75, methanesulfonic acid 4-(4-chloro-benzenesulfonylamine)-butyl ester, 
was obtained and purified, but different attempts to displace the mesylate ester with 
piperazine were unsuccessful. Only starting material 75 was recovered after reacting it 
with piperazine in THF and triethylamine for 48 h at r.t. Reaction conditions were then 
changed to reflux in EtOH for 24 h, using sodium bicarbonate as base. In this second 
reaction system, all starting material 75 was converted into its ring-closure derivative on 
the sulfonamide nitrogen, compound 76 (1-(4-chloro-benzenesulfonyl)-pyrrolidine). 
The reason of the formation of this side product could be explained by the reflux 
conditions, where the energy given by heating could enhance the intramolecular 
displacement of the mesylate leaving group by the sulfonamide group.  
Due to these unsuccessful attempts, it was decided to avoid any possible interference of 
the sulfonamide group by freezing its residual reactivity towards nucleophilic 
displacement through amine protection of 4-aminebutanol 71 with BOC, using di-tert-
butyl dicarbonate (BOC)2O, stable in basic environment and easily removed under 
acidic conditions. 
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The new synthetic pathway is shown in scheme 2.7. 
 
 
Scheme 2.7: Third synthetic pathway designed for compound 73 
 
In this third strategy, the free amine in 4-aminebutanol was first protected with BOC to 
give 78, and then a good leaving group was obtained by converting the hydroxy 
function to mesylate ester in compound 79. Once substituted the two amine groups of 
piperazine by nucleophilic displacement of the mesylate group (80), under reflux in 
ethanol and sodium bicarbonate, it was designed to deprotect the two terminal amine 
groups by hydrolysis of the carbamate ester with trifluoroacetic acid in compound 81. 
This fourth intermediate was not isolated, but precipitated as the trifluoroacetate salt 
from the reaction mixture, and directly treated with an excess of 4-chloro-
benzenesulfonyl chloride (13) in basic conditions, in order to obtain the desired final 
product 73. This third synthetic approach was successful and compound 73 was finally 
isolated after purification by flash column chromatography. Each step of this successful 
procedure will now be discussed. 
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Synthesis of (4-hydroxy-butyl)-carbamic acid tert-butyl ester (78)21 
The amine group of 4-aminebutanol 71 was protected by conversion to carbamic ester 
using the BOC protecting group, which was chosen due to its stability under basic 
conditions, required in the following reaction steps where a nucleophilic displacement 
was to be performed.21 Desired protected amine 78 was obtained in high yield (93%) 
after stirring the reagents at r.t. for 7 h in DCM and NEt3. 
 
Synthesis of methanesulfonic acid 4-tert-butoxycarbonylamine-butyl ester (79) 
The free hydroxy group of compound 78 was converted to a good leaving group, for the 
subsequent nucleophilic displacement with piperazine, by using mesyl chloride, in order 
to obtain a methanesulfonic ester function, easily replaced by nucleophiles, such as the 
secondary amine groups of piperazine.22 Also this second intermediate was obtained in 
high yield (86%) and purity. 
 
Synthesis of {4-[4-(4-tert-butoxycarbonylamine-butyl)-piperazin-1-yl]-butyl}-
carbamic acid tert-butyl ester (80) 
In order to achieve a double nucleophilic displacement by the piperazine amine groups 
on mesylate ester 79, the two starting materials were reacted for 24 h under reflux in 
ethanol, using sodium bicarbonate as base, in the same reaction conditions that had been 
previously adopted. Symmetrical piperazine intermediate 80 was obtained in 70 % yield 
and used for the following step without purification. 
 
Synthesis of N,N’-(4,4’-(piperazine-1,4-diyl)bis(butane-4,1-diyl))bis(4-
chlorobenzene-sulfonamide) (73) 
The two protected carbamic ester functions of compound 80 were converted to free 
amine groups by removal of the BOC protecting group, using trifluoroacetic acid. In the 
acidic reaction conditions, symmetrical tetra-amine 81, 4,4'-(piperazine-1,4-
diyl)bis(butan-1-amine), was present as a trifluoroacetate salt, that was precipitated after 
concentrating the reaction mixture under vacuum and pouring the residue into diethyl 
ether. The white precipitate formed was washed with diethyl ether and directly treated 
with an excess of 4-chlorobenzenesulfonyl chloride (13) and triethylamine. 
Compound 73 was finally obtained following this five-step synthetic route, after 
purification by flash column chromatography. 
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2.2.6 Biological evaluation in the HCV replicon and cytostatic assay 
 
HCV replicon systems, genetic elements that can replicate under their own control in a 
cell, are powerful tools to study HCV replication and evaluate the potential interference 
of chemical compounds.13 The most recent HCV subgenomic replicons are genetically 
modified to replace the region encoding the structural proteins with a reporter gene, 
such as firefly luciferase, that allows the evaluation of HCV replication inhibition 
through the measurement of the reduction of luciferase signal. 
For all compounds prepared, the subgenomic replicon assay in the human hepatoma cell 
line Huh-7 and the cytostatic assay were kindly performed in the Rega Institute for 
Medical Research, KU Leuven, Leuven, Belgium, under the supervision of Professor 
Johan Neyts.23 
Activity is expressed for each compound in terms of EC50, that is the effective 
concentration (M) of compound required to reduce HCV replication by 50%, and 
eventually EC90, that is the effective concentration (M) of compound required to 
reduce HCV replication by 90%. Cytotoxicity is evaluated in terms of CC50, that is the 
cytostatic/cytotoxic concentration (M) required to observe 50% of adverse effect on 
the host cell. The selectivity index, SI, is evaluated by calculating the ratio CC50/EC50. 
 
N,N’-(2,2’-(Piperazine-1,4-diyl)bis(propyl-2,1-diyl)) diaryl sulfonamides (12, 30-36) 
 
 
Compound Ar- EC50(M) CC50(M) EC90(M) SI 
12 4-Chlorophenyl 13 >182 - >14 
30 Phenyl 58.3 >104 - >1.7 
31 4-Methylphenyl 19 >197 >197 >10.4 
32 4-Methoxyphenyl >92.5 >92.5 >92.5 - 
33 4-Nitrophenyl 17.5 77.4 61.1 4.4 
34 3,4-Dimethoxyphenyl 82 >166 >166 2 
35 2,5-Dimethoxyphenyl >83 >83 >83 - 
36 2-Naphthyl 4.9 49.9 - 10.2 
 
Table 2.1: activity and cytotoxicity data for compounds 12, 30-36 
 
As can be inferred from table 2.1, compound 12 confirmed the activity potential 
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previously found, while a hydrophobic substituent in the para position in the aromatic 
rings was related to activity retention (compound 31). Compounds 33 and 36, with 
para-nitrophenyl and 2-naphthyl aromatic moieties, respectively, were associated with 
cytotoxicity, while the removal of the substituent or its replacement with methoxy 
groups led to loss of activity. 
 
N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl)) diaryl sulfonamides (46-53) 
 
 
Compound Ar- EC50(M) CC50(M) EC90(M) SI 
46 4-Chlorophenyl >95.9 >95.9 - - 
47 Phenyl >110 >110 - - 
48 4-Methylphenyl >104 >104 >104 - 
49 4-Methoxyphenyl >97.5 >97.5 >97.5 - 
50 4-Nitrophenyl 17.4 22.3 - 1.3 
51 3,4-Dimethoxyphenyl 85.8 >87.3 >87.3 >1 
52 2,5-Dimethoxyphenyl >87 >87 - - 
53 2-Naphthyl 10.6 >90.5 - >8.5 
 
Table 2.2: activity and cytotoxicity data for compounds 46-53 
 
Symmetrical shortening of the aliphatic linker was associated with loss of activity, 
indicating an important role played by the length of the linker for viral replication 
inhibition. The only exception to this trend was compound 53, where the presence of the 
2-naphthyl ring resulted in activity retention, while the shortening of the linker appears 
to reduce the toxic effect found for its three-carbon analogue, compound 36. 
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N,N’-(3,3’-(piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))diarylsulfonamides (62-
68) 
 
 
Compound Ar- EC50(M) CC50(M) EC90(M) SI 
62 4-Chlorophenyl - >86.6 - - 
63 Phenyl >197 >197 >197 - 
64 4-Methoxyphenyl - >87.9 - - 
65 4-Nitrophenyl 84 >167 >167 >1.9 
66 3,4-Dimethoxyphenyl >159 >159 >159 - 
67 2,5-Dimethoxyphenyl >79.5 >79.5 - - 
68 2-Naphthyl 12.4 40.8 78.3 3.3 
 
Table 2.3: activity and cytotoxicity data for compounds 62-68 
 
For the third series of symmetrical derivatives prepared, biological results indicate that 
either the presence of the positive charge on the two amine groups or the flexibility of 
the two linkers are important for viral replication inhibition, since this modification is 
correlated to loss of activity. The only exception is represented by compound 68, where 
the 2-naphthyl group is associated with retained activity, but also shows increased 
toxicity against the cell. 
 
N-(3-(Piperidin-1-yl)propyl)arylsulfonamides (69, 70) 
 
 
Compound Ar- EC50(M) CC50(M) EC90(M) SI 
69 4-Chlorophenyl 61 >157 - 2.5 
70 2-Naphthyl 12.7 70.4 - 5.5 
 
Table 2.4: activity and cytotoxicity data for compounds 69, 70 
 
Biological results for the two shorter unsymmetrical derivatives where the piperazine 
central core is replaced with a piperidine ring, compounds 69 and 70, confirmed the 
importance of the overall length of the molecule, since this last modification is 
associated with loss of activity for compound 69, while the values for the 2-naphthyl 
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analogue confirmed the cytotoxic effect associated with this substitution. 
 
N,N’-(4,4’-(Piperazine-1,4-diyl)bis(butane-4,1-diyl))bis(4-chlorobenzene 
sulfonamide) (73) 
 
 
Compound EC50(M) CC50(M) EC90(M) SI 
73 69 >173 164 >2.5 
 
Table 2.5: activity and cytotoxicity data for compound 73 
 
Loss of activity associated with a longer aliphatic linker of four methylene groups, in 
compound 73, confirmed that the length of the original molecule 12 plays an important 
role for the viral replication inhibition.  
 
2.2.7 Design of a new series of symmetrical derivatives 
 
Following the biological results obtained for the first series of analogues tested, a new 
series of compounds was designed, and for most of them the original three-carbon 
aliphatic linker was maintained. The new modifications planned aimed to explore the 
effect of the hydrophobic substituent in the aromatic system, by changing the position 
of the original chlorine to meta and ortho, and by replacing the hydrophobic group in 
the position para with a tert-butyl, trifluoromethyl and phenyl functions. In order to 
investigate the residual activity shown for the 4-nitro analogue 33, it was decided to 
insert a carboxylic function in the para position of the aromatic system, and also the 
carboxylate ethyl ester was chosen for preparation and biological evaluation. Moreover, 
the aromatic system in the original scaffold was replaced with heteroaromatic rings 
(pyridine, thiophene and quinoline), and the 2-naphthyl system in compound 33 was 
substituted with a 1-naphthyl group. In order to assess the importance of the two 
sulfonamide groups, it was decided to replace them with an amide group. Finally, the 
first non-piperazine derivative was designed, aiming to rigidify the original structure 
and to remove its double positive charge, while maintaining the opportunity of 
hydrogen-bond formation. To achieve this result, the scaffold of para-phenylendiamine 
was chosen to replace piperazine.  
Chapter 2: Piperazines 
 
71 
 
2.2.8 N,N’-(3,3’-(piperazine-1,4-diyl)bis(propane-3,1-diyl))diarylsulfonamides 
(100-108, 111, 116) 
 
Nine new derivatives with a linear three-carbon linker were prepared following the 
previously applied two-step synthetic pathway, starting from sulfonyl chlorides 82-90, 
preparing intermediate alkyl bromides 91-99, and finally alkylating piperazine amine 
groups to obtain symmetrical products 100-108, as shown in scheme 2.8. 
 
 
Starting Sulfonyl 
Chloride 
Ar 
Bromide 
intermediate 
Yield % Product 
Yield 
% 
82 3-Chlorophenyl 91 75 100 79 
83 4-tert-Butylphenyl 92 77 101 82 
84 4-Trifluoromethylphenyl 93 80 102 61 
85 4-Biphenyl 94 67 103 87 
86 1-Naphthyl 95 95 104 91 
87 8-Quinoline 96 73 105 63 
88 1-Thiophene 97 89 106 83 
89 3-Pyridine 98 56 107 63 
90 4-Ethylcarboxyphenyl 99 66 108 41 
 
Scheme 2.8: Synthesis of compounds 100-108 
 
Sulfonyl chlorides 82-88 were commercially available, while 3-pyridine sulfonyl 
chloride (89) and ethyl 4-(chlorosulfonyl)benzoate (90) were synthesised starting from 
pyridine-3-sulfonic acid (109) and 4-chlorosulfonyl benzoic acid (110), respectively. 
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Synthesis of pyridine-3-sulfonyl chloride (89)24 
 
 
Scheme 2.9: Synthesis of sulfonyl chloride 89 
 
Following reported procedures, compound 89 was obtained by refluxing over night 
pyridine-3-sulfonic acid (109) with phosphorus pentachloride and phosphorus 
oxychloride, in order to perform a substitutive chlorination of the sulfonic acid function 
to sulfonyl chloride.24 
 
Synthesis of 4-chlorosulfonyl-benzoic acid ethyl ester (90) 
The carboxylic function of 4-chlorosulfonyl benzoic acid (110) was converted to its 
ethyl ester derivative following procedures reported for the preparation of the methyl 
ester (scheme 2.9).25 
 
 
Scheme 2.9: Synthesis of sulfonyl chloride 90 
 
Starting material 110 was first treated with thionyl chloride in DCM, refluxing the 
reaction mixture for 2 h prior removal of the solvent at reduced pressure, thus obtaining 
the acyl chloride. This intermediate was immediately treated with cold ethanol at 0°C, 
allowing the nucleophilic substitution of the chloride leaving group with the formation 
of the ethyl ester derivative, compound 90. 
 
3-(N-(3-(4-(3-(4-Carboxyphenylensulfonamide)propyl)piperazin-1-yl)propyl) 
sulfamoyl)benzoic acid (111) 
The designed derivative 111 with a carboxylic substituent in the para position of the 
aromatic group in the lateral chain was obtained through a base-catalysed hydrolysis of 
the two ester functional groups of compound 108, as shown in scheme 2.10. 
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Scheme 2.10: Synthesis of compound 111 
 
Ethyl ester groups in compound 108 were hydrolysed into the free carboxylic acids with 
lithium hydroxide, stirring the reaction mixture at 80°C over night. The final product 
111 was precipitated after removal of the organic solvent and subsequent acidification 
of the water residue to pH 5. 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(2-chlorobenzene-
sulfonamide) (116) 
In order to move the original 4-chloro aromatic substituent into the ortho position, 2-
chlorobenzenesulfonamide (112) was the only starting material available. The first step 
of the usual synthetic pathway had therefore to be changed to obtain this derivative 
(scheme 2.11). 
 
 
Scheme 2.11: Synthesis of compound 116 
 
Synthesis of N-(3-bromo-propyl)-2-chloro-benzenesulfonamide (115) 
Intermediate alkyl bromide 115 was obtained by reacting 2-chlorobenzene sulfonamide 
(112) with 1,3-dibromopropane (113). One proton of the sulfonamide nitrogen was first 
removed by treating with 1 equivalent of NaH in anhydrous DMF, followed by the 
addition of compound 113 to the mixture, in order to obtain the displacement of one of 
the bromides by the nitrogen lone pair.26 
Desired intermediate 115 was not the main product formed: most of the starting material 
was converted into the product of the double substitution on the sulfonamide nitrogen, 
to give compound 114, while compound 116 was obtained in 39% yield.  
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2.2.9 N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl)diquinoline-8-
sulfonamide (118) 
 
Due to the activity potential revealed for compound 53, which shows a shorter two-
carbon linker and a 2-naphthalene aromatic system, it was thought that the insertion of 
another bicyclic aromatic system could maintain a certain activity in the shorter 
scaffold. One new symmetrical derivative was therefore prepared with a two-carbon 
linker, through the usual synthetic approach, starting from 8-quinoline sulfonyl chloride 
(87) (scheme 2.12). 
 
 
Scheme 2.12: Synthesis of compound 118 
 
2.2.10 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-chloro 
benzamide) (122) 
 
In order to investigate the role of the sulfonamide group for antiviral activity, it was 
replaced with an amide group. The synthetic pathway carried out was the same 
previously used (scheme 2.13). 
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Scheme 2.13: Synthesis of compound 122 
 
Synthesis of N-(3-bromopropyl)-4-chlorobenzamide (120) 
As was done for the synthesis of previous intermediate alkyl bromides, 4-chlorobenzoyl 
chloride (119) was converted into the corresponding benzamide 120 through a 
nucleophilic substitution with 3-bromopropylamine hydrobromide (21) in the presence 
of triethylamine. 
 
Synthesis of N,N’-(3,3’-(piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-chloro-
benzamide) (122) 
A first attempt to obtain final product 122 was made by heating compound 120 at reflux 
with piperazine in ethanol and sodium bicarbonate, following the usual strategy 
previously used for sulfonamide products. Nevertheless, under these conditions all of 
the starting material was converted into its internal closure product, compound 121: the 
energy given by heating could enhance an intramolecular reaction with the formation of 
a cyclic side-product. Before changing the synthetic strategy, in was decided to repeat 
the reaction without heating, using triethylamine and THF at r.t. for 48 h: this second 
attempt was successful and the desired product 122 was obtained in a 36% yield. 
 
2.2.11 N,N’-(2,2’-(1,4-Phenylenebis(azanediyl))bis(ethane-2,1-diyl))bis(4-
chlorobenzenesulfonamide) (125) 
 
At this point of the study, a modification of the piperazine central nucleus was designed, 
in order to rigidify the molecule and remove the positive charge associated with the two 
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amine groups, while keeping the opportunity of hydrogen-bond formation. The structure 
of 4-phenylendiamine (123) was chosen as a new scaffold, separated by two methylene 
groups from the two terminal arylsulfonamide groups, in order to maintain the original 
length of compound 12. Different strategies were attempted to obtain one derivative 
with the new central system. 
As shown in scheme 2.14, a first attempt began with the formation of N,N'-bis-(2-
amine-ethyl)-benzene-1,4-diamine 124 as the first intermediate. Subsequent substitution 
of the free amine groups with 4-chlorobenzenesulfonyl chloride was planned to obtain 
compound 125.27-28 
 
 
Scheme 2.14: First synthetic pathway designed for compound 125 
 
The first step was attempted by stirring of 4-phenylendiamine (123) with 2-
bromoethylamine hydrobromide (37) for half of the reaction time in the appropriate 
solvent before adding the base, pyridine or triethylamine. These two attempts to obtain 
intermediate 124, using different base/solvent systems, were unsuccessful. A different 
strategy was therefore planned, starting from intermediate alkyl bromide 38 and trying 
to obtain a double nucleophilic displacement by the two aromatic amine groups of 
compound 123 (scheme 2.15). 
 
 
Scheme 2.15: Second strategy attempted for the synthesis of compound 125 
 
The reaction was first tried by heating under reflux in ethanol and sodium bicarbonate. 
This attempt gave a complex mixture of products that was not possible to purify 
Chapter 2: Piperazines 
 
77 
 
successfully. 
The reaction system was therefore changed, and the reaction was repeated at room 
temperature for 72 h, using triethylamine and THF as base/solvent. Also in this case the 
formation of a complex mixture of products was observed, but after a series of 
chromatographic purifications, which reduced the yield of the reaction to 17%, it was 
possible to isolate desired pure product 125. 
 
2.2.12 Biological evaluation 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))diaryl sulfonamides (100-108, 
111, 116) 
 
 
Compound Ar- EC50(M) CC50(M) EC90(M) SI 
100 3-Chlorophenyl 76.9 >182 173 >2.4 
101 4-tert-Butylphenyl- 4.9 91.5 42.9 18.6 
102 4-Trifluoromethylphenyl 6.5 >162 - >24.9 
103 4-Biphenyl <1.2 4.25 - >3.5 
104 1-Naphthyl >172 >172 >172 - 
105 8-Quinoline 42.5 >182 173 >4.3 
106 1-Thiophene 62 >203 156 >3.3 
107 3-Pyridine >207 >207 >207 - 
108 4-Ethylcarboxyphenyl 56.2 >160 - >2.8 
111 4-Carboxyphenyl >176 >176 - - 
116 2-Chlorophenyl 39.6 >182 >182 >4.6 
 
Table 2.5: activity and cytotoxicity data for compounds 100-108, 111, 116 
 
As can be inferred from table 2.5, the presence of a para-hydrophobic aromatic 
substituent in the original scaffold seems necessary for retention of activity: moving the 
4-chloro group to position 2 and 3 is associated with loss of activity, while the presence 
of a bulkier lipophilic substituent in the para position, such as a tert-butyl in compound 
101 and a trifluoromethyl in compound 102, results in retained activity. The lowest 
EC50 value is reached when a second phenyl group replaced the original 4-chloro 
(compound 103): however, this last modification also shows an increased toxic effect. 
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Replacement of the two phenyl rings with heteroaromatic ones leads to loss of activity, 
and the same effect can be noticed for the substitution of the previous 2-naphthyl group 
(compound 36) with 1-naphthyl: cytotoxicity is reduced in compound 104, but activity 
potential against viral replication is lost as well. 
Trying to mimic the effect of a 4-nitro group (compound 33), a 4-carboxylate function 
was introduced as aromatic substituent (compound 111): with this last modification, 
toxic effect is lost, but the same can be said for antiviral activity. A mild inhibition of 
viral replication is observed for ethyl ester derivative 108, but antiviral potential is 
reduced in comparison with compound 12. 
 
N,N'-(Piperazine-1,4-diylbis(ethane-2,1-diyl))bis(quinoline-8-sulfonamide) 
 
 
Compound EC50(M) CC50(M) EC90(M) SI 
118 >180 >180 >180 - 
 
Table 2.6: activity and cytotoxicity data for compound 118 
 
The same trend shown in the three-carbon linker series, where replacement of the 2-
naphthyl group with a 1-naphthyl or a 8-quinoline substituent led to loss of activity, can 
be observed in the two-carbon linker series: activity previously found for compound 53 
is lost when a 8-quinoline moiety replaces the 2-naphthyl. 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-chlorobenzamide) (122) 
 
 
Compound EC50(M) CC50(M) EC90(M) SI 
122 >209 >209 >209 - 
 
Table 2.7: activity and cytotoxicity data for compound 122 
 
Along with the presence of a 4-hydrophobic aromatic substituent, the two sulfonamide 
groups seem to play an essential role for antiviral activity: their replacement with an 
amide group in compound 122 is associated with a dramatic loss of antiviral potential. 
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N,N’-(2,2’-(1,4-Phenylenebis(azanediyl))bis(ethane-2,1-diyl))bis(4-chlorobenzene 
sulfonamide) (124) 
 
 
Compound EC50(M) CC50(M) EC90(M) SI 
124 12.1 22 - 1.8 
 
Table 2.8: activity and cytotoxicity data for compound 124 
 
Biological results for compound 124, with which the structure of compound 12 was 
rigidified and the positive charges removed with the introduction of a new 4-
phenylendiamine central scaffold, show that this modification does not seem to be 
successful for cytotoxicity reasons: even though activity is retained from an EC50 point 
of view, compound 124 is mainly associated with an adverse effect against cells. 
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2.3 Synthesis of unsymmetrical piperazines 
 
In order to explore the importance of symmetry in the original scaffold, three series of 
new derivatives were designed to introduce small asymmetry elements in the structure, 
without dramatically modifying its overall length or chemical nature, and considering 
the biological results obtained for the previous series of derivatives. 
In all new compounds designed, the presence of two aromatic sulfonamide groups was 
to be maintained, along with a para hydrophobic substituent in at least one phenyl ring. 
Another element to be kept was the central piperazine nucleus and one three-carbon 
linker. 
 
2.3.1 Unsymmetrical N-{3-[4-(3-arylsulfonylamine-propyl)-piperazin-1-yl]-
propyl}-arylsulfonamides (126-138) 
 
A first series of unsymmetrical derivatives was designed to maintain the original 
scaffold while introducing different para hydrophobic substituents in the two aromatic 
rings, combining together the most successful substitutions previously obtained (4-
chloro, 4-methyl, 4-tert-butyl and 4-trifluoromethyl), along with the unsubstituted 
phenyl moiety and the biphenyl one (for which the lowest EC50 value had been found, 
but was also associated with a toxic effect in compound 103). 
To achieve the desired results, the two amine groups of the central piperazine core had 
to be functionalised with two different N-(3-bromopropyl)arylsulfonamide 
intermediates. 
Starting from alkyl bromide intermediates 22-24, 92-94, a first strategy was attempted 
to obtain the final products in a one-pot manner, as shown in scheme 2.16. 
 
 
 
Scheme 2.16: First strategy attempted for the synthesis of compounds 126-138. Conditions: 1. NaHCO3, 
EtOH, reflux, o.n.; 2. Reflux, 24h  
 
In this attempt, the first alkyl bromide (22) was refluxed in ethanol o.n. with an 
equimolar quantity of piperazine, in the presence of NaHCO3, in order to allow the 
Chapter 2: Piperazines 
 
81 
 
formation of the product of the nucleophilic displacement by one of piperazine amine 
groups, monitoring the presence of this intermediate by TLC. The second alkyl bromide 
(23) was subsequently added in small excess to the reaction mixture, leaving it stirring 
under reflux for a further 24 h. Formation of the desired product 126 was confirmed by 
both NMR and MS experiments, but it was not possible to purify, due to the 
simultaneous formation of both the two symmetrical products, confirmed by MS. 
Several attempts were made in terms of molar ratio of the starting materials and reaction 
conditions, in order to enhance the formation of the unsymmetrical product, but it was 
not possible to purify it by either chromatographic techniques or re-crystallisation. 
In order to overcome purification difficulties, it was decided to first isolate the pure 
products of monosubstitution on the level of piperazine, and then react these 
intermediates with the second alkyl bromide, thus obtaining unsymmetrical products 
126-138 after chromatographic purification (scheme 2.17). 
Chapter 2: Piperazines 
 
82 
 
 
Alkyl bromide 1 R1 Mono-intermediate Yield % Alkyl bromide 2 R2 Product Yield % 
22 -Cl 139 56 23 -H 126 68 
22 -Cl 139 - 24 -Me 127 86 
22 -Cl 139 - 92 -tBu 128 60 
22 -Cl 139 - 93 -CF3 129 85 
22 -Cl 139 - 94 -Ph 130 71 
92 -tBu 142 71 23 -H 131 54 
92 -tBu 142 - 24 -Me 132 83 
92 -tBu 142 - 93 -CF3 133 70 
92 -tBu 142 - 94 -Ph 134 58 
24 -Me 141 59 23 -H 135 52 
24 -Me 141 - 94 -Ph 136 67 
94 -Ph 143 41 23 -H 137 71 
23 -H 140 71 93 CF3 138 50 
 
Scheme 2.17: Final pathway for the synthesis of compounds 126-138 
 
Synthesis of N-(3-piperazin-1-yl-propyl)-arylsulfonamides (139-143) 
Pure mono-substituted piperazine intermediates 139-143 were obtained with a 
nucleophilic displacement by one of the piperazine amine groups on the bromide 
leaving group. In order to reduce the formation of double substitution products, which 
was always noticed with different molar ratios and reaction systems attempted, the 
starting alkyl bromide was treated with a large excess of piperazine, and the mixture 
was heated at reflux in ethanol for 24 h. Pure intermediates were isolated by flash 
column chromatography before being used for the final step. 
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Synthesis of N-{3-[4-(3-arylsulfonylamine-propyl)-piperazin-1-yl]-propyl}-
arylsulfonamides (126-138) 
Final unsymmetrical products 126-138 were prepared by treating mono-substituted 
intermediates 139-143 with a small excess of the second alkyl bromide, in order to 
obtain a further nucleophilic displacement by the piperazine secondary amine while 
refluxing the mixture in ethanol for 24 h, in the presence of NaHCO3, added to 
neutralise the hydrobromic acid formed. 
 
2.3.2 Unsymmetrical N-(3-(4-(2-(arylsulfonamide)ethyl)piperazin-1yl)propyl)aryl 
sulfonamides (144-146) 
 
A second small series of unsymmetrical derivatives was designed to maintain the same 
para hydrophobic substituent in the two aromatic rings, while reducing the length of 
one of the two linkers from three to two methylene groups. According to biological 
results obtained for the previous series of compounds, it was chosen to synthesise 
corresponding derivatives with a 4-chloro and a 4-tert-butyl substituent respectively, 
along with the unsubstituted phenyl derivative. 
The synthetic strategy applied was the same designed for compounds 126-138: final 
products 144-146 were obtained by reacting mono-substituted intermediates 139, 140, 
142 with N-(2-bromoethyl)arylsulfonamides 38, 39, 147, as shown in scheme 2.18. 
 
 
Ethyl bromide Mono-intermediate R Product Yield % 
38 139 -Cl 144 72 
39 140 -H 145 47 
147 142 -tBu 146 53 
 
Scheme 2.18: Synthetic pathway for compounds 144-146 
 
The previous system NaHCO3/ethanol under reflux conditions was used to obtain final 
products 144-146 from mono-substituted intermediates 139, 140 and 142, reacting them 
with N-(2-bromoethyl)arylsulfonamides in order to displace the bromide leaving group 
with the secondary amine group of piperazine. N-(2-Bromoethyl)-4-(tert-butyl) 
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benzenesulfonamide 147 was prepared by reacting 4-tert-butylbenzene sulfonyl 
chloride 83 with 2-bromopropylamine, following the procedure previously applied for 
the synthesis of ethyl bromide intermediates 38-45. 
 
2.3.3 Unsymmetrical N-(3-(4-((arylsulfonamide)propanoyl)piperazin-1-yl)-3-oxo 
propyl)aryl sulfonamides (148-152) 
 
A third and final series of unsymmetrical derivatives was designed to functionalise one 
amine group in the original structure to amide, thus removing one positive charge and 
partially rigidifying the scaffold, while keeping the overall length of the molecule and 
the same hydrophobic substituent in the para position of the two aromatic rings. A 
derivative with an unsubstituted phenyl moiety was chosen as well for preparation, to 
potentially confirm the importance of a 4-hydrophobic substituent for antiviral activity. 
Starting from mono-substituted intermediates 139-143, it was planned to convert the 
piperazine secondary amine group to amide by inserting an oxypropylic spacer in the 
structure, using the scaffold of -alanine (54), following a TBTU-assisted coupling 
reaction (scheme 2.19), as had been done previously for symmetrical compounds 62-68. 
 
 
Propionic acid Mono-intermediate R Product Yield % 
55 139 -Cl 148 46 
56 140 -H 149 37 
57a 141 -Me 150 34 
153 142 -tBu 151 47 
154 143 -Ph 152 47 
 
Scheme 2.19: Pathway for the synthesis of compounds 148-152 
 
Intermediate propanoic acids 153 and 154 were prepared by reacting 4-tert-
butylbenzene sulfonyl chloride 83 and 4-biphenyl sulfonyl chloride 85, respectively, 
with  β-alanine, according to the same procedure previously followed for compounds 55-
61. 
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2.3.4 Biological evaluation 
 
N-{3-[4-(3-Arylsulfonylamine-propyl)-piperazin-1-yl]-propyl}-arylsulfonamides 
 
 
Compound R1 R2 EC50(M) CC50(M) EC90(M) SI 
126 -Cl -H 18.6 81.5 >64.1 4.4 
127 -Cl -CH3 8.7 48.8 36.2 5.6 
128 -Cl -tBu 1.9 8.7 4.9 4.6 
129 -Cl -CF3 10.1 68.7 33.5 6.8 
130 -Cl -Ph 2.1 3.9 - 1.9 
131 -tBu -H 3.8 18.8 - 4.9 
132 -tBu -CH3 3.8 14.3 9.4 3.8 
133 -tBu -CF3 7.4 25.5 13.8 3.4 
134 -tBu -Ph 1.5 4.1 3.1 2.7 
135 -CH3 -H 26.4 138 >66.7 5.2 
136 -CH3 -Ph 2.1 6.1 - 2.9 
137 -Ph -H 2.9 12.1 - 4.2 
138 -H - CF3 11.9 70 - 5.9 
 
Table 2.9: activity and cytotoxicity data for N-{3-[4-(3-arylsulfonylamine-propyl)-piperazin-1-yl]-
propyl}-arylsulfonamides 
 
Biological data for compounds 126-138 suggest that a different para-hydrophobic 
substitution in the two aromatic rings of the original scaffold is tolerated and does not 
decrease viral replication inhibition: the EC50 values for most compounds tested are in 
the range of 1-10 M. Nevertheless, the small modifications carried out on the original 
structures seem to strongly affect cytotoxicity: for all newly synthesised compounds the 
selectivity index is below 10, and an increased toxic effect against cells appears to be 
the most evident trend for this series of compounds. 
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N-(3-(4-(2-(Arylsulfonamide)ethyl)piperazin-1-yl)propyl)arylsulfonamides 
 
 
Compound R EC50(M) CC50(M) EC90(M) SI 
144 -Cl 5.6 32.5 - 5.8 
145 -H 69.2 >214 212 >3.1 
146 -tBu 1.7 5.09 - 3 
 
Table 2.10: activity and cytotoxicity data for N-(3-(4-(2-(arylsulfonamide)ethyl)piperazin-1-
yl)propyl)arylsulfonamides 
 
Except for compound 145, which does not show relevant activity nor cytotoxicity, 
unsymmetrical shortening of one aliphatic linker is associated with a retained antiviral 
effect, suggesting that symmetry is not an essential requirement for activity. 
Nevertheless, also in this second series of unsymmetrical compounds the small 
structural modification seems to be related to an increased cytotoxic effect. 
 
N-(3-(4-(3-(Arylsulfonamide)propanoyl)piperazin-1-yl)-3-oxopropyl)aryl 
sulfonamides 
 
 
Compound R EC50(M) CC50(M) EC90(M) SI 
148 -Cl 8.5 69.1 25.9 8.1 
149 -H >202 >202 >202 - 
150 -Me 64.3 >191 173 3 
151 -tBu 4.1 28 >4.9 6.8 
152 -Ph 3.0 7.52 - 2.5 
 
Table 2.11: activity and cytotoxicity data for N-(3-(4-(3-(arylsulfonamide)propanoyl) piperazin-1-yl)-3-
oxopropyl)arylsulfonamides 
 
Biological results for the final family of unsymmetrical derivatives highlight the same 
trend found for the previous two series of compounds: antiviral potential seems to be 
retained by functionalising one of the piperazine nitrogens to amide, but toxic effect 
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against cells is enhanced, since the selectivity index for all new compounds is below 10. 
The only exception to this trend is again represented by the unsubstituted phenyl- 
derivative, compound 149: as expected, it does not show antiviral activity, confirming 
the essential role played by a para-hydrophobic aromatic group for viral replication 
inhibition, but represents at the same time the unique analogue for which cytotoxic 
effect is not observed. 
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2.4 Conclusions 
 
In the course of this first part of the study, the application of computer-aided techniques 
led to the identification of compound 12, which showed antiviral potential against HCV 
replication in the replicon assay. 
Starting from its structure, a series of modifications was designed to explore the 
potential activity associated with this molecule, and 61 new compounds were 
subsequently synthesised and sent for biological evaluation. The antiviral activity 
originally found for compound 12 was confirmed, and with the evaluation of its 
derivatives it was possible to identify several structural analogues with a retained 
antiviral effect against HCV replication. 
 
 
 
Different structural modifications were explored in order to understand the role of 
aromatic substituents, sulfonamide groups, linker chains, piperazine central nucleus and 
symmetry of the original molecule. Two equal phenyl rings with a hydrophobic 
substituent in the para position are essential for antiviral activity, along with the 
presence of the two sulfonamide groups and the central piperazine ring. The length and 
nature of the two linker chains is also important for activity retention: a three-carbon 
aliphatic linker is required on both sides of the structure, while shortening or elongating 
either one or two of them is associated with loss of activity. The same effect can be 
observed with the functionalization of piperazine amine groups to amide, by inserting a 
carbonyl group in the terminal methylene group of the linker either by one side of the 
structure or both. Replacement of the piperazine central ring with the ones of 
phenylendiamine or piperidine is associated with loss of activity. The overall symmetry 
of the structure plays as well an important role for activity retention: the insertion of 
small asymmetry elements in the structure has a negative impact on the cytotoxicity, 
and most unsymmetrical derivatives prepared show low values of CC50 and SI. 
Even if a clear trend was identified for the antiviral potential of this family of 
compounds, the modifications attempted so far did not lead to a significant 
improvement in terms of activity. For this reason, a further modification of the structure 
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of compound 12 was planned: a ligand-based in silico comparative analysis against 
known symmetrical inhibitors of the HCV NS3 helicase was performed, in order to 
replace and expand the central piperazine linker while maintaining the two sulfonamide 
groups and the symmetry of the molecule. 
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3.1 Ligand-based optimisation of compound 12 
 
With the aim to further modify the structure of compound 12, its symmetrical scaffold 
was the object of a computer-based comparative analysis against the structures of 
known symmetrical HCV NS3 helicase inhibitors, in order to evaluate possible 
similarities in their chemical features. 
Symmetrical known inhibitors considered are shown in figure 3.1. 
 
 
 
Figure 3.1: Chemical structures and inhibitory activities of known symmetrical inhibitors considered1,2 
 
3.1.1 Flexible alignment of compound 12 and known symmetrical inhibitors 
 
In order to identify a common structural pattern between the known inhibitors and 
compound 12, the Flexible Alignment application available in MOE 2010.10 was used:3 
its main function is to flexibly align (or superimpose) small molecules by maximising 
steric and feature overlap while minimising internal ligand strain.4 
For each alignment performed, the average internal strain energy U, the total mutual 
similarity score F (the lower value it assumes, the more similar two structures appear to 
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be), and the value of the objective function S (corresponding to the sum of U and F 
values for a given alignment, the lower the better) are evaluated. Alignments with a low 
S value usually correspond to the best alignments. Nevertheless, since the application 
balances intramolecular strain forces and intermolecular pharmacophoric features, 
pharmacophoric forces can overpower internal strain energies in a molecular system, 
giving an alignment with large similarity scores, associated with large positive dU 
values. A good alignment should present a dU value lower than 1 kcal/mol. 
Once flexibly aligned the structure of compound 12 (in pink) to the ones of the known 
symmetrical inhibitors (in green), alignments with a dU value up to 3 kcal/mol were 
analysed, in order to evaluate potential structural overlapping that could be achieved by 
chemically modifying compound 12 (figures 3.2-3.9). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Aligned compound 12 and DB2 Figure 3.3: Aligned compound 12 and (BIP)2B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Aligned compounds 12 and 4  Figure 3.5: Aligned compounds 12 and 5a 
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 Alignment compound 11-compound 5b  Alignment comp 
 
 
 
 
 
 
 
 
 
Figure 3.6: Aligned compounds 12 and 5b  Figure 3.7: Aligned compounds 12 and 5d 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Aligned compounds 12 and 5e  Figure 3.9: Aligned compounds 12 and 6 
 
From the alignment results, the structure of compound 12 appears to be too short to 
allow a good spatial superimposition with the known inhibitors, but a common 
overlapping feature can be identified: the aromatic sulfonamide group of compound 12 
shows good superimposition with the benzimidazole ring of the known inhibitors, in 
particular with its NH group, present in most of the structures analysed. 
This overlapping feature was taken as the starting point to modify the scaffold of 
compound 12. 
 
3.1.2 Design of new derivatives of compound 12 
 
The structures of four inhibitors, BD2, (BIP)2B, compounds 4 and 5a, were chosen as 
reference scaffolds for the optimisation of compound 12. New derivatives were 
designed with the aim to maintain the two equal aromatic sulfonamide groups, while 
varying the linker between them, according to the evaluation of the conformational 
overlap with the corresponding known inhibitor. Both structures analysed in each pair 
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(reference known inhibitor and newly designed derivative) were kept as flexible in 
MOE’s  Flexible  Alignment, as had previously been done for compound 12. 
Trying to combine the structures of compound 12 and DB2 in order for the sulfonamide 
groups to better overlap with the internal benzimidazole cycles, three new scaffolds 
were designed and analysed for their alignment with the reference inhibitor. Their 
structures and alignments are shown in table 3.1. 
 
 
 
 
 
 
 
 
Compound 155: dU= 0 kcal/mol 
 
 
 
 
 
 
Compound 156: dU= 4 kcal/mol 
 
 
 
 
Compound 157: dU= 7 kcal/mol 
 
 
Table 3.1: Structures and alignment results of designed compounds 155-157 
 
All three new derivatives present an improved overlapping with the known inhibitor 
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DB2, with the sulfonamide groups superimposing well with the internal benzimidazole 
portions of the reference compound. Among them, the scaffold of compound 155 was 
chosen to be further developed, since it corresponds to the only alignment with a dU 
value lower than 1 kcal/mol. 
The same approach was applied for the design of new derivatives starting from the 
structural combination of compound 12 and (BIP)2B, compound 4 and 5a. 
 
 
 
 
 
 
 
 
Compound 158: dU= 0 kcal/mol 
 
 
 
 
Compound 159: dU= 0 kcal/mol 
 
 
 
Table 3.2: Structures and alignment results of designed compounds 158, 159 
 
Both new derivatives present a dU value equal to zero kcal/mol, but only the scaffold of 
compound 158 was chosen for further evaluation, since it was considered more 
accessible from a synthetic point of view. 
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Compound 160: dU= 0 kcal/mol 
 
 
 
 
Compound 161: dU= 5.1 kcal/mol 
 
 
 
Table 3.3: Structures and alignment results of designed compounds 160, 161 
 
Between the two structures designed to achieve a good overlapping with compound 4, 
only compound 160 shows a dU <1 kcal/mol: its structure was selected for further 
developement. 
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Compound 162: dU= 0 kcal/mol  
 
 
 
 
Compound 163: dU= 0.7 kcal/mol 
 
 
 
Table 3.4: Structures and alignment results of designed compounds 162, 163 
 
Designed to achieve a better overlapping with compound 5a, both compounds 162 and 
163 are associated with dU values <1 kcal/mol. Compound 162 was more accessible 
synthetically, and its scaffold was chosen to be further developed. 
In order to better validate the selected scaffolds of compounds 155, 158, 161 and 162, 
their structures were analysed with a molecular docking study on the enzyme open 
conformation. The GlideSP docking algorithm was chosen for this purpose, using a 16 
Å binding site grid derived from the 3KQH crystal structure.5 
All the structures analysed demonstrate a good fitting of the RNA binding pocket, with 
a good spatial occupation of the region at the interface of the three main domains, and 
all show probable hydrophobic and hydrogen-bond interactions with several target 
residues, including Trp501, Arg393, Glu493, Thr411, Ser287, Asn556 and Phe557 
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(figure 3.10 a-d). 
 
a)                                                                                    b)                                                       
 
c)                                                                          d) 
 
 
Figure 3.10 a-d: Predicted binding mode for compounds 155, 158, 160, 162, respectively 
 
As their potential as helicase inhibitors was confirmed by a structure-based docking 
analysis, all four new scaffolds were chosen for synthetic development. 
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3.2 Synthesis of phenylendiamine- and ethylendiamine-based 
structures 
 
The four new symmetrical scaffolds were synthesised according to two different 
procedures, a general one for compounds 158, 160 and 162, and a second one for 
compound 155. Moreover, in the case of molecular structures 158, 160 and 162, 
different substituents in the para position of the sulfonamide aromatic rings were 
explored, in order to follow the initial SAR data obtained for compound 12, where a 
hydrophobic group in this position had proven to be important for antiviral activity. In 
particular, a 4-chloro, 4-methyl and eventually an unsubstituted aromatic ring were 
chosen for a first series of new compounds. 
The common synthetic pathway applied for the scaffolds of compounds 158, 160 and 
162 is shown in scheme 3.1. 
 
 
 
Scheme 3.1: Common synthetic strategy applied for compounds 158, 170, 160, 171-172, 162, 173-174 
 
Synthesis of N-(4-amino-phenyl)-arylsulfonamides (164-166) 
Two possible strategies were evaluated for the synthesis of common intermediates 164-
166. One option could have been to first react arylsulfonyl chlorides with 4-nitroaniline, 
in order to obtain the product of nucleophilic displacement of the chloride leaving group 
by the free aromatic amino group, and subsequently reduce the nitro function to amine 
to isolate the desired intermediate. Comparing yields and reaction times of reported 
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procedures, it was decided to follow a one-step synthetic pathway, and react the starting 
sulfonyl chloride with an excess of 4-phenylendiamine (123), in anhydrous conditions, 
using DIPEA to neutralise the hydrochloric acid formed.6 The desired intermediates, 
product of the monosubstitution of one free amino group of compound 124, were then 
purified by flash column chromatography. 
 
3.2.1 N,N'-Bis-(4-arylsulfonylamino-phenyl)-terephthalamides (158, 170) 
 
A first small series of two compounds was prepared by reacting intermediates 164 and 
165 with terephthaloyl chloride (167), in order to obtain a double nucleophilic 
displacement of the two chloride leaving groups by the free aromatic amine group of the 
intermediates (scheme 3.2). 
 
 
Intermediate R Yield % Product Yield % 
164 -Cl 75 158 36 
165 -Me 73 170 69 
 
Scheme 3.2: Final step for the synthesis of compounds 158, 170 
 
3.2.2 N,N'-Bis-(4-arylsulfonylamino-phenyl)-fumaramides (160, 171-172) 
 
Three new derivatives were obtained with the scaffold of compound 160 by reacting an 
excess of intermediates 164-165 with fumaryl chloride (168) (scheme 3.3). 
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Intermediate R Yield % Product Yield % 
164 -Cl - 160 61 
165 -Me - 171 47 
166 -H 77 172 39 
 
Scheme 3.3: Final step for the synthesis of compounds 160, 171-172 
 
3.2.3 N,N'-Bis-(4-(arylsulfonamido)phenyl)-succinamides (162, 173-174) 
 
The same strategy applied for the previous compounds was followed to obtain a small 
series of new derivatives with the structural scaffold of compound 162, by reacting an 
excess of intermediates 164-166 with  succinyl chloride (169) (scheme 3.4). 
 
 
Intermediate R Product Yield % 
164 -Cl 162 48 
165 -Me 174 36 
166 -H 174 64 
 
Scheme 3.4: Final step for the synthesis of compounds 162, 173-174 
 
3.2.4 N,N'-Bis-(2-(4-chlorophenylsulfonamido)ethyl)-succinamide (155) 
 
Compound 155 was obtained following the previous two-step synthetic strategy, with 
the only difference being the use of an excess of 1,2-diaminoethane 175 in the first 
reaction step (scheme 3.5). 
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Scheme 3.5: Synthetic pathway for compound 155 
 
Synthesis of N-(2-aminoethyl)-4-chlorobenzenesulfonamide (176) 
Intermediate 176 was prepared by reacting 4-chlorobenzenesulfonyl chloride (13) with 
an excess of ethylendiamine 175, in order to achieve a single nucleophilic displacement 
on the chloride leaving group.  
 
Synthesis of N,N'-bis-(2-(4-chlorophenylsulfonamido)ethyl)-succinamide (155) 
Final compound 155 was obtained with a double nucleophilic displacement of the two 
leaving groups of succinyl chloride by the free amine group of intermediate 176. 
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3.2.5 Biological evaluation 
 
All new derivatives were evaluated for their potential inhibition of HCV replication in 
the subgenomic replicon assay,7 as well as for their toxicity in the cytostatic assay. 
Their biological data are shown in tables 3.5-3.9. 
 
N,N'-Bis-(4-arylsulfonylamino-phenyl)-fumaramides 
 
 
Compound R EC50(M) CC50(M) EC90(M) SI 
158 -Cl 140.9 >143.8 >143.8 >1 
170 -Me 25.2 >152.7 >152.7 >6 
 
Table 3.5: Activity and cytotoxicity data for compounds 158, 170 
 
N,N'-Bis-(4-arylsulfonylamino-phenyl)-fumaramides 
 
 
Compound R EC50(M) CC50(M) EC90(M) SI 
160 -Cl >154.9 >154.9 >154.9 - 
171 -Me 42 >82.7 - >2 
172 -H >173.4 >173.4 >173.4 - 
 
Table 3.6: Activity and cytotoxicity data for N,N'-bis-(4-arylsulfonylamino-phenyl)-fumaramides 
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N,N'-Bis-(4-(arylsulfonamido)phenyl)-succinamides 
 
 
Compound R EC50(M) CC50(M) EC90(M) SI 
162 -Cl 10.8 >154.4 140.7 >14.3 
173 -Me 52.4 >164.8 >164.8 >3.1 
174 -H 31.6 172.8 - 5.5 
 
Table 3.7: Activity and cytotoxicity data for N-(3-(4-(2-(arylsulfonamido)ethyl)piperazin-1-
yl)propyl)arylsulfonamides 
 
N,N'-Bis-(2-(4-chlorophenylsulfonamido)ethyl)-succinamide 
 
 
Compound EC50(M) CC50(M) EC90(M) SI 
155 >181.3 >181.3 - - 
 
Table 3.8: Activity and cytotoxicity data for compound 155 
 
Among the new scaffolds designed to optimise compound 12, compound 162 is 
associated with a positive antiviral effect against HCV replication, with an EC50 value 
that indicates retention of activity compared to compound 12. The activity pattern of its 
analogues 173 and 174 seems to indicate the same effect for a para-hydrophobic 
substituent in the sulfonamide aromatic ring previously seen for the first structural 
analogues of compound 12, where antiviral activity was positively correlated with an 
increased hydrophobic group in this position. 
In order to better investigate the antiviral potential of compound 162, its scaffold was 
chosen to be further modified. 
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3.2.6 Synthesis of a second series of N,N'-bis-(4-(arylsulfonamido)phenyl)-
succinamides 
 
The first modification designed for compound 162 was the substitution of the aromatic 
sulfonamide groups, in order to explore different hydrophobic groups in the para 
position and increase their occupational volume inserting a condensed aromatic ring. 
The synthetic pathway followed for this new series of compounds was the same 
previously carried out for 162: starting from the appropriate sulfonyl chloride (83-87), 
N-(4-amino-phenyl)-arylsulfonamides 177-181 were obtained in the first reaction step, 
and then reacted in excess with succinyl chloride (169) to give final products 182-186. 
 
 
Intermediate Ar Yield % Product Yield % 
177 4-tert-butylphenyl 82 182 39 
178 4-trifluoromethylphenyl 93 183 42 
179 4-biphenyl 69 184 44 
180 1-naphthyl 84 185 53 
181 8-quinoline 53 186 35 
 
Scheme 3.6: Synthetic pathway for compounds 182-186 
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3.2.7  Biological evaluation of compounds 182-186 
 
The five new N,N'-bis-(4-(arylsulfonamido)phenyl)-succinamide derivatives were 
evaluated for their antiviral potential and cytotoxicity in the subgenomic replicon assay 
(table 3.9).7 
 
 
Compound Ar EC50(M) CC50(M) EC90(M) SI 
182 4-tert-butylphenyl 14.6 >144.7 34.1 >10.7 
183 4-trifluoromethylphenyl 86.5 >139.9 >139.9 >1.6 
184 4-biphenyl 12.2 >136.8 55 >11.2 
185 1-naphthalene 32.9 >147.3 >147.3 >4.5 
186 8-quinoline >146.9 >146.9 >146.9 - 
 
Table 2.20: Biological data for compounds 132-136 
 
As can be inferred from the data above, the most successful modification corresponds to 
compound 182, where the presence of a tert-butyl substituent in the para position of the 
phenylsulfonamide groups is associated with activity retention and to an improved EC90 
value. A similar trend is found for compound 184, where the presence of a 
biphenylsulfonamide group is still associated with activity retention. The other three 
modifications attempted are related to loss of activity, thus confirming the importance 
of a para-hydrophobic substituent in the molecule, but suggesting a negative influence 
of a bicyclic or heterocyclic aromatic ring.  
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3.3 Conclusions 
 
In silico comparative analyses of compound 12 against the structures of known 
symmetrical inhibitors of the HCV NS3 helicase led to the design of four new structural 
scaffolds, derived to maximise the functional overlapping shared between compound 12 
and some of the known active molecules. 
 
 
 
The newly designed compounds show the presence of the two equal phenyl-
sulfonamide groups of compound 12, while the linker was modified to achieve a better 
structural superimposition with the known symmetrical inhibitors. For each new 
structural family a small series of new derivatives was synthesised and sent for 
biological evaluation in the HCV replicon assay. One of these families showed antiviral 
activity in the range of the low micromolar concentration, and was therefore chosen for 
further development. Data found so far suggest that antiviral activity is associated with 
the presence of two equal phenylendiamine rings in the linker, connected by a central 
succinamide group. As had been found for compound 12, a hydrophobic substituent in 
the para position of the two terminal phenyl groups is required for activity retention. 
Due to the positive results initially obtained, a second series of new compounds was 
designed to explore different aromatic rings on the terminal part of the structure. Two 
new succinamide analogues, compound 182 and 184, with a 4-tert-butylphenyl and a 4-
biphenyl substituent on the two sulfonamide groups, respectively, were found to inhibit 
HCV replication with EC50 values in the range of the low M. As had happened for the 
previous series of derivatives of compound 12, a significant improvement in terms of 
antiviral activity was not achieved with the modifications attempted so far. With the aim 
to find more potent inhibitors of the HCV replication with different structural scaffolds, 
a new structure-based virtual screening was planned and carried out. 
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4.1 Structure-based virtual screening on the enzyme open 
conformation 
 
The structure of the enzyme in the open-conformation, high-affinity complex with the 
single-stranded oligonucleotide substrate was considered for a structure-based 
evaluation of potential inhibitors of RNA binding. The 3KQH crystal structure 
(resolution 2.4 Å) was used for all analyses performed.1 
In the high-affinity complex of the enzyme, domain 2 is shifted outwards from domain 
1, and the substrate is located in a wide binding cleft within the interface of the three 
domains. In order to select a restricted region within this large RNA-binding space, the 
five structures corresponding to the three main steps of DNA unwinding (PDB IDs 
3KQH, 3KQK, 3KQL, 3KQN, 3KQU) were compared to one another:1 the aim was to 
identify a relatively fixed region, in which protein residues conserve their relative 
positions more than the other ones surrounding. A subsite with similar characteristic 
could represent a good target to inhibit substrate binding. 
The sequences of the five structures were aligned and the residues defining the known 
RNA binding pocket were selected and evaluated with the RMSD function available in 
MOE 2010.10.2 By measuring the Root Mean Square Deviation of the relative positions 
among different protein conformations, it was possible to identify the positional shift of 
each residue from its starting position, defined as the one found in the 3KQH crystal 
structure. Following this analysis, significant positional changes were observed for most 
selected residues, with the main deviations found in domain 2. 
Due to the overall elevate of RMSD values, it was decided to focus attention on 
residues with RMSD values below 3 Å with respect to all the proteins (in blue in figure 
4.1), and to consider as fixed regions including residues with RMSD values below 2 Å 
(in pink in figure 4.1). 
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Figure 4.1: Residues with low RMSD values (<3 Å in blue, < 2Å in pink) shown within the 3KQH RNA 
binding cleft 
 
The residues with the lowest RMSD were identified in Glu493, Asn556 and Phe557, 
located in the middle of the three domains: this region, and in particular a possible 
interaction with Glu493, that is essential for enzymatic activity, or the close Asp296, 
was chosen as the target for the identification of potential inhibitors. 
A new pharmacophoric model was built to pre-screen the SPECS database;3 based on 
the mutagenesis studies reported for HCV NS3 helicase,4 the residues essential for 
enzymatic activity located within the known RNA binding pocket were identified: 
Thr269, Arg393, Thr411, Glu493 and Trp501 (figure 4.2). 
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Figure 4.2: Essential residues for helicase activity within the DNA binding cleft  
 
These residues were considered for the pharmacophoric filter, along with the occupation 
of the region in the middle of the three domains, included in the query as a polar 
interaction with either Glu493 (F2:Don in figure 4.3) or Asn556 (F3:Don), none of 
which was set as essential. Other three features were added to target Trp501 
(F1:Aro|Hyd), Arg393 (F5:Acc|Ani), both required as essential, and Thr411 
(F4:Ani|Acc). 
 
 
 
Figure 4.3: Pharmacophoric model based on the 3KQH crystal structure 
 
Once added the exclusion volumes corresponding to the protein surface, a partial match 
of four was required, and approximately 3000 matching hits were selected for the 
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docking phase. 
In the first virtual screening on the 3KQN structure (Chapter 2.1), the Glide docking 
program had shown the best potential in locating the greatest number of compounds 
within the RNA binding cleft, while with Plants and FlexX many structures had to be 
discarded due to their placement in different subsites. For this reason, it was decided to 
use the only Glide docking algorithm, run in the standard precision SP mode.5 The 
output poses were re-scored with the Glide extra precision scoring function XP, that has 
been proven to increase effective binding prediction potential after SP docking,6 Plants 
ChemPLP and FlexX scoring functions,7-8 which were combined in a consensus scoring 
procedure (Chapter 2.1). The 25% best performing structures were visually inspected to 
identify which ones could best interact with the selected residues and fit the target 
defined by Glu493 (figure 4.4). 
 
 
 
Figure 4.4: Ideal binding mode considered within the 3KQH target site 
 
Twenty-one new compounds were purchased from the SPECS company and tested in 
the HCV replicon assay (Appendix I). One of them, compound 187 (figure 4.5), showed 
antiviral activity against HCV replication, with an EC50 value lower than 1M. 
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Figure 4.5: Structure and predicted binding mode for compound 187 
 
As shown in figure 4.5, the predicted binding mode found for compound 187 suggests a 
good spatial occupation of the target site, with the cyclohexyl portion of the molecule in 
close proximity to Trp501, the pyrimidine ring filling the space defined by Glu493 and 
Asn556, and the opportunity of hydrogen-bond   formation   between   the   2’-
hydroxyphenyl group and Arg393 lateral chain. 
Given its potential to inhibit HCV replication, compound 187 was chosen for further 
investigation. 
Moreover, a structural parallelism could be observed between compound 187 and 
previously published helicase inhibitors QU663 and compound 7 (figure 4.6).9 
 
 
 
Figure 4.6: Chemical structure of QU663 and compound 7 
 
Occupational volume and predicted binding mode for compound 187 were found to be 
similar to the ones of the known inhibitors, further confirming the potential of this hit 
molecule as a selective NS3 helicase inhibitor. 
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4.2 Synthesis of tetrahydrobenzo[b]thienopyrimidines 
 
Compound 187 presents a central thieno-pyrimidinic nucleus, which is condensed with 
a tetrahydrobenzene system in position 4 and 5 of the thiophene ring, and functionalised 
with a 2,5-dihydroxyphenyl-ethylidene moiety via a hydrazone linker in position 4 of 
pyrimidine (figure 4.7). 
 
 
 
Figure 4.7: Structural features of compound 187 
 
Compound 187 was resynthesised, in order to confirm the activity values found for the 
batch bought from the SPECS company, and a first series of new derivatives was 
prepared to explore different aromatic substituents on the phenylethylidene portion. 
 
4.2.1 (5,6,7,8-Tetrahydro-benzo [4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazones 
(187, 215-234) 
 
Following reported procedures for the preparation of tetrahydrobenzothieno-
pyrimidines, the synthetic pathway shown in scheme 4.1 was planned to resynthesise 
compound 187 and prepare a first series of new analogues.10-11 
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Scheme 4.1: Synthetic pathway for the synthesis of compounds 187, 214-234 
 
The planned strategy started with the preparation of 2-amino-4,5,6,7-tetrahydrobenzo[b] 
thienophene-3-carboxylic acid ethyl ester (190) through a Gewald reaction, followed by 
treatment of 190 with an excess of formamide to obtain cyclic pyrimidinone 191, that 
was subsequently chlorinated using phosphorus oxychloride to give compound 192. 
Aromatic nucleophilic displacement of the chloride leaving group with aqueous 
hydrazine was carried out to form aromatic hydrazine derivative 193, which was finally 
used to obtain a Schiff base with ketones 194-203 and aldehydes 204-214, giving 
desired compound 187 and its analogues 215-234. 
In order to obtain a preliminary SAR for the scaffold of compound 187, it was decided 
to react final intermediate 193 with readily available, differently substituted 
benzaldehydes and acetophenones, changing only the last step in the reaction scheme to 
prepare several new derivatives. 
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The first four common steps of the synthetic route needed to be optimised, due to a 
significant loss in yield subsequent to the scale up of the starting materials, to allow the 
use of fourth intermediate 193 for the formation of multiple final products. 
 
Synthesis of ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thienophene-3-carboxylate 
(190)12-13 
A widely used method to prepare poly-substituted 2-aminothiopenes is the Gewald 
reaction, which involves the condensation of a ketone or aldehyde with an -cyanoester 
in the presence of elemental sulphur and a base. The postulated mechanism for this 
reaction is shown in scheme 4.2.14-16 
 
 
Scheme 4.2: Postulated mechanism for the formation of 2-amino substituted thiophenes 
 
The first step for the formation of the thiophene ring is a Knoevenagel condensation 
between the ketone and the -cyanoester, to produce a stable intermediate to which 
elemental sulphur is added by a mechanism which is still unclear. The intermediate 
formed is postulated to undergo cyclisation and tautomerisation to give the final poly-
substituted 2-aminothiophene. 
Compound 190 was obtained by heating cyclohexanone, ethyl cyanoacetate and sulphur 
at reflux in absolute ethanol, after adding triethylamine. 
By changing the reaction time from 16 to 24 h and the purification procedure from flash 
column chromatography to recrystallisation from EtOH/H2O, it was possible to improve 
the yield of this step from 70 to 85%. 
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Synthesis of 5,6,7,8-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyrimidin-4-one (191) 
Thienopyrimidinones and their derivatives can be obtained by reaction between 2-
amino-3-ethoxycarbonylthiophenes and amides, through the formation of intermediate 
amidines, that undergo an intramolecular cyclisation to give thienopyrimidinones.17 
Along with compound 190, formamide was used in excess, as reagent and solvent. The 
yield was improved from 50 to 93% by refluxing the mixture for 8 h instead of 2 h, and 
purifying the product by recrystallisation from EtOH/H2O. 
 
Synthesis of 4-chloro-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine (192) 
Following reported procedures, pyrimidone derivative 191 was chlorinated by refluxing 
with an excess of the chlorinating agent, phosphoryl chloride, to afford the formation of 
the thienopyrimidine system in compound 192.12 The yield of this third reaction step 
was optimised from 20 to 79% by refluxing the mixture for 8 h instead of 3 h, and 
changing the purification method from recrystallisation from MeOH to flash column 
chromatography. 
 
Synthesis of (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine 
(193) 
Hydrazine derivative 193 was prepared through a nucleophilic aromatic substitution of 
the chloride leaving group on the pyrimidine system, by reacting compound 192 with an 
excess of hydrazine monohydrate, and refluxing the mixture in methanol. Desired 
product was obtained with an improved yield, from 70 to 89%, by refluxing the reaction 
for 8 h instead of 3 h and changing the recrystallisation system from MeOH to 
EtOH/H2O. 
 
Synthesis of (5,6,7,8-tetrahydro-benzo [4,5]thieno[2,3 d]pyrimidin-4-yl)-hydrazones 
(187, 215-234) 
A first series of twenty new derivatives was readily prepared, along with compound 
187, through the formation of a Schiff base between compound 193 and differently 
substituted acetophenones (194-203) and benzaldehydes (204-214), by refluxing the 
two starting materials in ethanol for 24 h. 
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Aldehyde/ketone Product R1 R2 Yield % 
194 187 Me 2,5-OH 66 
195 215 Me H 62 
196 216 Me 4-OMe 28 
197 217 Me 3,4,5-OMe 74 
198 218 Me 3-F, 4-OMe 75 
199 219 Me 3,4-O-CH2-O 27 
200 220 Me 4-NO2 76 
201 221 Me 4-C6H11 76 
202 222 Me 2-OH 98 
203 223 Me 3-OH 99 
204 224 H H 46 
205 225 H 4-OMe 75 
206 226 H 2-OMe 75 
207 227 H 3-OMe 57 
208 228 H 3,4,5-OMe 91 
209 229 H 3,4-OEt 77 
210 230 H 4-OH 34 
211 231 H 4-Br 36 
212 232 H 3-Br 65 
213 233 H 4-tBu 61 
214 234 H 4-iPr 38 
 
Scheme 4.3: Synthesis of final compounds 187, 215-234 
 
4.2.2 Biological evaluation of compounds 187, 215-234 
 
Before proceeding with further modifications on the structure of compound 187, the 
first series of tetrahydrobenzo[b]thienopyrimidines prepared was evaluated for potential 
antiviral activity in the HCV replicon assay,18 as well as for associated cytotoxicity, in 
order to obtain a rational criterion for further studies. 
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Compound R1 R2 EC50(M) CC50(M) EC90(M) SI 
193 - - 23 243 45.1 10.6 
187 Me 2,5-OH <1 >282 135 >282 
215 Me H 33.6 53.4 >310 1.6 
216 Me 4-OMe 17.5 86 >284 4.9 
217 Me 3,4,5-OMe 17 43.5 >242 2.6 
218 Me 3-F, 4-OMe >270 5.9 >270 - 
219 Me 3,4-O-CH2-O 28.5 116 - 4.1 
220 Me 4-NO2 60.8 192 - 3.2 
221 Me 4-C6H11 61.2 235 >309 3.8 
222 Me 2-OH 2.28 154 4.36 67 
223 Me 3-OH 403 >443 >443 >1.1 
224 H H 23.8 41.9 - 1.8 
225 H 4-OMe 26.3 40.4 >295 1.5 
226 H 2-OMe 6.8 45.6 - 6.7 
227 H 3-OMe 21.3 32.9 - 1.5 
228 H 3,4,5-OMe 121 204 - 1.7 
229 H 3,4-OEt >252 >252 >252 - 
230 H 4-OH 24.8 40.6 - 1.6 
231 H 4-Br 15.4 54.7 30 3.6 
232 H 3-Br 8.04 60.2 19.6 7.5 
233 H 4-tBu 7.83 >274 >274 >35.1 
234 H 4-iPr 11.3 178 - 15.8 
 
Table 4.1: Biological data for compounds 187, 215-234 
 
Considering biological results, position and nature of the two hydroxy substituents on 
the phenylethylidene system seem to play an important role for antiviral potential: all 
attempted modifications in compounds 215-234  were associated with loss of activity, 
except for compound 222, where activity improved for the EC90 value. 
Most of the antiviral potential seems to be associated with the hydroxy substitution in 
position 2: compound 223, with the sole 3’-hydroxy group, shows a significant loss of 
activity in comparison to compound 187.  
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As for the phenylidene derivatives 224-234, at a first evaluation the absence of the 
phenylethylidene methyl group seems associated with an increased toxicity against 
cells, showing most of these derivatives low values of CC50 and SI. Activity seems to be 
partially retained only in compound 233, where the hydrophobic substituent in para 
position is associated with a reduced cytotoxicity while a relatively low EC50 value is 
preserved. 
In order to further explore antiviral potential of compounds 187 and 222, three new 
series of derivatives were designed. The first new modification was to study the role of 
the two hydroxy groups and their possible replacement; the second had the purpose of 
modifying the hydrazone linker, known to be poorly stable in aqueous systems, with a 
sulfonyl hydrazide and a hydrazide function, respectively, thus increasing stability in 
water, while maintaining the same length of the original functional group. 
 
4.2.3 Design of a second series of 5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d] 
pyrimidin-4-yl)-hydrazones 
 
Aiming to understand the role of the two hydroxy groups, in particular in  position  2’, a 
second series of N-(1-aryl-ethylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazines was designed, to change the position of the hydroxy 
groups from 2 and 5 to 4 in the phenylethylidene ring, and to replace them with 
methoxy and halogen groups (chlorine and fluorine). 
Moreover, in order to mimic polarity of the original substituents and opportunity of 
hydrogen bond formation, it was planned to replace the phenyl ring with heteroaromatic 
systems, such as pyrazine, 2-pyridine, indole and benzimidazole, by reacting their 
ethanone derivatives with final intermediate 193. The insertion of a pyrazine and 2-
pyridine system in this part of the molecule was also supported by the structural 
similarity observed for compound 187 and helicase inhibitors QU663 and compound 7.9 
Since the presence of a pyrazine or 2-pyridine group had been demonstrated to be 
important for inhibitory activity of the published compounds, these same modifications 
were attempted for compound 187. 
Once synthetically obtained non-commercially available 1-(1H-indol-2-yl)ethanone 
(235) and 1-(1H-benzo[d]imidazol-2-yl)ethanone (236), 14 new derivatives were 
prepared following the same synthetic route previously used, where only the last 
reaction step needed to be changed to obtain different final compounds. 
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In order to understand the function of the phenylethylidene methyl group for antiviral 
activity, it was decided to synthesise 2,5-dihydroxy derivative without this methyl 
function, reacting intermediate 193 with 2,5-dihydroxybenzaldehyde (191), according to 
the usual strategy. 
 
Synthesis of 1-(1H-indol-2-yl)ethanone (235) 
The 2-acetylate form of indole was obtained starting from indole-2-carboxylic acid 
(238), converted to the desired product using methyllithium as a nucleophilic methyl 
source, as shown in scheme 4.4.  
 
 
Scheme 4.4: Synthesis of ethanone 235 
 
Following reported procedures, the reaction was performed at 0°C in anhydrous diethyl 
ether, in order to control the methylating agent high reactivity towards water.19 
 
Synthesis of 1-(1H-benzimidazol-2-yl)-ethanone (236) 
A two-step synthetic approach was followed, as shown in scheme 4.5, to prepare the 
acetylate form in position 2 of benzimidazole. 
 
 
Scheme 4.5: Synthetic strategy for ethanone 236 
 
Following reported procedures, the 2-substituted benzimidazole nucleus was first 
obtained through an acid-catalysed ring condensation between o-phenylenediamine 239 
and D,L-lactic acid, with the formation of a secondary alcohol intermediate, 1-(1H-
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benzimidazol-2-yl)-ethanol (240). The secondary alcoholic function of intermediate 240 
was subsequently oxidised to ketone using potassium dichromate in diluted sulphuric 
acid, following an oxidoreduction reaction.20 
 
Synthesis of (5,6,7,8-tetrahydro-benzo [4,5]thieno[2,3 d]pyrimidin-4-yl)-hydrazones 
(252-265) 
Newly designed compounds 252-265 were prepared according to the previously 
optimised synthetic strategy, by reacting final intermediate 193 in the fifth step with 
ketones 241, 242-251, 235, 236 and 2,5-dihydroxy-benzaldehyde (237). 
 
 
Aldehyde/ketone R Ar Product Yield % 
241 Me 4-hydroxy-phenyl 252 66 
237 H 2,5-dihydroxyphenyl 253 61 
242 Me 2,5-dimethoxyphenyl 254 41 
243 Me 2-methoxyphenyl 255 51 
244 Me 3-methoxyphenyl 256 35 
245 Me 2,5-dichlorophenyl 257 74 
246 Me 2-chlorophenyl 258 94 
247 Me 4-chlorophenyl 259 77 
248 Me 2,5-difluorophenyl 260 45 
249 Me 2-fluorophenyl 261 42 
250 Me pyrazine 262 55 
251 Me 2-pyridine 263 81 
235 Me 2-indole 264 53 
236 Me 2-benzimidazole 265 42 
 
Table 4.2: Newly synthesised compounds 252-265 
 
4.2.4 N'-(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-sulfonyl- 
hydrazides (218-220) 
 
In a first attempt to replace the poorly stable hydrazone linker, it was thought to insert a 
sulfonyl hydrazide group in the molecule, thus maintaining the same length of the 
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original structure. Three derivatives with this linker were obtained by reacting final 
intermediate 193 with sulfonyl chlorides 13, 83, 266.  
Due to the impossibility to preserve the original hydroxy groups in the starting 
arylsulfonyl chlorides, on the basis of the residual activity of compound 233, a 
hydrophobic para substituent was chosen for aryl sulfonyl hydrazides, in particular 4-
tert-butyl and 4-chloro, along with a 2-pyridine system, in an attempt to reproduce 
polarity associated with the 2’-hydroxy group. 
The synthetic strategy applied is shown in scheme 4.6. 
 
 
Aryl sulfonyl chloride Ar Product Yield % 
83 4-tert-butylphenyl 267 38 
13 4-chlorophenyl 268 46 
266 2-pyridine 269 34 
 
Scheme 4.6: Synthetic strategies for compounds 267-269 
 
Synthesis of 2-pyridinesulfonyl chloride (266) 
2-Pyridinesulfonyl chloride was not commercially available, and it was therefore 
synthesised, according to reported procedures, by oxidising the thiol group of 2-
mercaptopyridine (270) to sulfonyl chloride, using NaOCl and sulphuric acid, as shown 
in scheme 4.7.21 
 
 
 
Scheme 4.7: Synthesis of 2-pyridine sulfonyl chloride 266 
 
Synthesis of N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-sulfonyl-
hydrazides (267-269) 
As reported in scheme 4.7, a first attempt was made to obtain compound 267 by 
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reacting the two starting materials in anhydrous DCM and adding triethylamine to 
neutralise the hydrochloric acid formed: in these conditions, a complex mixture of 
multiple products was obtained, and it was not possible to purify desired compound 267 
by chromatographic or recrystallisation techniques. Following reported procedures, the 
reaction was repeated in anhydrous pyridine, and in this second system desired products 
267-279 were finally obtained after flash column chromatography purification.22 
 
4.2.5 N'-(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazides 
(272-273, 278-281) 
 
A second attempt was made to replace the hydrazone bond with a more stable chemical 
function, while maintaining the length of the linker: a hydrazide group was chosen for a 
new series of six derivatives. These compounds were obtained according to two 
different synthetic approaches: compounds 272-273, carrying a para hydrophobic 
substituent in the phenyl ring, were prepared following the same strategy and reaction 
conditions used for compounds 267-269, reacting intermediate 193 with acyl chlorides 
271 and 119, as shown in scheme 4.8. 
 
 
Acyl chloride Ar Product Yield % 
271 4-tert-butylphenyl 272 86 
119 4-chlorophenyl 273 37 
 
Scheme 4.8: Synthetic strategy for compounds 272-273 
 
A further small series of four derivatives was obtained through a coupling reaction 
between intermediate 193 and differently substituted carboxylic acids 274-277, using 
TBTU as the coupling agent as done for several previous compounds (Chapter 2). 
Starting from carboxylic acids instead of chlorides, it was possible to obtain, along with 
pyrazine and 2-pyridine products 280 and 281, hydrazides 278 and 279, where the 
hydroxy groups of the original active structure are maintained, thus allowing a direct 
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comparison between the two series of compounds (scheme 4.9). 
 
 
Carboxylic acid Ar Product Yield % 
274 2,5-dihydroxyphenyl 278 28 
275 2-hydroxyphenyl 279 35 
276 pyrazine 280 29 
277 2-pyridine 281 67 
 
Scheme 4.9: Synthesis of hydrazide compounds 278-281 
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4.2.6 Biological evaluation 
 
Newly synthesised thieno-pyrimidines were tested for antiviral activity in the 
subgenomic replicon and cytostatic assays.18 Their biological results are shown in tables 
4.3-4.5. 
 
(5,6,7,8-Tetrahydro-benzo [4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazones 
 
 
Compound R Ar EC50(M) CC50(M) EC90(M) SI 
252 Me 4-hydroxy-phenyl >295 >295 >295 - 
253 H 2,5-dihydroxyphenyl 0.84 18.2 3.1 21.7 
254 Me 2,5-dimethoxyphenyl 36.7 63.6 - 1.7 
255 Me 2-methoxyphenyl 8.1 48.9 18.8 6 
256 Me 3-methoxyphenyl 16 30 - 1.9 
257 Me 2,5-dichlorophenyl 9.4 >256 55.1 >27.2 
258 Me 2-chlorophenyl 10.9 70 34.7 6.4 
259 Me 4-chlorophenyl 18.6 187 96 10.1 
260 Me 2,5-difluorophenyl 30.9 60.3 33.5 2 
261 Me 2-fluorophenyl 22.3 39.3 - 1.8 
262 Me pyrazine 0.355 21.1 0.775 59.4 
263 Me 2-pyridine 1.04 8.06 3.34 7.8 
264 Me 2-indole 17.8 26.3 >277 1.5 
265 Me 2-benzimidazole 2.97 50.1 7.94 16.9 
 
Table 4.3: Antiviral and cytotoxicity data for compounds 252-265 
 
Biological results for compounds 252-265 further confirm the importance of a hydroxy 
substituent  in  position  2’  and  5’  of  the original scaffold: their replacement with methoxy 
and halogen groups is associated with activity reduction. The same negative effect is 
observed  with  a  4’-hydroxy substituent in the aromatic ring, while the absence of the 
acetophenylic methyl group in compound 253 leads to activity retention, but is 
associated with increased toxicity against cells, with a CC50 value much lower than its 
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analogue 187. 
A successful replacement of the original hydroxy functions is achieved with the 
introduction of heteroaromatic rings in the ethylidene portion of the molecule: the 
presence of pyrazine (262), 2-pyridine (263) and 2-benzimidazole (265) is tolerated, 
with compound 262 showing the best activity profile found so far. This conclusion 
cannot be extended to compound 264, where the 2-indole ring appears to be associated 
with loss of activity. 
 
N'-(5,6,7,8-Tetrahydro-benzo [4,5]thieno [2,3-d]pyrimidin-4-yl)-sulfonylhydrazides 
 
 
Compound Ar EC50(M) CC50(M) EC90(M) SI 
267 4-tert-butylphenyl 42.8 116 - 2.7 
268 4-chlorophenyl 57.6 253 - 4.4 
269 2-pyridine 43.9 145 83.2 3.3 
 
Table 4.4: Antiviral and cytotoxicity data for compounds 267-269 
 
The first attempt to replace the hydrazone bond with a sulfonylhydrazide does not seem 
to be successful: for all three compounds prepared, this modification is associated with 
loss of activity. 
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N'-(5,6,7,8-Tetrahydro-benzo [4,5]thieno [2,3-d]pyrimidin-4-yl)-hydrazides 
 
 
Compound Ar EC50(M) CC50(M) EC90(M) SI 
272 4-tert-butylphenyl 13.9 >263 - >18.9 
273 4-chlorophenyl 9.2 12.9 - 1.4 
278 2,5-dihydroxyphenyl 0.51 99.9 0.939 195.9 
279 2-hydroxyphenyl 0.301 66.4 0.549 221 
280 pyrazine 1.12 7.76 2.55 6.9 
281 2-pyridine 1.11 8.34 0.819 7.5 
 
Table 4.5: Antiviral and cytotoxicity data for compounds 272-273, 278-281 
 
Greater success is associated with the replacement of the hydrazone group with a 
hydrazide: except for compounds 272 and 273, all remaining derivatives of this series 
show EC50 values equal to or below 1 M, with good SI values for two of them, 
compounds 278 and 279. Moreover, while a successful replacement of the hydrazone 
linker was achieved, the importance of the original hydroxyl groups is further confirmed 
(compounds 278 and 279), along with their potential replacement with heteroaromatic 
moieties such as pyrazine (280) and 2-pyridine (281), as shown for the hydrazone 
scaffold (compounds 262 and 263). Compound 279 in particular shows the lowest EC50 
value found so far, and represents an encouraging starting point for further studies. 
 
4.2.7 Design and synthesis of heteroaromatic-hydrazones (290-294) and 
hydrazides (302-309) 
 
Due  to  the  successful  replacement  of  the  2’,5’-dihydroxyphenyl group in compound 187 
with heteroaromatic rings, it was decided to expand the phenylethylidene series: 
inserting 2-quinoline, to see how the expansion of occupational volume on this level 
might affect antiviral activity, 3-pyridine, to determine whether the presence of a 
nitrogen in position 2 is essential for activity retention with the same trend observed for 
2’-hydroxy group, 2-pyrrole, 2-furan and 2-thiophene, in order to explore the effect of a 
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smaller heteroaromatic ring in this portion of the structure. 
Moreover, due to the improved activity profile associated with the hydrazide linker, it 
was planned to further explore this series of compounds. In order to assess whether the 
activity pattern follows the one observed for hydrazone compounds, it was decided to 
first replace the aromatic hydrazide substituent with the 3-hydroxyphenyl and the 3-
pyridine groups, and then to carry out the same heteroaromatic modifications of the 
hydrazone series, corresponding to the insertion of 2-indole, 2-benzimidazole, 2-
quinoline, 2-pyrrole, 2-furan and 2-thiophene substituents on the hydrazide group. 
Once prepared non-commercially available 2-acetylquinoline 285, five new hydrazone-
derivatives were synthesised following the usual route, changing only the last reaction 
step to obtain final products 283-286. 
 
Synthesis of 2-acetylquinoline (285) 
A three-step synthetic approach was followed to prepare acetylate quinolone in position 
2, as shown in scheme 4.10. 
 
 
Scheme 4.5: Synthetic strategy for 2-acetylquinoline (282) 
 
Starting from quinaldic acid (282), following reported procedures, it was decided to first 
prepare methyl ester 283, in order to perform a Claisen condensation with ethyl acetate 
and  obtain  β-ketoester 284.  The  β-ketoester was subsequently treated with hydrochloric 
acid while heating to give ester hydrolysis first, and then decarboxylation of the free 
acid formed the desired ketone 285.23 
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Synthesis of (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazones 
(290-294) 
Five new hydrazone compounds 290-294 were prepared following the synthetic route 
previously optimised, by reacting intermediate 193 with ketones 285-289. 
 
 
Aldehyde/ketone Ar Product Yield % 
285 2-quinoline 290 71 
286 3-pyridine 291 61 
287 2-pyrrole 292 62 
288 2-furan 293 36 
289 2-thiophene 294 44 
 
Table 4.6: Synthesis of compounds 290-294 
 
Synthesis of N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-
hydrazides (302-309) 
Eight new hydrazide products were synthesised by a coupling reaction between aryl 
carboxylic acids 282, 295-301 and intermediate 193, following the same procedure used 
for compounds 274-277 (table 4.7). 
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Carboxylic acid Ar Product Yield % 
295 3-hydroxyphenyl 302 29 
296 3-pyridine 303 23 
297 2-indole 304 36 
298 2-benzoimidazole 305 26 
282 2-quinoline 306 68 
299 2-pyrrole 307 65 
300 2-furan 308 35 
301 2-thiophene 309 15 
 
Table 4.7: Synthesis of compounds 302-309 
Chapter 4: Thienopyrimidines 
 
136 
 
4.2.8 Biological evaluation 
 
Newly synthesised heteroaromatic hydrazones and hydrazides were evaluated for 
inhibition of HCV replication in the HCV replicon and cytostatic assay.18 Biological 
results are shown in table 4.8. 
 
 
Compound Ar Linker X EC50(M) CC50(M) EC90(M) SI 
290 2-quinoline hydrazone <0.697 7.23 t.b.d. t.b.d. 
291 3-pyridine hydrazone 79.4 >309 >103 3.9 
292 2-pyrrole hydrazone 4.8 17 12.8  
293 2-furan hydrazone 14.9 61.5 - 4.1 
294 2-thiophene hydrazone 22.3 49.8 - 2.2 
302 3-hydroxyphenyl hydrazide 210 90.9 >220 >1.4 
303 3-pyridine hydrazide 128 >307 >307 2.4 
304 2-indole hydrazide 14.8 64.7 - 4.4 
305 2-benzimidazole hydrazide 0.193 2.92 0.679 15.1 
306 2-quinoline hydrazide 23.9 59 - 2.4 
307 2-pyrrole hydrazide 147 >319 - >2.2 
308 2-furan hydrazide 199 230 - 1.2 
309 2-thiophene hydrazide 31.1 36.7 - 1.2 
 
Table 4.8: Antiviral and cytotoxicity data for compounds 272-273, 278-281 
 
Biological data for hydrazone compounds 290-294 suggest, for the presence of a 
heteroaromatic nitrogen in the phenylethylidene substituent, the same trend in antiviral 
activity found for hydroxy groups: loss of activity associated with 3-pyridine derivative 
291 indicates the same essential role for a nitrogen in position 2 (present in pyrazine and 
2-pyridine analogues 262 and 263), already noticed for the 2’-hydroxyphenyl group. 
Furthermore, replacement of 6-membered heteroaromatic rings with 5-membered rings 
is associated with loss of activity. 
The same considerations can be extended to the hydrazide series of compounds: among 
this family of structures, the presence of a 2-hydroxyphenyl group is essential for 
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activity retention. As observed in the hydrazone derivatives, replacement of the 2-
pyridine group with 3-pyridine (compound 303) is associated with loss of activity, 
suggesting the same effect for a heteroaromatic ring with a nitrogen in position 2 and a 
2-hydrophenyl substituent. Also for this series of compounds, 5-member heteroaromatic 
groups in the hydrazide part of the molecule are associated with loss of activity, while 
2-benzimidazole is correlated to activity retention, but an increased toxicity against the 
cell can be noticed for this modification. Finally, a 2-indole or 2-quinoline group in the 
hydrazide scaffold are associated with a decreased antiviral potential. 
In conclusion, the general trend in activity profile appears to be the same for the two 
families of structures, hydrazones and hydrazides: this evidence could suggest the same 
mechanism of action for the two structural scaffolds, and represents a further 
confirmation of the successful replacement of the hydrazone linker with a hydrazide 
function. 
 
4.2.9 Design and synthesis of N-aryl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidin-4-amines (310-312) 
 
Conformational search on compound 222 
In an attempt to understand the role of the 2’-hydroxy group in compound 187 and 222, 
a conformational search was performed on the structure of 222. 
Using the Conformational Search tool in MOE2010.10,2 the lowest energy 
conformation for compound 222 was found to show an internal hydrogen bond between 
the  2’-hydroxy group and the nitrogen of the hydrazone linker (figure 4.8). 
 
 
Figure 4.8: Lowest energy conformation found for compound 222 
 
In order to freeze this interaction and explore a new linker modification, it was planned 
to replace the hydrazone bond with an aromatic amino group, to be functionalised with 
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heteroaromatic bicyclic rings, such as benzimidazole (312) and quinoline (311), along 
with naphthalene ring (310), to be used as potential reference for activity evaluation. 
Before carrying out this new modification from a synthetic point of view, MOE Flexible 
Alignment was used to superimpose the newly designed compounds with the low-
energy conformation found for compound 222, kept rigid during the analysis, to 
confirm the volume overlapping shared between the modified structures and the parent 
molecule (figure 4.9).24 
 
a.          b.                  c. 
 
 
Figure 4.9: Flexible Alignment results of the superimposition between compound 222, in pink, and a. 
310, in blue; b. 311, in purple; c. 312, in green 
 
All alignments shown in figure 4.9 correspond to dU values equal to 0 kcal/mol and 
large negative S values. The best alignment is found for compound 312 (S= -163): 
freezing the internal H-bond found in the low energy conformation of compound 222 
seems to be most successful with this last modification, where the 2-
hydroxyphenylidene function is replaced by a 2-aminobenzimidazole group (312, figure 
4.9c). With this designed compound, the benzene ring of benzimidazole overlaps 
completely with the phenyl ring of compound 222, and the formation of an internal 
hydrogen bond between imidazole NH group and pyrimidine aromatic nitrogen could 
make the conformation found for this alignment particularly stable, confirming the good 
superimposition of benzimidazole ring with the 2-hydoxyphenyl group of the parent 
molecule. 
Alignment results show that in the case of compounds 310 (S= -121) and 311 (S=-128) 
spatial superimposition of the condensed bicyclic aromatic rings and the 
phenylethylidene group of 222 is not as good as the one found for compound 312: 1-
naphthyl and 8-quinoline groups, respectively, only partially overlap the volume 
occupied by the 2-hydroxyphenyl hydrazine function. Nevertheless, all three 
modifications were chosen for synthetic development, in order to use their biological 
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results as reference for the evaluation of compound 312. 
 
Synthesis of N-aryl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amines 
(310-312) 
In order to replace the hydrazone linker with an amino function, it was planned to react 
the third intermediate of the usual synthetic pathway, 4-chloro-5,6,7,8-tetrahydro-
benzo[4,5]thieno[2,3-d]pyrimidine (192), with commercially available bicyclic aromatic 
amines. 
In a first attempt, chloride 192 was treated with an excess of 1-naphthylamine (313) and 
heated under reflux in anhydrous DMF for 20 h. Under these conditions, the only new 
species formed and isolated after column chromatography purification was undesired 
product 316, as shown in scheme 4.6. In an attempt to see if the formation of the side 
product was due to a low reactivity of the amine used, the reaction was tried in the same 
conditions using an excess of 2-aminobenzimidazole (315), but also in this case the only 
new species isolated after column chromatography was compound 316. 
 
 
Scheme 4.6: First attempt for the synthesis of compounds 310-312 
 
To avoid the interference of DMF with the reaction, the solvent was changed, and a 
second attempt was made refluxing chloride 192 with an excess of 2-
aminobenzoimidazole (315) in pyridine for 20 h. In this second case, the formation of a 
mixture of different new species was observed by T.L.C., but all attempts to isolate 
desired compound 312 by column chromatography or recrystallization were 
unsuccessful (scheme 4.7.). 
The reaction mixture was then refluxed in isopropanol, but only the two starting 
materials 192 and 315 were recovered after 72 h, with no new species observed by 
monitoring the reaction via T.L.C. 
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A successful method was finally identified by adding to the isopropanol solvent 
NaHCO3 as base: as shown in scheme 4.7, the three desired products 310-312 were 
obtained according to this procedure, in low yield. 
 
 
Arylamine Ar Product Yield % 
313 1-naphthyl 310 21 
314 8-quinoline 311 14 
315 2-benzimidazole 312 12 
 
Scheme 4.7: Synthesis of compounds 310-312 
 
4.2.10 Biological evaluation 
 
Compounds 310-312 were evaluated for their antiviral potential in the HCV replicon 
assay. 
 
 
Compound Ar EC50(M) CC50(M) EC90(M) SI 
310 1-naphthyl 32.4 281 >33.5 8.7 
311 8-quinoline 186 >301 >100 >1.6 
312 2-benzimidazole 55.4 231 >104 4.2 
 
Table 4.9: Antiviral and cytotoxicity data for compounds 310-312 
 
Biological results indicate that the last modification, attempted to replace the hydrazone 
linker and freeze the internal hydrogen bond found for compound 187, is associated 
with a significant loss of activity.  
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4.3 Synthesis of thieno[2,3-d]pyrimidines 
 
Due to the wide exploration of the phenylethylidene aromatic portion and the hydrazone 
linker done so far, it was decided to start and investigate the role of the tetrahydrobenzo 
substituent on the thiophene ring. 
Several series of new derivatives were designed to remove or replace this part of the 
molecule, while maintaining the central thienopyrimidine nucleus, either the hydrazone 
or hydrazide linker, and the most successful modifications on the level of the original 
2’,5’-dihydroxyphenyl ring. 
In particular, five new families of structures were chosen, inserting an unsubstituted 
thieno-pyrimidine system, a cyclopentane ring condensed to the thiophene ring, an 
oxidised benzene substituent, two methyl groups, and finally an unsymmetrical 
substitution with one methyl and one ethyl group. 
In order to insert an unsubstituted thienopyrimidine system in the original scaffold, the 
same five-step synthetic pathway previously validated was used, as shown in scheme 
4.8. 
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Scheme 4.8: Synthetic pathway applied for compounds 322-329 
 
The only step that changed corresponds to the preparation of ethyl 2-aminothienophene-
3-carboxylate (318), which takes place through a different version of the Gewald 
reaction, in which 1,4-dithiane-2,5-diol 317 is condensed with ethyl cyanoacetate.22 The 
four remaining steps followed the strategy and conditions already applied for previous 
tetrahydrobenzo[b]thienopyrimidines. 
 
Synthesis of ethyl 2-aminothienophene-3-carboxylate (318)25 
An improved version of the Gewald reaction uses dimeric forms of an -
sulfanylcarbonyl compound, that is condensed with an -activated acetonitrile in the 
presence of a base. 
Desired condensation to give 2-aminothiophene 318 was obtained by adding 
triethylamine to a mixture of ethyl cyanoacetate (189) and 1,4-dithiane-2,5-diol (317), 
in anhydrous DMF, and heating at 45 °C for 30 min. The ester intermediate 318 was 
isolated after flash column chromatography in 64% yield. 
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4.3.1 N-(1-Aryl-ethylidene)-N'-(thieno[2,3-d]pyrimidin-4-yl)-hydrazines (322-325) 
 
Four new derivatives were prepared through the formation of a Schiff base between 
hydrazine intermediate 321 and ketones 194, 202, 203 and 250, by refluxing the two 
starting materials in ethanol for 24 h. 
 
 
Ketone Ar Product Yield % 
194 2,5-dihydroxyphenyl 322 81 
202 2-hydroxyphenyl 323 61 
203 3-hydroxyphenyl 324 37 
250 pyrazine 325 96 
 
Scheme 4.9: Synthesis of compounds 322-325 
 
4.3.2 N'-(Thieno[2,3-d]pyrimidin-4-yl)arylcarbohydrazides (326-329) 
 
A small series of four compounds was obtained with a hydrazide linker in the new 
thiophene scaffold by reacting intermediate 321 with carboxylic acids 274-277, 
according to the coupling procedure previously applied for amide bond formation.  
 
 
Carboxylic acid Ar Product Yield % 
274 2,5-dihydroxyphenyl 326 15 
275 2-hydroxyphenyl 327 19 
276 pyrazine 328 31 
277 2-pyridine 329 30 
 
Scheme 4.10: Synthesis of compounds 326-327 
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4.3.3 Biological evaluation 
 
Newly synthesised thienopyrimidine derivatives were tested for inhibition of viral 
replication in the HCV replicon assay:18 data are shown for both families, hydrazones 
and hydrazides, in table 4.10. 
 
 
Compound Ar Linker X EC50(M) CC50(M) EC90(M) SI 
322 2,5-dihydroxyphenyl hydrazone 2.99 226 4.55 75.6 
323 2-hydroxyphenyl hydrazone 4.75 77.2 >10.6 16.3 
324 3-hydroxyphenyl hydrazone 52 78.1 - 1.1 
325 pyrazine hydrazone 4.39 11.9 4.19 2.7 
326 2,5-dihydroxyphenyl hydrazide 2.75 >165 9.4 >60 
327 2-hydroxyphenyl hydrazide 12.9 >349 >38.8 >27 
328 pyrazine hydrazide 0.85 233 2.28 274.1 
329 2-pyridine hydrazide 0.31 138 0.67 445 
 
Table 4.10: Antiviral and cytotoxicity data for compounds 322-329 
 
Biological data for hydrazone compounds 323-325 suggest loss of activity and an 
increased toxic effect against cells associated with the removal of the tetrahydrobenzene 
substituent. Along with lower CC50 and SI values in comparison to their original 
analogues, compounds 323-325 also show higher EC50 values, indicating a cytotoxic 
rather than antiviral effect associated with this modification. Compound 322 represents 
an exception to this trend: data found so far suggested activity retention for this 
derivative. 
An inconsistent pattern is also found for hydrazide derivatives 326-329: for hydroxy 
analogues 326 and 327 antiviral potential seems to be reduced in comparison to original 
tetrahydrobenzothienyl compounds 278 and 279, while for pyrazine and 2-pyridine 
derivatives 328 and 329 this last modification seems to be successful both for activity 
retention and for a decrease in cytotoxic effect, since their CC50 and SI values are higher 
than the ones found for compounds 280 and 281. 
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In conclusion, removal of the substituent on the thiophene portion does not have a 
consistent effect between the two families of compounds, nor does it show the same 
trend in activity and toxicity profiles. For hydrazone compounds 323-325, it is 
associated with loss of activity and increased cytotoxicity, while among the hydrazide 
family, it has a different effect on hydroxyphenyl compounds 326-327, where activity 
potential is reduced, and heteroaromatic products 328-329, for which both activity and 
cytotoxicity profiles are improved. 
Chapter 4: Thienopyrimidines 
 
146 
 
4.4 Synthesis of cyclopentane[b]thienopyrimidines 
 
With the aim to replace the tetrahydrobenzene ring in compound 187 with a condensed 
cyclopentane system, the previous synthetic pathway was followed, with the only 
difference being the use, in the first synthetic step corresponding to the Gewald 
condensation of 2-aminothiophene nucleus, of cyclopentanone (330) instead of 
cyclohexanone, as shown in scheme 4.11. All reagents and conditions for the 
preparation of the four common intermediates and the two series of final products, 
hydrazones and hydrazides, were the same previously discussed for tetrahydrobenzo-
thienopyrimidine compounds. 
The rationale that guided the selection of ketones and acids to react with the fourth 
intermediate 334 in the fifth reaction step, for the formation of final products, was the 
biological evaluation of the previous series of compounds: for both hydrazone and 
hydrazide series, the aim was to choose the most significant modifications on the 
phenylethylidene or hydrazide portion of the molecule, to better understand the effect of 
the new modification on the antiviral potential associated with these structures. 
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Scheme 4.11: Synthetic pathway applied for compounds 335-346 
 
4.4.1 N-(2,3-Dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-N'-(1-phenyl-
ethylidene)-hydrazines (335-340) 
 
Six new derivatives were prepared according to the usual procedure for Schiff base 
formation, by reacting intermediate 334 with ketones 194, 202, 203, 250, 251 and 298, 
under reflux conditions in EtOH for 24h. 
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Ketone Ar Product Yield % 
194 2,5-dihydroxyphenyl 335 74 
202 2-hydroxyphenyl 336 71 
203 3-hydroxyphenyl 337 64 
250 pyrazine 338 42 
251 2-pyridine 339 36 
298 2-benzoimidazole 340 58 
 
Scheme 4.12: Synthesis of compounds 335-340 
 
4.4.2 N'-(6,7-Dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)arylcarbo 
hydrazides (341-346) 
 
A second series of six new compounds was obtained with a coupling reaction between 
intermediate 334 and carboxylic acids 274-277, 297 and 298, using TBTU as coupling 
agent as previously done for all the previous compounds with this functional group. 
 
 
Carboxylic acid Ar Product Yield % 
274 2,5-dihydroxyphenyl 341 26 
275 2-hydroxyphenyl 342 30 
276 pyrazine 343 15 
277 2-pyridine 344 30 
297 2-indole 345 38 
298 2-benzimidazole 346 47 
 
Scheme 4.12: Synthesis of compounds 341-346 
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4.4.3 Biological evaluation 
 
Biological results in the HCV replicon assay for compounds 335-346 are shown in table 
4.11.18 
 
 
Compound Ar Linker X EC50(M) CC50(M) EC90(M) SI 
335 2,5-dihydroxyphenyl hydrazone 17.8 >367 25.7 >20.6 
336 2-hydroxyphenyl hydrazone 1.72 141 4.07 81.9 
337 3-hydroxyphenyl hydrazone 88 >385 >385 >4.4 
338 pyrazine hydrazone 0.688 1.12 <0.839 1.6 
339 2-pyridine hydrazone 1.18 14 1.44 11.9 
340 2-benzimidazole hydrazone 0.802 6.68 <2.24 8.3 
341 2,5-dihydroxyphenyl hydrazide 2.13 198 3.67 92.9 
342 2-hydroxyphenyl hydrazide 0.186 119 0.352 639.8 
343 pyrazine hydrazide 0.0759 3.18 <0.256 41.9 
344 2-pyridine hydrazide 0.745 6.61 1.79 8.9 
345 2-indole hydrazide - 47.8 - - 
346 2-benzimidazole hydrazide 0.594 6.9 1.11 11.6 
 
Table 4.11: Antiviral and cytotoxicity data for compounds 335-346 
 
As had been noticed for unsubstituted thienopyrimidine compounds 322-329, 
replacement of the tetrahydrobenzene substituent with a cyclopentyl ring does not have 
a consistent effect in terms of antiviral activity between the two families of analogues 
synthesised, hydrazones and hydrazides, and among different compounds belonging to 
the same structural family. In the case of hydrazone stuctures, with the exception of 
compound 335, which is associated with loss of activity in terms of EC50 in comparison 
to compound 187, activity potential seems to be retained, but the modification is 
associated with an increased toxic effect against cells in the case of heteroaromatic 
derivatives 338-340. 
In the case of hydrazide structures 341-346, while compound 345 is associated with a 
toxic effect only, for all remaining analogues in this group activity potential seems to be 
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retained, and for two of them, compounds 342 and 343, an improvement can be noticed 
both in terms of EC50 and SI. Moreover, the EC50 associated with compound 343 
reaches the lowest value found so far, in the nanomolar range. 
Despite the differences found, this last modification is mainly associated with a retained 
or improved activity profile, suggesting a role in antiviral activity for a cyclic aliphatic 
substituent on the thiophene ring. 
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4.5 Synthesis of benzo[b]thienopyrimidines 
 
With the purpose to better understand and explore the role of the tetrahydrobenzene 
substituent on the thiophene, it was planned to aromatise this group and prepare a new 
series of compounds with a third aromatic ring condensed to the thienopyrimidine 
system. 
In order to obtain final hydrazones and hydrazides with the new tricyclic aromatic 
nucleus, it was decided to oxidise the cyclohexyl ring in ester intermediate 190, and 
then insert aromatised aminoester 347 in the usual synthetic route, as shown in scheme 
4.13. 
 
 
Scheme 4.13: Synthetic approach for compounds 351-358 
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Synthesis of ethyl 2-aminobenzo[b]thiophene-3-carboxylate (347) 
Following reported procedures, a first strategy was carried out to aromatise the 
tetrahydrobenzene ring in compound 190 as shown in scheme 4.14.26 
 
 
Scheme 4.14: First strategy attempted for the preparation of compound 347 
 
This first attempt began with the protection of aromatic amine in 190 to 
cyclopropanecarboxamide in compound 359, followed by oxidation of the cyclohexyl 
ring with manganese dioxide in intermediate 360. The protected amine group was then 
to be deprotected from the cyclopropylamide group with methyl sulphate, to give 
tricyclic aromatic ester 347. 
The first step in this pathway, corresponding to the protection of the amine group, was 
carried out by adding cyclopropane carbonyl chloride to compound 190 in pyridine at 
5°C: after 1h the desired product was obtained by acidification of the reaction mixture 
and precipitation, in 83% yield. The following oxidation step was attempted by adding a 
large excess of MnO2 to compound 359 in toluene, and refluxing the mixture for 5 days. 
After this time, starting material 359 was still the main species present in the reaction 
mixture, and only 5% product 360 was obtained after flash column chromatography. 
Due to the low yield of this second step, it was decided to attempt a different oxidative 
strategy, without protecting the amino group in compound 190. The new approach 
attempted, shown in scheme 4.15, followed the catalytic oxidation of tetrahydrobenzene 
ring over Pd/C.27 
 
 
Scheme 4.15: Catalytic aromatization of compound 190 
 
This second strategy was attempted a first time by refluxing compound 190 and 10% 
Pd/C in toluene for 48 h: most of the starting material was still present, and only 10% of 
desired product 347 was obtained after chromatographic purification. The reaction was 
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then repeated by heating at reflux the mixture for 5 days, and in this case 41% of 
desired product 347 was obtained. Even though the yield was not high and there were 
four other steps ahead in the synthetic route to obtain final products 351-358, this 
second method was preferred for its better yield and the requirement of only one 
reaction step. 
As previously discussed (scheme 4.13), oxidized intermediate 347 was inserted in the 
usual synthetic route for the preparation of final hydrazones 351-354 and hydrazides 
355-358. 
 
4.5.1 4-(2-(1-Arylethylidene)hydrazinyl)benzo[4,5]thieno[2,3-d]pyrimidines (351-
354) 
 
Four new hydrazone compounds were obtained by reacting hydrazine intermediate 350 
with hydroxyphenyl ketones 194 and 202 and heteroaromatic ketones 250 and 298. 
 
 
Ketone Ar Product Yield % 
194 2,5-dihydroxyphenyl 351 73 
202 2-hydroxyphenyl 352 81 
250 pyrazine 353 73 
298 2-benzimidazole 354 62 
 
Scheme 4.16: Synthesis of compounds 351-354 
 
4.5.2 N'-(Benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)arylcarbohydrazides (355-358) 
 
Another small series of four new hydrazide compounds was prepared reacting 
intermediate 350 and carboxylic acids 274-277, all characterised by the presence of 
either hydrophenylfunctions or heteroaromatic rings. 
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Carboxylic acid Ar Product Yield % 
274 2,5-dihydroxyphenyl 355 17 
275 2-hydroxyphenyl 356 14 
276 pyrazine 357 21 
277 2-pyridine 358 28 
 
Scheme 4.17: Synthesis of compounds 355-358 
 
4.5.3 Biological evaluation 
 
Compounds 351-358 were evaluated for their antiviral potential in the HCV replicon 
assay (table 4.12).18 
 
 
Compound Ar Linker X EC50(M) CC50(M) EC90(M) SI 
351 2,5-dihydroxyphenyl hydrazone 0.343 20.3 0.968 59.2 
352 2-hydroxyphenyl hydrazone 0.0861 12 0.421 139.4 
353 pyrazine hydrazone 0.415 1.99 0.858 6.4 
354 2-benzoimidazole hydrazone 1.1 18.6 3.25 16.9 
355 2,5-dihydroxyphenyl hydrazide 0.715 43.6 2.14 61 
356 2-hydroxyphenyl hydrazide 0.832 108 1.6 129.8 
357 pyrazine hydrazide 0.0783 1.31 0.143 17 
358 2-pyridine hydrazide 0.461 1.54 1.01 3.3 
 
Table 4.12: Antiviral and cytotoxicity data for compounds 351-358 
 
Aromatisation of the cyclohexyl ring is associated with a retained or improved antiviral 
potential in comparison to the original structures. In the hydrazone family, improved 
activity profiles are found for hydroxy derivatives 351 and 352, with compound 352 
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showing an EC50 value in the nanomolar range. For heteroaromatic hydrazones 353 and 
354, antiviral profile originally identified for tetrahydrobenzene analogues 262 and 265 
appears to be retained. Among the hydrazide family, for hydroxy derivatives 355 and 
356 antiviral potential is retained, while heteroaromatic hydrazides 357 and 358, even if 
showing low EC50 values (in the nanomolar range for compound 357), are still 
associated with a toxic effect against cells, as their tetrahydrobenzene analogues 280 
and 281. 
In conclusion, this last modification is associated with activity retention, indicating that 
the rigidity due to a tricyclic system in this part of the molecule is tolerated, and further 
confirming the importance of the occupational volume, given by an aliphatic or 
aromatic cyclic substituent, on the the thiophene ring for antiviral activity. 
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4.6 Synthesis of dimethyl[b]thienopyrimidines and 6-ethyl-5-
methylthieno[2,3-d]pyrimidines 
 
Aiming to further explore the role of the cyclic substituent on the thiophene ring, it was 
decided to prepare a small series of new derivatives replacing the cyclohexyl group with 
two methyl groups and a 5-methyl-6-ethyl substituent. 
In order to achieve this result, the usual synthetic pathway was followed. Thiophene 
ring with the desired substituents was obtained according to the Gewald condensation, 
by reacting ethyl cyanoacetate (189) with 2-butanone (361) and 2-pentanone (362) 
respectively, as shown in scheme 4.18. The first step in the synthetic route was the only 
one that needed to be changed. 
 
 
Scheme 4.18: Synthetic approach for compounds 371-374 
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4.6.1 4-(2-(1-Arylethylidene)hydrazinyl)-5,6-dimethylthieno[2,3-d]pyrimidines 
(371-372) and 2-(1-(2-(6-ethyl-5-methylthieno[2,3-d]pyrimidin-4-yl)hydrazono) 
ethyl)benzene-1,4-diol (373) 
 
Three new hydrazone compounds were prepared by reacting final intermediates 369 and 
370 with hydroxyphenyl ketones 194 and 202, as shown in scheme 4.19. 
 
 
Ketone Product R Ar Yield % 
194 371 Me 2,5-dihydroxyphenyl 71 
202 372 Me 2-hydroxyphenyl 54 
194 373 Et 2,5-dihydroxyphenyl 53 
 
Scheme 4.19: Synthesis of compounds 371-373 
 
4.6.2 N'-(5,6-Dimethylthieno[2,3-d]pyrimidin-4-yl)pyrazine-2-carbohydrazide 
(374) 
 
One new product was obtained by a coupling reaction between hydrazine intermediate 
369 and pyrazine carboxylic acid (276). 
 
 
Scheme 4.20: Synthesis of compound 374 
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4.6.3 Biological evaluation 
 
Biological data in the HCV replicon assay for compounds 371-374 are shown in table 
4.13.18 
 
 
Compound R Ar Linker X EC50(M) CC50(M) EC90(M) SI 
371 Me 2,5-dihydroxyphenyl hydrazone 1.3 >305 4.65 >305 
372 Me 2-hydroxyphenyl hydrazone 0.384 93.6 <1.28 243.8 
373 Et 2,5-dihydroxyphenyl hydrazone 0.803 >292 1.62 >363.6 
374 Me pyrazine hydrazide 0.091 1.58 0.26 17.3 
 
Table 4.13: Antiviral and cytotoxicity data for compounds 371-374 
 
Hydrazone structures 371-373 are associated with activity retention in comparison to 
tetrahydrobenzene analogues 187 and 202: both in the case of 5,6-dimethyl derivative 
372 and 5-methyl-6-ethyl compound 373 improved activity and SI values are found. 
Biological data for new hydrazide derivative 374 suggest activity retention associated 
with the new modification: even though it is associated with a lower CC50 value 
compared to original derivative 280, the EC50 found for this structure is in the 
nanomolar range. 
What these data seem to suggest is that replacement of the cyclic substituent on the 
thiophene system with non-cyclic aliphatic groups is associated with activity retention. 
In order to further validate the evidence found so far, it was decided to explore new 
modifications on the thiophene ring. 
New non-cyclic aliphatic modifications were planned: in particular, it was decided to 
replace one of the 5,6-dimethyl groups with a chlorine, a methoxy and an ethyl ester. 
To evaluate the impact of the cyclic substituents, it was decided to increase the size of 
the aliphatic ring from cyclohexyl to cycloheptyl, and to insert heteroatoms in the 
cyclohexyl moiety. 
Finally, it was planned to explore the role of the pyrimidine aromatic proton, by 
replacing it with a methyl group. 
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4.7 Synthesis of 6-chloro-5-methyl-thieno[2,3-d]pyrimidines 
 
Aiming to further explore the role of the substituent on the thiophene ring, it was 
decided to prepare a small series of new derivatives by replacing the 6-methyl group 
with a 6-chloro, 6-methoxy and 6-ethyl carboxylate. 
In order to obtain a direct comparison for activity of the new series of compounds, it 
was decided to prepare  one  or  two  hydrazone  derivatives,  with  a  2’-hydroxyphenyl and 
a   pyrazine   substituent,   and   one   or   two   hydrazide   derivatives,   with   the   same   2’-
hydroxyphenyl and a 2-pyridine group, for each one of the new families. 
Insertion of a chlorine in position 6 of the thienopyrimidine ring, according to reported 
procedures, was planned starting with the preparation of mono-methylated thiophene 
derivative 376, by reacting acetone (375) and ethyl cyanoacetate (189) in the usual 
conditions for the Gewald condensation.28 Intermediate aminoester 376 was then 
condensed with formamide in order to obtain the pyrimidinone ring closure in 
compound 377, and position 6 of intermediate 377 was then chlorinated with N-
chlorosuccinimide. 
Once the 6-chloro intermediate 378 was obtained, the usual two remaining steps were 
followed for the formation of hydrazine intermediate 380, to be finally functionalised to 
hydrazones 381-382 and hydrazides 383-384 (scheme 4.21). 
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Scheme 4.21: Synthetic route for compounds 381-384 
 
Synthesis of 6-chloro-5-methylthieno[2,3-d]pyrimidin-4(3H)-one (379) 
As can be seen in scheme 4.21, chlorination of pyrimidinone intermediate 377 was 
carried out using N-chlorosuccinimide as chlorinating agent. The two reagents were 
heated in glacial acetic acid for 1.5 h under reflux conditions, and the desired 
chlorinated product 379 was isolated after precipitation from H2O in 63% yield. 
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4.7.1 6-Chloro-5-methyl-4-(2-(1-arylethylidene)hydrazinyl)thieno[2,3-d] 
pyrimidines (381-382) 
 
Hydrazine intermediate 380 was reacted with ketones 202 and 250, in the usual 
conditions applied for Schiff base formation, to give hydrazone products 381-382. 
 
 
Ketone Ar Product Yield % 
202 2-hydroxyphenyl 381 77 
250 pyrazine 382 64 
 
Scheme 4.22: Synthesis of compounds 381-382 
 
4.7.2 N'-(6-Chloro-5-methylthieno[2,3-d]pyrimidin-4-yl)arylcarbohydrazides 
(355-358) 
 
A small series of two new hydrazide compounds was obtained with the usual TBTU 
coupling reaction between intermediate 380 and aryl carboxylic acids 275 and 277. 
 
 
Carboxylic acid Ar Product Yield % 
275 2-hydroxyphenyl 383 19 
277 2-pyridine 384 61 
 
Scheme 4.23: Synthesis of compounds 383-384 
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4.7.3 Biological evaluation 
 
Newly synthesised compounds 381-384 were evaluated for their antiviral potential in 
the HCV replicon assay (table 4.14).18 
 
 
Compound Ar Linker X EC50(M) CC50(M) EC90(M) SI 
352 2-hydroxyphenyl hydrazone 0.17 >9.01 t.b.d. >56.1 
353 pyrazine hydrazone 0.058 3.13 0.289 53.9 
356 2-hydroxyphenyl hydrazide 0.159 >8.96 t.b.d. >56.1 
358 2-pyridine hydrazide 0.088 >9.38 0.286 >106 
 
Table 4.14: Antiviral and cytotoxicity data for compounds 381-382 
 
The presence of a chloride moiety on the thiophene ring is associated with activity 
retention for the four new compounds prepared. However, the presence of a halogen in 
this part of the structure could influence the cytotoxicity in a negative fashion, since the 
CC50 values found so far for this new series of compounds, which need to be confirmed 
with further biological analyses, might be in the low µM range for all of them. 
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4.8 Synthesis of 6-methoxy-5-methyl-thieno[2,3-d]pyrimidines 
 
The 6-ethyl substituent on the thienopyrimidine system was modified to a methoxy 
group by changing the starting ketone in the first step of the previously validated 
synthetic pathway: as can be seen in scheme 4.24, methoxy-aminoester intermediate 
386 was obtained by Gewald condensation between methoxyacetone (385) and ethyl 
cyanoacetate (189). In this case, the first reaction step had to be repeated for a longer 
time than usual: after refluxing the reaction mixture for 24 h as was done for all 
previous series of compounds, desired product 386 was obtained in a low 30% yield 
after chromatographic purification. The reaction was repeated and left under reflux 
conditions for 72 h: in this case desired intermediate 386 was obtained in an improved 
yield of 49%, which was considered acceptable to perform the next reaction step. 
 
 
Scheme 4.24: Synthetic route for compounds 390-393 
 
Synthesis of 6-methoxy-5-methylthieno[2,3-d]pyrimidin-4(3H)-one (387) 
Condensation of the thienopyrimidinone ring had been previously carried out by 
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refluxing aminoester intermediates in formamide, which has a high boiling point of 
220°C and is difficult to be removed by chromatographic techniques. All previous 
thienopyrimidinone products of the condensation step had been precipitated out from 
the reaction mixture by addition of water. 
Due to the fact that intermediate aminoester 386 was isolated after column 
chromatography as an oil, and given the low reactivity of the starting materials in the 
first step of the synthetic pathway, it was thought to change the reaction system for this 
step, in order to use milder conditions and allow a potential recovery of the starting 
material, compound 386. For these reasons it was decided to avoid formamide as 
reagent and solvent, and pyrimidinone ring condensation was attempted using 
formamidine acetate salt in anhydrous DMF, heating the mixture at 100 °C for 16 h. 
After removal of the solvent under vacuum, desired thienopyrimidinone product 388 
was precipitated from water and obtained pure in a 52% yield. 
 
4.8.1 6-Methoxy-5-methyl-4-(2-(1-arylethylidene)hydrazinyl)thieno[2,3-d] 
pyrimidines (390-391) 
 
Two new hydrazone products were prepared for this series of compounds, by reacting 
final intermediate 389 with a small excess of ketones 202 and 250 (scheme 4.25). 
 
 
Ketone Ar Product Yield % 
202 2-hydroxyphenyl 390 50 
250 pyrazine 391 43 
 
Scheme 4.25: Synthesis of compounds 390-391 
 
4.8.2 N'-(6-Methoxy-5-methylthieno[2,3-d]pyrimidin-4-yl)arylhydrazides (392-
393) 
 
Two new hydrazide derivatives were obtained according to the coupling procedure 
previously carried out for all hydrazide analogues prepared, reacting compound 389 
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with carboxylic acids 275 and 277. 
 
 
Carboxylic acid Ar Product Yield % 
275 2-hydroxyphenyl 392 19 
277 2-pyridine 393 61 
 
Scheme 4.26: Synthesis of compounds 392-393 
 
4.8.3 Biological evaluation 
 
Biological data (HCV replicon assay) for newly synthesised compounds 390-393 are 
shown in table 4.15.18 
 
 
Compound Ar Linker X EC50(M) CC50(M) EC90(M) SI 
390 2-hydroxyphenyl hydrazone <0.264 >305 t.b.d. >1155 
391 pyrazine hydrazone <0.267 0.337 <0.267 >1.22 
392 2-hydroxyphenyl hydrazide <0.263 30.5 <0.788 >138 
393 2-pyridine hydrazide <0.275 16.5 <0.275 >60 
 
Table 4.15: Antiviral and cytotoxicity data for compounds 390-393 
 
The presence of a methoxy substituent on the thiophene ring is generally associated 
with a retained antiviral potential among the four new compounds tested. However, this 
modification is also related to an inconsistent effect as for the cytotoxicity: the CC50 and 
SI values found for compound 391 indicate a toxic effect induced by this last 
modification in the case of the pyrazine-hydrazone substrate. This trend cannot be seen 
in the other three derivatives prepared. Further studies are ongoing to establish EC50 and 
EC90 values for the new compounds and to confirm the trend found so far. 
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4.9 Synthesis of ethyl-5-methyl-thieno[2,3-d]pyrimidine-6-
carboxylates 
 
With the purpose to replace the ethyl group in position 6 of thienopyrimidine system 
with an ethyl ester function, the usual five-step synthetic route was attempted, as shown 
in scheme 4.27, by changing the ketone in the first step and starting from Gewald 
condensation between ethyl acetoacetate (394) and ethyl cyanoacetate (189). 
 
 
Scheme 4.27: Strategy attempted for the synthesis of compounds 399-401 
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The first step was successful with the usual condition applied for the Gewald 
condensation, and desired aminoester 395 was obtained after chromatographic 
purification in 66% yield. 
The following two steps however, corresponding to pyrimidinone ring condensation and 
chlorination of pyrimidinone intermediate with aromatisation of pyrimidine ring, did not 
work in the usual conditions optimised with the previous series of compounds, and 
needed to be attempted in different systems. 
 
Synthesis of ethyl 5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-
carboxylate (396) 
In the case of diester 395, condensation with formamide to give pyrimidinone 
compound 396 did not work in the usual reflux conditions. As can be seen in scheme 
4.27, a first attempt was made by refluxing intermediate 395 in formamide for 2 h. In 
this case, starting material 395 was completely consumed, but the formation of a 
complex mixture of products was observed, and it was not possible to purify desired 
product 396 nor to confirm its formation either by NMR or MS experiments. 
Following reported procedures, it was decided to add a catalytic amount of acetic acid, 
and the reaction was repeated under reflux in formamide.29 
 
 
Scheme 4.28: Second and third attempts for the synthesis of compound 396 
 
As shown in scheme 4.28, catalytic AcOH was added to compound 395 in formamide, 
and the reaction mixture was heated under reflux for 2h. In this case, the formation of a 
thienopyrimidinone product was observed, and it was isolated and purified by 
recrystallization. However, NMR experiments suggest that the new pyrimidinone 
species corresponds to decarboxylation product 377: this was attributed to the 
combination of the presence of an acid catalyst and the strong heating conditions. 
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Before trying with a different condensation system, such as formamidine acetate in 
DMF, the reaction was repeated at a lower temperature, 150°C. In this third attempt, the 
conversion of starting material 395 into a new species was monitored by T.L.C., and 
after 5 days of heating, desired product 396 was finally obtained in 71% yield after 
recystallisation from EtOH/H2O. 
 
Ethyl 4-chloro-5-methylthieno[2,3-d]pyrimidine-6-carboxylate (397) 
A first attempt was made to chlorinate and aromatise intermediate 396 to obtain chloro-
pyrimidine 397 in the usual reaction system. With this procedure, the formation of a 
mixture of different products was noticed, and it was not possible to purify nor confirm 
the presence of desired compound 397. 
According to literature, it was decided to use POCl3 only as reagent, changing the 
solvent to toluene, and to add a base to neutralise phosphoric acid formed (scheme 
4.29).30 
 
 
Scheme 4.29: Modified conditions to obtain compound 397 
 
Following this new procedure, desired product 397 was obtained in 79% yield after 
flash column chromaphic purification. 
The remaining steps in the synthetic route were successful in the usual reaction 
conditions. 
 
4.9.1 Ethyl 5-methyl-4-(2-(1-phenylethylidene)hydrazinyl)thieno[2,3-
d]pyrimidine-6-carboxylates (399-400) 
 
Two hydrazone final products were obtained by reacting hydrazine intermediate 398 
with ketones 202 and 250 (scheme 4.30). 
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Ketone Ar Product Yield % 
202 2-hydroxyphenyl 399 29 
250 pyrazine 400 45 
 
Scheme 4.30: Synthesis of compounds 399-400 
 
4.9.2 Ethyl 5-methyl-4-(2-picolinoylhydrazinyl)thieno[2,3-d]pyrimidine-6-
carboxylate (401) 
 
One new hydrazide compound was prepared by a coupling reaction between 
intermediate 398 and picolinic acid (277) (scheme 4.31). 
 
 
Scheme 4.31: Synthesis of compound 401 
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4.9.3 Biological evaluation 
 
Ethyl ester compounds 399-401 were evaluated for their antiviral potential in the HCV 
replicon assay.18 Biological data are shown in table 4.16. 
 
 
Product Ar Linker X EC50(M) CC50(M) EC90(M) SI 
399 2-hydroxyphenyl hydrazone <0.234 187 <0.234 >799 
400 pyrazine hydrazone <0.244 0.281 <0.244 >1.16 
401 2-pyridine hydrazide <0.243 19.8 <0.243 >81.5 
 
Table 4.16: Antiviral and cytotoxicity data for compounds 399-401 
 
The presence of an ethyl ester substituent on the thiophene ring is in general associated 
with a retained antiviral effect, confirming the potential of structural expansion in this 
part of the molecule. Only in the case of compound 400, this last modification is also 
associated to an increased cytotoxic effect: further studies are ongoing to confirm this 
trend and establish the EC50 value for the three new compounds prepared. 
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4.10 Synthesis of 6,7,8,9-tetrahydro-3H-cyclohepta[4,5]thieno[2,3-
d]pyrimidines, 5,6-dihydro-3H-pyrano[4',3':4,5]thieno [2,3-
d]pyrimidines and 7-methyl-5,6,7,8-tetrahydropyrido 
[4',3':4,5]thieno[2,3-d]pyrimidines 
 
With the purpose to further modify the cyclic substituent on the thienopyrimidine ring, 
it was decided to expand the original cyclohexyl group to a cycloheptyl one, and to 
insert heteroatoms on the aliphatic six-member system. This result was achieved by 
using different cyclic ketones, cycloheptanone (402), tetrahydro-4H-pyran-4-one (403) 
and N-methyl-4-piperidone (404), respectively, in the first step of the previously 
optimised synthetic route (scheme 4.32). 
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Scheme 4.32: Strategy for the synthesis of compounds 417-428 
 
As shown above, the usual synthetic route fitted well the first two families of structures, 
with a cycloheptyl and a dihydropyran substituent attached to the thiophene ring. For 
the N-methyl-tetrahydropiridine series of compounds, the second step in the synthetic 
route needed to be changed from the usual conditions. 
 
Synthesis of 7-methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-
4(3H)-one (410) 
In the N-methyl-tetrahydropyridine series of compounds, condensation of the 
pyrimidinone nucleus was not successful with the usual reaction conditions: in a first 
attempt, aminoester intermediate 407 was refluxed with an excess of formamide for 8 h, 
Chapter 4: Thienopyrimidines 
 
173 
 
but even if formation of desired product 410 was confirmed by MS experiments, it was 
not possible to isolate it pure with recrystallisation or column chromatography 
techniques, due to its interaction with formamide, used in large excess. 
As shown in scheme 4.33, the reaction was repeated using DMF as solvent and 
formamidine acetate as reagent to obtain pyrimidinone ring condensation: also in this 
second attempt, it was not possible to completely purify desired product 410, due to its 
interaction with DMF. Most DMF was removed under high vacuum and the crude oily 
residue was used for the next step without further purification. 
 
 
Scheme 4.33: Attempts for the synthesis of compound 410 
 
4-Chloro-7-methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine (413) 
As discussed above, it was decided to use crude pyrimidinone intermediate 410 for the 
chlorination step without purification. Usual reaction conditions for this step require the 
addition of an excess of phosphorus oxychloride, reagent and solvent, and the mixture is 
refluxed for 6 h. In this case, the formation of a thick precipitate was noticed 
immediately after addition of POCl3, and monitoring of the reaction by T.L.C. did not 
indicate any conversion of the starting material into the product after 4 h. An insoluble 
salt on the methyl-tetrahydropyridine amine group might have been formed in the acid 
reaction environment. The reaction mixture was cooled to 0°C, a small excess of NEt3 
was then added to neutralise the potential salt, and finally the mixture was heated under 
reflux for 6 h. The solid precipitate solubilised immediately after addition of the base, 
while complete conversion of the starting material was confirmed by T.L.C. after 6 h. 
Chloro-pyrimidine intermediate 413 was isolated in 49% yield over two steps after flash 
column chromatography purification. 
 
4.10.1 4-(2-(1-Phenylethylidene)hydrazinyl)[4,5]thieno[2,3-d]pyrimidines (417-422) 
 
Hydrazine intermediates 414-416 were reacted with ketones 202 and 250 to obtain six 
new hydrazone products, as shown in scheme 4.34. 
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Ketone Product R Ar Yield % 
202 417 CH2CH2 2-hydroxyphenyl 39 
250 418 CH2CH2 pyrazine 43 
202 419 O 2-hydroxyphenyl 94 
250 420 O pyrazine 86 
202 421 NCH3 2-hydroxyphenyl 23 
250 422 NCH3 pyrazine 53 
 
Scheme 4.34: Synthesis of compounds 417-422 
 
4.10.2 [4,5]Thieno[2,3-d]pyrimidin-4-yl) arylhydrazides (423-428) 
 
Six new hydrazide products were obtained with a coupling reaction between 
intermediates 414-416 and aryl carboxylic acids 275 and 277. 
 
 
Ketone Product R Ar Yield % 
275 423 CH2CH2 2-hydroxyphenyl 38 
277 424 CH2CH2 2-pyridine 30 
275 425 O 2-hydroxyphenyl 23 
277 426 O 2-pyridine 83 
275 427 NCH3 2-hydroxyphenyl 30 
277 428 NCH3 2-pyridine 41 
 
Scheme 4.35: Synthesis of compounds 423-428 
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4.10.3 Biological evaluation 
 
Newly synthesised compounds 417-428 were evaluated in the HCV replicon assay.18 
 
 
Compound R Ar Linker X EC50(M) CC50(M) EC90(M) SI 
417 CH2CH2 2-hydroxyphenyl hydrazone 0.268 51.5 0.757 192 
418 CH2CH2 pyrazine hydrazone 0.195 3.83 0.368 19.6 
419 O 2-hydroxyphenyl hydrazone 0.512 >294 1.59 574 
420 O pyrazine hydrazone 0.528 4.42 1.22 8.4 
421 NCH3 2-hydroxyphenyl hydrazone 0.834 30 1.79 36 
422 NCH3 pyrazine hydrazone <0.767 >295 <0.767 >384 
423 CH2CH2 2-hydroxyphenyl hydrazide 0.451 144 <1.65 319 
424 CH2CH2 2-pyridine hydrazide 0.272 16.6 1.74 61 
425 O 2-hydroxyphenyl hydrazide 0.887 202 1.65 227.7 
426 O 2-pyridine hydrazide 1.19 62.3 2.05 52.4 
427 NCH3 2-hydroxyphenyl hydrazide <0.733 >281 <0.733 >383 
428 NCH3 2-pyridine hydrazide 1.45 99.7 2.47 68.8 
 
Table 4.17: Antiviral and cytotoxicity data for compounds 417-428 
 
As can be deduced from table 4.17, the new modifications on the level of the thiophene 
substituent are associated with activity retention, both for hydrazone and hydrazide 
series of compounds. Data obtained so far suggest that the enlargement of the 
cyclohexyl ring does not affect antiviral potential, and the same indication can be 
obtained also in the case of the insertion of a heteroatom in the original six-membered 
aliphatic ring. The presence of an N-methyl group in the ring is as well associated with 
activity retention. 
In conclusion, modifications carried out so far suggest that an expanded or heteroatomic 
aliphatic ring on the thiophene is tolerated and does not interfere with antiviral activity: 
while the presence of a substituent seems to be required for activity retention, data 
found so far indicate the potential for expansion of the occupational volume in this part 
of the molecule. 
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4.11 Synthesis of 5,6,7,8-tetrahydropyrido[4',3':4,5]thieno [2,3-
d]pyrimidines 
 
Aiming to evaluate the effect of heteroatoms in the aliphatic cyclohexyl substituent on 
the thiophene system, along with the preparation of previously discussed dihydropyran 
and N-methyl-tetrahydropyridine compounds, a tetrahydropyridine ring was inserted in 
this part of the structure. 
In order to avoid potential interference of a free amine group in the first three steps of 
the usual synthetic pathway, 4-piperidone hydrochloride (429) was protected with BOC 
protecting group. Protected ketone tert-butyl 4-oxopiperidine-1-carboxylate (430) was 
then inserted in the usual synthetic route, and used to form thieno-aminoester 
intermediate 431 according to Gewald condensation, followed by pyrimidinone ring 
closure in compound 432, and chlorination with aromatisation of pyrimidine system in 
compound 433. As can be seen in scheme 4.34, the plan at this point was to deprotect 
the amino group of compound 433 into free amine 434, which was then to be reacted 
with hydrazine to give final intermediate 435. 
The deprotection step in this first strategy attempted was not straightforward. 
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Scheme 4.34: First synthetic strategy attempted for tetrahydropyridine compounds 
 
Synthesis of tert-butyl 4-chloro-5,6-dihydropyrido[4',3':4,5]thieno[2,3-
d]pyrimidine-7(8H)-carboxylate (433) 
Following reported procedures, the protected pyridmidinone system was aromatised 
into pyrimidine 433 and chlorinated using phosphorus oxichloride in the presence of 
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triethylamine.31 The reaction mixture was stirred under milder heating than the usual 
reflux conditions, and desired product 433 was isolated in 96% yield after flash column 
chromatography. 
 
Synthesis of 4-hydrazinyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-
d]pyrimidine (435) 
In the first strategy attempted, as shown in scheme 4.34, intermediate 433 was to be 
deprotected and the remaining steps in the synthetic pathway were to be completed with 
the free amine group in the tetrahydropyridine ring. 
Nevertheless, after removal of the BOC group in acid conditions using a saturated 
solution of HCl in dioxane, it was not possible to obtain deprotected intermediate 434 as 
a pure species: all attempts to precipitate it from the reaction mixture failed, and this 
compound could only be isolated as an impure oily residue after several neutralisations 
and extractions. The following step of aromatic nucleophilic displacement with 
hydrazine was performed anyway, and even if the presence of desired hydrazine 
intermediate 435 as the main species was confirmed by MS, its isolation was not 
successful, and the oily residue obtained was considered not pure enough to attempt any 
further reaction. 
Attempting to reduce purification difficulties, it was decided to carry out the aromatic 
nucleophilic displacement to obtain hydrazine species on BOC-protected chloride 433 
(scheme 4.35). 
 
 
Scheme 4.35: Second deprotecting strategy applied to obtain intermediate 435 
 
BOC-protected hydrazine intermediate 436 was successfully obtained in the usual 
reaction system, with 46% yield after recrystallization from EtOH/H2O. 
Deprotection of compound 436 was then performed using trifluoroacetic acid in DCM: 
it was not possible to obtain the free-amine product 435 as a pure compound, due to its 
oily nature. MS experiments confirmed however its presence as the main species in the 
crude residue; it was therefore decided to use it in the final step for the formation of two 
hydrazone products. This decision was taken due to the high solubility of crude oily 
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compound 435 in EtOH and to the fact that all hydrazone products prepared so far were 
isolated by precipitation from the reaction mixture and subsequent recrystallisation. 
Also in this case, Schiff base products could be isolated in the same manner, thus 
removing the impurities present in the starting material. 
 
4.11.1 4-(2-(1-Phenylethylidene)hydrazinyl)-5,6,7,8-tetrahydropyrido[4',3':4,5] 
thieno [2,3-d]pyrimidines (437-438) 
 
Two new hydrazone compounds were finally obtained for this series, by reacting final 
intermediate 435 with ketones 202 and 250 (scheme 4.36). Both of them precipitated as 
yellow solids from the reaction mixture, and were recrystallised from EtOH. 
 
 
Ketone Ar Product Yield % 
202 2-hydroxyphenyl 437 23 
250 pyrazine 438 10 
 
Scheme 4.36: Synthesis of compounds 437-438 
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4.11.2 Biological evaluation 
 
Biological data in the HCV replicon assay for compounds 437-438 are shown in table 
4.16.18 
 
 
Compound Ar EC50(M) CC50(M) EC90(M) SI 
437 2-hydroxyphenyl 0.061 >2.95 t.b.d. >47.7 
438 pyrazine 0.038 7.71 t.b.d. 201 
 
Table 4.16: Antiviral and cytotoxicity data for compounds 437-438 
 
The presence of a tetrahydropiridine substituent on the thiophene ring is associated with 
a retained activity profile in the hydrazone family of structures: the two new derivatives 
prepared, compounds 437 and 438, show EC50 values in the nanomolar range.
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4.12 Synthesis of 2-methyl-5,6,7,8-tetrahydro[1]benzothieno[2,3-
d]pyrimidines 
 
With the purpose to explore the role of the aromatic proton in the pyrimidine ring in the 
original tetrahydrobenzothiophene nucleus, its replacement with a methyl group was 
designed and carried out. 
As shown in scheme 4.37, this result was achieved by condensing aminoester 
intermediate 190 with acetonitrile instead of formamide, in order to obtain pyrimidinone 
intermediate 439 with a methyl group replacing the aromatic proton. Compound 439 
was then inserted in the previously optimised synthetic route, to give functionalised 
hydrazine intermediate 441, which was reacted to give both hydrazone and hydrazide 
products, as had been done for the past series of derivatives. 
 
 
Scheme 4.37: Synthetic approach for compounds 442-445 
 
Synthesis of 2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-
one (439) 
According to optimised reported procedures, the methyl-pyrimidinone ring in 
compound 439 was condensed reacting aminoester 190 with acetonitrile in a saturated 
HCl solution in dioxane, under pressure in a sealed tube.32 Aminoester 190 forms a 
thick precipitate in the reaction system; the mixture was therefore sonicated in an 
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ultrasonic bath for 4 h, in order to solubilise the starting material, and then heated at 
100°C for 16 h. Desired pyrimidinone intermediate 439 was then precipitated off by 
addition of water, filtered, dried and obtained in high purity with 40% yield. 
 
4.12.1 2-Methyl-4-(2-(1-arylethylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo[4,5] 
thieno[2,3-d]pyrimidines (442, 443) 
 
Two hydrazone final products were prepared for this family of compounds by reacting 
hydrazine intermediate 441 with ketones 202 and 250. 
 
 
Ketone Ar Product Yield % 
202 2-hydroxyphenyl 442 86 
250 pyrazine 443 59 
 
Scheme 4.38: Synthesis of compounds 442 and 443 
 
4.12.2 N'-(2-Methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)aryl 
hydrazides (444, 445) 
 
A small series of two new hydrazide compounds was synthesised reacting intermediate 
441 and carboxylic acids 275 and 277, following as usual a TBTU-promoted coupling 
reaction. 
 
 
Carboxylic acid Ar Product Yield % 
275 2-hydroxyphenyl 444 36 
277 2-pyridine 445 38 
 
Scheme 4.39: Synthesis of compounds 444 and 445 
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4.12.3 Biological evaluation 
 
Compounds 442-445 were tested for their antiviral potential in the HCV replicon assay 
(table 4.12).18 
 
 
Compound Ar Linker X EC50(M) CC50(M) EC90(M) SI 
442 2-hydroxyphenyl hydrazone >284 >284 >284 - 
443 pyrazine hydrazone 0.069 >3 0.24 >42.7 
444 2-hydroxyphenyl hydrazide 1.26 25 3.07 19.8 
445 2-pyridine hydrazide 0.077 >2.95 0.32 >38.1 
 
Table 4.17: Antiviral and cytotoxicity data for compounds 442-445 
 
Methylation of the pyrimidine ring is associated with an inconsistent effect among the 
series of compounds tested: while in general this modification induces activity 
retention, with EC50 values in the nanomolar range for compounds 443 and 445, 
antiviral potential is completely lost in compound 442,   carrying   a   2’-hydorxyphenyl 
group in the original hydrazone structure. Further biological studies are ongoing to 
confirm the heterogeneous activity profile found for this last modification. 
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4.13 Synthesis of 6-ethylthieno[2,3-d]pyrimidines 
 
A series of recently published structures were considered interesting for a potential 
comparison with thienopyrimidine compounds synthesised and evaluated so far: 
compound 446 (figure 4.8) was discovered as the most potent derivative of a series of 
inhibitors of cyclin-dependent kinase CDK4, with IC50 values of 0.75 µg/mL for the 
inhibition of CDK4 activity, 1.610 µg/mL for antiproliferative activity in human colon 
carcinoma HCT116 cell lines, and 0.556 µg/mL antiproliferative activity in human lung 
carcinoma PC6 cell lines.33 
 
 
Figure 4.8: Structure of compound 446 
 
Cyclin-dependent kinases CDKs are a family of kinases involved in the regulation of 
growth, proliferation and apoptosis of eukaryotic cells;34 they coordinate the progress of 
cells through the phases of the cell cycle and phosphorylate the retinoblastoma tumour 
suppressor protein Rb. When hyperphosphorylated, Rb triggers the release of E2F 
proteins, transcription factors which cause activation of gene expression, leading cells to 
enter the S phase.35 CDK activities are down-regulated in normal cells by tumour 
suppressor p16 and other kinase inhibitors.36 In many tumours, mutations, deletions and 
silencing of p16 or Rb gene are found, and deregulation of Rb pathway and CDK4 
seems to play an important role in cancer progression.37 
Inhibition of CDK4 expression has been demonstrated to cause hypophosphorylation of 
Rb, with a subsequent accumulation of cells in G1 phase,38 while CDK4 knockdown in 
mammary tumour cells inhibits tumour formation.39 CDK4 inhibitors represent 
therefore a potential anticancer strategy. 
Evidence has been found suggesting that up-regulation of CDK4 and its regulatory 
subunit cyclin D1 are activated in cirrhosis, a precancerous condition that leads to the 
development of HCC, hepatocellular carcinoma, and this up-regulation is related to 
differentiation and progression of HCC.40 Moreover, HCV core protein has been 
recognised to be strongly involved in HCC pathogenesis: it interacts with cellular 
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proteins and transduction pathways which regulate transcription of proto-oncogenes, 
and has been proven to be directly implicated in transformation and immortalisation of 
cells.41 In this scenario, one of the regulatory systems led to up-regulation is cyclin D1-
CDK4,42 while inactivation of p16 gene is frequently associated with HCC tumours.43 
Due to the fact that the HCV replicon assay is performed on a human hepatoma cell 
line, the opportunity of an interaction with an overexpressed cellular factor, such as 
CDK4, was taken into consideration for thienopyrimidine structures evaluated so far, 
due to the structural similarities they share with compound 446. Their potential 
inhibition of kinases is going to be evaluated in future studies. 
Nevertheless, as a proof of concept, it was decided to re-synthesise compound 446 and 
have it tested against HCV replication in the replicon assay. Moreover, its 6-
ethylthienopyrimidine scaffold was used to prepare four new compounds, two 
hydrazone and two hydrazide derivatives, with the most successful hydroxyphenyl and 
heteroaromatic substitutions found for the previous series of structures discussed in this 
study. Finally, a sixth new product was designed to insert the thiophen-2-ylmethylene 
substituent of compound 446 in the tetrahydrobenzothienopyrimidine scaffold of 
compound 187. 
As can be seen in scheme 4.40, starting from butyraldehyde 447 in the first step of 
Gewald condensation, the usual five-step synthetic approach was followed to obtain 
compound 446 and final products 452-456. 
Chapter 4: Thienopyrimidines 
 
186 
 
 
Scheme 4.40: Synthetic approach for compounds 442-445 
 
4.13.1 6-Ethyl-4-(2-(1-arylethylidene)hydrazinyl)thieno[2,3-d]pyrimidines (446, 
453-454) 
 
Along with compound 446, two hydrazone final products were obtained for this group 
of compounds, through Schiff base formation between hydrazine intermediate 451 and 
carbonyl compounds 452, 202 and 250. 
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Aldehyde/Ketone R Ar Product Yield % 
452 H 2-thiophene 446 46 
202 Me 2-hydroxyphenyl 453 44 
250 Me pyrazine 454 71 
 
Scheme 4.41: Synthesis of compounds 446, 453-454 
 
4.13.2 N'-(6-Ethylthieno[2,3-d]pyrimidin-4-yl)-2-arylcarbohydrazides (455-456) 
 
Two hydrazide compounds were prepared by reacting intermediate 451 with carboxylic 
acids 275 and 277. 
 
 
Carboxylic acid Ar Product Yield % 
275 2-hydroxyphenyl 455 28 
277 2-pyridine 456 26 
 
Scheme 4.42: Synthesis of compounds 444-445 
 
4.13.3 4-(2-(Thiophen-2-ylmethylene)hydrazinyl)-5,6,7,8-tetrahydrobenzo[4,5] 
thieno[2,3-d]pyrimidine (457) 
 
Thiophene-2-carboxaldehyde 452 was reacted with compound 193 to obtain final 
product 457, as shown in scheme 4.43. 
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Scheme 4.43: Synthesis of compound 457 
 
4.13.4 Biological evaluation 
 
Compounds 446 and 453-457 were evaluated in the HCV replicon assay.18 Biological 
results are shown in table 4.18. 
 
 
Compound R Ar Scaffold EC50(M) CC50(M) EC90(M) SI 
446 H 2-thiophene A 4.69 22.8 - 4.9 
453 Me 2-hydroxyphenyl A 1.8 24.6 - 13.7 
454 Me pyrazine A 0.895 4.55 0.662 5.1 
455 - 2-hydroxyphenyl B 1.46 >318 2.97 >217.8 
456 - 2-pyridine B 1.12 41.1 2 36.7 
457 H 2-thiophene C 4.91 40.5 - 8.2 
 
Table 4.18: Antiviral and cytotoxicity data for compounds 446, 453-547 
 
Biological data for compound 446 do not suggest significant activity against viral 
replication: its effect seems to be more correlated to cytotoxicity rather than inhibition 
of HCV replication, with a profile similar to the ones found for some of the previously 
tested hydrazone compounds (215-234, 252-265, 290-294), which were not considered 
as potential antiviral hits. 
The same observation can be extended to compound 457: as its ethenyl-thiophene 
analogue 294, it is not associated with a significant antiviral potential. These data are in 
line with the trend previously found in the structure-activity relationships observed so 
far for these compounds. 
As for the 6-ethyl substitution on the thienopyrimidine system in hydrazone compounds 
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453 and 454, this modification is associated with loss of activity in the case of 2-
hydroxyphenyl product 453, and to an increased cytotoxic effect in the case of pyrazine 
derivative 454, in comparison to previously discussed analogues carrying these two 
ethenylic aromatic groups. 
This observation cannot be transferred to hydrazide products 455 and 456: these 
compounds show a retained antiviral profile in comparison to previously tested 
analogues with the same aromatic hydrazide substituents. 
What can be concluded is that, as for CDK4 inhibitor 446, its biological evaluation does 
not suggest the same antiviral potential found for thienopyrimidine hit structures 
identified in the course of this study. This assumption needs however to be confirmed 
with specific enzymatic tests, which may or may not exclude inhibition of CDK4 as the 
mechanism of action for compound 187 and its analogues. 
Regarding instead the 6-ethyl substitution on the thienopyrimidine system, this 
modification seems to have a different influence between the two series of structures, 
hydrazones and hydrazides: while in the first case it is associated with loss of antiviral 
potential, in the second it appears instead to confer retention of antiviral activity. This 
evidence may indicate that the substituent on the thienopyrimidine system has a greater 
influence on antiviral activity for hydrazone structures, and its effect may be 
compensated in the hydrazide series by a stronger interaction with the target given by 
the hydrazide group. 
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4.14 Conclusions 
 
Following molecular modelling studies, compound 187 was identified as a hit for the 
inhibition of HCV replication in the HCV replicon assay. Its structure was the starting 
point for the design and synthesis of 128 new analogues, which were evaluated for their 
antiviral potential against the HCV replication. 
 
 
 
According to biological results obtained so far, antiviral activity originally found for 
compound 187 was confirmed, and several new derivatives showed an improved 
antiviral effect, with some of them being associated with EC50 values in the nanomolar 
range. 
 
 
 
Structure-activity relationships could be identified with the modifications performed on 
the structural scaffold of compound 187: the presence of a hydrazone linker in the 
molecule is essential, but this bond can be successfully replaced with a hydrazide group, 
which is believed to be more stable in aqueous conditions. Moreover, an ethylidene 
group on the hydrazone bond is important for the cytotoxicity profile: the absence of the 
methyl group on this bond is associated with low CC50 and SI values. 
In the case of both hydrazone and hydrazide structures, the linker has to be 
functionalised with a six-membered aromatic ring carrying a hydroxyl group in position 
2, or a heteroaromatic ring with a nitrogen in position 2: among the different series of 
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derivatives prepared, the most successful modifications are obtained with a 2-
hydroxyphenyl, a 2-pyridine or a pyrazine group in this part of the structure. The 
presence of a 2-bendimidazole group is tolerated, while all the other modifications 
attempted were associated with loss of activity. 
The presence of an aliphatic or aromatic substituent on the thienopyrimidine nucleus 
appears to be essential for activity retention, and suggests expansion potential for this 
part of the structure: when the original tetrahydrobenzene ring is completely removed, 
an enhanced cytotoxic effect can be observed, while the aromatisation of this group is 
associated with activity retention. Replacement of this substituent with a smaller 
cyclopentyl ring or with a bigger cycloheptyl group is associated with a retained 
antiviral profile, and the same effect is seen with the insertion of heterocyclic functions 
such as an N-methyl-tetrahydropyridine ring, a pyran group or a tetrahydropiridine ring. 
The original tetrahydrobenzene group on the thiophene ring can also be replaced with 
aliphatic groups such as methyl, ethyl, methoxy and ethyl ester moieties: all these 
modifications are associated with retention of activity. Biological data obtained so far 
suggest that the occupational volume in this part of the molecule is important for 
antiviral activity. 
The role of the pyrimidine proton has also been explored: its replacement with a methyl 
group is associated with an inconsistent effect among the structural derivatives 
prepared, and even if the general trend suggests activity retention, further biological 
evaluations are required to confirm this assumption. 
The most promising modifications found so far are summarised in table 4.19. 
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Compound Ar Linker X R1, R2 EC50(M) CC50(M) EC90(M) SI 
343 pyrazine hydrazide cyclopentyl 0.0759 3.18 <0.256 41.9 
352 2-
hydroxyphenyl 
hydrazone benzene 0.0861 12 0.421 139.4 
357 pyrazine hydrazide benzene 0.0783 1.31 0.143 17 
374 pyrazine hydrazide dimethyl 0.091 1.58 0.26 17.3 
437 2-
hydroxyphenyl 
hydrazone tetrahydropyridine 0.061 >2.95 t.b.d. >47.7 
438 pyrazine hydrazone tetrahydropyridine 0.038 7.71 t.b.d. 201 
 
Table 4.19: Thienopyrimidine derivatives with EC50 values in the nanomolar range. 
 
Future modifications of the original structure could involve the replacement of the 
central thienopyrimidine nucleus with different heteroaromatic scaffolds, in order to 
determine the impact of this condensed ring on antiviral activity. 
Further biological studies are ongoing in order to determine the actual EC50, EC90 and 
CC50 values for some of the compounds prepared, along with the determination of the 
viral or cellular target of these structures, and potentially their mechanism of action. 
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5.1 Ligand-based Virtual Screening 
 
An essential requirement for mutual recognition between small molecules and their 
protein targets is shape complementarity.1 Common docking-based virtual screening 
techniques, even though evaluating shape complementarity between a hit and the 
binding pocket, usually estimate the ligand binding energy by a scoring procedure that 
emphasises electrostatics rather than shape.2 In ligand-based screening methods, for 
which a high accuracy in finding active molecules has been demonstrated, the shapes of 
known ligands are compared with unknown ones, while the chemical properties of 
known molecules can be included in the comparison as pharmacophoric or electrostatic 
models. These methods based on ligand similarity can evaluate two-dimensional 
similarities, such as fingerprints,3 or three-dimensional similarities, focusing on the 
occupational volume acquired by molecules. While 2D comparison methods tend to 
find hits with the same functional groups of the query molecule,4 3D methods are 
focused on the occupational volume associated with each molecule, thus allowing the 
identification of novel lead structures with a higher level of scaffold diversity. In 3D 
similarity search softwares such as ROCS, pharmacophoric properties or associated 
electrostatic potential of the query molecule can be implemented to the search, thus 
enriching the use of complementarity shape with chemical features that might be 
important for ligand-target recognition.5 
In order to explore the potential of a shape-comparison method in the search for HCV 
NS3 helicase inhibitors, this type of approach was applied for a new screening of the 
SPECS library. 
Due to the wide chemical diversity and variability of target subsites associated with 
known helicase inhibitors, the structures of the dye soluble blue HT, compound 1, and 
its chemical derivatives were chosen as a starting point,6 since compound 1 is the only 
helicase inhibitor for which a crystal structure in complex with the enzyme is available 
(PDB ID 1ZJO, figure 5.1).7 
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Figure 5.1:  1ZJO crystal structure. Compound 1 in complex with the HCV NS3 helicase 
 
Many of the published HCV NS3 helicase inhibitors have recently been re-tested in 
both an optimised enzymatic assay and a replicon cell-based assay:8 among them, one 
structural derivative of compound 1, the triphenylmethane analogue 458 (figure 5.2),6 
has been confirmed to inhibit both the enzyme (IC50 17 +/- 7 M) and the viral 
replication (~80% inhibited at 10 M compound) without relevant cytotoxicity (~75% 
cell viability at 10 M compound).8 
 
 
Figure 5.2: Structure of compounds 1 and 458 
 
Due to its activity profile, the structure of compound 458 was chosen as the query 
molecule for a shape comparison-based screening of the SPECS library,9 performed 
with ROCS 3D similarity search software.5 
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5.1.1 Conformational search for ROCS query edition 
 
In order to evaluate the shape complementarity between target query and screened 
compounds, the program considers the shape-density overlapping volumes of molecular 
shape in each superimposition, and the superimposed molecules are scored on the basis 
of a Tanimoto-like overlapping value of molecular volumes, the higher it is (between 0 
and 1), the most similar the two compared volumes are considered. 
In such context, the conformational state of the query molecule plays an essential role 
for hits selection, since all analysed structures will be scored on the basis of their 
overlapping with the target conformation. Conformation selection for the query 
structure becomes crucial, along with the evaluation of the different three-dimensional 
states that the molecules to screen can assume. 
As had been previously done for the two pharmacophoric searches of the SPECS 
library, a conformational search with MOE2010.10 was performed for the creation of a 
conformational database of the compounds to be screened.10 
A conformational analysis was performed on the srtucture of compound 458, in order to 
identify low-energy three-dimensional states to be used as the query in the shape 
screening. Multiple low-energy conformations were obtained. For a more accurate 
selection of the target query, results found for compound 458 were compared to the 
conformation of compound 1 in the 1ZJO crystal structure: MOE Flexible Alignment 
tool was used for this purpose.11 The low-energy conformations found for compound 
458 were rigidly aligned to compound 1, and the one corresponding to the best 
alignment (dU=0 kcal/mol, S= -220, figure 5.3) was chosen as target query for ROCS 
screening. 
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Figure 5.3: Conformational superimposition between compound 1, coloured in blue, and compound 458, 
in cyan. 
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5.1.2 Shape complementarity search of the SPECS database 
 
The conformational database obtained for SPECS compounds was analysed against the 
selected conformation of compound 458 with the vROCS 3.1.2 software,5 considering 
both shape and electrostatics complementarity with the target query for the evaluation 
of screened structures. 
All screened conformations were ranked on the basis of their similarity score with the 
given target molecule. In order to choose a small number of hits to purchase and test in 
the cell-based replicon assay, a selection was made among the screened molecules in 
order to identify those showing the highest values of similarity index (Combo-shape 
tanimoto score) and the major number of different conformations matching the query. 
On the basis of these parameters, six compounds were finally selected (Appendix I). 
One of them, compound 459 (figure 5.4), showed antiviral effect in the replicon assay, 
with an EC50 and EC90 value of 38 and 149 M, respectively, and a CC50>204 M. Its 
scaffold was chosen for further development.  
 
 
 
 
 
 
 
Figure 5.4: chemical structure and best alignment of compound 459 (aligned in green against compound 
458, in blue) 
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5.2 Synthesis of 1-aryl-3-arylidene-5-phenyl-1H-pyrrol-2(3H)-ones 
 
The structure of compound 459 shows a central pyrrolone nucleus, substituted in 
position 1 and 5 with two aromatic rings, and linked in position 2 with a phenylidene 
system (figure 5.5). 
 
 
 
Figure 5.5: Chemical features of compound 459 
 
In order to confirm the antiviral potential associated with this scaffold, it was decided to 
synthesise, along with the original structure, a preliminary series of triphenyl-pyrrolone 
derivatives by only varying the aromatic substituents on the 1-phenyl and 3-phenylidene 
rings. For the preparation of desired compounds, a two-step synthetic pathway was 
planned, as shown in scheme 5.1. 
 
 
Scheme 5.1: Synthetic pathway planned for compounds 459, 475-482 
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The strategy carried out began with the condensation between 3-benzoyl propanoic acid 
(460) and differently para substituted benzaldehydes, with the formation of 
intermediates 466-470 through furanone ring closure, followed by phenyl-amine 
displacement of the cyclic ester with the formation of the pyrrolone system in final 
products 459, 475-482. 
 
Synthesis of ethyl 4-formylbenzoate (461)12 
Due to the presence of a 4-benzoic acid ethyl ester substituent in the structure of 
compound 459, benzaldehyde 461 was synthesised by a Fischer esterification of 4-
formyl-benzoic acid (483), which was refluxed with ethanol in presence of sulphuric 
acid to give desired ethyl 4-formylbenzoate (461), as shown in scheme 5.2. 
 
 
Scheme 5.2: Synthesis of starting bendaldehyde 461 
 
5.2.1 3-Arylidene-5-phenylfuran-2(3H)-ones (466-470) 
 
Following reported procedures, furanone intermediates 258-262 were obtained by 
heating the starting materials at 95 °C in acetic anhydride in presence of sodium acetate. 
13 The formation of the central butenolide ring is believed to follow a Perkin 
condensation between the -benzoylpropionic acid and aryl aldehyde,14 which are 
thought to form an aldol-condensation product that subsequently undergoes internal 
cyclisation with the formation of furanone ring, as shown in scheme 5.3. 
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Scheme 5.3: Postulated mechanism for the formation of compounds 466-470 
 
Following this procedure, five butenolide intermediates were prepared by changing the 
starting benzaldehyde (table 5.1). For this preliminary series of compounds it was 
decided to maintain a common unsubstituted phenyl ring in position 5 of the final 
pyrrolone derivatives, while exploring a few different substitutions in the para position 
of the 3-phenylidene system. 
 
 
Aldehyde R1 Furanone intermediate Yield % 
461 COOEt 466 31 
462 H 467 35 
463 OMe 468 33 
464 Br 469 51 
465 Ph 470 41 
 
Table 5.1: Chemical structure of furanone intermediates 466-470 
 
5.2.2 1-Aryl-3-arylidene-5-phenyl-1H-pyrrol-2(3H)-ones (459, 475-482) 
 
According to reported procedures, a first attempt to obtain final compound 459 was 
made by heating at 100 °C in toluene furanone intermediate 466 with 2-bromo-4-
methyl-aniline (471). 15-16 Formation of the final pyrrolone product is thought to take 
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place through an intermediate stage where the furanone ring is opened as a result of the 
ammonolysis of the starting compound by the aromatic amine. The amide initially 
formed is then believed to undergo cyclisation to a tautomeric 5-hydroxyl species, 
followed by dehydration with the formation of pyrrolone ring (scheme 5.4).16 
 
 
Scheme 5.4: Postulated mechanism for the formation of compounds 459, 475-482 
 
The reaction was tried with different molar ratios of the reagents and time was increased 
from 12 to 48 h, but formation of desired product 459 was not observed in this solvent 
system, while the starting material 461 was recovered after flash column 
chromatography purification. 
Following reported procedures for the synthesis of phthalimides,17 in an attempt to 
enhance the elecrophilic characteristics of the ketone carbonyl carbon of the 
intermediate amide, and in order to create a dehydrating environment to favour the 
formation of final pyrrolone products, toluene was replaced with glacial acetic acid, and 
the mixture was heated under reflux for 22 h, as shown in scheme 5.5. 
 
 
Scheme 5.5: Attempted conditions for the synthesis of compounds 459, 475-482 
 
Eight new derivatives, along with compound 459, were obtained with the new synthetic 
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procedure, by combining intermediates 461-465 with differently substituted anilines 
(471-474). Their structures are shown in table 5.2. 
 
 
Furanone intermediate R1 Aniline R2 Product Yield % 
461 COOEt 471 2-Br, 4-Me 459 44 
462 H 472 H 475 34 
461 COOEt 472 H 476 57 
463 OMe 472 H 477 39 
464 Br 472 H 478 29 
465 Ph 472 H 479 27 
461 COOEt 473 4-Me 480 32 
461 COOEt 474 2,3-Me 481 56 
462 H 471 2-Br, 4-Me 482 50 
 
Table 5.2: Structure of compounds 459, 475-482 
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5.2.3 Biological evaluation 
 
Newly synthesised triphenylpyrrolone structures were tested for antiviral activity in the 
subgenomic replicon and cytostatic assays.18 Their biological results are shown in table 
5.3. 
 
Product R1 R2 EC50(M) CC50(M) EC90(M) SI 
459 COOEt 2-Br, 4-Me 20.2 >205 61.7 >10.1 
475 H H 4.9 29 15.3 5.9 
476 COOEt H 22.8 99.6 73.2 3.2 
477 OMe H 5.31 97.2 21.6 18.3 
478 Br H 3.52 25.7 11.6 7.3 
479 Ph H 17.4 156 61.7 8.9 
480 COOEt 4-Me 22.9 >244 82 >10.7 
481 COOEt 2,4-Me 43.1 90.8 - - 
482 H 2-Br, 4-Me 3.3 >240 11.3 >73 
 
Table 5.3: Biological results for compounds 459, 475-482 
 
Re-synthesised compound 459 confirmed its activity profile, with EC50, EC90 and CC50 
values close to the ones previously found for the batch acquired from SPECS. 
Considering the substitutions attempted so far, the presence of an ethyl ester function in 
the 3-phenylidene ring does not appear to be essential for activity retention, since 
compound 482, where this group is removed, is the most active found for this series of 
compounds, with EC50 and EC90 values in the low µM range. A similar profile can be 
found also for derivatives 475, 477 and 478, where the 1-phenyl ring is unsubstituted 
and the ethyl ester group is replaced respectively with 4-H, 4-Me and 4-Br groups, but 
these modifications are associated with increased cytotoxicity. 
Antiviral potential associated with triphenylpyrrolone compounds was only partially 
explored with the modifications carried out so far, but activity confirmation obtained for 
compound 459 and improved antiviral profile found for derivative 482 could be an 
encouraging starting point for future development.  
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5.3 Conclusions 
 
In the course of this final part of the study, ligand-based molecular modelling 
techniques were applied to the analysis of the HCV NS3 helicase enzyme. 
A shape-comparison screening of commercially available compounds led to the 
identification of a third hit molecule, compound 459, associated with a positive anti-
HCV potential in cellular assays. The original structure was successfully re-synthesised, 
together with a preliminary series of eight new analogues, all of which have been tested 
in the HCV replicon assay. 
 
 
 
The antiviral potential originally found was confirmed for compound 459, and new 
structural derivatives were associated with an improved antiviral activity in the low µM 
range: the most active analogue in this first series of structures is compound 482, for 
which an improvement of antiviral potential is observed in terms of both EC50 and CC50 
values. A preliminary SAR evaluation suggests that the antiviral effect is mainly due to 
the N-phenyl substituent: the original 2-bromo-4-methyl-phenyl ring is essential for 
activity, while with the removal of the ethyl ester function on the phenylethylidene ring 
of compound 459 is associated with an improved antiviral profile. These results 
represent a promising starting point for future studies, with which different substituents 
could be investigated for all the three aromatic rings, along with the replacement of the 
central pyrrolone nucleus with new scaffolds. 
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In the course of this study, different molecular modelling techniques were applied to the 
analysis of the NS3 helicase enzyme with the aim to identify potential inhibitors of 
HCV replication. 
A first virtual screening study on the enzyme closed conformation allowed the 
identification of compound 12, which was associated to low-µM antiviral effect in the 
replicon assay. 
 
 
 
Starting from the structure of compound 12, 61 new derivatives were designed and 
synthesised to explore the antiviral effect associated to its scaffold, and several 
compounds were found to inhibit the viral replication at low µM concentration. The 
presence of two equally substituted phenyl-sulfonamide groups is essential for retention 
of activity, along with the presence of the central piperazine nucleus and two equal 
three-carbon aliphatic linkers. A hydrophobic substituent in the para position of the 
terminal aromatic rings is also essential for antiviral activity, along with the 
preservation of the symmetry of the molecule. A significant improvement in terms of 
potency could not be achieved with this series of structures, therefore further computer-
based analyses were planned and carried out. 
A ligand-based optimisation approach on compound 12 guided the synthesis of a first 
series of nine derivatives belonging to four new structural scaffolds. 
 
 
 
Due to the antiviral potential associated to one of the new structures synthesised, 
compound 162, an extended series of five new analogues was synthesised, and two 
derivatives showed anti-HCV activity in the low µM range. Two equal para-
phenylendiamine groups are required in the linker for activity retention, along with the 
presence of a central succinamide group and a para-hydrophobic substituent on the two 
phenyl-sulfonamide groups. Even if activity retention was obtained with different new 
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compounds, the desired improvement in potency was not achieved for the antiviral 
effect of this new series of compounds. A second virtual screening study was therefore 
planned with the aim to find more potent inhibitors of the HCV replication. 
The second virtual screening was performed on the crystal structure of the NS3 helicase 
enzyme in the open conformation, and among the new structures screened and selected 
for biological evaluation compound 187 was identified as a HCV replication inhibitor 
with a sub-µM activity: its structure was the starting point for the design and synthesis 
of 128 derivatives, which were biologically evaluated against HCV replication in the 
replicon assay. 
 
 
 
Structural modifications aiming to explore the antiviral potential associated with this 
new scaffold led to the synthesis of several new compounds with an improved antiviral 
potential, and some of them were associated to EC50 values in the nanomolar range. The 
presence of an aliphatic, aromatic or heterocyclic substituent on the thiophene ring is 
essential for antiviral activity, along with a hydrazone or hydrazide linker group 
between the thienopyrimidine ring and a second aromatic group. This second aromatic 
ring has to be a 2-hydroxyphenyl group or a six-membered heteroaromatic ring with a 
nitrogen in position 2, such as 2-pyridine or pirazine. Further biological evaluations are 
ongoing to identify the biological target and the mechanism of action of these promising 
antiviral agents, while future studies could include the substitution of the central 
thienopyrimidine ring with different heteroaromatic moieties, further expansion of the 
occupational volume of the substituent on the thiophene ring, and the replacement of the 
pyrimidine proton with new functional groups, since the only modification carried out 
so far on this part of the structure was the insertion of a methyl group. 
Finally, a shape-comparison ligand-based screening allowed to the identification of a 
third hit molecule, compound 459, associated to antiviral effect in the low µM range. Its 
structure was successfully re-synthesised, along with a first series of eight new 
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analogues. 
 
 
 
Among the small series of compounds prepared, the antiviral potential originally found 
was confirmed for compound 459, while its derivative compound 482 shows improved 
antiviral activity in the replicon assay. Biological data obtained so far suggest that 
inhibition of the viral replication is mainly associated with the 2-bromo, 4-methyl 
substituents on the N-phenyl ring, which are essential for activity, while the removal of 
the ethyl ester function on the phenylethylidene moiety leads to an improved activity 
profile. The results found so far for this last series of compounds represent a promising 
starting point for future structural modifications, which could include the exploration of 
different aromatic modifications on the three phenyl rings, the removal of these rings 
one at a time, the substitution of the central pyrrolone group with different heterocycles. 
Even though these findings represent a successful application of computer-aided 
techniques for the identification of biologically active compounds, specific studies are 
required to define the mechanism of action of these molecules, and confirm whether or 
not their molecular target can be identified as the HCV NS3 helicase. 
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6.1 General information 
All chemicals, reagents and solvents were purchased from Aldrich or purified by 
standard techniques. 
 
Thin Layer Chromatography 
Silica gel plates (Merck Kieselgel 60F254) were used and were developed by the 
ascending method. After solvent evaporation, compounds were visualised by irradiation 
with UV light at 254 nm and 366 nm. 
 
Column Chromatography 
Glass columns were dry packed in the appropriate eluent under gravity, with Woelm 
silica (32-63 mm). Samples were applied as a concentrated solution in the same eluent. 
Fractions containing the product were identified by TLC, combined and the solvent 
removed in vacuo. 
 
NMR Spectroscopy 
1H, 13C, NMR spectra were recorded on a Bruker AVANCE 500 spectrometer (500 
MHz and 75 MHz respectively) and auto calibrated to the deuterated solvent reference 
peak. Chemical shifts are given in  relative to tetramethylsilane (TMS); the coupling 
constants (J) are given in Hertz. TMS was used as an internal standard ( = 0 ppm) for 
1H NMR and CDCl3 served as an internal standard ( = 77.0 ppm) for 13C NMR. 
 
6.1.1 Molecular Modelling 
 
All molecular modelling studies were performed on a MAC pro 2.66 GHz Quad-Core 
Intel Xeon, running Ubuntu. 
Molecular Operating Environment (MOE) 2010.10 and Maestro (Schrodinger version 
9.0) were used as molecular modelling softwares. 
All minimisations were performed with MOE until RMSD gradient of 0.001 Kcal mol-1 
Å-1 with the AMBER99 force field. Partial charges were automatically calculated. 
Conformational analyses were performed with MOE 2010.10; conformers with a strain 
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energy >4 kcal/mol were discarded, and the maximum number of conformations per 
ligand was set to 500. In every step MOE default settings were applied. 
Pharmacophoric filters were created within MOE 2010.10 choosing the PCH (polar-
charged-hydrophobic) scheme. 
Docking experiments were carried out using LEadIT-FlexX version 2.1.0, Plants 
version 1.1 and GlideSP module in Maestro with the default options.  
Outputs of all docking experiments were refined with Glide SP refine-do not dock tool. 
All refined docking results were rescored using Plants ChemPLP, FlexX and Glide SP 
scoring functions. 
Selection of the best docked poses was made by building a consensus scoring function 
as follows: in each docking study, for each scoring function applied the first quartile 
value, fquart, was evaluated to determine the threshold limit under which relies the best 
25% of the scoring results (negative energy values). The mathematical function Sign 
was then applied for each scoring value of each docked pose, in order to determine 
whether it belongs to the best 25% (sign +1) or not (sign -1). Finally, the three sign 
values, each one corresponding to the performance according to one scoring function, 
for a given docked pose were summed and only the ones with a sign sum equal to +3 (or 
+2, meaning that one of the assigned scoring values was equal to the fquart value) were 
chosen. 
Referring to the three scoring functions Glide SP, Plants ChemPLP and FlexX as A, B 
and C respectively, the consensus scoring function equation for a given docked pose X 
was the following: 
 
Sign sum(X) = sign(fquartA – XA) + sign(fquartB – XB) + sign(fquartc – Xc) 
 
Shape-comparison screening was performed with vROCS version 3.1.2. Both shape and 
colour screen criteria were applied to the query. Output conformations were ranked by 
the Tanimoto Combo score and the Shape Tanimoto score. 
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6.2 Synthesis of piperazine structures 
 
6.2.1 General procedures 1-11 
 
General procedure 1: synthesis of N-(3-bromopropyl)arylsulfonamides 
 
 
 
Arylsulfonyl chloride (4 mmol) and 3-bromopropylamine hydrobromide (21) (1.0 g, 4.6 
mmol) were suspended in anhydrous DCM (14 mL) under nitrogen atmosphere. The 
reaction mixture was cooled to 0°C in an ice-bath and then treated dropwise with 
triethylamine (1.34 mL, 9.6 mmol) over a period of 10 min. 
The reaction mixture was stirred for 10 min under ice-cooling, then diluted with DCM 
(50 mL) and washed with 2M hydrochloric acid solution (2 x 60 mL) and brine (2 x 60 
mL). The organic solvent was evaporated at reduced pressure after drying over MgSO4 
to give the pure N-(3-bromopropyl)arylsulfonamides. 
 
General procedure 2: N-(2-bromoethyl)arylsulfonamides 
 
 
 
Arylsulfonyl chloride (4.2 mmol), and 2-bromoethylamine hydrobromide (37) (1.0 g, 
4.8 mmol) were suspended in anhydrous DCM (14 mL) under nitrogen atmosphere. The 
reaction mixture was cooled to 0°C in an ice-bath and then treated dropwise with 
triethylamine (1.4 mL, 10 mmol) over a period of 10 min. 
The reaction mixture was stirred for ten min under ice-cooling, then diluted with DCM 
(50 mL) and washed with 2M hydrochloric acid solution (2 x 60 mL) and brine (2 x 60 
mL). The organic solvent was evaporated at reduced pressure after drying over MgSO4 
to give pure N-(2-bromoethyl)arylsulfonamides. 
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General procedure 3: synthesis of arylsulfonylamino propionic acids 
 
 
 
To partially dissolved -alanine (54) (0.6 g, 6.8 mmol) in distilled water (4 mL) was 
added a solution of aqueous NaOH 2M (3.4 mL), followed by the portionwise addition 
of arylsulfonyl chloride (9.6 mmol). The reaction mixture was stirred at 35°C and a 
solution of 1 M aqueous NaOH was added portionwise to maintain a pH of 
approximately 9. After complete consumption of alkali, stirring was continued at 35°C 
for an additional 1 h. Unreacted arylsulfonyl chloride was removed by filtration, and the 
reaction mixture was acidified with 5M aqueous HCl at 0°C to pH 2. The aqueous 
solution with solid precipitate was stored at 4°C o.n. The crystals formed were collected 
by filtration, washed with cold water and dried at reduced pressure to afford pure 3-
arylsulfonylamino propionic acids. 
 
General procedure 4: synthesis of N,N’-(3,3’-(piperazine-1,4-diyl)bis(propane-3,1-
diyl))diarylsulfonamides 
 
 
 
Piperazine (0.050 g, 0.6 mmol) and NaHCO3 (0.109 g, 1.3 mmol) were suspended in 
absolute ethanol (9 mL). N-(3-Bromopropyl)arylsulfonamide (1.3 mmol), was then 
added portionwise to the suspension and the reaction mixture was stirred under reflux 
for 24 h. The solvent was evaporated under reduced pressure and the crude residue was 
purified by flash column chromatography to afford pure N,N’-(3,3’-(piperazine-1,4-
diyl)bis(propane-3,1-diyl))diarylsulfonamides. 
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General procedure 5: synthesis of N,N’-(2,2’-(piperazine-1,4-diyl)bis(ethane-2,1-
diyl)) diarylsulfonamides 
 
 
 
Piperazine (0.050 g, 0.6 mmol) and NaHCO3 (0.109 g, 1.3 mmol) were suspended in 
absolute ethanol (9 mL). N-(2-Bromoethyl)arylsulfonamide (1.3 mmol), was then added 
portionwise to the suspension and the reaction mixture was stirred under reflux for 24 h. 
The solvent was evaporated under reduced pressure and the crude residue was purified 
by flash column chromatography to afford pure N,N’-(2,2’-(piperazine-1,4-
diyl)bis(ethane-2,1-diyl))diaryl sulfonamides. 
 
General procedure 6: N,N’-(3,3’-(piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl)) 
diarylsulfonamides 
 
 
 
3-Arylsulfonylamino propionic acid (1.3 mmol), TBTU (0.45 g, 1.4 mmol) and HOBt 
(0.19 g, 1.4 mmol) were suspended in anhydrous THF (9 mL) at r.t. DIPEA (0.7 mL, 
4.2 mmol) was then added to the reaction mixture, followed by piperazine (41) (0.05 g, 
0.6 mmol). The reaction mixture was left stirring at r.t. for 4 h. The organic solvent was 
then removed at reduced pressure and the residue was suspended in EtOAc (100 mL). 
The organic layer was washed with saturated NaHCO3 solution (2 x 70 mL), then with 
saturated NH4Cl solution (2 x 70 mL) and finally with brine (70 mL). The organic 
solvent was removed under vacuum after drying over MgSO4. The crude residue was 
purified by flash column chromatography to afford pure N,N’-(3,3’-(piperazine-1,4-
diyl)bis(3-oxopropane-3,1-diyl))-diarylsulfonamides. 
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General procedure 7: synthesis of N-(3-(piperidin-1-yl)propyl)arylsulfonamides 
 
 
 
Piperidine (0.1 mL, 1.2 mmol) and NaHCO3 (0.109 g, 1.3 mmol) were suspended in 
absolute ethanol (9 mL). N-(3-Bromopropyl)arylsulfonamide (1.3 mmol), was then 
added portionwise to the suspension and the reaction mixture was stirred under reflux 
for 24 h. The solvent was evaporated under reduced pressure and the crude residue was 
purified by flash column chromatography to afford pure N-(3-(piperidin-1-
yl)propyl)aryl sulfonamides. 
 
General procedure 8: synthesis of N-(3-piperazin-1-yl-propyl)-arylsulfonamides 
 
 
 
Piperazine (2.00 g, 23.2 mmol) and NaHCO3 (3.25 g, 38.7 mmol) were suspended in 
absolute ethanol (21 mL). N-(3-Bromopropyl)arylsulfonamide (7.7 mmol) was then 
added portionwise to the suspension and the reaction mixture was stirred under reflux 
for 24 h. The reaction mixture was then concentrated under reduced pressure. The 
residue was diluted with EtOAc (30 mL), washed with water (3 x 30 mL) and the 
organic solvent was removed under vacuum after drying over MgSO4. The crude 
residue was purified by flash column chromatography to afford pure N,N’-(3,3’-
(piperazine-1,4-diyl)bis(propane-3,1-diyl))diaryl- sulfonamides. 
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General procedure 9: synthesis of N-{3-[4-(3-arylsulfonylamino-propyl)-piperazin-
1-yl]-propyl}-arylsulfonamides 
 
 
 
A mixture of N-(3-piperazin-1-yl-propyl)-arylsulfonamide (1.0 mmol), N-(3-
bromopropyl)arylsulfonamide (1.5 mmol) and NaHCO3 (0.16 g, 2 mmol) in absolute 
ethanol (7 mL) was stirred under reflux for 24 h. The solvent was then evaporated under 
reduced pressure and the crude residue was purified by flash column chromatography to 
afford pure N,N’-(3,3’-(piperazine-1,4-diyl)bis(propane-3,1-diyl))diarylsulfonamides. 
 
General procedure 10: synthesis of N-(3-(4-(2-(arylsulfonamido)ethyl)piperazin-1-
yl) propyl)arylsulfonamides 
 
 
 
A mixture of N-(3-piperazin-1-yl-propyl)-arylsulfonamide (1.0 mmol), N-(2-
bromoethyl)arylsulfonamide (1.5 mmol) and NaHCO3 (0.16 g, 2 mmol) in absolute 
ethanol (7 mL) was stirred under reflux for 24 h. 
The solvent was evaporated under reduced pressure and the crude residue was purified 
by flash column chromatography to afford pure N-(3-(4-(2-(arylsulfonamido) 
ethyl)piperazin-1-yl)propyl)arylsulfonamides. 
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General procedure 11: synthesis of N-(3-(4-(3-(arylsulfonamido)propanoyl) 
piperazin-1-yl)-3-oxopropyl)aryl sulfonamides 
 
 
 
3-Arylsulfonylamino propionic acid (1.1 mmol) and TBTU (0.38 g, 1.2 mmol) were 
suspended in anhydrous THF (6 mL) at r.t. DIPEA (0.4 mL, 2.4 mmol) was then added 
to the reaction mixture, followed by N-(3-piperazin-1-yl-propyl)-arylsulfonamide (1 
mmol). The reaction mixture was left stirring at r.t. for 4 h. The organic solvent was 
then removed at reduced pressure and the residue was diluted with EtOAc (30 mL). The 
organic layer was washed with saturated NaHCO3 solution (2 x 30 mL) and brine (30 
mL). The organic solvent was removed under vacuum after drying over MgSO4. The 
crude residue was purified by flash column chromatography to afford pure N-(3-(4-(3-
(arylsulfonamido)propanoyl)piperazin-1-yl)propyl) arylsulfonamides. 
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6.2.2 Arylsulfonyl chlorides (89, 90) 
 
Pyridine-3-sulfonyl chloride (89)1 
(C5H4ClNO2S; M.W.= 177.6) 
 
 
    109        89 
 
A mixture of pyridine-3-sulfonic acid (109) (2 g, 12.6 mmol), phosphorous 
pentachloride (3.91 g, 18.8 mmol) and phosphorous oxychloride (10 mL) was heated at 
120°C o.n. Excess phosphorous oxychloride was then evaporated under reduced 
pressure and the residue was quenched with ice and partitioned between water (50 mL) 
and diethyl ether (50 mL). The pH of the aqueous phase was adjusted by addition of 
solid sodium bicarbonate to pH 8, then the organic layer was separated and washed 
successively with saturated sodium bicarbonate solution (40 mL), water (40 mL) and 
brine (40 mL). The organic phase was dried over Na2SO4 and concentrated under 
reduced pressure to give pure pyridine-3-sulfonyl chloride (89) as a yellow oil. 
Yield: 1.45 g (65%) 
1H-NMR (CDCl3), : 7.62 (m, 1H, H-aromatic), 8.34 (m, 1H, H-aromatic), 8.99 (m, 
1H, H-aromatic), 9.28 (s, 1H, H-2). 
13C-NMR (CDCl3), : 124.23, 134.60 (CH, C-aromatic), 141.15 (C, C-1), 147.62, 
155.46 (CH, C-aromatic). 
 
4-Chlorosulfonyl-benzoic acid ethyl ester (90)2 
(C9H9ClO4S; M.W.= 248.6) 
 
 
               110    90 
 
4-Chlorosulfonylbenzoic acid (110) (1 g, 4.5 mmol) was suspended in thionyl chloride 
(8 mL) and DCM (4 mL) and the reaction was heated at reflux for 2 h. The solvent was 
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removed in vacuo and ice-cold ethanol (4 mL) was added to the residue. The mixture 
was stirred for 10 min. in an ice-bath before the addition of 7 mL of ice-cold water. 
The resulting precipitate was collected by filtration, washed with cold water and dried 
under vacuum to afford pure 4-chlorosulfonyl-benzoic acid ethyl ester (90) as a white 
solid. 
Yield: 0.64 g (57%) 
1H-NMR (CDCl3), : 1.45 (t, J= 7.1 Hz, 3H, H-3’),  4.47  (q,  J=  7.1  Hz,  2H,  H-2’),  8.13  
(d, J= 8.8 Hz, 2H, H-aromatic), 8.29 (d, J=8.8, 2H, H-aromatic). 
13C-NMR (CDCl3), : 14.22 (CH3, C-3’),  62.14  (CH2, C-2’),  127.02, 130.81 (CH, C-
aromatic), 136.45, 147.36 (C, C-1, 4), 164.44 (C, C-1’). 
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6.2.3 N-(3-Bromopropyl)arylsulfonamides (22-29, 91-99) 
 
N-(3-Bromo-propyl)-4-chloro-benzenesulfonamide (22)3 
(C9H11BrClNO2S; M.W.= 312.6) 
 
 
    13   22 
 
General procedure 1; 
Pale yellow wax; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.35. 
Yield: 1.16 g (94%) 
1H-NMR (CDCl3), : 2.03-2.09 (m, 2H, H-2’),  3.12-3.18 (m, 2H, H-1’),  3.45  (t,  J=  6.2  
Hz, 2H, H-3’),  4.86  (t, J= 6.2 Hz, 1H, NH), 7.53 (d, J= 8.6 Hz, 2H, H-aromatic), 7.84 
(d, J= 8.6 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 29.99, 32.26, 41.47 (CH2, C-2’,  1’,  3’),  128.54,  129.54  (CH,  C-
aromatic), 138.29, 139.39 (C, C-1, 4). 
 
N-(3-Bromo-propyl)-benzenesulfonamide (23)4 
(C9H12BrNO2S; M.W.= 278.1) 
 
 
    14   23 
 
General procedure 1; 
Pale yellow oil; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.31. 
Yield: 1.06 g (97%) 
1H-NMR (CDCl3), : 2.03-2.07 (m, 2H, H-2’),  3.12-3.16 (m, 2H, H-1’),  3.43  (t,  J=6.2,  
2H, H-3’),  5.05  (t, J= 6.2, 1H, NH), 7.52-7.58 (m, 2H, H-3), 7.61 (tt, J1= 7.4, J2= 1.4, 
1H, H-4), 7.88-7.92 (m, 2H, H-2). 
13C-NMR (CDCl3), : 30.11, 32.34, 41.46 (CH2, C-2’,  1’,  3’), 126.94, 129.24, 132.83 
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(CH, C-3, 4, 2), 139.73(C, C-1). 
 
N-(3-Bromo-propyl)-4-methyl-benzenesulfonamide (24)5 
(C10H14BrNO2S; M.W.= 292.1) 
 
 
    15   24 
 
General procedure 1; 
White solid; 
T.L.C. System: DCM 100%, Rf: 0.51 
Yield: 1.02 g (89%) 
1H-NMR (CDCl3), : 2.02-2.07 (m, 2H, H-2’),  2.45  (s,  3H,  H-4’),  3.11-3.15 (m, 2H, H-
1’),  3.44  (t,  J=  6.4  Hz,  2H,  H-3’),  4.77  (t,  J=  6.4  Hz,  1H,  NH), 7.34 (d, J= 8.3 Hz, 2H, 
H-aromatic), 7.78 (d, J= 8.3 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 21.54 (CH3, C-4’),   30.17, 32.33, 41.43 (CH2, C-2’,   1’,   3’),  
127.11, 129.83 (CH, C-aromatic), 136.74, 143.64 (C, C-4, 1). 
 
N-(3-Bromo-propyl)-4-methoxy-benzenesulfonamide (25)4 
(C10H14BrNO3S; M.W.= 308.1) 
 
 
    16   25 
 
General procedure 1; 
Pale yellow oil; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.25 
Yield: 1.04 g (86%) 
1H-NMR (CDCl3), : 2.04 (m, 2H, H-2’),  3.12  (q,  J=  6.4  Hz,  2H,  H-1’),  3.44  (t,  J=  6.4  
Hz, 2H, H-3’),  3.89  (s,  3H,  H-4’),  4.77  (t,  J=  6.4  Hz,  1H,  NH), 7.01 (d, J= 8.8 Hz, 2H, 
H-aromatic), 7.83 (d, J= 8.8 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 30.49, 32.53, 41.87 (CH2, C-2’,   1’,   3’), 56.01 (CH3, C-5’),  
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114.30, 125.36 (CH, C-aromatic), 130.87 (C, C-1), 165.56 (C, C-4). 
 
N-(3-Bromo-propyl)-4-nitro-benzenesulfonamide (26)4 
(C9H11BrN2O4S; M.W.= 323.1) 
 
 
    17   26 
 
General procedure 1; 
Pale yellow solid; 
T.L.C. System: DCM 100%, Rf: 0.44 
Yield: 0.94 g (73%) 
1H-NMR (CDCl3), : 2.09 (m, 2H, H-2’),  3.22  (q,  J=  6.3  Hz,  2H,  H-1’),  3.45  (t,  J=  6.3  
Hz, 2H, H-3’),  5.03  (t,  J=  6.3  Hz,  1H,  NH), 8.09 (d, J= 8.7 Hz, 2H, H-aromatic), 8.40 
(d, J= 8.7 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 29.81, 32.25, 41.62 (CH2, C-2’,  1’,  3’),  124.53,  128.35  (CH,  C-
aromatic), 145.67, 150.21 (C, C-1, 4). 
 
N-(3-Bromo-propyl)-3,4-dimethoxy-benzenesulfonamide (27) 
(C11H16BrNO4S; M.W.= 338.2) 
 
 
    18   27 
 
General procedure 1; 
Pale yellow oil; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.33 
Yield: 0.82 g (61%) 
1H-NMR (CDCl3), : 2.04 (m, 2H, H-2’),  3.12  (q,  J=  6.4  Hz,  2H,  H-1’),  3.44  (t,  J=  6.4  
Hz, 2H, H-3’),  3.94   (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 4.88 (t, J= 6.4 Hz, 1H, NH), 
6.96 (d, J= 8.5 Hz, 1H, H-5), 7.37 (d, J= 2.1 Hz, 1H, H-2), 7.51 (dd, J1= 8.5 Hz, J2= 2.1 
Hz, 1H, H-6). 
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13C-NMR (CDCl3), : 30.20, 32.26, 41.45 (CH2, C-2’,  1’,  3’),  56.21,  56.30  (CH3, C-4’,  
5’), 109.59, 110.65, 121.07 (CH, C-5, 2, 6), 131.30, 149.30, 152.71 (C, C-1, 3, 4). 
 
N-(3-Bromo-propyl)-2,5-dimethoxy-benzenesulfonamide (28) 
(C11H16BrNO4S; M.W.= 338.2) 
 
 
    19   28 
 
General procedure 1; 
White solid; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.37 
Yield: 0.94 g (70%) 
1H-NMR (CDCl3), : 2.15 (m, 2H, H-2’),  3.17  (q,  J=  6.4  Hz,  2H,  H-1’),  3.56 (t, J= 6.4 
Hz, 2H, H-3’), 3.79 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 5.21 (t, J= 6.4 Hz, 1H, NH), 
6.97 (d, J= 8.9 Hz, 2H, H-3), 7.11 (dd, J1= 8.9 Hz, J2= 3.1 Hz, 2H, H-4), 7.53 (d, J= 3.1, 
2H, H-6). 
13C-NMR (CDCl3), : 30.12, 32.29, 41.37 (CH2, C-2’,  1’,  3’),  56.14, 57.21 (CH3, C-5’,  
6’),  113.93, 114.56, 120.22 (CH, C-3, 4, 6), 131.94 (C, C-1), 150.16, 153.31 (C, C-3, 4). 
 
Naphthalene-2-sulfonic acid (3-bromo-propyl)-amide (29)6 
(C13H14BrNO2S; M.W.= 328.2) 
 
 
    20   29 
 
General procedure 1; 
White solid; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.43 
Yield: 1.16 g (89%) 
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1H-NMR (CDCl3), : 2.07 (m, 2H, H-2’),  3.20  (q,  J=  6.4  Hz,  2H,  H-1’),  3.45  (t,  J=  6.4  
Hz, 2H, H-3’),  4.85  (t,  J=  6.4  Hz,  1H,  NH), 7.67 (m, 2H, H-aromatic), 7.87 (dd, J1= 8.6 
Hz, J2= 1.8 Hz, 1H, H-aromatic), 7.95 (d, J= 7.9 Hz, 1H, H-aromatic), 8.00 (m, 2H, H-
aromatic), 8.48 (s, 1H, H-1). 
13C-NMR (CDCl3), : 30.03, 32.31, 41.38 (CH2, C-2’,  1’,  3’),  123.97,  127.53,  127.80,  
128.41, 129.14, 129.36, 129.70 (CH, C-1, 3, 4, 6, 7, 8, 9), 129.14, 129.36, 129.70 (C, C-
2, 5, 10). 
 
N-(3-Bromo-propyl)-3-chloro-benzenesulfonamide (91) 
(C9H11BrClNO2S; M.W.= 312.6) 
 
 
    82   91 
 
General procedure 1; 
Pale yellow oil; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.32 
Yield: 0.92 g (75%) 
1H-NMR (CDCl3), : 2.08 (m, 2H, H-2’),  3.18  (q,  J=  6.4  Hz,  2H,  H-1’),  3.45  (t,  J=  6.4  
Hz, 2H, H-3’),  4.85  (t,  J=  6.4  Hz,  1H,  NH), 7.50 (t, J= 7.8 Hz, 1H, H-5), 7.59 (dt, J1= 
7.8 Hz, J2= 1.4 Hz, 1H, H-aromatic), 7.79 (dt, J1= 7.8 Hz, J2= 1.4 Hz, 1H, H-aromatic), 
7.89 (t, J= 1.4 Hz, 1H, H-2). 
13C-NMR (CDCl3), : 29.94, 32.31, 41.53 (CH2, C-2’, 1’,  3’),  125.13,  127.18,  130.55,  
132.98 (CH, C-2, 4, 5, 6), 135.46, 141.54 (C, C-1, 3). 
 
N-(3-Bromo-propyl)-4-tert-butyl-benzenesulfonamide (92) 
(C13H20BrNO2S; M.W.= 334.2) 
 
 
    83   92 
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General procedure 1; 
White solid; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.52 
Yield: 1.02 g (77%) 
1H-NMR (CDCl3), : 1.36 (s, 9H, H-5’), 2.05-2.09 (m, 2H, H-2’),  3.12-3.17 (m, 2H, H-
1’),  3.44 (t, J= 6.4 Hz, 2H, H-3’),  4.93 (t, J= 6.4 Hz, 1H, NH), 7.55 (d, J= 8.6 Hz, 2H, 
H-aromatic), 7.82 (d, J= 8.6 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 30.17 (CH2, C-2’),  31.09 (CH3, C-5’), 32.42 (CH2, C-1’),  35.17  
(C, C-4’),  41.44 (CH2, C-3’),  126.20, 126.93 (CH, C-aromatic), 136.63 (C, C-4), 156.63 
(C, C-1). 
 
N-(3-Bromo-propyl)-4-trifluoromethyl-benzenesulfonamide (93)7 
(C10H11BrF3NO2S; M.W.= 346.1) 
 
 
    84   93 
 
General procedure 1; 
White solid; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.38 
Yield: 1.10 g (80%) 
1H-NMR (CDCl3), : 2.06-2.10 (m, 2H, H-2’),  3.17-3.21 (m, 2H, H-1’),  3.45  (t,  J=  6.4  
Hz, 2H, H-3’),  4.98 (t, J= 6.4 Hz, 1H, NH), 7.82 (d, J= 8.4 Hz, 2H, H-aromatic), 8.04 
(d, J= 8.4 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 29.86, 32.29, 41.55 (CH2, C-2’,  1’,  3’), 126.42, 127.59 (CH, C-
aromatic), 134.48, 134.74, 143.43 (C, C-1,  4,  4’). 
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Biphenyl-4-sulfonic acid (3-bromo-propyl)-amide (94) 
(C15H16BrNO2S; M.W.= 354.2) 
 
 
    85   94 
 
General procedure 1; 
Colourless oil; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.26 
Yield: 0.95 g (67%) 
1H-NMR (CDCl3), : 2.07-2.12 (m, 2H, H-2’),  3.18-3.23 (m, 2H, H-1’),  3.47  (t,  J=  6.3  
Hz, 2H, H-3’),  4.87  (t,  J=  6.3  Hz,  1H,  NH), 7.45 (t, J= 7.1 Hz, 1H, H-7’),  7.48-7.53 (m, 
2H, H-aromatic), 7.62-7.65 (m, 2H, H-aromatic), 7.76 (d, J= 8.5 Hz, 2H, H-aromatic), 
7.97 (d, J= 8.5 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 30.14, 32.39, 41.52 (CH2, C-2’,  1’,  3’),  127.34,  127.60,  127.85,  
128.55, 129.08 (CH, C-aromatic), 138.30, 139.25, 145.80 (C, C-aromatic). 
 
Naphthalene-1-sulfonic acid (3-bromo-propyl)-amide (95)9 
(C13H14BrNO2S; M.W.= 328.2) 
 
 
    86   95 
 
General procedure 1; 
Colourless oil; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.39 
Yield: 1.44 g (95%) 
1H-NMR (CDCl3), : 1.91 (m, 2H, H-2’),  3.08  (q,  J=  6.3  Hz,  2H,  H-1’),  3.26  (t, J= 6.3 
Hz, 2H, H-3’),  5.68  (t,  J=  6.3  Hz,  1H,  NH), 7.52 (t, J= 7.7 Hz, 1H, H-aromatic), 7.58 
(m, 1H, H-aromatic), 7.64 (m, 1H, H-aromatic), 7.93 (d, J= 8.1 Hz, 1H, H-aromatic), 
8.06 (d, J= 8.2 Hz, 1H, H-aromatic), 8.28 (dd, J1= 7.3 Hz, J2= 1.1 Hz, 1H, H-aromatic), 
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8.72 (d, J= 8.5 Hz, 1H, H-aromatic). 
13C-NMR (CDCl3), : 30.32, 32.36, 41.45 (CH2, C-2’,  1’,  3’),  124.24,  124.59,  127.20  
(CH, C-aromatic), 128.51 (C, C-aromatic), 128.83, 129.52, 129.92 (CH, C-aromatic), 
134.41, 134.47 (C, C-aromatic), 134.61 (CH, C-aromatic). 
 
Quinoline-8-sulfonic acid (3-bromo-propyl)-amide (96)9 
(C12H13BrN2O2S; M.W.= 329.2) 
 
 
   87   96 
 
General procedure 1; 
White crystals; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.48 
Yield: 0.96 g (73%) 
1H-NMR (CDCl3), : 2.05 (m, 2H, H-2’),  3.03  (q,  J=  6.4  Hz,  2H,  H-1’),  3.45  (t,  J=  6.1  
Hz, 2H, H-3’),  6.52  (t,  J=  6.4  Hz,  1H,  NH), 7.59 (dd, J1= 8.3 Hz, J2= 4.3 Hz, 1H, H-
aromatic), 7.68 ( t, J= 7.7 Hz, 1H, H-aromatic), 8.09 (dd, J1= 8.3 Hz, J2= 1.4 Hz, 1H, H-
aromatic), 8.31 (dd, J1= 8.3 Hz, J2= 1.7 Hz, 1H, H-aromatic), 8.45 (dd, J1= 7.7 Hz, J2= 
1.4 Hz, 1H, H-aromatic), 9.05 (dd, J1= 4.3 Hz, J2= 1.7 Hz, 1H, H-aromatic). 
13C-NMR (CDCl3), : 30.40, 32.49, 41.56 (CH2, C-2’,  1’,  3’),  122.36,  125.77  (CH,  C-
aromatic), 128.83 (C, C-aromatic), 131.24, 133.44 (CH, C-aromatic), 135.69 (C, C-
aromatic), 137.17 (CH, C-aromatic), 143.18 (C, C-aromatic), 151.37 (CH, C-aromatic). 
 
Thiophene-2-sulfonic acid (3-bromo-propyl)-amide (97)8 
(C7H10BrNO2S2; M.W.= 284.1) 
 
 
    88   97 
 
General procedure 1; 
Pale yellow oil; 
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T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.52 
Yield: 1.01 g (89%) 
1H-NMR (CDCl3), : 2.09 (m, 2H, H-2’),  3.24  (q,  J=  6.1  Hz,  2H,  H-1’),  3.46  (t,  J=  6.1  
Hz, 2H, H-3’),  4.94  (bs,  1H,  NH), 7.12 (m, 1H, H-aromatic), 7.64 (m, 2H, H-aromatic). 
13C-NMR (CDCl3), : 30.10, 32.22, 41.73 (CH2, C-2’,  1’,  3’),  127.51,  132.09,  132.37  
(CH, C-aromatic), 140.63 (C, C-1). 
 
Pyridine-3-sulfonic acid (3-bromo-propyl)-amide (98) 
(C8H11BrN2O2S; M.W.= 279.1) 
 
 
    89   98 
 
General procedure 1; 
Yellow oil; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.36. 
Purification: flash column chromatography (DCM- nhexane 50:50 v/v increasing to 
DCM- nhexane 100:0 v/v). 
Yield: 0.62 g (56%) 
1H-NMR (CDCl3), : 1.97 (m, 2H, H-2’),  3.08  (q,  J=  6.3,  2H,  H-1’),  3.34  (t,  J=6.3,  2H,  
H-3’),  6.56  (t,  J=  6.3,  1H,  NH), 7.44 (dd, J1= 8.1 Hz, J2= 4.9 Hz, 1H, H-4), 8.11 (dt, J1= 
8.1 Hz, J2= 1.9 Hz, 1H, H-5), 8.71 (dd, J1= 4.9 Hz, J2= 1.4 Hz, 1H, H-3), 8.97 (d, J= 1.9 
Hz, 1H, H-2). 
13C-NMR (CDCl3), : 30.35, 32.26, 41.29 (CH2, C-2’,  1’,  3’),  124.19,  135.04  (CH,  C-
4, 5), 136. 74 (C, C-1), 147.58, 153.01 (CH, C-3, 2). 
 
4-(3-Bromo-propylsulfamoyl)-benzoic acid ethyl ester (99) 
(C12H16BrNO4S; M.W.= 350.2) 
 
 
    90   99 
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General procedure 1; 
Yellow oil; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.32. 
Yield: 0.92 g (66%) 
1H-NMR (CDCl3), : 1.34 (t, J= 7.1 Hz, 3H, H-6’),  1.97  (m,  2H,  H-2’),  3.07  (q,  J=  6.3,  
2H, H-1’),  3.35  (t,  J=6.3,  2H,  H-3’), 4.34 (q, J= 7.1 Hz, 2H, H-5’),  5.73  (t,  J=  6.3,  1H,  
NH), 7.89 (d, J= 8.3 Hz, 2H, H-aromatic), 8.10 (d, J= 8.3 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 14.21 (CH3, C-6’),  30.05,  32.45,  41.49,  61.63  (CH2, C-2’,  1’,  3’,  
5’),  127.64,  130.52  (CH,  C-aromatic), 134.14, 143.62 (C, C-1, 4), 165.24 (C, C-4’). 
 
N-(3-Bromo-propyl)-2-chloro-benzenesulfonamide (115)8 
(C9H11BrClNO2S; M.W.= 312.6) 
 
 
   112  113   115 
 
A mixture of 2-chlorobenzenesulfonamide (112) (1 g, 5.2 mmol) and NaH (0.2088 g, 
5.2 mmol) in anhydrous DMF (7 mL) was stirred under nitrogen atmosphere for 1 h at 
r.t. The reaction mixture was then cooled to 0°C with an ice bath and added of 1,3-
dibromopropane (113) (3.2 mL, 31.3 mmol) before being stirred for 10 min. under ice-
cooling. The organic solvent and the excess 113 were removed under high vacuum. The 
crude residue was suspended in DCM (25 mL), washed with water (2 x 50 mL) and 
with brine (50 mL). The organic layer was then dried over MgSO4 and dried under 
vacuum. The crude residue was purified by flash column chromatography (DCM-
nhexane 50:50 v/v increasing to DCM-nhexane 80:20 v/v) to give pure N-(3-bromo-
propyl)-2-chloro-benzenesulfonamide (115) as a colourless oil. 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.51. 
Yield: 0.6382 g (39%) 
1H-NMR (CDCl3), : 2.01 (m, 2H, H-2’),  3.08  (q,  J=  6.4  Hz,  2H,  H-1’),  3.40  (t,  J=  6.4  
Hz, 2H, H-3’),  5.47  (t,  J=  6.4  Hz,  1H,  NH), 7.41 (m, 1H, H-aromatic), 7.51 (d, J=4.4 
Hz, 2H, H-aromatic), 8.07 (d, J=7.8 Hz, 1H, H-aromatic). 
13C-NMR (CDCl3), : 30.30, 32.35, 41.48 (CH2, C-2’,  1’,  3’),  127.41,  131.01  (CH,  C-
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aromatic), 131.38 (C, C-aromatic), 132.07, 134.05 (CH, C-aromatic), 136.87 (C, C-
aromatic). 
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6.2.4 N-(2-Bromoethyl)arylsulfonamides (85-87) 
 
N-(2-Bromo-ethyl)-4-chloro-benzenesulfonamide (38)10 
(C8H9BrClNO2S; M.W.= 298.5) 
 
 
    13   38 
 
General procedure 2; 
White solid; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.25. 
Yield: 1.08 g (87%) 
1H-NMR (CDCl3), : 3.39-3.46 (m, 4H, H-1’,  2’),  5.04 (bs, 1H, NH), 7.53 (d, J= 8.6 
Hz, 2H, H-aromatic), 7.84 (d, J= 8.6 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 31.56, 44.56 (CH2, C-1’,  2’),  128.48, 129.59 (CH, C-aromatic), 
138.47, 139.56 (C, C-1, 4). 
 
N-(2-Bromo-ethyl)-benzenesulfonamide (39)11 
(C8H10BrNO2S; M.W.= 264.1) 
 
 
    14   39 
 
General procedure 2; 
White solid; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.52. 
Yield: 0.88 g (80%) 
1H-NMR (CDCl3), : 3.39-3.43 (m, 4H, H-1’,   2’),   5.11   (bs,   1H,  NH), 7.54-7.58 (m, 
2H, H-3), 7.60-7.64 (m, 1H, H-4), 7.90 (d, J= 8.0, 2H, H-2). 
13C-NMR (CDCl3), : 31.48, 44.58 (CH2, C-1’,  2’),  126.98, 129.31, 132.99 (CH, C-3, 
4, 2), 139.89 (C, C-1). 
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N-(2-Bromo-ethyl)-4-methyl-benzenesulfonamide (40)12 
(C9H12BrNO2S; M.W.= 278.1) 
 
 
    15   40 
 
General procedure 3; 
White solid; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.59. 
Yield: 0.96 g (83%) 
1H-NMR (CDCl3), : 2.46 (s, 3H, H-3’),  3.40   (m,  4H,  H-1’,  2’),   4.96   (bs,   1H,  NH), 
7.34 (d, J= 8.2 Hz, 2H, H-aromatic), 7.78 d, J= 8.2 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 21.54 (CH3, C-3’),  31.70,  44.55  (CH2, C-1’,  2’),  127.05,  129.89  
(CH, C-aromatic), 136.93, 143.86 (C, C-4, 1). 
 
N-(2-Bromo-ethyl)-4-methoxy-benzenesulfonamide (41) 
(C9H15BrNO3S; M.W.= 294.1) 
 
 
    16   41 
 
General procedure 2; 
White solid; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.28. 
Yield: 0.92 g (75%) 
 
1H-NMR (CDCl3), : 3.40 (m, 4H, H-1’,  2’),   3.90   (s,   3H,  H-3’), 4.92 (bs, 1H, NH), 
7.01 (d, J= 8.8 Hz, 2H, H-aromatic), 7.83 (d, J= 8.8 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 33.40, 44.50 (CH2, C-1’,  2’),  56.78  (CH3, C-3’),  117.27,  127.84  
(CH, C-aromatic), 131.33, 165.21 (C, C-1, 4). 
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N-(2-Bromo-ethyl)-4-nitro-benzenesulfonamide (42)13 
(C8H9BrN2O4S; M.W.= 309.1) 
 
 
    17   42 
 
General procedure 2; 
White solid; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.33. 
Purification: flash column chromatography (DCM-nhexane 50:50 v/v increasing to 
DCM-nhexane 100:0). 
Yield: 0.84 g (65%) 
1H-NMR (CDCl3), : 3.47 (m, 4H, H-1’,  2’),  5.11  (bs,  1H,  NH), 8.10 (d, J= 8.9 Hz, 2H, 
H-aromatic), 8.41 (d, J= 8.9 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 31.47, 44.67 (CH2, C-1’,  2’),  124.55,  128.29  (CH,  C-aromatic), 
145.87, 150.26 (C, C-1, 4). 
 
N-(2-Bromo-ethyl)-3,4-dimethoxy-benzenesulfonamide (43)7 
(C10H14BrNO4S; M.W.= 324.1) 
 
 
    18   43 
 
General procedure 2; 
White solid; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.41. 
Yield: 0.5649 g (83%) 
1H-NMR (CDCl3), : 3.41 (m, 4H, H-1’,  2’),  3.96  (s,  3H,  OCH3), 3.97 (s, 3H, OCH3), 
4.96 (bs, 1H, NH), 6.97 (d, J= 8.4 Hz, 1H, H-5), 7.36 (d, J= 2.2 Hz, 1H, H-2), 7.52 (dd, 
J1= 8.4 Hz, J2= 2.2 Hz, 1H, H-6). 
13C-NMR (CDCl3), : 32.94, 44.72 (CH2, C-1’,   2’),   56.47, 56.75 (CH3, C-3’,  
4’),112.60, 115.22, 119.46 (CH, C-5, 2, 6), 132.53 (C, C-1), 147.24, 151.19 (C, C-3, 4). 
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N-(2-Bromo-ethyl)-2,5-dimethoxy-benzenesulfonamide (44) 
(C10H14BrNO4S; M.W.= 324.1) 
 
 
    19   44 
 
General procedure 2; 
White solid; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.47. 
Yield: 1.1 g (81%) 
1H-NMR (CDCl3), : 3.37 (m, 4H, H-1’,  2’),  3.82  (s,  3H,  OCH3), 3.97 (s, 3H, OCH3), 
5.55 (bs, 1H, NH), 6.99 (d, J= 8.9 Hz, 1H, H-3), 7.10 (dd, J1= 8.9 Hz, J2= 2.6 Hz, 1H, 
H-4), 7.44 (d, J= 2.6, Hz, 1H, H-6). 
13C-NMR (CDCl3), : 31.65, 45.10 (CH2, C-1’,   2’),   56.06, 56.87 (CH3, C-3’,   4’),  
113.56, 114.38, 120.59 (CH, C-3, 4, 6), 127.64 (C, C-1), 150.11, 153.27 (C, C-2, 5). 
 
Naphthalene-2-sulfonic acid (2-bromo-ethyl)-amide (45) 
(C12H12BrNO2S; M.W.= 314.1) 
 
 
    20   45 
 
General procedure 2; 
White solid; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.62. 
Yield: 0.57 g (87%) 
1H-NMR (CDCl3), : 3.44 (m, 4H, H-1’,   2’),   5.16   (bs,   1H,   NH), 7.67 (m, 2H, H-
aromatic), 7.87 (dd, J1= 8.6 Hz, J2= 1.8 Hz, 1H, H-aromatic), 7.95 (d, J= 7.9 Hz, 1H, H-
aromatic), 8.00 (m, 2H, H-aromatic), 8.48 (s, 1H, H-1). 
13C-NMR (CDCl3), : 33.40, 44.56 (CH2, C-1’,   2’),   122.98,   125.93,   126.07,   126.59,  
128.74, 128.96, 129.11 (CH, C-1, 3, 4, 6, 7, 8, 9), 130.14, 130.46, 130.71 (C, C-2, 5, 
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10). 
 
Quinoline-8-sulfonic acid (2-bromo-ethyl)-amide (117)10 
(C11H11BrN2O2S; M.W.= 315.1) 
 
 
    87   117 
 
General procedure 2; 
White solid; 
T.L.C. System: DCM-nhexane 4:1 v/v, Rf: 0.40. 
Yield: 0.43 g (65%) 
1H-NMR (CDCl3), : 3.30 (q, J= 6.1 Hz, 2H, H-1’),  3.38  (t,  J=  6.1,  4H,  H-2’),  6.91  (t,  
J= 6.1 Hz, 1H, NH), 7.67 (m, 2H, H-aromatic), 7.56 (dd, J1= 8.2 Hz, J2= 4.3 Hz, 1H, H-
aromatic), 7.64 (t, J= 7.7 Hz, 1H, H-aromatic), 8.07 (dd, J1= 8.2 Hz, J2= 1.2 Hz, 1H, H-
aromatic), 8.29 (dd, J1= 8.3 Hz, J2= 1.6 Hz, 1H, H-aromatic), 8.39 (dd, J1= 7.2 Hz, J2= 
1.2 Hz, 1H, H-aromatic), 9.03 (dd, J1= 4.3 Hz, J2= 1.6 Hz, 1H, H-aromatic). 
13C-NMR (CDCl3), : 31.43, 45.31 (CH2, C-1’,  2’),  122.47,  125.06  (CH,  C-aromatic), 
128.53 (C, C-aromatic), 129.44, 131.14 (CH, C-aromatic), 132.79 (C, C-aromatic), 
135.05 (CH, C-aromatic), 143.02 (C, C-aromatic), 151.45 (CH, C-aromatic). 
 
N-(2-Bromo-ethyl)-4-tert-butyl-benzenesulfonamide (147)7 
(C9H12BrNO2S; M.W.= 320.25) 
 
 
    83   147 
 
General procedure 2; 
White solid; 
T.L.C. System: DCM- nhexane 4:1 v/v, Rf: 0.60. 
Yield: 1.04 g (78%) 
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1H-NMR (CDCl3), : 1.36 (s, 9H, H-4’), 3.37-3.45 (m, 4H, H-1’,  2’),  5.13 (t, J= 6.1 
Hz, 1H, NH), 7.55 (d, J= 8.7 Hz, 2H, H-aromatic), 7.81 (d, J= 8.7 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 31.07 (CH3, C-4’), 31.07 (CH2), 35.18 (C, C-3’),  44.57  (CH2), 
126.26, 126.58 (CH, C-aromatic), 136.77, 156.83 (C, C-4, 1). 
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6.2.5 3-Arylsulfonylamino propionic acids (55-61, 57a, 153, 154) 
 
3-(4-Chloro-benzenesulfonylamino)-propionic acid (55)14 
(C9H10ClNO4S; M.W.= 263.6) 
 
 
    13   55 
 
General procedure 3; 
White solid; 
Yield: 1.14 g (64%) 
1H-NMR (DMSO-d6), : 2.36 (t, J= 6.9 Hz, 2H, H-2’),  2.92-2.98 (m, 2H, H-3’),  7.68  
(d, J= 8.4 Hz, 2H, H-aromatic), 7.75 (bs, 1H, NH), 7.80 (d, J= 8.4 Hz, 2H, H-aromatic). 
13C-NMR (DMSO-d6), : 34.10, 38.52 (CH2, C-2’,  1’),  128.46, 129.34 (CH, C-
aromatic), 137.26, 139.12 (C, C-1, 4), 172.15 (C, C-1’). 
 
3-Benzenesulfonylamino-propionic acid (56)15 
(C9H11NO4S; M.W.= 229.2) 
 
 
    14   56 
 
General procedure 3; 
White solid; 
Yield: 0.81 g (52%) 
1H-NMR (DMSO-d6), : 2.36 (t, J= 7.0 Hz, 2H, H-2’),  2.92-2.96 (m, 2H, H-3’),  7.62-
7.68 (m, 3H, H-aromatic), 7.61 (bs, 1H, NH), 7.78-7.82 (m, 2H, H-aromatic). 
13C-NMR (DMSO-d6), : 34.12, 38.54 (CH2, C-2’,  1’),  126.47,  129.20,  132.41  (CH,  C-
2, 3, 4), 140.17 (C, C-1), 172.20 (C, C-1’). 
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3-(4-Methoxy-benzenesulfonylamino)-propionic acid (57)14 
(C10H13NO5S; M.W.= 259.2) 
 
 
    16   57 
 
General procedure 3; 
White solid; 
Yield: 1.26 g (72%) 
1H-NMR (CDCl3), : 2.64 (t, J= 5.8 Hz, 2H, H-2’),  3.21  (m,  2H,  H-3’),  3.90  (s,  3H,  H-
4’),   5.72   (bs,   1H,  NH), 7.01 (d, J= 8.7, 2H, H-aromatic), 7.83 (d, J= 8.7 Hz, 2H, H-
aromatic), 12.31 (s, 1H, COOH). 
13C-NMR (DMSO-d6), : 34.02, 38.47 (CH2, C-2’,   1’),   55.56   (CH3, C-4’),   114.33,  
131.49 (CH, C-aromatic), 131.49, 162.16 (C, C-1, 4), 172.47 (C, C-1’). 
 
3-(4-Nitro-benzenesulfonylamino)-propionic acid (58)14 
(C9H10N2O6S; M.W.= 274.2) 
 
 
    17   58 
 
General procedure 3; 
Pale yellow solid; 
Yield: 0.94 g (51%) 
1H-NMR (DMSO-d6), : 2.38 (t, J= 6.9 Hz, 2H, H-2’),  3.02  (m,  2H,  H-3’),  8.05  (d,  J=  
8.9 Hz, 2H, H-aromatic), 8.08 (bs, 1H, NH), 8.42 (d, J= 8.9, 2H, H-aromatic), 12.39 (s, 
1H, COOH). 
13C-NMR (DMSO-d6), : 34.12, 38.56 (CH2, C-2’,   1’),   124.57,   128.09   (CH,   C-
aromatic), 145.88, 149.57 (C, C-1, 4), 172.08 (C, C-1’). 
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3-(3,4-Dimethoxy-benzenesulfonylamino)-propionic acid (59)16 
(C11H15NO6S; M.W.= 289.3) 
 
 
    18   59 
 
General procedure 3; 
White solid; 
Yield: 1.14 g (58%) 
1H-NMR (DMSO-d6), : 2.35 (t, J= 7.0 Hz, 2H, H-2’),  2.91  (m,  2H,  H-3’),  3.82  (s,  3H,  
OCH3), 3.84 (s, 3H, OCH3), 7.13 (d, J= 8.5 Hz, 1H, H-5), 7.30 (d, J= 2.1 Hz, 1H, H-2), 
7.37 (dd, J1= 8.5 Hz, J2= 2.1 Hz, 1H, H-6), 7.49 (t, J= 5.7 Hz, 1H, NH), 12.25 (s, 1H, 
COOH). 
13C-NMR (DMSO-d6), : 34.06, 38.55 (CH2, C-2’,  1’),  55.71,  55.78  (CH3, C-4’,  5’),  
109.37, 111.11, 120.23 (CH, C-5, 2, 6), 131.68, 148.68, 151.86 (C, C-1, 3, 4), 172.29 
(C, C-1’). 
 
3-(2,5-Dimethoxy-benzenesulfonylamino)-propionic acid (60)16 
(C11H15NO6S; M.W.= 289.3) 
 
 
    19   60 
 
General procedure 3; 
White solid; 
Yield: 1.22 g (64%) 
1H-NMR (CDCl3), : 2.61 (t, J= 5.9 Hz, 2H, H-2’),  3.21   (m,  2H,  H-3’),  3.84  (s,  3H,  
OCH3), 3.95 (s, 3H, OCH3), 5.78 (t, J= 6.6 Hz, 1H, NH), 7.00 (d, J= 8.9 Hz, 1H, H-3), 
7.11 (dd, J1= 8.9 Hz, J2= 3.0 Hz, 1H, H-4), 7.47 (d, J= 3.0 Hz, 1H, H-6),  11.89 (s, 1H, 
COOH). 
13C-NMR (DMSO-d6), : 33.88, 38.65 (CH2, C-1’,  2’),  55.73,  56.43  (CH3, C-4’,  5’),  
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114.21, 114.24, 119.49 (CH, C-3, 4, 6), 128.16, 150.21, 152.28 (C, C-1, 2, 5), 172.42 
(C, C-1’). 
 
3-(Naphthalene-2-sulfonylamino)-propionic acid (61)17 
(C13H13NO4S; M.W.= 279.3) 
 
 
    20   61 
 
General procedure 3; 
White solid; 
Yield: 1.16 g (61%) 
1H-NMR (CDCl3), : 2.38 (t, J= 7.1 Hz, 2H, H-2’),  2.99  (m,  2H,  H-3’),  7.69  (m,  3H, 
H-aromatic, NH), 7.82 (m, 2H, H-aromatic), 8.05 (d, J= 8.1 Hz, 1H, H-aromatic), 8.15 
(m, 2H, H-aromatic), 8.45 (s, 1H, H-1), 12.22 (bs, 1H, COOH). 
13C-NMR (DMSO-d6), : 34.16, 38.59 (CH2, C-1’,  2’),  123.97,  127.53,  127.80,  128.41,  
129.14, 129.36, 129.70 (CH, C-aromatic), 131.70, 134.12, 137.20 (C, C-2, 5, 10), 
172.21 (C, C-1’). 
 
3-(Toluene-4-sulfonylamino)-propionic acid (57a)14 
(C10H13NO4S; M.W.= 243.2) 
 
 
    15   57a 
 
General procedure 3; 
White solid; 
Yield: 0.95 g (58%) 
1H-NMR (CDCl3), : 2.35 (t, J= 7.1 Hz, 2H, H-2’),  2.39 (s, 3H, H-4’), 2.89-2.94 (m, 
2H, H-3’), 7.40 (d, J= 8.1 Hz, 2H, H-aromatic), 7.57 (t, J= 5.7 Hz, 1H, NH), 7.68 (d, J= 
8.1 Hz, 2H, H-aromatic), 12.25 (s, 1H, COOH). 
13C-NMR (DMSO-d6), : 20.92 (CH3, C-4’), 34.10, 38.53 (CH2, C-2’,   1’),   126.54, 
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129.61 (CH, C-aromatic), 137.30, 142.64 (C, C-1, 4), 172.22 (C, C-1’). 
 
3-(4-tert-Butyl-benzenesulfonylamino)-propionic acid (153) 
(C13H19NO4S; M.W.= 285.36) 
 
 
    83   153 
 
General procedure 3; 
White solid; 
Yield: 1.04 g (54%) 
1H-NMR (CDCl3), : 1.31 (s, 9H, H-5’), 2.38 (t, J= 7.1 Hz, 2H, H-2’),  2.90-2.94 (m, 
2H, H-1’),  7.59 (t, J= 5.4 Hz, 1H, NH), 7.62 (d, J= 8.5 Hz, 2H, H-aromatic), 7.72 (d, J= 
8.5 Hz, 2H, H-aromatic), 12.26 (s, 1H, COOH). 
13C-NMR (DMSO-d6), : 30.78 (CH3, C-5’), 34.16 (CH2), 34.69 (C, C-4’),   38.57 
(CH2), 126.01, 126.40 (CH, C-aromatic), 137.27, 155.35 (C, C-1, 4), 172.25 (C, C-1’). 
 
3-(Biphenyl-4-sulfonylamino)-propionic acid (154) 
(C15H15NO4S; M.W.= 305.3) 
 
 
    85   154 
 
General procedure 3; 
White solid; 
Yield: 0.93 g (45%) 
1H-NMR (CDCl3), : 2.40 (t, J= 7.0 Hz, 2H, H-2’),  2.96-3.00 (m, 2H, H-1’),  7.45 (t, J= 
7.4 Hz, 1H, H-7’),  7.50-7.54 (m, 2H, H-aromatic), 7.70-7.70 (m, 3H, 2H-aromatic, NH), 
7.87 (d, J= 8.5 Hz, 2H, H-aromatic), 7.90 (d, J= 8.5 Hz, 2H, H-aromatic), 12.28 (bs, 1H, 
COOH). 
13C-NMR (DMSO-d6), : 34.18, 38.60 (CH2, C-1’,  2’),  127.05, 127.19, 127.40, 128.45, 
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129.09 (CH, C-aromatic), 138.53, 138.94, 143.92 (C, C-1,  4,  4’), 172.23 (C, C-1’). 
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6.2.6 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))diarylsulfonamides 
(12, 30-36, 100-108, 111) 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-chlorobenzene-
sulfonamide) (12) 
(C22H30Cl2N4O4S2; M.W.= 549.5) 
 
 
  22      12 
 
General procedure 4; 
Pale yellow solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.61. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.21 g (64%) 
Melting Point: 168-170°C 
MS (ESI)+: 549.0, 551.0 [M+H]+ 
1H-NMR (CDCl3), : 1.65-1,71 (m, 4H, H-2’),  2.41-2.54 (m, 12H, H-3’,  4’),  3.09  (t,  J=  
5.6 Hz, 4H, H-1’),  7.34  (bs,  2H,  NH), 7.51 (d, J= 8.6 Hz, 4H, H-aromatic), 7.80 (d, J= 
8.6 Hz, 4H, H-aromatic). 
13C-NMR (DMSO-d6), : 26.02, 40.84, 52.58, 54.74 (CH2, C-1’,   2’,   3’,   4’),   128.42,  
129.31 (CH, C-aromatic), 137.13, 139.39 (C, C-1, 4). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))dibenzene-sulfonamide (23) 
(C22H32N4O4S2; M.W.= 480.6) 
 
 
  23      30 
 
General procedure 4; 
White solid; 
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T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.46. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.18 g (64%) 
Melting Point: 136-138°C 
MS (ESI)+: 481.1 [M+H]+ 
1H-NMR (CDCl3), : 1.60 (m, 4H, H-2’),  2.38  (m,  12H,  H-3’,  4’),  3.04  (t,  J= 5.8 Hz, 
4H, H-1’),  7.10  (bs,  2H,  NH), 7.50 (m, 4H, H-3), 7.56 (m, 2H, H-4), 7.83 (m, 4H, H-2). 
13C-NMR (CDCl3), : 24.09, 44.04, 53.00, 57.95 (CH2, C-1’,   2’,   3’,   4’),   126.88,  
129.03, 132.65 (CH, C-3, 4, 2), 140.16 (C, C-1). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-methylbenzene-
sulfonamide) (31)18 
(C24H36N4O4S2; M.W.= 508.6) 
 
 
  24      31 
 
 
General procedure 4; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.67. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 95:5 
v/v). 
Yield: 0.20 g (68%) 
Melting Point: 176-178°C (lit. 181-183°C)18 
MS (ESI)+: 509.1 [M+H]+ 
1H-NMR (CDCl3), : 1.65 (m, 4H, H-2’),  2.46  (bs,  18H,  H-3’,  4’,  5’),  3.07  (t,  J=  5.6  
Hz, 4H, H-1’),  7.12  (bs,  2H,  NH), 7.32 (d, J= 8.2 Hz, 4H, H-aromatic), 7.74 (d, J= 8.2 
Hz, 4H, H-aromatic). 
13C-NMR (DMSO-d6), : 20.91 (CH3, C-5’),  26.02,  40.91,  52.60,  54.88  (CH2, C-1’,  2’,  
3’,  4’),  126.50,  129.56  (CH,  C-aromatic), 137.80 (C, C-4), 142.47 (C, C-1). 
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N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-methoxybenzene-
sulfonamide) (32) 
(C24H36N4O6S2; M.W.= 540.6) 
 
 
  25      32 
 
General procedure 4; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.72. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 91:9 
v/v). 
Yield: 0.19 g (60%) 
Melting Point: 172-174°C 
MS (ESI)+: 541.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.47 (m, 4H, H-2’),  2.18  (bs,  12H,  H-3’,  4’),  2.72  (m,  4H,  H-
1’),  3.83  (s,  6H,  H-5’),  7.11  (d,  J=  8.3  Hz,  4H, H-aromatic), 7.41 (t, J= 5.6 Hz, 2H, NH), 
7.70 (d, J= 8.3 Hz, 4H, H-aromatic). 
13C-NMR (DMSO-d6), : 25.63, 39.78, 51.90, 54.38 (CH2, C-1’,   2’,   3’,   4’),   56.01  
(CH3, C-5’),  114.44,  126.56  (CH,  C-aromatic), 131.80 (C, C-1), 165.27 (C, C-4). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-nitrobenzene-
sulfonamide) (33) 
(C22H30N6O8S2; M.W.= 570.6) 
 
 
  26      33 
 
General procedure 4; 
Pale yellow solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.59. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 91:9 
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v/v). 
Yield: 0.14 g (43%) 
Melting Point: 226-228°C 
MS (ESI)+: 571.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.49 (m, 4H, H-2’),  2.18  (m,  12H,  H-3’,  4’),  2.82  (t,  J=  6.8  
Hz, 4H, H-1’),  7.98  (bs,  2H,  NH), 8.03 (d, J= 8.7 Hz, 4H, H-aromatic), 8.42 (d, J= 8.7 
Hz, 4H, H-aromatic). 
13C-NMR (DMSO-d6), : 26.11, 40.87, 52.58, 54.66 (CH2, C-1’,   2’,   3’,   4’),   124.57,  
128.02 (CH, C-aromatic), 146.14, 149.50 (C, C-1, 4). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(3,4-dimethoxybenzene-
sulfonamide) (34) 
(C26H40N4O8S2; M.W.= 600.7) 
 
 
  27      34 
 
General procedure 4; 
Yellow solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.70. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 95:5 
v/v). 
Yield: 0.23 g (65%) 
Melting Point: 152-154°C 
MS (ESI)+: 601.1 [M+H]+ 
1H-NMR (CDCl3), : 1.66 (m, 4H, H-2’),  2.47  (m,  12H,  H-3’,  4’),  3.06  (t,  J=  5.7  Hz,  
4H, H-1’),  3.93  (s,  6H,  OCH3), 3.96 (s, 6H, OCH3), 6.53 (bs, 2H, NH), 6.95 (d, J= 8.4 
Hz, 2H, H-5), 7.33 (d, J= 2.1, 2H, H-2), 7.46 (dd, J1= 8.4 Hz, J2= 2.1 Hz, 2H, H-6). 
13C-NMR (CDCl3), : 24.14, 44.09, 53.06, (CH2, C-2’,  3’,  4’),  56.18,  56.25  (CH3, C-5’,  
6’),  57.79  (CH2, C-1’),  109.76,  110.59,  120.77  (CH,  C-5, 2, 6), 131.93 (C, C-1), 149.09, 
152.37 (C, C-3, 4). 
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N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(2,5-dimethoxybenzene-
sulfonamide) (35) 
(C26H40N4O8S2; M.W.= 600.7) 
 
 
  28      35 
 
General procedure 4; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.73. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 95:5 
v/v). 
Yield: 0.25 g (71%) 
Melting Point: 170-172°C 
MS (ESI)+: 601.1 [M+H]+ 
1H-NMR (CDCl3), : 1.71 (m, 4H, H-2’),  2.55  (bs, 12H, H-5’,  6’),  3.00  (t,  J=  6.2  Hz,  
4H, H-1’),  3.83  (s,  6H,  OCH3), 3.95 (s, 6H, OCH3), 6.22 (bs, 2H, NH), 7.00 (d, J= 8.9 
Hz, 2H, H-3), 7.08 (dd, J1= 8.9 Hz, J2= 3.1 Hz, 2H, H-4), 7.47 (d, J= 3.1, 2H, H-6). 
13C-NMR (CDCl3), : 25.35, 44.4, 52.56, 55.45 (CH2, C-2’,   3’,  4’,  1’),   56.04,  57.27  
(CH3, C-5’,   6’),   114.16,   114.89,   120.22   (CH,   C-3, 4, 6), 132.02 (C, C-1), 150.41, 
153.37 (C, C-3, 4). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))dinaphthalene-2-sulfonamide 
(36) 
(C30H36N4O4S2; M.W.= 580.7) 
 
 
  29      36 
 
General procedure 4; 
White solid; 
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T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.62. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.27 g (79%) 
Melting Point: 186-188°C 
MS (ESI)+: 581.1 [M+H]+ 
1H-NMR (CDCl3), : 1.66 (m, 4H, H-2’),  2.46  (bs,  12H,  H-3’,  4’),  3.13  (t,  J=  5.5  Hz,  
4H, H-1’),  7.32  (bs,  2H,  NH), 7.66 (m, 4H, H-aromatic), 7.83 (dd, J1= 8.7 Hz, J2= 1.8 
Hz, 2H, H-aromatic), 7.95 (d, J= 7.9, 2H, H-aromatic), 7.99 (m, 4H, H-aromatic), 8.44 
(s, 2H, H-1). 
13C-NMR (DMSO-d6), : 25.97, 40.88, 52.43, 54.72 (CH2, C-2’,   3’,   4’,   1’),   122.24,  
127.33, 127.51, 127.77, 128.60, 129.11, 129.33 (CH, C-aromatic), 131.70, 134.08, 
137.41 (C, C-2, 5, 10). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(3-chlorobenzene-
sulfonamide) (100) 
(C21H36Cl2N4O4S2; M.W.= 549.5) 
 
 
  91      100 
 
General procedure 4; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.66. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.26 g (79%) 
Melting Point: 156-158°C 
MS (ESI)+: 549.0, 551.0 [M+H]+ 
1H-NMR (DMSO-d6), : 1.48 (m, 4H, H-2’),  2.20  (m,  12H,  H-3’,  4’),  2.79  (m,  4H,  H-
1’),  7.64  (t,  J=  7.8  Hz,  2H,  H-aromatic), 7.74 (m, 6H, 4x H-aromatic, 2 x NH), 7.78 (t, 
J= 1.8 Hz, 2H, H-2).  
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13C-NMR (DMSO-d6), : 26.03, 40.86, 52.57, 54.70 (CH2, C-2’,   3’,   4’,   1’),   125.17,  
126.04, 131.30, 132.29, 133.79 (CH, C-aromatic), 133.79, 142.46(C, C-1, 3). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-tertbutylbenzene-
sulfonamide) (101) 
(C30H48N4O4S2; M.W.= 592.8) 
 
 
  92      101 
 
General procedure 4; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.59. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.29 g (82%) 
Melting Point: 188-190°C 
MS (ESI)+: 593.3 [M+H]+ 
1H-NMR (DMSO-d6), : 1.31 (s, 18H, H-6’),  1.46  (m,  4H,  H-2’),  2.16  (m,  12H,  H-3’,  
4’),   2.75   (m,   4H,   H-1’),   7.49   (t,   J=   5.8   Hz,   2H,   NH), 7.60 (d, J= 8.4 Hz, 4H, H-
aromatic), 7.70 (d, J= 8.4 Hz, 4H, H-aromatic).  
13C-NMR (DMSO-d6), : 26.03 (CH2, C-2’), 30.79 (CH3, C-6’),   34.77 (C, C-5’), 
40.87, 52.55, 54.82 (CH2, C-3’,   4’,   1’),   125.93,   126.35   (CH,   C-aromatic), 137.68, 
155.19 (C, C-4,1). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-(trifluoromethyl)-
benzenesulfonamide) (102) 
(C24H30F6N4O4S2; M.W.= 616.6) 
 
 
  93      102 
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General procedure 4; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.65. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.22 g (61%) 
Melting Point: 184-186°C 
MS (ESI)+: 617.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.48 (m, 4H, H-2’),  2.16  (bs,  12H,  H-3’,  4’),  2.81  (m,  4H,  H-
1’),  7.49  (bs,  2H,  NH), 7.99 (m, 8H, H-aromatic).  
13C-NMR (DMSO-d6), : 26.02, 40.80, 52.52, 54.61 (CH2, C-2’,  3’,  4’,  1’),  122.41 (C, 
C-5’),  126.40,  127.44  (CH,  C-aromatic), 132.20, 144.50 (C, C-4,1). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(biphenyl-sulfonamide) 
(103) 
(C34H40N4O4S2; M.W.= 632.8) 
 
 
  94      103 
 
General procedure 4; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.59. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.76 g (87%) 
Melting Point: 183-185°C 
MS (ESI)+: 633.2 [M+H]+ 
1H-NMR (DMSO-d6), : 1.46-1.50 (m, 4H, H-2’),  2.12-2.22 (m, 12H, CH2), 3.51-3.56 
(m, 4H, CH2), 7.41-7.44 (m, 2H, H-4’’),  7.49-7.53 (m, 4H, H-aromatic), 7.62 (bs, 2H, 
NH), 7.71-7.75 (m, 4H, H-aromatic), 7.84-7.89 (m, 8H, H-aromatic). 
13C-NMR (DMSO-d6), : 26.04, 40.91, 52.58, 54.81 (CH2, C-1’,   2’,   3’,   4’),   127.01,  
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127.15, 127.33, 128.42, 129.08 (CH, C-aromatic), 138.53, 139.25, 143.80 (C, C-1, 4, 
1’’). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))dinaphthalene-2-sulfonamide 
(104) 
(C30H36N4O4S2; M.W.= 580.7) 
 
 
  95      104 
 
General procedure 4; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.67. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.31 g (91%) 
Melting Point: 216-218°C 
MS (ESI)+: 581.2 [M+H]+ 
1H-NMR (DMSO-d6), : 1.36 (m, 4H, H-2’),  1.93  (bs,  8H,  H-4’),  1.99  (t,  J=  6.8  Hz,  
4H, H-3’),  2.79  (m,  4H,  H-1’),  7.67  (m,  6H,  H-aromatic), 7.91 (bs, 2H, NH), 8.10 (m, 
4H, H-aromatic), 8.22 (d, J= 8.2 Hz, 2H, H-aromatic), 8.64 (d, J= 8.4 Hz, 2H, H-
aromatic).  
13C-NMR (DMSO-d6), : 25.88, 40.73, 52.33, 54.65 (CH2, C-2’,   3’,   4’,   1’),   124.45, 
124.64, 126.77 (CH, C-aromatic), 127.56 (C, C-aromatic), 127.73, 128.54, 128.91, 
133.62 (CH, C-aromatic), 133.87, 135.49 (C, C-aromatic). 
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N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))diquinoline-8-sulfonamide 
(105) 
(C28H34N6O4S2; M.W.= 582.7) 
 
 
  96      105 
 
General procedure 4; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.73. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.26 g (76%) 
Melting Point: 200-202°C 
MS (ESI)+: 583.2 [M+H]+ 
1H-NMR (CDCl3), : 1.67 (m, 4H, H-2’),  2.37 (bs, 12H, H-3’,  4’),  2.95  (m,  4H,  H-1’),  
6.79 (bs, 2H, NH), 7.59 (dd, J1= 8.4, J2= 4.2, 2H, H-aromatic), 7.68 (t, J= 7.6 Hz, 2H, 
H-aromatic), 8.08 (d, J=8.0 Hz, 2H, H-aromatic), 8.31 (d, J= 8.0 Hz, 2H, H-aromatic), 
8.46 (d, J= 7.1 Hz, 2H, H-aromatic), 9.04 (m, 2H, H-aromatic). 
13C-NMR (CDCl3), : 26.13, 42.47, 52.92, 56.08 (CH2, C-2’,  3’,  4’,  1’),  122.22,  125.75  
(CH, C-aromatic), 128.80 (C, C-aromatic), 131.44, 133.19 (CH, C-aromatic), 136.09 
(C, C-aromatic), 136.99 (CH, C-aromatic), 143.46 (C, C-8), 151.16 (CH, C-aromatic). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))dithiophene-2-sulfonamide 
(106) 
(C18H28N4O4S4; M.W.= 492.6) 
 
 
  97      106 
 
General procedure 4; 
White solid; 
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T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.45. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.24 g (83%) 
Melting Point: 138-140°C 
MS (ESI)+: 493.0 [M+H]+ 
1H-NMR (DMSO-d6), : 1.52 (m, 4H, H-2’),  2.24  (m,  12H,  H-3’,  4’),  2.86  (m,  4H,  H-
1’),   7.18 (dd, J1= 5.1, J2= 3.7, 2H, H-3), 7.57 (dd, J1= 3.7, J2= 1.3, 2H, H-aromatic), 
7.79 (bs, 2H, NH), 7.92 (dd, J1= 5.1, J2= 1.3, 2H, H-aromatic).  
13C-NMR (DMSO-d6), : 25.88, 41.22, 52.62, 54.92 (CH2, C-2’,   3’,   4’,   1’),   127.61,  
131.38, 132.29 (CH, C-2, 3, 4), 141.44 (C, C-1). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))dipyridine-3-sulfonamide 
(107) 
(C20H30N6O4S2; M.W.= 482.6) 
 
 
  98      107 
 
General procedure 4; 
Pale yellow solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.52. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 91:9 
v/v). 
Yield: 0.18 g (63%) 
Melting Point: 140-142°C 
MS (ESI)+: 483.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.50 (m, 4H, H-2’),  2.20  (bs,  12H,  H-3’,  4’),  2.82  (bs,  4H,  H-
1’),  7.65 (dd, J1= 8.0 Hz, J2= 4.9 Hz, 2H, H-4), 7.85 (bs, 2H, NH), 8.16 (dt, J1= 8.0 Hz, 
J2= 1.9 Hz, 2H, H-5), 8.82 (dd, J1= 4.9 Hz, J2= 1.9 Hz, 2H, H-3), 8.94 (d, J= 2.2 Hz, 2H, 
H-2). 
13C-NMR (DMSO-d6), : 26.05, 40.80, 52.50, 54.65 (CH2, C-2’,   3’,   4’,   1’),   124.26, 
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134.46 (CH, C-4, 5), 136.88 (C, C-1), 146.99, 152.93 (CH, C-3, 2). 
 
Ethyl 3-(N-(3-(4-(3-(4-carboxyphenylensulfonamido)propyl) piperazin-1-yl)propyl) 
sulfamoyl)benzoate (108) 
(C28H40N4O8S2; M.W.= 624.7) 
 
 
  99      108 
 
General procedure 4; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.56. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.15 g (41%) 
Melting Point: 170-172°C 
MS (ESI)+: 625.2 [M+H]+ 
1H-NMR (CDCl3), : 1.44 (t, J= 7.1 Hz, 6H, H-7’),  1.67  (m,  4H,  H-2’),  2.47  (m,  12H,  
H-3’,  4’),   3.11   (t,   J=  5.6  Hz,  4H,  H-1’),   4.44   (q,   J=  7.1  Hz,  4H,  H-6’),   7.45   (bs,  2H,  
NH), 7.92 (d, J= 8.5 Hz, 4H, H-aromatic), 8.19 (d, J= 8.5 Hz, 4H, H-aromatic). 
13C-NMR (CDCl3), : 14.27 (CH3, C-7’),  23.81,  44.39,  53.05,  57.97,  61.68  (CH2, C-2’,  
3’,  4’,  1’,  6’),  126.88,  130.21  (CH,  C-aromatic), 133.99, 144.15 (C, C-4, 1), 165.22 (C, 
C-6’). 
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3-(N-(3-(4-(3-(4-Carboxyphenylensulfonamido)propyl)piperazin-1-yl)-propyl)-
sulfamoyl)benzoic acid (111) 
(C24H32N4O8S2; M.W.= 568.6) 
 
 
                    111 
 
Compound 108 (0.15 g, 0.25 mmol) was dissolved 3 mL of THF. LiOH monohydrate 
(0.07 g, 1.7 mmol) was dissolved in 4 mL of distilled water and added to the THF 
solution. The reaction was stirred o.n. at 80°C. The organic solvent was then removed at 
reduced pressure and the water residue was acidified to pH 5 with 1M HCl solution. 
The resulting precipitate was filtered, washed with water and dried under vacuum to 
afford pure 3-(N-(3-(4-(3-(4-carboxyphenylensulfonamido)propyl)piperazin-1-yl)-
propyl)sulfamoyl)benzoic acid 111 as a white solid. 
Yield: 0.07 g (51%) 
Melting Point: > 260°C 
MS (ESI)+: 591.1 [M+Na]+ 
Sodium salt 1H-NMR (D2O), : 1.48 (m, 4H, H-2’),  2.15  (t,  J=  7.8 Hz, 4H, H-3’),  2.31  
(bs, 8H, H-4’),  2.69  (t,  J=  7.1  Hz,  4H,  H-1’),  7.72  (d,  J=  8.1  Hz,  4H,  H-aromatic), 7.88 
(d, J= 8.1 Hz, 4H, H-aromatic). 
Sodium salt 13C-NMR (D2O), : 27.83, 43.54, 51.57, 55.62 (CH2, C-2’,   3’,   4’,   1’),  
126.20, 129.17 (CH, C-aromatic), 138.69, 145.22 (C, C-4, 1), 174.53 (C, C-6’). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(2-chlorobenzene-
sulfonamide) (116) 
(C21H36Cl2N4O4S2; M.W.= 549.5) 
 
 
  115      116 
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General procedure 4; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.79. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 98:2 
v/v). 
Yield: 0.26 g (80%) 
Melting Point: 162-164°C 
MS (ESI)+: 549.1, 551.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.49 (m, 4H, H-2’),  2.17  (m, 12H, H-3’,  4’),  2.85  (m,  4H,  H-
1’),  7.54  (td,  J1= 7.4 Hz, J2= 1.5 Hz, 2H, H-aromatic), 7.65 (m, 4H, H-aromatic), 7.88 (t, 
J= 5.1 Hz, 2H, NH), 7.96 (dd, J1= 7.9 Hz, J2= 1.3 Hz, 2H, H-aromatic). 
13C-NMR (DMSO-d6), : 25.78, 41.02, 52.52, 54.93 (CH2, C-2’,   3’,   4’,   1’),   127.63,  
130.51 (CH, C-aromatic), 130.59 (C, C-aromatic), 131.71, 133.90 (CH, C-aromatic), 
137.83 (C, C-aromatic). 
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6.2.7 N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl)) diarylsulfonamides (46-
53, 118) 
 
N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(4-chlorobenzene 
sulfonamide) (46) 
(C20H26Cl2N4O4S2; M.W.= 521.4) 
 
 
   38              46 
 
General procedure 5; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.66. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 95:5 
v/v). 
Yield: 0.14 g (45%) 
Melting Point: 218-220°C 
MS (ESI)+: 521.0, 523.0 [M+H]+ 
1H-NMR (CDCl3), : 2.17, (bs, 8H, H-3’),  2.43  (t,  J=  5.5,  4H,  H-2’),  3.08  (m,  4H,  H-
1’),  5.14  (bs,  2H,  NH), 7.51 (d, J= 8.5 Hz, 4H, H-aromatic), 7.82 (d, J= 8.5 Hz, 4H, H-
aromatic). 
13C-NMR (DMSO-d6), : 40.97, 52.84, 54.95 (CH2, C-1’,  2’,  3’),  128.67,  129.75  (CH,  
C-aromatic), 137.95, 139.82 (C, C-1, 4). 
 
N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))dibenzenesulfonamide (47) 
(C20H28N4O4S2; M.W.= 452.5) 
 
 
   39             47 
 
General procedure 5; 
White solid; 
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T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.40. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.12 g (52%) 
Melting Point: 158-160°C 
MS (ESI)+: 453.1 [M+H]+ 
1H-NMR (CDCl3), : 2.17, (s, 8H, H-3’),  2.39  (t,  J=  5.8,  4H,  H-2’),  3.00  (m,  4H,  H-1’),  
5.13 (bs, 2H, NH), 7.53 (m, 4H, H-3), 7.60 (tt, J1= 7.3 Hz, J2= 2.1 Hz, 2H, H-4), 7.88 
(m, 4H, H-2). 
13C-NMR (CDCl3), : 39.16, 52.27, 55.44 (CH2, C-1’,  2’,  3’),  127.07,  129.06,  132.64  
(CH, C-3, 4, 2 ), 139.64 (C, C-1). 
 
N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(4-methylbenzene-
sulfonamide) (48)19 
(C22H32N4O4S2; M.W.= 480.6) 
 
 
   40            48 
General procedure 5; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.59. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 98:2 
v/v). 
Yield: 0.25 g (89%) 
Melting Point: 182-184°C (lit. 185-187°C)19 
MS (ESI)+: 481.1 [M+H]+ 
1H-NMR (CDCl3), : 2.24, (bs, 8H, H-3’),  2.39  (t,  J=  5.7,  4H,  H-2’),  2.45  (s,  6H,  H-
4’),  2.98  (m,  4H,  H-1’),  5.10  (bs,  2H,  NH), 7.32 (d, J= 8.2 Hz, 4H, H-aromatic), 7.57 (d, 
J= 8.2 Hz). 
13C-NMR (DMSO-d6), : 20.91 (CH3, C-4’),  40.05,  52.43,  56.74  (CH2, C-1’,  2’,  3’),  
126.49, 129.52 (CH, C-aromatic ), 137.68, 142.46 (C, C-4, 1). 
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N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(4-methoxy-
benzenesulfonamide) (49) 
(C22H32N4O6S2; M.W.= 512.6) 
 
 
   41                49 
 
General procedure 5; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.45. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.23 g (78%) 
Melting Point: 170-172°C 
MS (ESI)+: 513.1 [M+H]+ 
1H-NMR (CDCl3), : 2.24, (bs, 8H, H-3’),  2.40  (t,  J=  5.4,  4H,  H-2’),  2.97  (m,  4H,  H-
1’),  3.89 (s, 6H, H-4’),  5.07 (bs, 2H, NH), 6.99 (d, J= 8.8 Hz, 4H, H-aromatic), 7.81 (d, 
J= 8.8 Hz, 4H, H-aromatic). 
13C-NMR (CDCl3), : 39.12, 52.32, 55.49 (CH2, C-1’,   2’,   3’),   55.63   (CH3, C-4’),  
114.19, 129.23 (CH, C-aromatic ), 131.19, 162.89 (C, C-1, 4). 
 
N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(4-nitrobenzene-
sulfonamide) (50) 
(C20H26N4O8S2; M.W.= 542.5) 
 
 
   42                50 
 
General procedure 5; 
Pale yellow solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.68. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
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v/v). 
Yield: 0.20 g (63%) 
Melting Point: 212-214°C 
MS (ESI)+: 543.0 [M+H]+ 
1H-NMR (DMSO-d6), : 2.18, (bs, 8H, H-3’),  2.55  (t,  J=  6.6,  4H,  H-2’),  2.98  (t,  J=  6.6  
Hz, 4H, H-1’),  7.92  (bs,  2H,  NH), 8.05 (d, J= 8.8 Hz, 4H, H-aromatic), 8.40 (d, J= 8.8 
Hz). 
13C-NMR (DMSO-d6), : 40.06, 52.33, 56.83 (CH2, C-1’,  2’,  3’),  124.47, 127.98 (CH, 
C-aromatic ), 146.45, 149.44 (C, C-1, 4). 
 
N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(3,4-dimethoxy-
benzenesulfonamide) (51) 
(C24H36N4O8S2; M.W.= 572.6) 
 
 
   43                51 
 
General procedure 5; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.53. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.25 g (74%) 
Melting Point: 152-154°C 
MS (ESI)+: 573.1 [M+H]+ 
1H-NMR (CDCl3), : 2.26, (bs, 8H, H-3’),  2.40  (t,  J=  5.6,  4H,  H-2’),  2.99  (m,  4H,  H-
1’),   3.94   (s,   6H,   OCH3), 3.96 (s, 6H, OCH3), 5.11 (bs, 2H, NH), 6.94 (m, 2H, H-
aromatic), 7.34 (m, 2H, H-aromatic), 7.49 (m, 2H, H-aromatic). 
13C-NMR (CDCl3), : 39.19, 52.35, 56.21 (CH2, C-1’,  2’,  3’),  56.28, 56.30 (CH3, C-4’,  
5’),  109.66,  110.51,  121.03  (CH,  C-2, 5, 6), 131.27, 149.19, 152.58 (C, C-1, 3, 4). 
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N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(2,5-dimethoxy-
benzenesulfonamide) (52) 
(C24H36N4O8S2; M.W.= 572.6) 
 
 
   44           52 
 
General procedure 5; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.47. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 95:5 
v/v). 
Yield: 0.26 g (77%) 
Melting Point: 176-178°C 
MS (ESI)+: 573.1 [M+H]+ 
1H-NMR (CDCl3), : 2.31, (bs, 8H, H-3’),  2.42  (t,  J=  5.6,  4H,  H-2’),  2.98  (m,  4H,  H-
1’),  3.83  (s,  6H,  OCH3), 3.92 (s, 6H, OCH3), 5.58 (t, J= 4.9 Hz, 2H, NH), 6.96 (d, J= 9.1 
Hz, 2H, H-3), 7.08 (dd, J1=9.1 Hz, J2= 3.1 Hz, 2H, H-4), 7.47 (d, J= 3.1 Hz, 2H, H-6). 
13C-NMR (CDCl3), : 39.85, 52.64, 56.04 (CH2, C-3’,  2’,  1’),  56.05,  57.08  (CH3, C-4’,  
5’),  113.74,  114.86,  120.35  (CH,  C-3, 4, 6), 127.83, 150.25, 153.35 (C, C-1, 2, 5). 
 
N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))dinaphthalene-2-sulfonamide 
(53) 
(C28H32N4O4S2; M.W.= 552.7) 
 
 
   45              53 
 
General procedure 5; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.56. 
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Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.27 g (82%) 
Melting Point: 176-178°C 
MS (ESI)+: 553.1 [M+H]+ 
1H-NMR (CDCl3), : 2.18, (bs, 8H, H-3’),  2.37  (t,  J=  5.8,  4H,  H-2’),  3.01  (m,  4H,  H-
1’),  5.22  (bs,  2H,  NH), 7.66 (m, 4H, H-aromatic), 7.82 (dd, J1= 8.8 Hz, J2= 1.8 Hz, 2H, 
H-aromatic), 7.92 (d, J= 8.1 Hz, 2H, H-aromatic), 7.97 (m, 4H, H-aromatic), 8.45 (s, 
2H, H-1). 
13C-NMR (CDCl3), : 39.17, 52.26, 55.46 (CH2, C-3’,  2’,  1’),  122.22,  127.65,  127.91,  
128.56, 128.84, 129.18, 129.42 (CH, C-aromatic), 131.98, 134.66, 137.32 (C, C-2, 5, 
10). 
 
N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))diquinoline-8-sulfonamide 
(118) 
(C26H30N6O4S2; M.W.= 554.6) 
 
 
   117              118 
 
General procedure 5; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.52. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.17 g (52%) 
Melting Point: charring > 220°C 
MS (ESI)+: 555.1 [M+H]+ 
1H-NMR (CDCl3), : 1.89, (bs, 8H, H-3’),  2.29   (t,  J=  5.8,  4H,  H-2’),  2.97  (q,  J=  5.8  
Hz, 4H, H-1’),  5.22  (t,  J=  5.8  Hz,  2H,  NH), 7.55 (dd, J1= 8.6 Hz, J2= 4.2 Hz, 2H, H-
aromatic), 7.68 (t, J= 7.8 Hz, 2H, H-aromatic), 8.07 (dd, J1= 8.1 Hz, J2= 1.2 Hz, 2H, H-
aromatic), 8.28 (dd, J1= 8.4 Hz, J2= 1.6 Hz, 2H, H-aromatic), 8.45 (dd, J1= 7.2 Hz, J2= 
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1.4 Hz, 2H, H-aromatic), 9.02 (dd, J1= 4.3 Hz, J2= 1.7 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 38.97, 51.86, 55.10 (CH2, C-3’,  2’,  1’),  121.78,  124.95  (CH,  C-
aromatic), 127.70 (C, C-aromatic), 130.94, 132.87 (CH, C-aromatic), 135.59 (C, C-
aromatic), 136.39 (CH, C-aromatic), 142.76 (C, C-8), 150.66 (CH, C-aromatic). 
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6.2.8 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))diaryl 
sulfonamides (62-68) 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))bis(4-chlorobenzene-
sulfonamide) (62) 
(C22H26Cl2N4O6S2; M.W.= 576.1) 
 
 
   55                62 
 
General procedure 6; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.76. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 98:2 
v/v). 
Yield: 0.14 g (41%) 
Melting Point: 206-208°C 
MS (ESI)+: 598.9, 600.9 [M+Na]+ 
1H-NMR (CDCl3), : 2.62 (t, J= 5.2 Hz, 4H, H-2’),  3.33  (m,  4H,  H-1’),  3.43  (m,  4H,  
CH2), 3.56 (m, 4H, CH2), 7.1 (bs, 2H, NH), 7.52 (d, J= 8.5 Hz, 4H, H-aromatic), 7.83 
(d, J= 8.5 Hz, 4H, H-aromatic). 
13C-NMR (DMSO-d6), : 32.58, 32.60, 38.85, 40.62, 40.94, 44.33, 44.60 (CH2, C-2’,  
1’,  4’,  4’’), 128.48, 129.32 (CH, C-aromatic), 137.22, 139.21 (C, C-1, 4), 168.60 (C, C-
3’). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl)dibenzenesulfonamide 
(63) 
(C22H28N4O6S2; M.W.= 508.1) 
 
 
   56                63 
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General procedure 6; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.57. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.17 g (57%) 
Melting Point: 194-196°C 
MS (ESI)+: 531.0 [M+Na]+ 
1H-NMR (CDCl3), : 2.59 (bs, 4H, H-2’),  3.26  (m,  4H,  H-1’),  3.40  (m,  4H,  CH2), 3.60 
(m, 4H, CH2), 5.55 (bs, 2H, NH), 7.54 (m, 4H, H-aromatic), 7.59 (m, 2H, H-4), 7.89 (m, 
4H, H-aromatic). 
13C-NMR (DMSO-d6), : 32.56, 32.62, 38.89, 40.61, 40.92, 44.32, 44.61 (CH2, C-1’,  
2’,  4’,  4’’),  126.46,  129.20,  132.38   (CH,  C-aromatic), 140.28 (C, C-1), 168.64 (C, C-
3’). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))bis(4-methoxybenzene-
sulfonamide) (64) 
(C24H32N4O8S2; M.W.= 568.2) 
 
 
   57                 64 
 
General procedure 6; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.65. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 98:2 
v/v). 
Yield: 0.15 g (46%) 
Melting Point: 178-180°C 
MS (ESI)+: 591.1 [M+Na]+ 
1H-NMR (CDCl3), : 2.59 (t, J= 5.6 Hz, 4H, H-2’),  3.23  (m,  4H,  H-1’),  3.42  (m,  4H,  
CH2), 3.60 (m, 4H, CH2), 3.89 (s, 6H, H-5’),  5.42  (bs,  2H,  NH), 7.00 (d, J= 8.8 Hz, 4H, 
H-aromatic), 7.82 (d, J= 8.8 Hz, 4H, H-aromatic). 
 Chapter 6: Experimental 
 
 
273 
 
13C-NMR (CDCl3), : 33.03, 33.16, 39.01, 39.07, 41.22, 44.79, 44.96 (CH2, C-2’,  1’,  
4’,  4’’), 55.64 (CH3, C-5’), 114.32, 129.10 (CH, C-aromatic), 131.72, 162.89 (C, C-1, 
4), 168.88 (C, C-3’). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))bis(4-nitrobenzene-
sulfonamide) (65) 
(C22H26N4O10S2; M.W.= 598.1) 
 
 
   58                 65 
 
General procedure 6; 
Pale yellow solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.70. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 95:5 
v/v). 
Yield: 0.12 g (35%) 
Melting Point: charring > 270°C 
MS (ESI)+: 621.0 [M+Na]+ 
1H-NMR (CDCl3), : 2.66 (t, J= 5.3 Hz, 4H, H-2’),  3.29  (m,  4H,  H-1’),  3.46 (m, 4H, 
CH2), 3.65 (m, 4H, CH2), 5.76 (bs, 2H, NH), 8.08 (d, J= 8.9 Hz, 4H, H-aromatic), 8.39 
(d, J= 8.9 Hz, 4H, H-aromatic). 
13C-NMR (DMSO-d6), : 32.18, 32.34, 38.85, 40.02, 40.44, 44.31, 44.58 (CH2, C-2’,  
1’,  4’,  4’’), 124.57, 128.08 (CH, C-aromatic), 145.95, 149.56 (C, C-1, 4), 168.70 (C, C-
3’). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))bis(3,4-dimethoxy-
benzenesulfonamide) (66) 
(C26H36N4O10S2; M.W.= 628.2) 
 
 
   59                66 
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General procedure 6; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.65. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 98:2 
v/v). 
Yield: 0.17 g (47%) 
Melting Point: 102-104°C 
MS (ESI)+: 651.1 [M+Na]+ 
1H-NMR (CDCl3), : 2.80 (bs, 4H, CH2), 3.21 (m, 4H, CH2), 3.55 (m, 4H, CH2), 3.95 
(m, 12H, OCH3), 4.04 (bs, 4H, CH2), 5.25 (bs, 1H, NH), 5.54 (bs, 1H, NH), 6.97 (m, 
2H, H-aromatic), 7.33 (m, 2H, H-aromatic), 7.49 (m, 2H, H-aromatic). 
13C-NMR (CDCl3), : 33.05, 33.27, 38.81, 39.08, 41.19, 41.34, 44.95, 45.09 (CH2, C-
1’,   2’,   4’,   4’’), 56.20, 56.27, 56.36, 56.49 (CH3, C-5’,   6’),   109.57,   109.70,   110.62,  
110.68, 120.85, 120.93 (CH, C-aromatic), 129.96, 131.59, 149.25, 149.52, 152.00, 
152.76 (C, C-1, 3, 4), 169.84, 171.89 (C, C-3’). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))bis(2,5-dimethoxy-
benzenesulfonamide) (67) 
(C26H36N4O10S2; M.W.= 628.2) 
 
 
   60              67 
 
General procedure 6; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.63. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.19 g (52%) 
Melting Point: 90-92°C 
MS (ESI)+: 651.1 [M+Na]+ 
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1H-NMR (CDCl3), : 2.55 (t, J= 6.0 Hz, 4H, H-2’),  3.22  (m,  4H,  H-1’),  3.37  (m,  4H,  
H-4’,  4’’),  3.60  (m,  4H, CH2), 3.84 (s, 6H, OCH3), 3.97 (s, 6H, OCH3), 5.92 (t, J= 6.1 
Hz, 2H, NH), 7.00 (d, J= 9.0 Hz, 2H, H-3), 7.09 (dd, J1= 9.0 Hz, J2= 3.0 Hz, 2H, H-4), 
7.46 (d, J= 3.0 Hz, H-6). 
13C-NMR (DMSO-d6), : 32.21, 32.51, 38.90, 40.52, 40.79, 44.23, 44.47 (CH2, C-1’,  
2’,   4’,   4’’),   55.76,   56.53   (CH3, C-5’,   6’),   114.15,   114.26,   119.50   (CH,   C-3, 4, 6), 
128.22, 150.17, 152.34 (C, C-1, 2, 5), 168.92 (C, C-3’). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))dinaphthalene-2-
sulfonamide (68) 
(C30H32N4O6S2; M.W.= 608.2) 
 
 
   61                 68 
 
General procedure 6; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.79. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.19 g (54%) 
Melting Point: 228-230°C 
MS (ESI)+: 631.0 [M+Na]+ 
1H-NMR (CDCl3), : 2.55 (m, 4H, CH2), 3.28 (m, 8H, CH2), 3.52 (4H, m, CH2), 5.61 
(bs, 2H, NH), 7.66 (m, 4H, H-aromatic), 7.86 (dd, J1= 8.7 Hz, J2= 1.7 Hz, 2H, H-
aromatic), 7.93 (d, J= 7.9 Hz, 2H, H-aromatic), 7.99 (m, 4H, H-aromatic), 8.45 (s, 2H, 
H-1). 
13C-NMR (DMSO-d6), : 32.59, 32.63, 38.90, 40.54, 40.83, 44.25, 44.49 (CH2, C-1’,  
2’,  4’,  4’’),  122.27,  127.36,  127.55,  127.79,  128.67,  129.13,  129.36  (CH,  C-aromatic), 
131.69, 134.11, 137.32 (C, C-2, 5, 10), 168.58 (C, C-3’). 
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6.2.9 N-(3-(Piperidin-1-yl)propyl)arylsulfonamides (69, 70) 
 
4-Chloro-N-(3-piperidin-1-yl-propyl)-benzenesulfonamide (69) 
(C14H21ClN2O2S; M.W.= 316.8) 
 
 
   22              69 
 
General procedure 7; 
Pale yellow oil; 
T.L.C. System: DCM-MeOH 95:5 v/v, Rf: 0.30. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 93:7 
v/v). 
Yield: 0.28 g (75%) 
MS (ESI)+: 317.1, 319.1 [M+H]+ 
1H-NMR (CDCl3), : 1.50 (bs, 2H, CH2), 1.67 (m, 6H, CH2), 2.43 (m, 6H, CH2), 3.09 
(t, J= 5.3 Hz, 2H, H-1’),  7.50  (d,  J=  8.5  Hz,  2H,  H-aromatic), 7.82 (d, J= 8.5 Hz, 2H, H-
aromatic), 8.03 (bs, 1H, NH). 
13C-NMR (CDCl3), : 23.60, 24.00, 25.70, 44.32, 54.39, 58.71 (CH2, C-1’,  2’,  3’,  4’, 
5’,  6’  ),  128.42,  129.21 (CH, C-aromatic), 138.61, 138.98 (C, C-1, 4). 
 
N-(3-Piperidin-1-yl-propyl)-naphthalene-2-sulfonamide (70) 
(C18H24N2O2S; M.W.= 332.5) 
 
 
   29              70 
 
General procedure 7; 
Brownish oil; 
T.L.C. System: DCM-MeOH 95:5 v/v, Rf: 0.37. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 95:5 
v/v). 
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Yield: 0.28 g (71%) 
MS (ESI)+: 333.1 [M+H]+ 
1H-NMR (CDCl3), : 1.48 (bs, 2H, CH2), 1.63 (m, 6H, CH2), 2.34 (m, 6H, CH2), 3.11 
(t, J= 5.7 Hz, 2H, H-1’),  7.64  (m,  2H, H-aromatic), 7.86 (dd, J1= 8.6 Hz, J2= 1.8 Hz, 1H, 
H-aromatic), 7.93 (d, J= 7.9 Hz, 1H, H-aromatic), 7.98 (m, 3H, 2 x H-aromatic, NH), 
8.45 (s, 1H, H-1). 
13C-NMR (CDCl3), : 23.61, 24.20, 26.03, 44.73, 54.47, 59.00 (CH2, C-1’,  2’,  3’,  4’, 
5’,   6’   ),   122.43, 127.43, 127.89, 128.16, 128.50, 129.13, 129.25 (CH, C-aromatic), 
132.23, 134.67, 137.16 (C, C-1, 5, 10). 
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6.2.10 N,N’-(4,4’-(Piperazine-1,4-diyl)bis(butane-4,1-diyl))bis(4-chlorobenzene-
sulfonamide) (73) 
 
(4-Hydroxy-butyl)-carbamic acid tert-butyl ester (78)20 
(C9H19NO3; M.W.= 189.3) 
 
 
  71   77    78 
Di-tert-butyl dicarbonate (77) (2.69 g, 12.3 mmol) was dissolved at °C in 3 mL of 
anhydrous DCM and added dropwise to a stirred solution of 4-amino-1-butanol (71) 
(1g, 11.2 mmol) and triethylamine (1.7 mL, 12.3 mmol), in 6 mL of anhydrous DCM. 
The resulting mixture was stirred at r.t. for 7 h. The reaction mixture was then diluted 
with DCM and washed with saturated NH4Cl solution (2 x 25 mL) and brine (25 mL). 
The organic extract was dried over MgSO4 and the solvent was removed at reduced 
pressure to afford pure 4-hydroxy-butyl)-carbamic acid tert-butyl ester (78) as a pale 
yellow oil. 
Yield: 1.97 g (93%) 
1H-NMR (CDCl3), : 1.44 (s, 9H, H-3’,   4’,   5’),   1.58   (m,   4H,  H-2, 3), 2.05 (bs, 1H, 
OH), 3.15 (m, 2H, CH2), 3.66 (m, 2H, CH2), 4.70 (bs, 1H, NH). 
13C-NMR (CDCl3), : 26.60 (CH2, C-aliphatic), 28.41 (CH3, C-3’,  4’,  5’),  29.71,  40.29  
62.34 (CH2, C-aliphatic), 79.17 (C, C-2’),  156.15  (C,  C-1’). 
 
Methanesulfonic acid 4-tert-butoxycarbonylamino-butyl ester (79)21 
(C10H21NO5S; M.W.= 267.3) 
 
 
   78              79 
 
To a solution of Boc-4-aminobutanol (78) (1 g, 5.3 mmol) and triethylamine (1.5 mL, 
10.6 mmol) in 7 mL of anhydrous DCM was added dropwise methane sulfonyl chloride 
(0.66 g, 5.8 mmol) over a period of 10 min at 0°C. The mixture was then stirred for an 
additional 1 h at 0°C and 1 h at r.t. The reaction mixture was diluted with DCM (20 mL) 
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and washed with cold saturated NaHCO3 solution (2 x 30 mL). The organic layer was 
dried over MgSO4 and the solvent was removed under vacuum to give pure 
methanesulfonic acid 4-tert-butoxycarbonylamino-butyl ester (79) as a yellow oil. 
Yield: 1.21 g (86%) 
1H-NMR (CDCl3), : 1.44 (s, 9H, H-3’),  1.61  (m,  2H,  CH2), 1.79 (m, 2H, CH2), 3.01 
(s, 3H, H-6’),  3.16  (m,  2H,  CH2), 4.25 (t, J= 6.4 Hz, 2H, H-4), 4.64 (bs, 1H, NH). 
13C-NMR (CDCl3), : 26.26, 26.40 (CH2, C-2, 3), 28.38 (CH3, C-3’),  39.75  (CH3, C-
6’),  42.54,  69.62  (CH2, C-1, 4), 79.24 (C, C-2’),  155.99  (C,  C-1’). 
 
{4-[4-(4-tert-Butoxycarbonylamino-butyl)-piperazin-1-yl]-butyl}-carbamic acid 
tert-butyl ester (80) 
(C22H44N4O4; M.W.= 428.6) 
 
 
  79         80 
 
Piperazine (0.17 g, 2.1 mmol) and NaHCO3 (0.38, 4.5 mmol) were suspended in 3 mL 
of absolute ethanol and added dropwise of 79 (1.21 g, 4.5 mmol) diluted in 5 mL of 
ethanol. The reaction mixture was stirred under reflux for 24 h. The solvent was 
evaporated under vacuum, and the residue was suspended in DCM (30 mL) and washed 
with saturated NaHCO3 solution (2 x 30 mL) and brine (30 mL). The organic phase was 
evaporated at reduced pressure after drying over MgSO4 to give {4-[4-(4-tert-
Butoxycarbonylamino-butyl)-piperazin-1-yl]-butyl}-carbamic acid tert-butyl ester 80 as 
a yellow waxy solid. 
Yield: 0.63 g (70%) 
1H-NMR (CDCl3), : 1.37 (m, 18 H, H-3’), 1.63 (m, 8H, CH2), 2.32 (bs, 4H, CH2), 
2.56 (bs, 8H, CH2), 3.33 (t, J= 5.3 Hz, 4H, H-1), 5.56 (bs, 2H, NH). 
13C-NMR (CDCl3), : 24.40, 25.74 (CH2, C-aliphatic), 28.48, 28.56 (CH3, C-3’), 
40.53, 53.05, 58.05 (CH2, C-aliphatic), 78.86 (C, C-2’),  156.05  (C,  C-1’). 
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N,N’-(4,4’-(Piperazine-1,4-diyl)bis(butane-4,1-diyl))bis(4-chlorobenzene-
sulfonamide) (73) 
(C24H34N4O4 S2; M.W.= 577.6) 
 
 
             73 
 
Compound 80 (0.63 g, 1.5 mmol) was dissolved at 0°C in a mixture of 2 mL of TFA 
and 0.2 mL of distilled water. The reaction mixture was left stirring at r.t for 30 min., 
then the volume was reduced under vacuum and the remaining suspension was poured 
dropwise into 5 mL of ice-cooled diethyl ether. The resulting white precipitate was left 
in the fridge o.n. before being filtered and washed with cold diethyl ether. 
The white solid was suspended with 4-chlorobenzenesulfonyl chloride (13) (0.63 g, 3.0 
mmol) in 7 mL of anhydrous DCM; the resulting mixture was treated dropwise with 
triethylamine (1.3 mL, 9.5 mmol) under ice-cooling and stirred for 1 h at r.t. 
The reaction mixture was then diluted with DCM and washed with water (2 x 30 mL) 
and brine (30 mL). The organic solvent was removed under vacuum after drying over 
MgSO4 and the crude residue was purified by flash column chromatography 
(DCM:MeOH 100:0 v/v increasing to 91:9 v/v) to afford pure N,N’-(4,4’-(piperazine-
1,4-diyl)bis(butane-4,1-diyl))bis(4-chlorobenzenesulfonamide) (73) as a white solid. 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.64. 
Yield: 0.12 g (15%) 
Melting Point: 182-184°C 
MS (ESI)+: 577.1. 579.1 [M+H]+ 
1H-NMR (CDCl3), : 1.63 (m, 8H, CH2), 2.50 (bs, 4H, CH2), 2.77 (bs, 8H, CH2), 2.96 
(t, J= 5.3 Hz, 4H, H-1’),  7.49  (d,  J=  8.6  Hz,  4H,  H-aromatic), 7.81 (d, J= 8.6 Hz, 4H, H-
aromatic). 
13C-NMR (CDCl3), : 24.17, 28.29, 42.88, 51.81, 57.72 (CH2, C-1’,   2’,   3’,   4’,   5’),  
128.43, 129.29 (CH, C-aromatic), 138.66, 139.28 (C, C-1, 4). 
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6.2.11 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-
chlorobenzamide) (122) 
 
N-(3-Bromopropyl)-4-chlorobenzamide (120) 
(C10H11BrClNO; M.W.= 276.6) 
 
 
   119  21    120 
 
4-Chlorobenzoyl chloride (119) (0.5 g, 2.9 mmol) and 3-bromopropylamine 
hydrobromide (32) (0.69 g, 3.2 mmol) were suspended in anhydrous DCM (8 mL) 
under a nitrogen atmosphere. Triethylamine (0.9 mL, 6.6 mmol) was then added 
dropwise under ice-cooling and the reaction mixture was left stirring at 0°C for 10 min. 
and then at r.t. for 20 min.The reaction mixture was then diluted with DCM (20 mL) 
and washed with a 2M hydrochloric acid solution (2 x 30 mL) and brine (30 mL). The 
organic layer was dried over MgSO4 and the solvent was removed under vacuum to 
afford pure N-(3-bromopropyl)-4-chlorobenzamide (120) as a white solid. 
T.L.C. System: DCM- nhexane 4:1 v/v, Rf: 0.53. 
Yield: 0.63 g (78%) 
1H-NMR (CDCl3), : 2.23 (m, 2H, H-3’),  3.51  (t,  J=  6.4  Hz,  2H,  H-4’),  3.64  (m,  2H,  
H-2’),  6.38  (bs,  1H,  NH), 7.43 (d, J= 8.6 Hz, 2H, H-aromatic), 7.73 (d, J= 8.6 Hz, 2H, 
H-aromatic). 
13C-NMR (CDCl3), : 30.97, 32.01, 38.81 (CH2, C-3’,  4’,  2’),  128.31,  128.89  (CH,  C-
aromatic), 132.71, 137.87 (C, C-1, 4), 166.65 (C, C-1’). 
 
N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-chlorobenzamide) (122) 
(C24H30Cl2N4O2; M.W.= 477.4) 
 
 
  120      122 
 
A mixture of compound 120 (0.5 g, 1.8 mmol), piperazine (0.07 g, 0.8 mmol) and 
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triethylamine (0.24 mL, 1.7 mmol) in 7 mL of anhydrous THF was stirred under 
nitrogen atmosphere for 48 h. at r.t. The reaction mixture was then diluted with DCM 
(20 mL), washed with saturated NaHCO3 solution (2 x 30 mL) and brine (30 mL) and 
dried over MgSO4. The organic solvent was removed under vacuum and the crude 
residue was purified by flash column chromatography (DCM-MeOH 100:0 v/v 
increasing to DCM-MeOH 91:9 v/v) to afford pure N,N’-(3,3’-(piperazine-1,4-
diyl)bis(propane-3,1-diyl))bis(4-chlorobenzamide) (122) as a white solid. 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.63. 
Yield: 0.1375 g (36%) 
Melting Point: 180-182°C 
MS (ESI+): 477.1, 479.1 [M+H]+ 
1H-NMR (CDCl3), : 1.82 (m, 4H, H-3’),  2.56  (m,  12H,  H-4’,  5’),  3.59  (m,  4H,  H-2’),  
7.42 (d, J= 8.5 Hz, 4H, H-aromatic), 7.78 (d, J= 8.5 Hz, 4H, H-aromatic), 8.05 (bs, 2H, 
NH). 
13C-NMR (DMSO-d6), : 26.10, 37.92, 52.75, 55.64 (CH2, C-2’,   3’,   4’,   5’),   128.28,  
129.02 (CH, C-aromatic), 133.37, 135.79 (C, C-1, 4), 164.99 (C, C-1’). 
 Chapter 6: Experimental 
 
 
283 
 
6.2.12 N,N’-(2,2’-(1,4-Phenylenebis(azanediyl))bis(ethane-2,1-diyl))bis(4-
chlorobenzene-sulfonamide) (125) 
(C22H24Cl2N4O4S2; M.W.= 543.5) 
 
 
   38               125 
 
A mixture of compound 38 (1.05 g, 3.5 mmol), 4-phenylendiamine (123) (0.16 g, 1.5 
mmol) and triethylamine (0.47 mL, 3.4mmol) in 13 mL of anhydrous THF was stirred 
under nitrogen atmosphere for 72 h at r.t. The reaction mixture was then diluted with 
DCM (35 mL), washed with saturated NaHCO3 solution (2 x 30 mL) and brine (30 mL) 
and dried over MgSO4. The organic solvent was removed under vacuum and the crude 
residue was purified by flash column chromatography (nhexane-EtOAc 100:0 v/v 
increasing to nhexane-EtOAc 20:80 v/v) to afford pure N,N’-(2,2’-(1,4-
phenylenebis(azanediyl))bis(ethane-2,1-diyl))bis(4-chlorobenzenesulfonamide) (125) as 
a light brown solid. 
T.L.C. System: EtOAc-nhexane 8:2 v/v, Rf: 0.46. 
Yield: 0.13 g (17%) 
Melting Point: 162-164°C 
MS (ESI)+: 543.0, 545.0 [M+H]+ 
1H-NMR (DMSO-d6), : 2.87 (t, J= 6.5 Hz, 4H, CH2), 2.97 (m, 4H, CH2), 4.70 (t, J= 
6.1 Hz, 2H, NH), 6.32 (s, 4H, H-4’),  7.65  (d,  J=  8.6  Hz,  4H,  H-aromatic), 7.79 (d, J= 8.6 
Hz, 4H, H-aromatic), 7.81 (bs, 2H, NH). 
13C-NMR (DMSO-d6), : 41.84, 43.63 (CH2, C-1’,   2’),   113.74 (CH, C-4’),   128.39,  
129.31 (CH, C-aromatic), 137.20, 139.33, 139.64 (C, C-1,  4,  3’). 
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6.2.13 N-(3-Piperazin-1-yl-propyl)-arylsulfonamides (139-143) 
 
4-Chloro-N-(3-piperazin-1-yl-propyl)-benzenesulfonamide) (139) 
(C13H20ClN3O2S; M.W.= 317.1) 
 
 
    22    139 
 
General procedure 8; 
Pale yellow solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.73. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 1.37g (56%) 
1H-NMR (CDCl3), : 1.61-1.67 (m, 2H, H-2’),  2.35-2.46 (m, 6H, CH2), 2.91 (t, J= 4.8 
Hz, 4H, CH2), 3.07 (t, J= 5.8 Hz, 2H, CH2), 7.48 (d, J= 8.7 Hz, 2H, H-aromatic), 7.79 
(d, J= 8.7 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 23.70, 44.25, 44.41, 45.88, 46.09, 54.18, 58.58 (CH2, C-1’,  2’,  
3’,  4’,  5’), 128.40, 129.25 (CH, C-aromatic), 138.70, 138.94 (C, C-1, 4). 
 
N-(3-Piperazin-1-yl-propyl)-benzenesulfonamide (140)22 
(C13H21N3O2S; M.W.= 283.3) 
 
 
    23    140 
 
General procedure 8;  
Pale yellow oil; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.26. 
Purification: flash column chromatography (DCM:MeOH:NEt3 100:0:0 v/v increasing 
to DCM:MeOH:NEt3 90:9:1 v/v). 
Yield: 1.55 g (71%) 
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1H-NMR (CDCl3), : 1.60-1.66 (m, 2H, H-2’),  2.37-2.43 (m, 6H, CH2), 2.92 (t, J=3. 
4.8 Hz, 4H, CH2), 3.08 (t, J= 5.7 Hz, 2H, CH2), 7.50-7.54 (m, 2H, H-aromatic), 7.57 (tt, 
J1= 7.3 Hz, J2= 1.2 Hz, 1H, H-4), 7.87 (d, J= 7.2 Hz, 2H, H-2, 6). 
13C-NMR (CDCl3), : 23.85, 44.16, 45.80, 45.98, 53.43, 54.00, 58.46 (CH2, C-1’,  2’,  
3’,  4’,  5’), 126.91, 128.98, 132.32 (CH, C-aromatic), 140.30 (C, C-1). 
 
4-Methyl-N-(3-Piperazin-1-yl-propyl)-benzenesulfonamide (141) 
(C14H23N3O2S; M.W.= 297.4) 
 
 
    24    141 
 
General procedure 8; 
Pale yellow waxy solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.23. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 90:9:1 
v/v). 
Yield: 1.35 g (59%) 
1H-NMR (CDCl3), : 1.49-1.54 (m, 2H, H-2’),  2.24-2.30 (m, 6H, CH2), 2.32 (s, 3H, H-
6’),  2.80 (t, J= 4.7 Hz, 4H, CH2), 2.92 (t, J= 6.1 Hz, 2H, CH2), 7.21 (d, J= 8.1 Hz, 2H, 
H-aromatic), 7.64 (d, J= 8.1 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 21.39 (CH3, C-6’),  24.21, 43.56, 45.80, 53.91, 57.94 (CH2, C-1’,  
2’,  3’,  4’,  5’),  126.86, 129.52 (CH, C-aromatic), 137.25, 142.93 (C, C-1, 4). 
 
4-tert-Butyl-N-(3-piperazin-1-yl-propyl)-benzenesulfonamide (142) 
(C17H29N3O2S; M.W.= 339.5) 
 
 
   92     142 
General procedure 8; 
Yellow oil; 
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T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.24. 
Purification: flash column chromatography (DCM:MeOH:NEt3 100:0:0 v/v increasing 
to 90:9:1 v/v). 
Yield: 2.61 g (71%) 
1H-NMR (CDCl3), : 1.36 (s, 9H, H-7’),  1.62-1.67 (m, 2H, H-2’),  2.37-2.56 (m, 6H, 
CH2), 2.91 (t, J= 4.8 Hz, 4H, CH2), 3.09 (t, J=5.8 Hz, 2H, CH2), 7.52 (d, J= 8.5 Hz, 2H, 
H-aromatic), 7.78 (d, J= 8.5 Hz, 2H, H-aromatic).  
13C-NMR (CDCl3), : 23.88 (CH2, C-2’), 31.12 (CH3, C-7’),  35.09 (C, C-6’), 44.18, 
46.16, 54.29, 58.58 (CH2, C-3’,  4’,  1’,   5’), 125.91, 126.80 (CH, C-aromatic), 137.27, 
156.02 (C, C-4,1). 
 
Biphenyl-4-sulfonic acid (3-piperazin-1-yl-propyl)-amide (143) 
(C19H25N3O2S; M.W.= 359.5) 
 
 
   94     143 
 
General procedure 8; 
Colourless oil; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.33. 
Purification: flash column chromatography (DCM:MeOH:NEt3 100:0:0 v/v increasing 
to 90:9:1 v/v). 
Yield: 1.13g (41%) 
1H-NMR (CDCl3), : 1.62-1.67 (m, 2H, H-2’),  2.35-2.43 (m, 6H, CH2), 2.91 (t, J= 4.7 
Hz, 4H, CH2), 3.10 (t, J= 5.8 Hz, 2H, CH2), 7.40 (tt, J1= 7.3 Hz, J2= 2.1 Hz, 1H, H-4’’),  
7.45-7.49 (m, 2H, H-aromatic), 7.60 (d, J= 7.2 Hz, 2H, H-aromatic), 7.71 (d, J= 8.5 Hz, 
2H, H-aromatic), 7.91 (d, J= 8.5 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 24.05, 44.00, 45.97, 54.09, 58.31 (CH2, C-2’,   3’,   4’,   1’,   5’), 
126.99, 127.59, 127.91, 128.41, 129.04 (CH, C-aromatic), 138.92, 139.33, 145.20 (C, 
C-aromatic). 
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6.2.14 N-(3-(4-(3-Arylsulfonylamino-propyl)-piperazin-1-yl)-propyl)-aryl 
sulfonamides (126-138) 
 
N-{3-[4-(3-Benzenesulfonylamino-propyl)-piperazin-1-yl]-propyl}-4-chloro-
benzenesulfonamide (126) 
(C22H31ClN4O4S2; M.W.= 515.1) 
 
 
   139        126 
 
General procedure 9; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.59. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.35 g (68%) 
Melting Point: 128-130°C 
MS (ESI)+: 515.1, 517.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.44-1.51 (m, 4H, H-2’,  7’),  2.11-2.26 (m, 12H, CH2), 2.74-
2.79 (m, 4H, CH2), 7.56-7.62 (m, 3H, 2H-aromatic, NH), 7.61-7.64 (m, 1H, H-
aromatic), 7.66-7.70 (m, 3H, 2H-aromatic, NH), 7.78 (d, J= 8.3 Hz, 2H, H-aromatic). 
13C-NMR (DMSO-d6), : 26.02, 26.05, 40.85, 40.93, 52.59, 54.74, 54.86 (CH2), 
126.41, 128.42, 129.15, 129.31, 132.26 (CH, C-aromatic), 137.13, 139.39, 140.50 (C, 
C-1, 4,  4’’). 
 
4-Chloro-N-(3-(4-(3-(4-methylbenzenesulfonylamido)propyl)-piperazin-1-yl)-
propyl)benzenesulfonamide (127) 
(C23H33ClN4O4S2; M.W.= 529.1) 
 
 
                                   139               127 
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General procedure 9;  
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.57. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.45 g (86%) 
Melting Point: 172-174°C 
MS (ESI)+: 529.1, 531.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.43-1.51 (m, 4H, H-2’,  7’),  2.10-2.28 (m, 12H, CH2), 2.38 
(s, 3H, H-7’’),  2.69-2.81 (m, 4H, CH2), 7.39 (d, J= 8.1 Hz, 2H, H-aromatic),7.48 (t, J= 
5.6 Hz, 1H, NH), 7.64-7.71 (m, 5H, 4H-aromatic, NH), 7.79 (d, J= 8.7 Hz, 2H, H-
aromatic). 
13C-NMR (DMSO-d6), : 20.91 (CH3, C-7’’),  26.02, 40.85, 40.92, 52.59, 54.75, 54.89 
(CH2), 126.50, 128.42, 129.30, 129.55 (CH, C-aromatic), 137.13, 137.62, 139.40, 
142.46 (C, C-aromatic). 
 
4-tert-Butyl-N-(3-(4-(3-(4-chlorophenylsulfonylamido)propyl)-piperazin-1-yl)-
propyl)benzenesulfonamide (128) 
(C26H39ClN4O4S2; M.W.= 571.2) 
 
 
  139             128 
 
General procedure 9; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.44. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.34 g (60%) 
Melting Point: 130-132°C 
MS (ESI)+: 571.2, 573.2 [M+H]+ 
Microanalysis: Calculated for C26H39ClN4O4S2 (571.2); Theoretical: %C = 54.67, %H = 
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6.88, %N = 9.80; Found: %C = 54.51, %H = 6.41, %N = 9.61. 
1H-NMR (DMSO-d6), : 1.30 (s, 9H, H-8’’),  1.41-1.53 (m, 4H, H-2’,   7’),   2.11-2.35 
(m, 12H, CH2), 2.72-2.80 (m, 4H, CH2), 7.49 (t, J= 5.5 Hz, 1H, NH), 7.60 (d, J= 8.5 Hz, 
2H, H-aromatic), 7.65-7.72 (m, 5H, 4H-aromatic, NH), 7.78 (d, J= 8.5 Hz, 2H, H-
aromatic). 
13C-NMR (DMSO-d6), : 26.03 (CH2), 30.79 (CH3, C-8’’),  34.77 (C, C-7’’),  40.84, 
40.88, 52.55, 52.60, 54.75, 54.82 (CH2), 125.93, 126.35, 128.42, 129.31 (CH, C-
aromatic), 137.13, 137.68, 139.40, 155.19 (C, C-aromatic). 
 
4-Chloro-N-(3-(4-(3-(4-(trifluoromethyl)phenylsulfonylamido)propyl)-piperazin-1-
yl)-propyl)benzenesulfonamide (129) 
(C23H30ClF3N4O4S2; M.W.= 583.1) 
 
 
  139            129 
 
General procedure 9; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.61. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.49 g (85%) 
Melting Point: 158-160°C 
MS (ESI)+: 583.1, 585.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.44-1.51 (m, 4H, H-2’,  7’),  2.11-2.27 (m, 12H, CH2), 2.74-
2.83 (m, 4H, CH2), 7.67 (d, J= 8.5 Hz, 2H, H-aromatic), 7.69 (bs, 1H, NH), 7.78 (d, J= 
8.5 Hz, 2H, H-aromatic), 7.86 (bs, NH), 7. 94-8.03 (m, 4H, H-aromatic). 
13C-NMR (DMSO-d6), : 26.02, 40.84, 52.56, 54.65, 54.72 (CH2), 126.38, 126.41, 
126.44 (CH, C-3’’,   6’’),   127.44,   128.41,   129.29   (CH, C-aromatic), 131.95, 131.98, 
137.13, 139.40, 144.50 (C, C-aromatic). 
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N-(3-(4-(3-(4-Chlorophenylsulfonylamido)propyl)-piperazin-1-yl)-propyl)biphenyl-
4-sulfonamide (130) 
(C28H35ClN6O8S2; M.W.= 591.2) 
 
 
  139       130 
 
General procedure 9; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.63. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.42 g (71%) 
Melting Point: 138-140°C 
MS (ESI)+: 591.1, 593.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.42-1.54 (m, 4H, H-2’,  7’),  2.15-2.31 (m, 12H, CH2), 2.72-
2.81 (m, 4H, CH2), 7.44 (t, J= 5.7 Hz, 1H, NH), 7.50-7.54 (m, 2H, H-aromatic), 7.62 (t, 
J= 5.7 Hz, NH), 7.65-7.79 (m, 3H, H-aromatic), 7.74 (d, J= 7.1 Hz, 2H, H-aromatic), 
7.78 (d, J= 8.6 Hz, 2H, H-aromatic), 7.85 (d, J= 8.6 Hz, 2H, H-aromatic), 7.89 (d, J= 8.6 
Hz, 2H, H-aromatic). 
13C-NMR (DMSO-d6), : 26.01, 26.07, 40.84, 40.92, 52.58, 54.73, 54.82 (CH2), 
127.02, 127.15, 127.35, 128.42, 129.08, 129.30 (CH, C-aromatic), 137.13, 138.54, 
139.26, 139.39, 143.80 (C, C-aromatic). 
 
4-tert-Butyl-N-(3-(4-(3-(phenylsulfonylamido)propyl)-piperazin-1-yl)-
propyl)benzenesulfonamide (131) 
(C26H40N4O4S2; M.W.= 536.7) 
 
 
  142           131 
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General procedure 9; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.55. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.29 g (54%) 
Melting Point: 134-136°C 
MS (ESI)+: 537.2 [M+H]+ 
1H-NMR (DMSO-d6), : 1.30 (s, 9H, H-8), 1.43-1.49 (m, 4H, H-2’,  7’),  2.11-2.26 (m, 
12H, CH2), 2.72-2.78 (m, 4H, CH2), 7.49 (t, J= 5.6 Hz, 1H, NH), 7.58-7.62 (m, 5H, 4H-
aromatic, NH), 7.66-7.69 (m, 1H, H-aromatic), 7.70 (d, J= 8.5 Hz, 2H, H-aromatic), 
7.78 (d, J= 7.8 Hz, 2H, H-aromatic). 
13C-NMR (DMSO-d6), : 26.03, 26.06 (CH2, H-2’,  7’), 30.79 (CH3, C-8), 34.77 (C, C-
7), 40.88, 40.92, 52.56, 52.60, 54.82, 54.86 (CH2), 125.93, 126.35, 126.41, 129.15, 
132.26 (CH, C-aromatic), 137.68, 140.51, 155.20 (C, C-aromatic). 
 
4-tert-Butyl-N-(3-(4-(3-(4-methylphenylsulfonylamido)propyl)-piperazin-1-yl)-
propyl)benzenesulfonamide (132) 
(C26H42N4O4S2; M.W.= 550.7) 
 
 
  142             132 
 
General procedure 9; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.64. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.46 g (83%) 
Melting Point: 155-157°C 
MS (ESI)+: 573.2 [M+H]+ 
1H-NMR (DMSO-d6), : 1.30 (s, 9H, H-8), 1.43-1.49 (m, 4H, H-2’,  7’),  2.09-2.24 (m, 
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12H, CH2), 2.38 (CH3, C-7’’),   2.70-2.78 (m, 4H, CH2), 7.39 (d, J= 8.1 Hz, 2H, H-
aromatic), 7.49 (bs, 2H, NH), 7.60 (d, J= 8.5 Hz, 2H, H-aromatic), 7.66 (d, J= 8.1 Hz, 
2H, H-aromatic), 7.70 (d, J= 8.5 Hz, 2H, H-aromatic). 
13C-NMR (DMSO-d6), : 20.91 (CH3, C-7’’), 26.04 (CH2), 30.79 (CH3, C-8), 34.77 (C, 
C-7), 40.89, 40.92, 52.56, 52.61, 54.84, 54.90 (CH2), 125.93, 126.35, 126.50, 129.55 
(CH, C-aromatic), 137.63, 137.69, 142.44, 155.18 (C, C-aromatic). 
 
4-tert-Butyl-N-(3-(4-(3-(4-(trifluoromethyl)phenylsulfonylamido)propyl)-piperazin-
1-yl)-propyl)benzenesulfonamide (133) 
(C27H39F3N4O4S2; M.W.= 604.7) 
 
 
  142        133 
 
General procedure 9; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.76. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 95:5 
v/v). 
Yield: 0.42 g (70%) 
Melting Point: 156-158°C 
MS (ESI)+: 605.2 [M+H]+ 
1H-NMR (DMSO-d6), : 1.30 (s, 9H, H-8), 1.42-1.51 (m, 4H, H-2’,  7’),  2.09-2.26 (m, 
12H, CH2), 2.73-2.77 (m, 2H, CH2), 2.78-2.82 (m, 2H, CH2), 7.49 (t, J= 5.5 Hz, 1H, 
NH), 7.60 (d, J= 8.4 Hz, 2H, H-aromatic), 7.70 (d, J= 8.4 Hz, 2H, H-aromatic), 7.86 (bs, 
1H, NH), 7.97-9.01 (m, 4H, H-aromatic). 
13C-NMR (DMSO-d6), : 26.02 (CH2), 30.78 (CH3, C-8), 34.76 (C, C-7), 40.81, 40.87, 
52.53, 52.56, 54.64, 54.80 (CH2), 125.92, 126.35 (CH, C-aromatic), 126.41, 126.44 
(CH, C-3’’,  6’’), 127.44 (CH, C-aromatic), 132.20, 137.68, 144.50, 155.19 (C, C-7’’,  C-
aromatic). 
 Chapter 6: Experimental 
 
 
293 
 
N-(3-(4-(3-(4-tert-Butylphenylsulfonylamido)propyl)-piperazin-1-yl)-propyl) 
biphenyl-4-sulfonamide (134) 
(C34H44N4O4S2; M.W.= 612.8) 
 
 
  142                    134 
 
General procedure 9; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.62. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.36 g (58%) 
Melting Point: 146-148°C 
MS (ESI)+: 613.2 [M+H]+ 
1H-NMR (DMSO-d6), : 1.29 (s, 9H, H-8), 1.41-1.53 (m, 4H, H-2’,  7’),  2.07-2.25 (m, 
12H, CH2), 2.71-2.83 (m, 4H, CH2), 7.44 (t, J= 7.5 Hz, 1H, H-10’’),  7.47-7.53 (m, 3H, 
2H-aromatic, NH), 7.58-7.64 (m, 3H, 2H-aromatic, NH), 7.70 (d, J= 8.5 Hz, 2H, H-
aromatic), 7.74 (d, J= 7.2 Hz, 2H, H-aromatic), 7.85 (d, J= 8.5 Hz, 2H, H-aromatic), 
7.89 (d, J= 8.5 HZ, 2H, H-aromatic). 
13C-NMR (DMSO-d6), : 26.01, 26.07 (CH2, C-2’,  7’ ), 30.78 (CH3, C-8), 34.76 (C, C-
7), 40.87, 40.92, 52.55, 52.59, 54.82 (CH2), 125.92, 126.35, 127.01, 127.15, 127.34, 
128.42, 129.08 (CH, C-aromatic), 137.68, 138.53, 139.26, 143.79, 155.19 (C, C-
aromatic). 
 
4-Methyl-N-(3-(4-(3-(phenylsulfonylamido)propyl)-piperazin-1-yl)-propyl)benzene 
sulfonamide (135) 
(C23H34N4O4S2; M.W.= 494.6) 
 
 
  141            135 
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General procedure 5; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.65. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 95:5 
v/v). 
Yield: 0.26 g (52%) 
Melting Point: 137-139°C 
MS (ESI)+: 495.2 [M+H]+ 
1H-NMR (DMSO-d6), : 1.43-1.51 (m, 4H, H-2’,  7’),  2.13-2.26 (m, 12H, CH2), 2.38 
(s, 3H, H-7), 2.70-2.79 (m, 4H, CH2), 7.39 (d, J= 8.1 Hz, 2H, H-aromatic), 7.48 (t, J= 
5.4 Hz, 1H, NH), 7.56-7.62 (m, 3H, 2H-aromatic, NH), 7.66 (d, J= 8.1 Hz, 2H, H-
aromatic), 7.61-7.64 (m, 1H, H-aromatic), 7.78 (d, J= 7.5 Hz, 2H, H-aromatic). 
13C-NMR (DMSO-d6), : 20.91 (CH3, C-7), 26.01, 26.05 (CH2, C-2’,  7’),  40.93, 52.58, 
54.87 (CH2), 126.41, 126.50, 129.15, 129.55, 132.26 (CH, C-aromatic), 137.62, 140.51, 
142.46 (C, C-aromatic). 
 
N-(3-(4-(3-(4-Methylphenylsulfonylamido)propyl)-piperazin-1-yl)-propyl)biphenyl-
4-sulfonamide (136) 
(C29H38N4O4S2; M.W.= 570.77) 
 
 
  141                     136 
 
General procedure 9; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.58. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.38 g (67%) 
Melting Point: 134-136°C 
MS (ESI)+: 571.2 [M+H]+ 
1H-NMR (DMSO-d6), : 1.42-1.54 (m, 4H, H-2’,  7’),  2.13-2.25 (m, 12H, CH2), 2.37 
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(s, 3H, H-7), 2.69-2.74 (m, 2H, CH2), 2.78-2.83 (m, 2H, CH2), 7.38 (d, J= 8.1 Hz, 2H, 
H-aromatic), 7.44 (t, J= 7.3 Hz, 1H, H-10’’), 7.47 (t, J= 5.5 Hz, 1H, NH), 7.49-7.53 (m, 
2H, H-aromatic), 7.63 (t, J= 5.5 Hz, 1H, NH), 7.66 (d, J= 8.2 Hz, 2H, H-aromatic), 
7.72-7.75 (m, 2H, H-aromatic), 7.86 (d, J= 8.5 Hz, 2H, H-aromatic), 7.89 (d, J= 8.5 Hz, 
2H, H-aromatic). 
13C-NMR (DMSO-d6), : 20.91 (CH3, C-7), 26.00, 26.06 (CH2, C-2’,  7’),  40.91, 52.58, 
54.82, 54.87 (CH2), 126.50, 127.01, 127.16, 127.34, 128.43, 129.08, 129.55 (CH, C-
aromatic), 137.61, 138.53, 139.26, 142.46, 143.80 (C, C-aromatic). 
 
N-(3-(4-(3-(Phenylsulfonamido)propyl)-piperazin-1-yl)-propyl)biphenyl-4-
sulfonamide (137) 
(C28H36N4O4S2; M.W.= 556.7) 
 
 
  143                 137 
 
General procedure 9; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.47. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.39 g (71%) 
Melting Point: 124-126°C 
MS (ESI)+: 557.2 [M+H]+ 
1H-NMR (DMSO-d6), : 1.42-1.54 (m, 4H, H-2’,  7’),  2.11-2.25 (m, 12H, CH2), 2.73-
2.77 (m, 2H, CH2), 2.78-2.82 (m, 2H, CH2), 7.44 (t, J= 7.3 Hz, 1H, H-aromatic), 7.50-
7.53 (m, 2H, H-aromatic, NH), 7.56-7.61 (m, 3H, 2H-aromatic, NH), 7.61-7.66 (m, 2H, 
H-aromatic), 7.70 (d, J= 7.4 Hz, 2H, H-aromatic), 7.77-7.79 (m, 2H, H-aromatic), 7.85 
(d, J= 8.5 Hz, 2H, H-aromatic), 7.89 (d, J= 8.5 Hz, 2H, H-aromatic). 
13C-NMR (DMSO-d6), : 26.04, 40.92, 52.58, 54.82, 54.85 (CH2), 126.41, 127.02, 
127.15, 127.35, 128.43, 129.08, 129.14, 132.26 (CH, C-aromatic), 138.54, 139.26, 
142.50, 143.80 (C, C-aromatic). 
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N-(3-(4-(3-(Phenylsulfonamido)propyl)-piperazin-1-yl)-propyl)-4-(trifluoromethyl) 
benzenesulfonamide (138) 
(C23H31F3N6O4S2; M.W.= 548.6) 
 
 
  140         138 
 
General procedure 9; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.72. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 94:6 
v/v). 
Yield: 0.27 g (50%) 
Melting Point: 119-121°C 
MS (ESI)+: 549.2 [M+H]+ 
1H-NMR (DMSO-d6), : 1.43-1.51 (m, 4H, H-2’,  7’),  2.11-2.23 (m, 12H, CH2), 2.73-
2.77 (m, 2H, CH2), 2.78-2.82 (m, 2H, CH2), 7.58-7.61 (m, 4H, 3H-aromatic, NH), 7.62-
7.66 (m, 2H, 2H-aromatic), 7.77-7.79 (m, 2H, H-aromatic), 7.88 (bs, 1H, NH), 8.00 (s, 
4H, H-aromatic). 
13C-NMR (DMSO-d6), : 26.03, 40.81, 40.91, 52.53, 54.63, 54.82 (CH2), 126.41, 
126.45, 127.44, 129.14, 132.26 (CH, C-aromatic), 132.20, 137.68, 144.50 (C, C-7’’,  C-
aromatic). 
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6.2.15 N-(3-(4-(2-(Arylsulfonamido)ethyl)piperazin-1-yl)propyl)arylsulfonamides 
(144-146) 
 
4-Chloro-N-(3-(4-(2-(4-chlorophenylsulfonamido)ethyl)-piperazin-1-yl)-propyl) 
benzenesulfonamide (144) 
(C21H28Cl2N4O4S2; M.W.= 535.5) 
 
 
  139            144 
 
General procedure 10; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.46. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.38 g (72%) 
Melting Point: 133-135°C 
MS (ESI)+: 535.1, 537.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.43-1.51 (m, 2H, H-2’), 2.07-2.27 (m, 12H, CH2), 2.73-2.80 
(m, 2H, CH2), 2.82-2.87 (m, 2H, CH2), 7.58-7.73 (m, 6H, 4H-aromatic, 2NH), 7.76-
7.83 (m, 4H, H-aromatic). 
13C-NMR (DMSO-d6), : 26.00, 40.05, 40.82, 52.40, 52.56, 54.72, 56.78 (CH2), 
128.40, 128.42, 129.24, 129.30 (CH, C-aromatic), 137.07, 137.13, 139.38, 139.60 (C, 
C-1,  4,  4’’). 
 
N-(3-(4-(2-(Phenylsulfonamido)ethyl)-piperazin-1-yl)-propyl) benzenesulfonamide 
(145) 
(C21H30N4O4S2; M.W.= 466.6) 
 
 
  140           145 
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General procedure 10; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.69. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.22 g (47%) 
Melting Point: 135-137°C 
MS (ESI)+: 467.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.43-1.49 (m, 2H, H-2’),  2.14-2.28 (m, 12H, CH2), 2.73-2.78 
(m, 2H, CH2), 2.81-2.86 (m, 2H, CH2), 7.49 (bs, 1H, NH), 7.55-7.62 (m, 5H, 4H-
aromatic, NH), 7.61-7.66 (m, 2H, H-aromatic), 7.76-7.82 (m, 4H, H-aromatic). 
13C-NMR (DMSO-d6), : 26.04, 40.07, 40.91, 52.43, 52.58, 54.84, 56.75 (CH2), 
126.41, 129.12, 129.15, 132.27 (CH, C-aromatic), 140.49, 140.59 (C, C-4,  4’’). 
 
4-tert-Butyl-N-(3-(4-(2-(4-tert-butylphenylsulfonamido)ethyl)-piperazin-1-yl)-
propyl) benzenesulfonamide (145) 
(C29H46N4O4S2; M.W.= 578.8) 
 
 
                                   147         145 
 
General procedure 10;  
Pale yellow solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.55. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 96:4 
v/v). 
Yield: 0.31 g (53%) 
Melting Point: 86-88°C 
MS (ESI)+: 579.2 [M+H]+ 
1H-NMR (DMSO-d6), : 1.30 (s, 9H, H-tBu), 1.31 (s, 9H, H-tBu), 1.41-1.49 (m, 2H, 
H-2’),  2.05-2.21 (m, 12H, CH2), 2.71-2.77 (m, 2H, CH2), 2.78-2.84 (m, 2H, CH2), 7.40 
(bs, 1H, NH), 7.49 (t, J= 5.2 Hz, 1H, NH), 7.58-7.62 (m, 4H, H-aromatic), 7.68-7.73 
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(m, 4H, H-aromatic). 
13C-NMR (DMSO-d6), : 26.01 (CH2, H-2’), 30.79 (CH3, C-8,  8’’),  39.02  (C,  C-7,  7’’),  
40.08, 40.86, 52.41, 52.59, 54.81, 56.74 (CH2), 125.90, 125.91, 125.92, 126.34 (CH, C-
aromatic), 137.68, 137.74, 155.18 (C, C-aromatic). 
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6.2.16 N-(3-(4-(3-(Arylsulfonamido)propanoyl)piperazin-1-yl)-3-oxopropyl) 
aryl sulfonamides (148-152) 
 
4-Chloro-N-(3-(4-(3-(4-chlorophenylsulfonamido)propanoyl)piperazin-1-yl)-3-
oxopropyl)benzenesulfonamide (148) 
(C22H28Cl2N4O5S2; M.W.= 563.5) 
 
 
  139                148 
 
General procedure 11; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.48. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.26 g (46%) 
Melting Point: 72-74°C 
MS (ESI)+: 563.1, 565.1 [M+H]+ 
1H-NMR (CDCl3), : 1.64-1.70 (m, 2H, H-2’),  2.37-2.34 (m, 6H, CH2), 2.54 (t, J= 5.2 
Hz, 2H, CH2), 3.07 (t, J= 5.7 Hz, 2H, CH2), 3.18-3.24 (m, 2H, CH2), 3.37-3.41 (m, 2H, 
CH2), 3.54-3.60 (m, 2H, CH2), 5.84 (bs, 1H, NH), 6.63 (bs, 1H, NH), 7.47-7.51 (m, 4H, 
H-aromatic), 7.78-7.82 (m, 4H, H-aromatic). 
13C-NMR (CDCl3), : 24.74, 32.80, 39.22, 41.50, 43.32, 45.09, 52.61, 52.75, 57.08 
(CH2), 128.41, 128.45, 129.39, 129.43 (CH, C-aromatic), 138.72, 138.74, 138.96, 
138.98 (C, C-aromatic), 169.41 (C, C-6’). 
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N-(3-(4-(3-(Phenylsulfonamido)propanoyl)piperazin-1-yl)-3-oxopropyl)benzene 
sulfonamide (149) 
(C22H30N4O5S2; M.W.= 494.6) 
 
 
  140              149 
 
General procedure 11; 
Colourless oil; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.54. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.18 g (37%) 
MS (ESI)+: 495.1 [M+H]+ 
1H-NMR (CDCl3), : 1.59-1.64 (m, 2H, H-2’),  2.29 (t, J= 4.7 Hz, 2H, CH2), 2.32 (t, J= 
4.7 Hz, 2H, CH2), 2.37 (t, J= 6.0 Hz, 2H, CH2), 2.49 (t, J= 5.6 Hz, 2H, CH2), 3.04 (t, J= 
6.0 Hz, 2H, CH2), 3.17-3.21 (m, 2H, CH2), 3.33 (t, J= 4.7 Hz, 2H, CH2), 3.50-3.54 (m, 
2H, CH2), 5.80 (t, J= 6.2 Hz, 1H, NH), 6.66 (bs, 1H, NH), 7.48-7.52 (m, 4H, H-
aromatic), 7.54-7.58 (m, 2H, H-aromatic), 7.82-7.86 (m, 4H, H-aromatic). 
13C-NMR (CDCl3), : 24.80, 32.76, 39.22, 41.44, 43.16, 45.05, 52.54, 52.74, 56.87 
(CH2), 126.88, 126.89, 129.11, 129.16, 132.55, 132.59 (CH, C-aromatic), 140.11, 
140.21 (C, C-aromatic), 169.43 (C, C-6’). 
 
4-Methyl-N-(3-(4-(3-(4-methylphenylsulfonamido)propanoyl)piperazin-1-yl)-3-
oxopropyl)benzenesulfonamide (150) 
(C24H34N4O5S2; M.W.= 522.6) 
 
 
  141         150 
 
General procedure 11; 
White solid; 
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T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.64. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.17 g (34%) 
Melting Point: 149-151°C 
MS (ESI)+: 523.2 [M+H]+ 
1H-NMR (CDCl3), : 1.65-1.70 (m, 2H, H-2’),   2.36-2.42 (m, 6H, CH2), 2.44 (s, 3H, 
CH3), 2.45 (s, 3H, CH3), 2.54 (t, J= 5.5 Hz, 2H, CH2), 3.10 (t, J= 5.8 Hz, 2H, CH2), 
3.20-3.24 (m, 2H, CH2), 3.40 (t, J= 4.7 Hz, 2H, CH2), 3.59 (t, J= 4.7 Hz, 2H, CH2), 5.52 
(t, J= 6.7 Hz, 1H, NH), 6.40 (bs, 1H, NH), 7.31-7.35 (m, 4H, H-aromatic), 7.75 (d, J= 
8.3 Hz, 2H, H-aromatic), 7.77 (d, J= 8.3 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 21.20, 21.46 (CH3, C-7,  7’’), 24.61, 32.85, 39.16, 41.49, 43.56, 
45.07, 52.72, 52.78, 57.42 (CH2), 126.93, 126.99, 129.67, 129.74 (CH, C-aromatic), 
137.10, 137.18, 143.27, 143.28 (C, C-aromatic), 169.45 (C, C-6’). 
 
4-tert-Butyl-N-(3-(4-(3-(4-tert-butylphenylsulfonamido)propanoyl)piperazin-1-yl)-
3-oxopropyl)benzenesulfonamide (151) 
(C30H46N4O5S2; M.W.= 606.8) 
 
 
  142        151 
 
General procedure 11; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.61. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.28 g (47%) 
Melting Point: 189-191°C 
MS (ESI)+: 607.3 [M+H]+ 
Microanalysis: Calculated for C30H46N4O5S2 (606.8); Theoretical: %C = 59.38, %H = 
7.64, %N = 9.23; Found: %C = 59.22, %H = 8.08, %N = 9.04. 
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1H-NMR (CDCl3), : 1.36 (s, 9H, H-tBu), 1.37 (s, 9H, H-tBu), 1.66-1.71 (m, 2H, H-
2’),  2.37 (t, J= 5.0 Hz, 2H, CH2), 2.42 (t, J= 5.0 Hz, 2H, CH2), 2.46 (t, J= 5.9 Hz, 2H, 
CH2), 2.57 (t, J= 5.6 Hz, 2H, CH2), 3.11 (t, J= 5.9 Hz, 2H, CH2), 3.21-3.25 (m, 2H, 
CH2), 3.42 (t, J= 5.0 Hz, 2H, CH2), 3.60 (t, J= 5.0 Hz, 2H, CH2), 5.54 (t, J= 6.6 Hz, 1H, 
NH), 6.28 (bs, 1H, NH), 7.51-7.55 (m, 4H, H-aromatic), 7.78 (d, J= 8.5 Hz, 2H, H-
aromatic), 7.80 (d, J= 8.5 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 24.76 (CH2, C-2’),  31.11  (CH3, C-8,  8’’),  32.97 (CH2), 35.12 (C, 
C-7,  7’’), 39.19, 41.49, 43.43, 45.08, 52.72, 52.82, 57.29 (CH2), 126.03, 126.12, 126.80 
(CH, C-aromatic), 137.05, 137.12, 156.29, 156.32 (C, C-aromatic), 169.46 (C, C-6’). 
 
N-(3-(4-(3-(Biphenyl-4-ylsulfonamido)propanoyl)piperazin-1-yl)-3-oxopropyl) 
biphenyl-4-sulfonamide (152) 
(C34H38N4O5S2; M.W.= 646.8) 
 
 
  143      152 
 
General procedure 11; 
White solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.54. 
Purification: flash column chromatography (DCM:MeOH 100:0 v/v increasing to 97:3 
v/v). 
Yield: 0.30 g (47%) 
Melting Point: 176-178°C 
MS (ESI)+: 647.2 [M+H]+ 
1H-NMR (CDCl3), : 1.65-1.71 (m, 2H, H-2’),  2.35-2.39 (m, 4H, CH2), 2.42 (t, J= 5.8 
Hz, 2H, CH2), 2.56 (t, J= 5.5 Hz, 2H, CH2), 3.13 (t, J= 5.8 Hz, 2H, CH2), 3.25-3.29 (m, 
2H, CH2), 3.40 (t, J= 4.6 Hz, 2H, CH2), 3.59-3.61 (m, 2H, CH2), 5.75 (t, J= 6.3 Hz, 1H, 
NH), 6.53 (bs, 1H, NH), 7.40- 7.46 (m, 2H, H-aromatic), 7.47-7.51 (m, 4H, H-
aromatic), 7.60-7.64 (m, 4H, H-aromatic), 7.71-7.75 (m, 4H, H-aromatic), 7.91-7.96 (m, 
4H, H-aromatic). 
13C-NMR (CDCl3), : 24.77, 32.85, 39.28, 41.52, 43.42, 45.11, 52.70, 52.75, 57.16 
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(CH2), 127.28, 127.31, 127.48, 127.50, 127.68, 128.06, 128.46, 128.53, 129.06, 129.10 
(CH, C-aromatic), 138.75, 138.80, 139.24, 139.33, 145.44, 145.46 (C, C-aromatic), 
169.46 (C, C-6’). 
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6.3 Synthesis of p-phenylendiamine and ethylendiamine structures 
 
6.3.1 General procedures 12-15 
 
General procedure 12: synthesis of N-(4-amino-phenyl)-arylsulfonamides 
 
 
 
Arylsulfonyl chloride (5 mmol) and p-phenylendiamine (123) (1.62 g, 15 mmol) were 
suspended in 21 mL of anhydrous DCM under nitrogen atmosphere. The reaction 
mixture was cooled down to 0°C in an ice-bath and then treated dropwise with N,N-
diisopropylethylamine (4.15 mL, 25 mmol) over a period of 10 min. The reaction was 
stirred for 30 min. under ice-cooling, then diluted with DCM (100 mL) and washed with 
water (2 x 100 mL). The organic solvent was removed under vaccum after drying over 
MgSO4 and the crude residue was purified by flash column chromatography to give 
pure N-(4-amino-phenyl)-arylsulfonamides. 
 
General procedure 13: synthesis of N,N'-bis-(4-arylsulfonylamino-phenyl)-
terephthalamides 
 
 
 
N-(4-Amino-phenyl)-arylsulfonamide (1.5 mmol) was dissolved in 6 mL of anhydrous 
DCM under N2 atmosphere. Triethylamine (0.2 mL, 1.5 mmol) was added dropwise to 
the reaction mixture followed by terephthaloyl chloride (167) (0.10 g, 0.5 mmol) 
dissolved in 4 mL of anhydrous DCM. The reaction mixture was stirred at r.t. for 30 
min., then diluted with DCM (25 mL), washed with 2M aqueous HCl solution (2 x 30 
mL), saturated NaHCO3 solution (2 x 30 mL), and finally with brine (30 mL). The 
organic phase was concentrated at reduced pressure after drying over MgSO4 and the 
crude residue was purified by re-crystallisation from MeOH to afford pure N,N'-bis-(4-
arylsulfonylamino-phenyl)-terephthalamides. 
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General procedure 14: synthesis of N,N'-bis-(4-arylsulfonylamino-phenyl)-
fumaramides 
 
 
 
N-(4-Amino-phenyl)-arylsulfonamide (1.5 mmol), was dissolved in 10 mL of anhydrous 
DCM under N2 atmosphere. Triethylamine (0.2 mL, 1.5 mmol) was added dropwise to 
the reaction mixture followed by fumaryl chloride (168) (0.05 mL, 0.5 mmol). The 
reaction mixture was stirred at r.t. for 30 min., then diluted with DCM (25 mL), washed 
with 2M aqueous HCl solution (2 x 30 mL), saturated NaHCO3 solution (2 x 30 mL), 
and finally with brine (30 mL). The organic phase was concentrated at reduced pressure 
after drying over MgSO4 and the crude residue was purified by re-crystallisation from 
MeOH to afford pure N,N'-bis-(4-arylsulfonylamino-phenyl)-fumaramides. 
 
General procedure 15: synthesis of N,N'-bis-(4-(arylsulfonamido)phenyl)-
succinamides 
 
 
 
N-(4-Amino-phenyl)-arylsulfonamide (1.5 mmol) was dissolved in 10 mL of anhydrous 
DCM under N2 atmosphere. Triethylamine (0.2 mL, 1.5 mmol) was added dropwise to 
the reaction mixture followed by succinyl chloride (169) (0.07 mL, 0.5 mmol). The 
reaction mixture was stirred at r.t. for 30 min, then diluted with DCM (20 mL), washed 
with 2M aqueous HCl solution (2 x 30 mL), saturated NaHCO3 solution (2 x 30 mL), 
and finally with brine (30 mL). The organic phase was concentrated at reduced pressure 
after drying over MgSO4 and the crude residue was purified by re-crystallisation from 
MeOH to afford pure N,N'-bis-(4-(arylsulfonamido)phenyl)-succinamides. 
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6.3.2 N-(4-Amino-phenyl)-arylsulfonamides (164-166, 177-181) 
 
N-(4-Amino-phenyl)-4-chloro-benzenesulfonamide (164)23 
(C12H11ClN2O2S; M.W.= 282.7) 
 
 
    13   164 
 
General procedure 12; 
Pale yellow solid; 
T.L.C. System: nhexane -EtOAc 3:7 v/v, Rf: 0.71. 
Yield: 1.06 g (75%) 
1H-NMR (CD3OD), : 6.58 (d, J= 8.8 Hz, 2H, H-aromatic), 6.77 (d, J= 8.8 Hz, 2H, H-
aromatic), 7.48 (d, J= 8.8 Hz, 2H, H-aromatic), 7.63 (d, J= 8.8 Hz, 2H, H-aromatic). 
13C-NMR (CD3OD), : 116.66, 126.58 (CH, C-aromatic), 128.22 (C, C-aromatic), 
130.05 (CH, C-aromatic), 139.75, 139.82, 147.40 (C, C-aromatic). 
 
N-(4-Amino-phenyl)-4-methylbenzenesulfonamide (165) 
(C13H14N2O2S; M.W.= 262.3) 
 
 
    15   165 
 
General procedure 12; 
Yellow solid; 
T.L.C. System: nhexane-EtOAc 4:6 v/v, Rf: 0.52. 
Yield: 0.96 g (73%) 
1H-NMR (CD3OD), : 2.38 (s, 3H, H-7), 6.56 (d, J= 8.7 Hz, 2H, H-aromatic), 6.77 (d, 
J= 8.7 Hz, 2H, H-aromatic), 7.26 (d, J= 8.3 Hz, 2H, H-aromatic), 7.54 (d, J= 8.3 Hz, 
2H, H-aromatic). 
13C-NMR (CD3OD), : 21.43 (CH3, C-7), 116.66, 126.41, 128.40 (CH, C-aromatic), 
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128.72 (C, C-aromatic), 130.36 (CH, C-aromatic), 138.07, 144.66, 147.05 (C, C-
aromatic). 
 
N-(4-Amino-phenyl)-benzenesulfonamide (166)24 
(C12H12N2O2S; M.W.= 248.3) 
 
 
    14   166 
 
General procedure 12; 
Pale pink solid; 
T.L.C. System: nhexane -EtOAc 5:5 v/v, Rf: 0.35. 
Yield: 0.95 g (77%) 
1H-NMR (CD3OD), : 6.56 (d, J= 8.7 Hz, 2H, H-aromatic), 6.77 (d, J= 8.7 Hz, 2H, H-
aromatic), 7.43-7.48 (m, 2H, H-aromatic), 7.56 (tt, J1= 7.4 Hz, J2= 1.2 Hz, 1H, H-4), 
7.65-7.69 (m, 2H, H-aromatic). 
13C-NMR (CD3OD), : 116.65, 126.59, 128.34 (CH, C-aromatic), 128.55 (C, C-
aromatic), 129.84, 133.62 (CH, C-aromatic), 141.02, 147.17 (C, C-aromatic). 
 
N-(4-Amino-phenyl)-4-tert-butylbenzenesulfonamide (177) 
(C16H20N2O2S; M.W.= 304.4) 
 
 
    83   177 
 
General procedure 12; 
Yellow solid; 
T.L.C. System: nhexane -EtOAc 3:7 v/v, Rf: 0.66. 
Yield: 1.25 g (82%) 
1H-NMR (CD3OD), : 1.33 (s, 9H, H-8), 6.57 (d, J= 8.6 Hz, 2H, H-aromatic), 6.79 (d, 
J= 8.6 Hz, 2H, H-aromatic), 7.50 (d, J= 8.6 Hz, 2H, H-aromatic), 7.60 (d, J= 8.6 Hz, 
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2H, H-aromatic). 
13C-NMR (CD3OD), : 31.47 (CH3, C-8), 35.97 (C, C-7), 116.69, 126.28, 126.82, 
128.24 (CH, C-aromatic), 128.79, 138.12, 146.99, 157.52 (C, C-aromatic). 
 
N-(4-Amino-phenyl)-4-(trifluoromethyl)benzenesulfonamide (178)25 
(C13H11F3N2O2S; M.W.= 316.3) 
 
 
    84   178 
 
General procedure 12; 
Yellow solid; 
T.L.C. System: nhexane -EtOAc 3:7 v/v, Rf: 0.62. 
Yield: 1.47 g (93%) 
1H-NMR (CD3OD), : 6.59 (d, J= 8.6 Hz, 2H, H-aromatic), 6.79 (d, J= 8.6 Hz, 2H, H-
aromatic), 7.77 (d, J= 8.3 Hz, 2H, H-aromatic), 7.85 (d, J= 8.3 Hz, 2H, H-aromatic). 
13C-NMR (CD3OD), : 116.88, 123.84 (CH, C-aromatic), 126.95, 126.98, 127.01 (CH, 
C-3, 5), 127.93 (C, C-aromatic), 129.01 (CH, C-aromatic), 134.58, 134.84, 135.10, 
135.36 (C, C-7), 144.86, 147.53 (C, C-aromatic). 
 
N-(4-Amino-phenyl)biphenyl-4-sulfonamide (179)26 
(C18H16N2O2S; M.W.= 324.4) 
 
 
    85   179 
 
General procedure 12; 
Yellow solid; 
T.L.C. System: nhexane -EtOAc 6:4 v/v, Rf: 0.44. 
Yield: 1.11 g (69%) 
1H-NMR (DMSO-d6), : 4.95 (bs, 2H, NH2), 6.41 (d, J= 8.6 Hz, 2H, H-aromatic), 6.73 
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(d, J= 8.6 Hz, 2H, H-aromatic), 7.41-7.45 (m, 1H, H-10), 7.47-7.51 (m, 2H, H-
aromatic), 7.71-7.74 (m, 4H, H-aromatic), 8.83 (d, J= 8.4 Hz, 2H, H-aromatic), 9.53 (bs, 
1H, NH). 
13C-NMR (DMSO-d6), : 113.99, 124.55 (CH, C-aromatic), 125.28 (C, C-aromatic), 
126.99, 127.04, 127.40, 128.45, 129.06 (CH, C-aromatic), 138.37, 138.63, 143.75, 
146.53 (C, C-aromatic). 
 
N-(4-Aminophenyl)naphthalene-1-sulfonamide (180)27 
(C16H14N2O2S; M.W.= 298.3) 
 
 
    86   180 
 
General procedure 12; 
Yellow solid; 
T.L.C. System: nhexane -EtOAc 6:4 v/v, Rf: 0.63. 
Yield: 1.25 g (84%) 
1H-NMR (CD3OD), : 6.43 (d, J= 8.7 Hz, 2H, H-aromatic), 6.64 (d, J= 8.7 Hz, 2H, H-
aromatic), 7.43 (t, J= 7.8 Hz, 1H, H-aromatic), 7.59-7.63 (m, 1H, H-aromatic), 7.65-
7.70 (m, 1H, H-aromatic), 7.97 (d, J= 8.1 Hz, 1H, H-aromatic), 8.02-8.06 (m, 2H, H-
aromatic), 8.75 (d, J= 8.4 Hz, 1H, H-aromatic). 
13C-NMR (CD3OD), : 116.55, 125.11, 125.98, 126.39, 127.83 (CH, C-aromatic), 
128.29 (C, C-aromatic), 128.97 (CH, C-aromatic), 129.68 (C, C-aromatic), 130.06, 
131.30, 135.21 (CH, C-aromatic), 135.62, 136.04, 147.03 (C, C-aromatic). 
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N-(4-Aminophenyl)quinoline-8-sulfonamide (181)28 
(C15H13N3O2S; M.W.= 299.3) 
 
 
    87   181 
 
General procedure 12; 
Yellow solid; 
T.L.C. System: nhexane -EtOAc 6:4 v/v, Rf: 0.39. 
Yield: 79 g (53%) 
1H-NMR (DMSO-d6), : 4.83 (s, 2H, NH2), 6.25 (d, J= 8.7 Hz, 2H, H-aromatic), 6.57 
(d, J= 8.7 Hz, 2H, H-aromatic), 7.65 (t, J= 7.7 Hz, 1H, H-aromatic), 7.74 (dd, J1= 8.4 
Hz, J2= 4.2 Hz, 1H, H-aromatic), 8.18 (, J1= 7.3 Hz, J2= 1.3 Hz, 1H, H-aromatic), 8.24 
(dd, J1= 8.2 Hz, J2= 1.3 Hz, 1H, H-aromatic), 8.53 (dd, J1= 8.4 Hz, J2= 1.7 Hz, 1H, H-
aromatic), 9.13 (bs, 1H, NH), 9.17 (dd, J1= 4.2 Hz, J2= 1.7 Hz, 1H, H-aromatic). 
13C-NMR (DMSO-d6), : 113.73, 122.54, 124.12 (CH, C-aromatic), 125.45 (C, C-
aromatic), 125.59 (CH, C-aromatic), 128.27 (C, C-aromatic), 131.63, 133.74 (CH, C-
aromatic), 135.49 (C, C-aromatic), 137.01 (CH, C-aromatic), 142.74, 146.33 (C, C-
aromatic), 151.32 (CH, C-aromatic). 
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6.3.3 N-(2-Aminoethyl)-4-chlorobenzenesulfonamide (176)29 
(C8H11ClN2O2S; M.W.= 234.7) 
 
 
   13         175     176 
 
Ethylenediamine (175) (0.63 mL, 9.5 mmol) and triethylamine (3.27 mL, 23.7 mmol) 
were dissolved in 15 mL of anhydrous DCM under nitrogen atmosphere. A solution of 
4-chlorobenzenesulfonyl chloride (13) (1g, 4.7 mmol) in 7 mL of anhydrous DCM was 
added dropwise under ice-cooling over a period of 10 min. The reaction mixture was 
stirred at 0°C for 1 h and then at r.t. for further 2 h. The reaction system was diluted 
with DCM (70 mL) and washed with water (2 x 100 mL) and brine (100 mL). The 
organic solvent was removed under vacuum after drying over MgSO4 to give the title 
compound as a yellow solid. 
Yield: 0.65 g (59%) 
1H-NMR (CD3OD), : 2.29 (d, J= 6.2 HZ, 2H, CH2), 2.93 (d, J= 6.2 HZ, 2H, CH2), 
7.61 (d, J= 8.7 Hz, 2H, H-aromatic), 7.85 (d, J= 8.7 Hz, 2H, H-aromatic). 
13C-NMR (CD3OD), : 42.23, 46.48 (CH2, C-1’,  2’),  129.74,  130.48  (CH,  C-aromatic), 
139.84, 140.73 (C, C-1, 4) . 
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6.3.4 N,N'-Bis-(4-arylsulfonylamino-phenyl)-terephthalamides (158, 170) 
 
N,N'-Bis-[4-(4-chloro-benzenesulfonylamino)-phenyl]-terephthalamide (158) 
(C32H24Cl2N4O6S2; M.W.= 695.5) 
 
 
  164      158 
 
General procedure 13; 
White solid; 
Yield: 0.13 g (36%) 
Melting Point: >360°C 
MS (ESI)+: 695.0, 697.0 [M+H]+ 
1H-NMR (DMSO-d6), : 7.07 (d, J= 8.9 Hz, 4H, H-aromatic), 7.62-7.67 (m, 8H, H-
aromatic), 7.73 (d, J= 8.6 Hz, 4H, H-aromatic), 8.03 (s, 4H, H-9), 10.23 (bs, 2H, NH), 
10.37 (bs, 2H, NH). 
13C-NMR (DMSO-d6), : 121.23, 121.54, 127.62, 128.62, 129.36 (CH, C-aromatic), 
132.84, 135.83, 137.28, 137.70, 138.18 (C, C-aromatic), 164.58 (C, C-9). 
 
N,N'-Bis-[4-(4-methylbenzenesulfonylamino)-phenyl]-terephthalamide (170) 
(C34H30N4O6S2; M.W.= 654.7) 
 
 
  165      170 
 
General procedure 12; 
Pale yellow solid; 
Yield: 0.21 g (69%) 
Melting Point: >360°C 
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MS (ESI)+: 677.1 [M+Na]+ 
1H-NMR (DMSO-d6), : 2.34 (s, 6H, H-1’),  7.07 (d, J= 8.9 Hz, 4H, H-aromatic), 7.34 
(d, J= 7.5 Hz, 4H, H-aromatic), 7.61-7.65 (m, 8H, H-aromatic), 8.03 (s, 4H, H-9), 10.10 
(bs, 2H, NH), 10.30 (bs, 2H, NH). 
13C-NMR (DMSO-d6), : 20-92 (CH3, C-1’), 120.98, 121.23, 126.71, 127.58, 129.59 
(CH, C-aromatic), 133.43, 135.37, 136.59, 137.27, 143.10 (C, C-aromatic), 164.52 (C, 
C-9). 
 Chapter 6: Experimental 
 
 
315 
 
6.3.5 N,N'-Bis-(4-arylsulfonylamino-phenyl)-fumaramides (160, 171-172) 
 
N,N'-Bis-[4-(4-chloro-benzenesulfonylamino)-phenyl]-fumaramide (160) 
(C28H22Cl2N4O6S2; M.W.= 645.5) 
 
 
  164      160 
 
General procedure 14; 
Yellow solid; 
Yield: 0.19 g (61%) 
Melting Point: >360°C 
MS (ESI)+: 667.0, 669.0 [M+Na]+ 
1H-NMR (DMSO-d6), : 7.05 (d, J= 8.7 Hz, 4H, H-aromatic), 7.11 (s, 2H, H-10), 7.56 
(d, J= 8.7 Hz, 4H, H-aromatic), 7.62 (d, J= 8.5 Hz, 4H, H-aromatic), 7.71 (d, J= 8.5 Hz, 
4H, H-aromatic), 10.19 (bs, 2H, NH), 10.42 (bs, 2H, NH). 
13C-NMR (DMSO-d6), : 120.16, 121.75, 128.58, 129.36 (CH, C-aromatic, C-10), 
132.88 (C, C-aromatic), 133.83 (CH, C-aromatic), 135.62, 137.69, 138.22 (C, C-
aromatic), 161.82 (C, C-9). 
 
N,N'-Bis-[4-(4-methylbenzenesulfonylamino)-phenyl]-fumaramide (171) 
(C30H28N4O6S2; M.W.= 604.6) 
 
 
  165      171 
 
General procedure 14; 
Light brown solid; 
Yield: 0.14 g (47%) 
Melting Point: >360°C 
MS (ESI)+: 605.3 [M+H]+ 
1H-NMR (DMSO-d6), : 2.33 (s, 6H, H-1’),  7.05 (d, J= 8.3 Hz, 4H, H-aromatic), 7.10 
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(s, 2H, H-10), 7.33 (d, J= 7.7 Hz, 4H, H-aromatic), 7.53 (d, J= 8.3 Hz, 4H, H-aromatic), 
7.61 (d, J= 7.7 Hz, 4H, H-aromatic), 10.08 (bs, 2H, NH), 10.42 (bs, 2H, NH). 
13C-NMR (DMSO-d6), : 20.91 (CH3, C-1’), 120.13, 121.18, 126.69, 129.59 (CH, C-
aromatic, C-10), 133.44 (C, C-aromatic), 133.79 (CH, C-aromatic), 135.19, 136.57, 
143.12 (C, C-aromatic), 161.78 (C, C-9). 
 
N,N'-Bis-(4-phenylsulfonylamido)-phenyl)-fumaramide (172) 
(C28H24N4O6S2; M.W.= 576.6) 
 
 
  166      172 
General procedure 10; 
Pale yellow solid; 
Yield: 0.11 g (39%) 
Melting Point: 294-296°C 
MS (ESI)+: 599.0 [M+Na]+ 
1H-NMR (DMSO-d6), : 7.05 (d, J= 8.9 Hz, 4H, H-aromatic), 7.09 (s, 2H, H-10), 7.52-
7.56 (m, 8H, H-aromatic), 7.60 (tt, J1= 7.3 Hz, J2= 2.1 Hz, 2H, H-4), 7.73 (d, J= 8.0 Hz, 
4H, H-aromatic), 10.15 (bs, 2H, NH), 10.43 (bs, 2H, NH). 
13C-NMR (DMSO-d6), : 120.11, 121.37, 126.62, 129.16, 132.79 (CH, C-aromatic, C-
10), 133.28 (C, C-aromatic), 133.80 (CH, C-aromatic), 135.32, 139.42 (C, C-aromatic), 
161.78 (C, C-9). 
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6.3.6 N,N'-Bis-(4-(arylsulfonamido)phenyl)-succinamides (162, 173-174, 182-186) 
 
N,N'-Bis-(4-(4-chlorophenylsulfonamido)phenyl)succinamide (162) 
(C28H24Cl2N4O6S2; M.W.= 647.5) 
 
 
  164      162 
 
General procedure 15; 
Brown solid; 
Yield: 0.16 g (48%) 
Melting Point: 284-286°C 
MS (ESI)+: 669.0, 671.0 [M+Na]+ 
1H-NMR (DMSO-d6), : 2.54 (s, 4H, H-10), 6.97 (d, J= 8.8 Hz, 4H, H-aromatic), 7.44 
(d, J= 8.8 Hz, 4H, H-aromatic), 7.61 (d, J= 8.6 Hz, 4H, H-aromatic), 7.68 (d, J= 8.6 Hz, 
4H, H-aromatic), 9.92 (bs, 2H, NH), 10.08 (bs, 2H, NH). 
13C-NMR (DMSO-d6), : 31.00 (CH2, C-10), 119.59, 122.04, 128.56, 129.30 (CH, C-
aromatic), 131.02, 131.86, 137.62, 138.21 (C, C-aromatic), 170.11 (C, C-9). 
 
N,N'-Bis-(4-(4-methylphenylsulfonamido)phenyl)succinamide (173) 
(C30H30N4O6S2; M.W.= 606.7) 
 
 
  165      173 
 
General procedure 15; 
White solid; 
Yield: 0.11 g (36%) 
Melting Point: 284-286°C 
MS (ESI)+: 629.1 [M+Na]+ 
1H-NMR (DMSO-d6), : 2.33 (6H, H-1’),  2.56 (s, 4H, H-10), 6.97 (d, J= 8.3 Hz, 4H, 
H-aromatic), 7.32 (d, J= 7.7 Hz, 4H, H-aromatic), 7.41 (d, J= 8.3 Hz, 4H, H-aromatic), 
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7.58 (d, J= 8.6 Hz, 4H, H-aromatic), 9.88 (bs, 2H, NH), 9.95 (bs, 2H, NH). 
13C-NMR (DMSO-d6), : 20.91 (CH3, C-1’),   30.99 (CH2, C-10), 119.56, 121.47, 
126.67, 129.53 (CH, C-aromatic), 132.43, 135.94, 136.57, 143.01 (C, C-aromatic), 
170.07 (C, C-9). 
 
N,N'-Bis-(4-(phenylsulfonamido)phenyl)succinamide (174) 
(C28H26N4O6S2; M.W.= 578.6) 
 
 
  166      174 
 
General procedure 15; 
White solid; 
Yield: 0.18 g (64%) 
Melting Point: 270-272°C 
MS (ESI)+: 601.1 [M+Na]+ 
1H-NMR (DMSO-d6), : 2.56 (s, 4H, H-10), 6.97 (d, J= 8.8 Hz, 4H, H-aromatic), 7.41 
(d, J= 8.8 Hz, 4H, H-aromatic), 7.50-7.55 (m, 4H, H-aromatic), 7.57-7.61 (m, 2H, H-4), 
7.71-7.78 (m, 4H, H-aromatic), 9.89 (bs, 2H, NH), 10.02 (bs, 2H, NH). 
13C-NMR (DMSO-d6), : 31.00 (CH2, C-10), 119.54, 121.67, 126.61, 129.11 (CH, C-
aromatic), 132.24 (C, C-aromatic), 132.71 (CH, C-aromatic), 136.08, 139.40 (C, C-
aromatic), 170.08 (C, C-9). 
 
N,N'-Bis-(4-(4-tert-butylphenylsulfonamido)phenyl)succinamide (182) 
(C36H42N4O6S2; M.W.= 690.8) 
 
 
  177      182 
 
General procedure 15; 
Yellow solid; 
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Yield: 0.13 g (39%) 
Melting Point: 260-262°C 
MS (ESI)+: 713.2 [M+Na]+ 
1H-NMR (DMSO-d6), : 1.26 (18H, H-2’),  2.56  (s,  4H,  H-10), 7.01 (d, J= 8.6 Hz, 4H, 
H-aromatic), 7.42 (d, J= 8.6 Hz, 4H, H-aromatic), 7.55 (d, J= 8.4 Hz, 4H, H-aromatic), 
7.65 (d, J= 8.4 Hz, 4H, H-aromatic), 9.89 (bs, 2H, NH), 10.03 (bs, 2H, NH). 
13C-NMR (DMSO-d6), : 30.71 (CH3, C-2’),   30.99   (CH2, C-10), 34.80 (C, C-1’),  
119.60, 121.06, 125.98, 126.49 (CH, C-aromatic), 132.51, 135.81, 136.81, 155.68 (C, 
C-aromatic), 170.07 (C, C-9). 
 
N,N'-Bis-(4-(4-trifluoromethylphenylsulfonamido)phenyl)succinamide (183) 
(C30H24F6N4O6S2; M.W.= 714.1) 
 
 
  178      183 
 
General procedure 15; 
Grey solid; 
Yield: 0.15 g (42%) 
Melting Point: 306-308°C 
MS (ESI)+: 737.1 [M+Na]+ 
1H-NMR (DMSO-d6), : 2.57 (s, 4H, H-10), 6.99 (d, J= 8.8 Hz, 4H, H-aromatic), 7.45 
(d, J= 8.8 Hz, 4H, H-aromatic), 7.89 (d, J= 8.3 Hz, 4H, H-aromatic), 7.94 (d, J= 8.3 Hz, 
4H, H-aromatic), 9.94 (bs, 2H, NH), 10.26 (bs, 2H, NH). 
13C-NMR (DMSO-d6), : 30.98 (CH2, C-10),119.62, 122.18 (CH, C-aromatic), 124.43 
(C, C-aromatic), 126.40, 126.43 (CH, C-3, 6), 127.62 (CH, C-aromatic), 131.57 (C, C-
aromatic), 132.03, 132.29, 132.55, 132.80 (C, C-1’),   136.54,   143.28   (C, C-aromatic), 
170.17 (C, C-9). 
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N,N'-Bis-(4-(4-biphenyl-4-ylsulfonamido)phenyl)succinamide (184) 
(C40H34N4O6S2; M.W.= 730.8) 
 
 
  179      184 
 
General procedure 15; 
Brown solid; 
Yield: 0.16 g (44%) 
Melting Point: 290-292°C 
MS (ESI)+: 753.2 [M+Na]+ 
1H-NMR (DMSO-d6), : 2.56 (s, 4H, H-10), 7.03 (d, J= 8.8 Hz, 4H, H-aromatic), 7.41-
7.49 (m, 10H, H-aromatic), 7.70 (d, J= 7.3 Hz, 4H, H-aromatic), 7.77 (d, J= 8.5 Hz, 4H, 
H-aromatic), 7.83 (d, J= 8.5 Hz, 4H, H-aromatic), 9.90 (bs, 2H, NH), 10.10 (bs, 2H, 
NH). 
13C-NMR (DMSO-d6), : 31.01 (CH2, C-10), 119.61, 121.54, 127.02, 127.27, 127. 30, 
128.50, 129.05 (CH, C-aromatic), 132.29, 136.07, 138.27, 144.11 (C, C-aromatic), 
170.10 (C, C-9). 
 
N,N'-Bis-(4-(4-naphtalene-1-sulfonamido)phenyl)succinamide (185) 
(C36H30N4O6S2; M.W.= 678.7) 
 
 
  180      185 
 
General procedure 15; 
Brown solid; 
Yield: 0.18 g (53%) 
Melting Point: 270-272°C 
MS (ESI)+: 701.1 [M+Na]+ 
1H-NMR (DMSO-d6), : 2.48 (s, 4H, H-4’), 6.90 (d, J= 8.4 Hz, 4H, H-aromatic), 7.32 
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(d, J= 8.4 Hz, 4H, H-aromatic), 7.57 (t, J= 7.8 Hz, 2H, H-aromatic), 7.66 (t, J= 7.3 Hz, 
2H, H-aromatic), 7.71-7.75 (m, 2H, H-aromatic), 8.06 (d, J= 7.8 Hz, 2H, H-aromatic), 
8.13 (d, J= 7.0 Hz, 2H, H-aromatic), 8.18 (d, J= 7.9 Hz, 2H, H-aromatic), 8.73 (d, J= 8.5 
Hz, 2H, H-aromatic), 9.81 (bs, 2H, NH), 10.43 (bs, 2H, NH). 
13C-NMR (DMSO-d6), : 30.99 (CH2, C-10), 119.55, 120.66, 124.35, 124.38 (CH, C-
aromatic), 126.88 (C, C-aromatic), 127.46, 128.00, 129.00 (CH, C-aromatic), 129.79, 
132.13 (C, C-aromatic), 133.68 (CH, C-aromatic), 134.37, 135.66 (C, C-aromatic), 
169.99 (C, C-9). 
 
N,N'-Bis-(4-(4-quinoline-8-sulfonamido)phenyl)succinamide (186) 
(C34H28N4O6S2; M.W.= 680.7) 
 
 
  181      186 
 
General procedure 15; 
Brown solid; 
Yield: 0.12 g (35%) 
Melting Point: 296-298°C 
MS (ESI)+: 681.2 [M+Na]+ 
1H-NMR (DMSO-d6), : 2.45 (s, 4H, H-4’),  6.90  (d,  J=  8.9 Hz, 4H, H-aromatic), 7.23 
(d, J= 8.9 Hz, 4H, H-aromatic), 7.67 (t, J= 7.8 Hz, 2H, H-aromatic), 7.72 (dd, J1= 8.3 
Hz, J2= 4.3 Hz, 2H, H-aromatic), 8.24 (d, J= 8.3 Hz, 2H, H-aromatic), 8.28 (d, J= 7.2 
Hz, 2H, H-aromatic), 8.51 (dd, J1= 8.4 Hz, J2= 1.4 Hz, 2H, H-aromatic), 9.15 (dd, J1= 
4.3 Hz, J2= 1.4 Hz, 2H, H-aromatic), 9.74 (bs, 2H, NH), 9.79 (bs, 2H, NH). 
13C-NMR (DMSO-d6), : 30.95 (CH2, C-10), 119.32, 121.10, 122.58, 125.57 (CH, C-
134.08 (CH, C-aromatic), 135.11, 135.65 (C, C-aromatic), 136.96 (CH, C-aromatic), 
142.65 (C, C-aromatic), 151.39 (CH, C-aromatic), 169.93 (C, C-9). 
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6.3.7 N,N'-Bis-(2-(4-chlorophenylsulfonamido)ethyl)-succinamide (155) 
(C20H24Cl2N4O6S2; M.W.= 551.4) 
 
 
 176              169     155 
 
N-(2-Aminoethyl)-4-chlorobenzenesulfonamide (176) (0.35 g, 1.5 mmol) was dissolved 
in 9 mL of anhydrous DCM under N2 atmosphere. Triethylamine (0.2 mL, 1.5 mmol) 
was added dropwise to the reaction mixture followed by succinyl chloride (169) (0.07 
mL, 0.5 mmol). The reaction was stirred at r.t. for 1 h, then diluted with DCM (20 mL), 
washed with 2M aqueous HCl solution (2 x 30 mL), saturated NaHCO3 solution (2 x 30 
mL), and finally with brine (30 mL). The organic phase was concentrated at reduced 
pressure after drying over MgSO4 and the crude residue was purified by re-
crystallisation from MeOH to afford the title compound as a brown solid. 
Yield: 0.16 g (48%) 
Melting Point: 182-184°C 
MS (ESI)+: 573.0, 575.0 [M+Na]+ 
1H-NMR (DMSO-d6), : 2.23 (s, 4H, H-10), 2.74-2.79 (m, 4H, CH2), 3.03-3.08 (m, 
4H, CH2), 7.68 (d, J= 8.7 Hz, 4H, H-aromatic), 7.75 (t, J= 5.9 Hz, 2H, NH), 7.79 (d, J= 
8.7 Hz, 4H, H-aromatic), 7.83 (t, J= 5.6 Hz, 2H, NH). 
13C-NMR (DMSO-d6), : 31.00 (CH2, C-10), 38.42, 41.95 (CH2, C-7, 8), 128.40, 
129.35 (CH, C-aromatic), 137.25, 139.24 (C, C-aromatic), 171.54 (C, C-9). 
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6.4 Synthesis of thienopyrimidine structures 
 
6.4.1 General procedures 16-23 
 
General procedure 16: synthesis of ethyl 2-amino-thiophene-3-carboxylates  
 
 
 
To a mixture of ketone (1 eq.), ethyl cyanoacetate (189) (1 eq.), and elemental sulfur (1 
eq.) in absolute ethanol (1.7 mL/mmol eq.) was added triethylamine (1.5 eq.), and the 
mixture was refluxed for 24 h. The reaction mixture was then concentrated and the 
residue was partitioned between water (10 mL/mmol eq.) and ethyl acetate (10 
mL/mmol eq.). The organic layer was separated, dried over MgSO4, and concentrated, 
and the crude product was purified by recrystallization or flash column 
chromatography. 
 
General procedure 17: synthesis of thieno[2,3-d]pyrimidin-4-ones 
 
 
 
Intermediate ethyl 2-amino-thiophene-3-carboxylate (1 eq.) and formamide 
(3.2mL/mmol eq.) were refluxed for 8 h. The reaction mixture was then cooled in an 
ice-bath and added of cold water. The precipitate formed was collected by filtration, 
washed thoroughly with cold water and purified by re-crystallisation. 
 
General procedure 17a: synthesis of thieno[2,3-d]pyrimidin-4-ones 
 
 
 
A mixture of intermediate ethyl 2-amino-thiophene-3-carboxylate (1 eq.) and 
formamidine acetate salt (1.5 eq.) in DMF (2 mL/mmol eq.) was heated at 100°C for 16 
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h. The reaction mixture was then cooled to r.t., DMF removed under vacuum, and the 
solid residue obtained washed thoroughly with water and nhexane. 
 
General procedure 18: synthesis of 4-chloro-thieno[2,3-d]pyrimidines 
 
 
 
Intermediate thieno[2,3-d]pyrimidin-4-one (1 eq.) and phosphoryl chloride (2.9 
mL/mmol eq.) were refluxed for 8 h. The reaction mixture was then cooled in an ice-
bath and carefully neutralised by the addition of aqueous saturated NaHCO3 solution. 
The resulting mixture was extracted with ethyl acetate (15 mL/mmol eq.), the organic 
layer was separated, dried over MgSO4 and concentrated. The crude residue was 
purified by flash column chromatography. 
 
General procedure 19: synthesis of (thieno[2,3-d]pyrimidin-4-yl)-hydrazines 
 
 
 
Intermediate 4-chloro-thieno[2,3-d]pyrimidine (1 eq.) was suspended in MeOH (5.1 
mL/mmol eq.) and hydrazine hydrate 80% in water (2 eq.) and the mixture was refluxed 
for 5 h. Immediately after, hydrazine hydrate (2 eq.) was added to complete the reaction 
and the mixture was allowed to reflux for further 3 h. The reaction mixture was then 
cooled to r.t and placed in a fridge o.n. The resulting precipitate was filtered and 
recrystallised from a solution of 40% EtOH in water. 
 
General procedure 20: synthesis of N-(1-aryl-ethylidene)-N'-(thieno[2,3-
d]pyrimidin-4-yl)-hydrazines 
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Intermediate (thieno[2,3-d]pyrimidin-4-yl)-hydrazine (1 eq.) and arylketone or aldheyde 
(1.2) were dissolved in EtOH (12 mL/mmol eq.), and the mixture was refluxed for 24 h. 
The reaction mixture was then cooled to r.t and placed in a fridge o.n. The resulting 
precipitate was filtered, washed with a cold solution of 80% EtOH in water and re-
crystallised from EtOH. 
 
General procedure 21: synthesis of arylsulfonyl acid N'-(5,6,7,8-tetrahydro-
benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazides 
 
 
 
Compound 193 (0.20 g, 0.9 mmol) was suspended in pyridine (7 mL) under N2 
atmosphere. Arylsulfonyl chloride (0.7 mmol) dissolved in pyridine (3 mL) was then 
added dropwise to the reaction mixture under ice-cooling. The reaction mixture was 
stirred at 0°C for 1 h and then at r.t. for 20 h. The reaction mixture was then diluted with 
EtOAc (40 mL) and washed with 0.5 M HCl solution (2 x 50 mL). The water phase was 
then extracted with EtOAc (2 x 50 mL) and the organic layers were collected, dried 
over MgSO4 and concentrated under vacuum. The crude residue was purified by flash 
column chromatography to give pure sulfonyl acid N'-(5,6,7,8-tetrahydro-
benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazides.  
 
General procedure 22: synthesis of N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-arylcarbohydrazides 
 
 
 
Aryl carboxylic acid (1.1 eq.) and TBTU (1.2) were suspended in anhydrous THF (11 
mL/mmol eq.) at r.t. under N2 atmosphere. DIPEA (2.4 eq.) was then added dropwise to 
the reaction mixture, followed by intermediate (thieno[2,3-d]pyrimidin-4-yl)-hydrazine 
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(1 eq.) dissolved in anhydrous THF (11 mL/mmol eq.). The mixture was stirred at r.t. 
for 4 h, then concentrated under vacuum. The residue was dissolved in EtOAc (30 
mL/mmol eq.), washed with water (30 mL/mmol eq.), saturated NaHCO3 solution (30 
mL/mmol eq.), and finally with brine (30 mL/mmol eq.). The organic phase was 
concentrated under vacuum after drying over MgSO4. The crude residue was purified by 
re-crystallisation or flash column chromatography.  
 
General procedure 22a: synthesis of N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-arylcarbohydrazides 
 
 
 
Compound 193 (0.20 g, 0.9 mmol) was suspended in pyridine (7 mL) under N2 
atmosphere. Acyl chloride (0.7 mmol) dissolved in pyridine (3 mL) was then added 
dropwise to the reaction mixture under ice-cooling. The reaction mixture was stirred at 
0°C for 1 h and then at r.t. for 20 h. The reaction mixture was diluted with EtOAc (40 
mL) and washed with 0.5 M HCl solution (2 x 50 mL). The water phase was then 
extracted with EtOAc (2 x 50 mL) and the organic layers were collected, dried over 
MgSO4 and concentrated under vacuum. The crude residue was purified by flash 
column chromatography to give pure N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-arylcarbohydrazides. 
 
General procedure 23: synthesis of N-aryl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidin-4-amines 
 
 
 
Compound 192 (0.20 g, 0.9 mmol), arylamine (1.8 mmol) and NaHCO3 (0.15 g, 1.8 
mmol) were heated under reflux in iPrOH (8 mL) for 96 h. The reaction mixture was 
then cooled to r.t. and concentrated under vacuum. The crude residue was purified by 
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flash column chromatography to give pure N-aryl-5,6,7,8-
tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amines. 
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6.4.2 Tetrahydrobenzo[b]thienopyrimidines 
 
Ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (190)30 
(C11H15NO2S; M.W.= 225.3) 
 
 
            188    190 
 
General procedure 16; 
Reagent: cyclohexanone 188 (1g, 10.2 mmol); 
Purification: re-crystallisation from 60% EtOH/H2O; 
Light brown solid; 
Yield: 1.95 g (85%) 
1H-NMR (CDCl3), : 1.35 (t, J= 7.1 Hz, 3H, H-3’),  1.77  (m,  4H,  H-6, 7), 2.51 (m, 2H, 
CH2), 2.72 (m, 2H, CH2), 4.27 (q, J= 7.1 Hz, 2H, H-2’),  5.98  (bs,  2H,  NH2). 
13C-NMR (CDCl3), : 14.47 (CH3, C-3’), 22.85, 23.27, 24.54, 26.96 (CH2, C-5, 6, 7, 
8), 59.36 (CH2, C-2’),  105.73,  117.61,  132.46,  161.77  (C,  C-1, 2, 3, 4), 166.14 (C, C-
1’). 
 
5,6,7,8-Tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyrimidin-4-one (191)30 
(C10H10N2OS; M.W.= 206.3) 
 
 
   190     191 
 
General procedure 17; 
Reagent: ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 190 (2g, 8.8 
mmol); 
Purification: re-crystallisation from 40% EtOH/H2O; 
Light brown solid; 
Yield: 1.69 g (93%) 
1H-NMR (DMSO-d6), : 1.78 (m, 4H, H-6, 7), 2.73 (t, J= 6.1 Hz, 2H, CH2), 2.87 (t, J= 
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6.1 Hz, 2H, CH2), 7.98 (s, 1H, H-2), 12.28 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 21.73, 22.42, 24.40, 25.30 (CH2, C-5, 6, 7, 8), 122.67, 
130.79, 132.08 (C, C-aromatic), 144.81 (CH, C-2), 157.64 (C, C-aromatic), 162.39 (C, 
C-1). 
 
4-Chloro-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine (192)30 
(C10H9ClN2S; M.W.= 224.7) 
 
 
    191    192 
 
General procedure 18; 
Reagent: 5,6,7,8-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyrimidin-4-one 191 (1.5 g, 7.4 
mmol); 
T.L.C. System: nhexane-EtOAc 1:1 v/v, Rf: 0.85; 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 85:15 v/v); 
White solid; 
Yield: 1.31 g (79%) 
1H-NMR (CDCl3), : 1.85 (m, 4H, H-6, 7), 2.89 (m, 2H, CH2), 3.00 (m, 2H, CH2), 8.79 
(s, 1H, H-2). 
13C-NMR (CDCl3), : 21.59, 21.85, 25.39, 25.78 (CH2, C-5, 6, 7, 8), 126.60, 127.92, 
139.62 (C, C-aromatic), 151.77 (CH, C-2), 152.25, 168.02 (C, C-aromatic). 
 
(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193)31 
(C10H12N4S; M.W.= 220.3) 
 
 
    192           193 
 
General procedure 19; 
Reagent: 4-chloro-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine 192 (1.30 g, 
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5.8 mmol); 
Purification: recrystallization from 40 % EtOH/H2O; 
Yellow solid; 
Yield: 1.14 g (89%) 
1H-NMR (DMSO-d6), : 1.79 (m, 4H, H-6, 7), 2.75 (m, 2H, CH2), 2.92 (m, 2H, CH2), 
4.56 (bs, 2H, NH2), 7.87 (bs, 1H, NH), 8.33 (s, 1H, H-2). 
13C-NMR (DMSO-d6), : 22.00, 22.13, 24.84, 25.38 (CH2, C-5, 6, 7, 8), 114.79, 
126.77, 131.44 (C, C-aromatic), 152.46 (CH, C-2), 158.27, 163.90 (C, C-aromatic). 
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6.4.1.1 Aryl-ethanones(235, 236) 
 
1-(1H-Indol-2-yl)-ethanone (235)32 
(C10H9NO; M.W.= 159.1) 
 
 
    238    235 
 
A methyllithium 1.6 M solution in Et2O (15 mL, 24 mmol) was slowly added to a 
solution of indole-2-carboxylic acid (238) (2g, 12.4 mmol) in 100 mL of anhydrous 
Et2O cooled at 0°C and the mixture was refluxed for 1 h. Additional methyllithium 1.6 
M in Et2O (15 mL, 24 mmol) was added at r.t., and the reaction mixture was refluxed 
for additional 7 h. The reaction was then quenched by the addition of saturated aqueous 
NH4Cl solution (50 mL), diluted with Et2O (30 mL), and extracted with Et2O (2 x 50 
mL). The organic extracts were washed with water, dried over MgSO4, and evaporated 
under vacuum.  The crude residue was purified by flash column chromatography (100 
% DCM) to give pure 1-(1H-indol-2-yl)-ethanone (235) as a pink solid. 
T.L.C. System: 100 % DCM, Rf: 0.71. 
Yield: 1.37 g (69%) 
1H-NMR (CDCl3), : 2.65 (s, 3H, H-1), 7.17-7.21 (m, 1H, H-aromatic), 7.24 (dd, J1= 
2.2 Hz, J2= 0.9 Hz, 1H, H-aromatic), 7.37-7.40 (m, 1H, H-aromatic), 7.49 (dd, J1= 8.2 
Hz, J2= 0.9 Hz, 1H, H-aromatic), 7.75 (dd, J1= 8.2 Hz, J2= 0.9 Hz, 1H, H-aromatic), ( 
9.62 (bs, 1H, NH). 
13C-NMR (CDCl3), : 25.88 (CH3, C-1), 109.99, 112.35, 120.93, 123.04, 126.36 (CH, 
C-aromatic), 127.58, 135.43, 137.57 (C, C-aromatic), 190.71 (C, C-2). 
 
1-(1H-Benzoimidazol-2-yl)-ethanol (240)33 
(C9H10N2O; M.W.= 162.1) 
 
 
   239     240 
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A mixture of o-phenylendiamine (239) (2g, 18.5 mmol) and DL-lactic acid (2.1 mL, 
27.7 mmol) in 6N HCl (18.5 mL) was refluxed for 24 h. The reaction mixture was then 
cooled down in an ice-bath and neutralised with a 4N NaOH solution. The precipitate 
formed was collected, washed with water and dried under vacuum. The crude residue 
was purified by re-crystallisation from EtOH to give pure 1-(1H-benzoimidazol-2-yl)-
ethanol (240) as a white solid. 
Yield: 1.46 g (49%) 
1H-NMR (DMSO-d6), : 1.52 (d, J= 6.6 Hz, 3H, H-1), 4.92-4.98 (m, 1H, H-2), 5.75 (d, 
J= 4.8 Hz, 1H, OH), 7.10-7.16 (m, 2H, H-aromatic), 7.41-7.58 (m, 2H, H-aromatic), 
12.22 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 22.94 (CH3, C-1), 63.66 (CH, C-2), 111.20, 118.39, 120.83, 
121.53 (CH, C-aromatic), 158.83 (C, C-3, 4, 9). 
 
1-(1H-Benzoimidazol-2-yl)-ethanone (236)33 
(C9H8N2O; M.W.= 160.1) 
 
 
    240    236 
 
A mixture of 1-(1H-benzoimidazol-2-yl)-ethanol (240) (0.9 g, 5.4 mmol) in 5% HSO4 
(11 mL) was treated dropwise with a K2Cr2O7 solution (2.2 g, 7.5 mmol) in water (8 
mL) and concentrated H2SO4 (5 mL) and stirred for 3 h. The formed solid was filtered, 
washed thoroughly with water and re-crystallised from EtOH to give pure 1-(1H-
benzoimidazol-2-yl)-ethanone (236) as a light brown solid. 
Yield: 0.31 g (36%) 
1H-NMR (DMSO-d6), : 2.71 (s, 3H, H-1), 7.26-7.43 (m, 2H, H-aromatic), 7.53-7.59 
(m, 1H, H-aromatic), 7.80-7.87 (m, 1H, H-aromatic), 13.28 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 26.00 (CH3, C-1), 112.83, 121.06, 122.96, 125.54 (CH, C-
aromatic), 148.17 (C, C-3, 4, 9), 191.50 (C, C-2). 
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Methyl quinaldate (283)34 
(C11H9NO2; M.W.= 187.19) 
 
 
    282   283 
 
To a suspension of quinaldic acid (282) (2.0 g, 11.6 mmol) in MeOH (21 mL) was 
added a 1.25M HCl solution in MeOH (21 mL). The resulting mixture was refluxed for 
15 h, then cooled to r.t. and concentrated in vacuo. The residue was partitioned between 
saturated aqueous NaHCO3 solution (30 mL) and EtOAC (3 x 25 mL). The combined 
organic extracts were washed with saturated aqueous NaHCO3 (10 mL) and water (10 
mL), dried over MgSO4 and dried under vacuum to give methyl quinaldate (283) as a 
white solid. 
Yield: 2.16 g (76%) 
1H-NMR (CDCl3), : 4.10 (s, 3H, H-2’), 7.64-7.68 (m, 1H, H-aromatic), 7.78-7.82 (m, 
1H, H-aromatic), 7.89 (dd, J1= 8.1 Hz, J2= 1.1 Hz, 1H, H-aromatic), 8.21 (d, J= 8.5 Hz, 
1H, H-aromatic), 8.30-8.33 (m, 2H, H-aromatic). 
13C-NMR (CDCl3), : 53.18 (CH3, C-2’), 121.03, 127.55, 128.63 (CH, C-aromatic), 
129.36 (C, C-aromatic), 130.30, 130.71, 137.31 (CH, C-aromatic), 147.55, 147.92 (C, 
C-aromatic), 165.96 (C, C-1’). 
 
Ethyl 3-oxo-3-(quinolin-2-yl)propanoate (284)34 
(C14H13NO3; M.W.= 243.26) 
 
 
   283     284 
 
Solid tBuOK (1.32 g, 11.8 mmol) was slowly added to a solution of methyl quinaldate 
(283) (1.64 g, 8.8 mmol) in EtOAc (33 mL). The resulting mixture was stirred for 15 
min. at r.t., then quenched with water (10 mL). The organic layer was separated and the 
aqueous phase was extracted with EtOAc (3 x 25 mL). The combined organic extracts 
were washed with water (25 mL) and brine (25 mL), dried over MgSO4 and 
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concentrated under vacuum. The crude residue was purified by flash column 
chromatography (nhexane:EtOAc 100:0 v/v increasing to nhexane-EtOAc 90:10 v/v) to 
give pure ethyl 3-oxo-3-(quinolin-2-yl)propanoate (284) as an off-white paste. 
T.L.C. System: nhexane-EtOAc 8:2 v/v, Rf: 0.59. 
Yield: 0.68 g (29%) 
1H-NMR (CDCl3), : 1.25 (t, J= 7.1 Hz, 3H, H-5’),  4.23  (q,  J=  7.1  Hz,  2H,  H-4’),  4.37  
(s, 2H, H-2’),  7.66-7.70 (m, 1H, H-aromatic), 7.79-7.82 (m, 1H, H-aromatic), 7.90 (d, 
J= 8.2 Hz, 1H, H-aromatic), 8.16 (d, J= 8.4 Hz, 1H, H-aromatic), 8.17-8.20 (m, 1H, H-
aromatic), 8.30 (d, J= 8.4 Hz, 1H, H-aromatic). 
13C-NMR (CDCl3), : 14.12 (CH3, C-5’), 44.74 (CH2, C-4’),   61.13   (CH2, C-2’), 
118.08, 127.68, 128.88 (CH, C-aromatic), 129.77 (C, C-aromatic), 130.15, 130.59, 
137.13 (CH, C-aromatic), 147.10, 151.95 (C, C-aromatic), 168.38, 194.96 (C, C-1’,  3’). 
 
2-Acetylquinoline (285)34 
(C11H9NO; M.W.= 171.20) 
 
 
    284    285 
 
A solution of ethyl 3-oxo-3-(quinolin-2-yl)propanoate (284) (0.62 g, 2.5 mmol) in 1,4-
dioxane (7 mL) containing 1M aqueous HCl solution (7 mL) was stirred at 100°C for 15 
h, then cooled to r.t. and concentrated in vacuo. The residue was diluted with water (20 
mL) and extracted with EtOAc (3 x 25 mL). The combined organic extracts were 
washed with saturated aqueous NaHCO3 solution (20 mL) and brine (20 mL), dried 
over MgSO4 and concentrated under vacuum. The crude residue was filtered on a bed of 
silica gel (nhexane:DCM 1:4 v/v) to give pure 2-acetylquinoline (285) as a white solid. 
T.L.C. System: nhexane-DCM 1:4 v/v, Rf: 0.69. 
Yield: 0.27 g (62%) 
1H-NMR (CDCl3), : 2.89 (s, 3H, H-2’),  7.65-7.68 (m, 1H, H-aromatic), 7.78-7.82 (m, 
1H, H-aromatic), 7.88-7.90 (m, 1H, H-aromatic), 8.15 (d, J= 8.5 Hz, 1H, H-aromatic), 
8.21-8.23 (m, 1H, H-aromatic), 8.28 (d, J= 8.5 Hz, 1H, H-aromatic). 
13C-NMR (CDCl3), : 25.52 (CH3, C-2’), 117.96, 127.63, 128.53 (CH, C-aromatic), 
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129.58 (C, C-aromatic), 129.96, 130.59, 136.83 (CH, C-aromatic), 147.26, 153.28 (C, 
C-aromatic), 200.62 (C, C-1’). 
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6.4.1.2  N-(1-Aryl-ethylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d] 
pyrimidin-4-yl)-hydrazines (187, 215-223, 252, 254-265) and N-arylidene-N'-
(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazines (225-234, 
253, 457) 
 
2-{1-[(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazono]-
ethyl}-benzene-1,4-diol (187) 
(C18H18N4 O2S; M.W.= 354.4) 
 
 
   193  194   187 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
T.L.C. System: nhexane -EtOAc 1:1 v/v, Rf: 0.48. 
Yield: 0.08 g (66%) 
Melting Point: > 300 °C 
MS (ESI)+: 377.0 [M+Na]+ 
Two species observed. Major/minor species ratio: 2/1. 
1H-NMR (DMSO-d6), : (major species) 1.79 (bs, 4H, H-6, 7), 2.44 (s, 3H, H-2’),  2.74  
(bs, 2H, CH2), 3.04 (bs, 2H, CH2), 6.75 (bs, 2H, H-aromatic), 6.99 (bs, 1H, H-aromatic), 
7.73 (bs, 1H, NH), 8.88 (bs, 1H, H-2), 11.35 (bs, 1H, OH), 11.79 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 1.79 (bs, 4H, H-6, 7), 2.44 (s, 3H, H-2’),  2.74  
(bs, 2H, CH2), 3.07 (bs, 2H, CH2), 6.75 (bs, 2H, H-aromatic), 6.99 (bs, 1H, H-aromatic), 
8.51 (bs, 1H, NH), 8.88 (bs, 1H, H-2), 9.27 (bs, 1H, OH), 12.56 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 12.95, 13.33 (CH3, C-2’),  22.06,  
22.28, 24.71, 26.48 (CH2, C-5, 6, 7, 8), 113.42, 114.18, 116.92, 117.64, 118.11 (CH, C-
3’,  4’,  6’),  119.42,  121.00,  126.23, 130.75, 132.52, 133.84 (C, C-aromatic), 143.96 (CH, 
C-2), 145.28, 149.23, 150.97, 152.58 (CH, C-2), 153.82, 154.47, 156.57, 162.96, 165.74 
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(C, C-aromatic). 
N-(1-Phenyl-ethylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-
4-yl)-hydrazine (215)31 
(C18H18N4S; M.W.= 322.4) 
 
 
   193  195   215 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow crystals; 
Yield: 0.09 g (62%) 
Melting Point: 190-192°C 
MS (ESI+): 345.1 [M+Na]+ 
Two species observed. Major/minor species ratio: 2/1. 
1H-NMR (CDCl3), : (major species) 1.85-1.91 (m, 4H, CH2), 2.55 (s, 3H, H-2’),  2.79-
2.82 (m, 2H, CH2), 3.10-3.14 (m, 2H, CH2), 7.38-7.43 (m, 5H, H-aromatic), 7.66 (s, 1H, 
H-2), 10.36 (bs, 1H, NH). 
1H-NMR (CDCl3), : (minor species) 1.94-2.06 (m, 4H, CH2), 2.38 (s, 3H, H-2’),  2.86-
2.90 (m, 2H, CH2), 3.04-3.07 (m, 2H, CH2), 7.83-7.87 (m, 5H, H-aromatic), 8.50 (bs, 
1H, NH), 8.64 (s, 1H, H-2). 
13C-NMR (CDCl3), : (major and minor species) 13.52, 15.12 (CH3, C-2’),   22.22,  
22.38, 22.68, 22.76, 25.35, 25.47, 26.62, 26.72 (CH2), 120.56, 124.58 (C, C-aromatic), 
126.50, 126.74, 128.44, 129.11, 129.28, 129.54 (CH, C-aromatic), 129.87, 131.43, 
133.71, 134.41, 135.18, 135.31, 137.94 (C, C-aromatic), 139.34 (CH, C-aromatic), 
141.35, 148.05, 149.29 (C, C-aromatic), 153.45 (CH, C-aromatic), 156.79, 159.50 (C, 
C-aromatic). 
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N-[1-(4-Methoxy-phenyl)-ethylidene]-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (216) 
(C19H20N4OS; M.W.= 352.4) 
 
 
   196  196   216 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow crystals; 
Yield: 0.04 g (28%) 
Melting Point: 178-180°C 
MS (ESI+): 353.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.75-1.84 (m, 4H, CH2), 2.41 (s, 3H, H-2’),  2.71-2.78 (m, 2H, 
CH2), 3.00-3.04 (m, 2H, CH2), 3.81 (s, 3H, H-9’),  6.96 (d, J= 8.5 Hz, 2H, H-aromatic), 
7.75 (s, 1H, H-2), 8.00 (d, J= 8.5 Hz, 2H, H-aromatic), 11.53 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 14.08 (CH3, C-2’),  22.15, 22.39, 24.65, 26.38 (CH2), 55.17 
(CH3, C-7’),   113.42 (CH, C-aromatic), 119.66 (C, C-aromatic), 128.03 (CH, C-
aromatic), 130.84, 131.26, 132.05 (C, C-aromatic), 144.00 (CH, C-aromatic), 146.94, 
156.47, 157.14, 160.09 (C, C-aromatic). 
 
N-(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-N'-[1-(3,4,5-
trimethoxy-phenyl)-ethylidene]-hydrazine (217) 
(C21H24N4O3S; M.W.= 412.5) 
 
 
           193  197   217 
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General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.14 g (74%) 
Melting Point: 224-226°C 
MS (ESI+): 413.1 [M+H]+ 
Two species observed. Major/minor species ratio: 5/2. 
1H-NMR (CDCl3), : (major species) 1.84-1.91 (m, 4H, CH2), 2.51 (s, 3H, H-2’),  2.79-
2.83 (m, 2H, CH2), 3.09-3.13 (m, 2H, CH2), 3.94 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 
3.98 (s, 3H, OCH3), 7.07 (s, 2H, H-4’,  6’), 7.67 (s, 1H, H-2), 10.25 (bs, 1H, NH). 
1H-NMR (CDCl3), : (minor species) 1.95-2.05 (m, 4H, CH2), 2.35 (s, 3H, H-2’),  2.87-
2.91 (m, 2H, CH2), 3.04-3.08 (m, 2H, CH2), 3.93 (s, 3H, OCH3), 3.97 (s, 3H, OCH3), 
3.99 (s, 3H, OCH3), 7.07 (s, 2H, H-4’,  6’),  8.42  (bs,  1H,  NH), 8.61 (s, 1H, H-2). 
13C-NMR (CDCl3), : (major and minor species) 13.91, 15.57 (CH3, C-2’),   22.42, 
22.68, 22.77, 22.93, 25.35, 25.60, 26.64, 26.78 (CH2), 56.38, 60.94 (CH3, C-9’,  10’), 
104.24 (CH, C-aromatic), 131.42, 133.80, 135.08, 135.20 (C, C-aromatic), 141.27 (CH, 
C-aromatic), 147.63, 153.07 (C, C-aromatic), 153.23 (CH, C-aromatic), 156.71, 159.61 
(C, C-aromatic). 
 
N-[1-(3-Fluoro-4-methoxy-phenyl)-ethylidene]-N'-(5,6,7,8-tetrahydro-
benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (218) 
(C19H19FN4OS; M.W.= 370.4) 
 
 
193  198   218 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
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Yield: 0.13 g (75%) 
Melting Point: 192-194°C 
MS (ESI+): 371.1 [M+H]+ 
Two species observed. Major/minor species ratio: 5/2. 
1H-NMR (CDCl3), : (major species) 1.85-1.92 (m, 4H, CH2), 2.50 (s, 3H, H-2’),  2.78-
2.82 (m, 2H, CH2), 3.08-3.13 (m, 2H, CH2), 3.94 (s, 3H, H-9’),  6.92-6.99 (m, 1H, H-
aromatic), 7.49-7.53 (m, 1H, H-aromatic), 7.63-7.70 (m, 2H, H-aromatic), 10.33 (bs, 
1H, NH). 
1H-NMR (CDCl3), : (minor species) 1.93-2.03 (m, 4H, CH2), 2.32 (s, 3H, H-2’),  2.86-
2.90 (m, 2H, CH2), 3.02-3.06 (m, 2H, CH2), 3.93 (s, 3H, H-9’),  6.92-6.99 (m, 1H, H-
aromatic), 7.54-7.58 (m, 1H, H-aromatic), 7.63-7.70 (m, 1H, H-aromatic), 8.45 (bs, 1H, 
NH), 8.63 (s, 1H, H-aromatic). 
13C-NMR (CDCl3), : (major and minor species) 13.24, 14.75 (CH3, C-2’),   22.36, 
22.67, 22.93, 25.34, 25.57, 26.62 (CH2), 56.27 (CH3, C-9’,   10’),   112.63, 112.78, 
113.79, 113.94, 114.34, 122.64, 122.66 (CH, C-aromatic), 131.40, 132.62, 133.74, 
135.74 (C, C-aromatic), 141.35 (CH, C-aromatic), 147.38, 151.23, 153.18 (C, C-
aromatic), 153.28 (CH, C-aromatic), 157.03, 159.41 (C, C-aromatic). 
 
N-(1-Benzo[1,3]dioxol-5-yl-ethylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (219) 
(C19H18N4O2S; M.W.= 366.4) 
 
 
193  199   219 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.04 g (27%) 
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Melting Point: 215-217°C 
MS (ESI+): 389.0 [M+Na]+ 
Two species observed. Major/minor species ratio: 2/1. 
1H-NMR (CDCl3), : (major species) 1.84-1.92 (m, 4H, CH2), 2.50 (s, 3H, H-2’),  2.78-
2.82 (m, 2H, CH2), 3.09-3.12 (m, 2H, CH2), 6.01 (s, 2H, H-9’),  6.82-6.85 (m, 1H, H-
aromatic), 7.29-7.32 (m, 1H, H-aromatic), 7.45 (d, J= 1.6 Hz, 1H, H-8’),  7.67  (s,  1H,  H-
2), 10.30 (bs, 1H, NH). 
1H-NMR (CDCl3), : (minor species) 1.94-2.04 (m, 4H, CH2), 2.33 (s, 3H, H-2’), 2.86-
2.90 (m, 2H, CH2), 3.03-3.07 (m, 2H, CH2), 6.02 (s, 2H, H-9’),  6.82-6.85 (m, 1H, H-
aromatic), 7.29-7.32 (m, 1H, H-aromatic), 7.47 (d, J= 1.6 Hz, 1H, H-8’),  8.45  (bs,  1H,  
NH), 8.63 (s, 1H, H-2). 
13C-NMR (CDCl3), : (major and minor species) 13.64, 15.10 (CH3, C-2’),   22.38, 
22.68, 22.75, 22.94, 25.35, 25.57, 26.62, 26.69 (CH2), 106.42, 106.89, 107.86, 107.90 
(CH, C-aromatic), 119.99 (C, C-aromatic), 120.88, 121.06 (CH, C-aromatic), 125.40, 
131.40, 133.67, 134.25, 135.08 (C, C-aromatic), 141.36 (CH, C-aromatic), 147.69, 
147.81, 148.61, 150.75 (C, C-aromatic), 153.39 (CH, C-aromatic), 153.95, 157.44, 
158.81 (C, C-aromatic). 
 
N-[1-(4-Nitro-phenyl)-ethylidene]-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (220) 
(C18H17N5O2S; M.W.= 367.4) 
 
 
193  200   220 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Orange solid; 
Yield: 0.13 g (76%) 
Melting Point: 289-291°C 
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MS (ESI+): 390.0 [M+Na]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.76-1.86 (m, 4H, CH2), 2.38 (s, 3H, H-2’),  2.74-2.82 (m, 2H, 
CH2), 3.00-3.08 (m, 2H, CH2), 7.87 (s, 1H, H-2), 8.25 (d, J= 7.8 Hz, 2H, -aromatic), 
8.32 (d, J= 7.8 Hz, 2H, H-aromatic), 11.87 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 14.11 (CH3, C-2’),  22.11,  22.34,  24.71,  26.41  (CH2), 119.63 
(C, C-aromatic), 123.20, 127.41 (CH, C-aromatic), 130.81, 132.82 (C, C-aromatic), 
143.91 (CH, C-aromatic), 144.76, 147.17, 148.25, 155.43, 157.83 (C, C-aromatic). 
 
N-[1-(4-Cyclohexyl-phenyl)-ethylidene]-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno 
[2,3-d]pyrimidin-4-yl)-hydrazine (221) 
(C24H28N4S; M.W.= 404.6) 
 
 
        193   201   221 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.14 g (76%) 
Melting Point: 258-260°C 
MS (ESI+): 405.1 [M+Na]+ 
Two species observed. Major/minor species ratio: 2/1. 
1H-NMR (CDCl3), : major specis- 1.38-1.52 (m, 6H, CH2), 1.76-1.82 (m, 2H, CH2), 
1.85-1.98(m, 6H, CH2), 2.52-2.59 (m, 4H, H-2’,  9’), 2.79-2.82 (m, 2H, CH2), 3.11-3.14 
(m, 2H, CH2), 7.24-7.27 (m, 2H, H-aromatic), 7.65 (s, 1H, H-2), 7.76-7.80 (m, 2H, H-
aromatic), 10.34 (bs, 1H, NH). 
1H-NMR (CDCl3), : (minor species) 1.38-1.52 (m, 14H, CH2), 2.37 (s, 3H, H-2’),  
2.73-2.76 (m, 1H, H-9’),   2.87-2.90 (m, 2H, CH2), 3.06-3.09 (m, 2H, CH2), 7.24-7.27 
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(m, 2H, H-aromatic), 7.76-7.80 (m, 2H, H-aromatic), 8.49 (bs, 1H, NH), 8.64(s, 1H, H-
2). 
13C-NMR (CDCl3), : (major and minor species) 13.52, 15.11 (CH3, C-2’),   22.41, 
22.69, 22.77, 22.95, 25.35, 26.13, 26.62, 26.74, 26.78, 26.86, 34.30, 34.35, 34.49 (CH2), 
44.43 (CH, C-9’),  119.78, 126.51 (C, C-aromatic), 126.72, 126.76, 126.91, 128.21 (CH, 
C-aromatic), 131.42, 133.63, 134.30, 135.24, 136.98 (C, C-aromatic), 141.36 (CH, C-
aromatic), 147.81, 149.43, 149.57 (C, C-aromatic), 153.44 (CH, C-aromatic), 153.93, 
156.65, 159.63 (C, C-aromatic). 
 
2-{1-[(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazono]-
ethyl}-phenol (222) 
(C18H18N4OS; M.W.= 338.4) 
 
 
   193  202   222 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Pale yellow solid; 
Yield: 0.15 g (98%) 
Melting Point: 250-252°C 
MS (ESI+): 339.1 [M+H]+ 
Two species observed. Major/minor species ratio: 2/1. 
1H-NMR (DMSO-d6), : (major species) 1.76-1.91 (m, 4H, CH2), 2.52 (s, 3H, H-1’),  
2.73-2.85 (m, 2H, CH2), 2.97-3.19 (m, 2H, CH2), 6.89-6.93 (m, 2H, H-aromatic), 7.27-
7.31 (m, 1H, H-aromatic), 7.60-7.63 (m, 1H, H-aromatic), 7.75 (s, 1H, H-2), 11.40 (bs, 
1H, NH), 12.52 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 1.76-1.91(m, 4H, CH2), 2.52 (s, 3H, H-1’),  
2.73-2.85 (m, 2H, CH2), 2.97-3.19 (m, 2H, CH2), 6.89-6.93 (m, 2H, H-aromatic), 7.27-
7.31 (m, 1H, H-aromatic), 7.64-7.67 (m, 1H, H-aromatic), 8.54 (s, 1H, H-2), 9.38 (bs, 
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1H, NH), 13.33 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 12.97, 14.83 (CH3, C-1’), 22.08, 
22.32, 24.69, 25.00, 26.50 (CH2), 116.51, 117.28, 118.64 (CH, C-aromatic), 119.40, 
120.96, 126.34 (C, C-aromatic), 128.03, 128.71, 130.69 (CH, C-aromatic), 132.61, 
133.96 (C, C-aromatic), 144.02 (CH, C-aromatic), 145.33 (C, C-aromatic), 152.65 (CH, 
C-2), 153.91, 156.62, 158.22, 163.29 (C, C-aromatic). 
 
3-{1-[(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazono]-
ethyl}-phenol (223) 
(C18H18N4OS; M.W.= 338.4) 
 
 
   193  203   223 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Pale orange solid; 
Yield: 0.15 g (99%) 
Melting Point: 307-309°C 
MS (ESI+): 339.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.76-1.84 (m, 4H, CH2), 2.40 (s, 3H, H-1’),  2.73-2.76 (m, 2H, 
CH2), 3.01-3.05 (m, 2H, CH2), 6.79-6.83 (m, 1H, H-aromatic), 7.19-7.22(m, 1H, H-
aromatic), 7.37-7.39 (m, 1H, H-aromatic), 7.49 (d, J= 7.9 Hz, 1H, H-aromatic), 7.76 (s, 
1H, H-2), 9.39 (bs, 1H, OH), 11.54 (bs, 1H, NH), 
13C-NMR (DMSO-d6), : 14.47 (CH3, C-1’), 22.14, 22.39, 24.66, 26.40 (CH2), 113.54, 
115.92, 117.51 (CH, C-aromatic), 119.61 (C, C-aromatic), 128.87 (CH, C-aromatic), 
130.84, 132.20, 140.15 (C, C-aromatic), 144.01 (CH, C-aromatic), 147.25, 156.71, 
157.16, 157.71 (C, C-aromatic). 
 Chapter 6: Experimental 
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N-Benzylidene-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-
hydrazine (224)31 
(C17H16N4S; M.W.= 308.4) 
 
 
   193  204   224 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Pale yellow solid; 
Yield: 0.06 g (46%) 
Melting Point: 162-164°C (lit. 163°C)31 
MS (ESI+): 309.1 [M+H]+ 
Two species observed. Major/minor species ratio: 3/2. 
1H-NMR (CDCl3), : (major species) 1.85-1.91 (m, 4H, CH2), 2.78-2.83 (m, 2H, CH2), 
3.04-3.12 (m, 2H, CH2), 7.38-7.44 (m, 5H, H-aromatic), 7.70 (s, 1H, H-2), 8.50 (s, 1H, 
H-1’),  10.44 (bs, 1H, NH). 
1H-NMR (CDCl3), : (minor species) 1.94-2.02 (m, 4H, CH2), 2.86-2.89 (m, 2H, CH2), 
3.04-3.12 (m, 2H, CH2), 7.75-7.82 (m, 5H, H-aromatic), 8.02 (s, 1H, H-1’),   8.61   (bs,  
1H, NH), 8.65 (s, 1H, H-2). 
13C-NMR (CDCl3), : (major and minor species) 22.42, 22.54, 22.91, 25.35, 25.60, 
26.73, 26.93 (CH2), 119.79, 124.25 (C, C-aromatic), 127.50, 127.64, 128.67, 129.93, 
130.13 (CH, C-aromatic), 131.43, 132.55, 133.27, 134.18, 135.69 (C, C-aromatic), 
141.17, 145.15, (CH, C-aromatic), 149.57 (C, C-aromatic), 153.17 (CH, C-aromatic), 
153.79 (C, C-aromatic), 154.27 (CH, C-aromatic), 157.48 (C, C-aromatic). 
 Chapter 6: Experimental 
 
 
346 
 
N-(4-Methoxy-benzylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (225)31 
(C18H18N4OS; M.W.= 338.4) 
 
 
   193  205   225 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.11 g (75%) 
Melting Point: 193-195°C (lit. 184-185 °C)31 
MS (ESI+): 361.1 [M+Na]+ 
Two species observed. Major/minor species ratio: 5/4. 
1H-NMR (CDCl3), : (major species) 1.82-1.91 (m, 4H, CH2), 2.78-2.83 (m, 2H, CH2), 
3.04-3.11 (m, 2H, CH2), 3.86 (s, 3H, H-8’),  6.94 (d, J= 8.8 Hz, 2H, H-aromatic), 7.66-
7.75 (m, 3H, H-aromatic), 8.44 (s, 1H, CH), 10.40 (bs, 1H, NH). 
1H-NMR (CDCl3), : (minor species) 1.93-2.03 (m, 4H, CH2), 2.84-2.88 (m, 2H, CH2), 
3.04-3.11 (m, 2H, CH2), 3.86 (s, 3H, H-8’),  6.94 (d, J= 8.8 Hz, 2H, H-aromatic), 7.66-
7.75 (m, 2H, H-aromatic), 7.96 (s, 1H, CH), 8.53 (s, 1H, CH), 8.63 (s, 1H, NH). 
13C-NMR (CDCl3), : (major and minor species) 22.57, 22.90, 25.44, 26.79 (CH2), 
55.37 (CH3, C-8’),  114.50 (CH, C-aromatic), 119.82 (C, C-aromatic), 129.47 (CH, C-
aromatic), 124.15 (C, C-aromatic), 131.55, 135.92 (C, C-aromatic), 141.20 (CH, C-
aromatic), 149.51 (C, C-aromatic), 154.00 (CH, C-aromatic), 157.34, 166.56 (C, C-
aromatic). 
 Chapter 6: Experimental 
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N-(2-Methoxy-benzylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (226) 
(C18H18N4OS; M.W.= 338.4) 
 
 
   193  206   226 
 
General procedure 16; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.11 g (75%) 
Melting Point: 216-218°C 
MS (ESI+): 361.1 [M+Na]+ 
Two species observed. Major/minor species ratio: 3/2. 
1H-NMR (CDCl3), : (major species) 1.92-2.02 (m, 4H, CH2), 2.84-2.89 (m, 2H, CH2), 
3.04-3.12 (m, 2H, CH2), 3.90 (s, 3H, H-8’),  6.90-6.94 (m, 1H, H-aromatic), 6.95-7.03 
(m, 1H, H-aromatic), 7.34-7.39 (m, 1H, H-aromatic, H-2), 8.16 (d, J= 7.6 Hz, 1H, H-
aromatic), 8.41 (s, 1H, H-2), 8.62-8.66 (m, 2H, CH, NH). 
1H-NMR (CDCl3), : (minor species) 1.82-21.91 (m, 4H, CH2), 2.77-2.81 (m, 2H, 
CH2), 3.04-3.12 (m, 2H, CH2), 3.90 (s, 3H, H-8’),  6.90-6.94 (m, 1H, H-aromatic), 6.95-
7.03 (m, 1H, H-aromatic), 7.34-7.39 (m, 1H, H-aromatic, H-2), 7.67 (s, 1H, H-1’),  8.00 
(d, J= 7.6 Hz, 1H, H-aromatic), 8.88 (s, 1H, H-2), 10.47 (bs, 1H, NH). 
13C-NMR (CDCl3), : (major and minor species) 22.42, 22.59, 22.93, 25.35, 25.58, 
26.73, 26.86 (CH2), 55.54 (CH3, C-8’),  110.80, 111.21 (CH, C-aromatic), 119.79 (C, C-
aromatic), 120.60, 120.96 (CH, C-aromatic), 124.10, 124.25, 124.79 (C, C-aromatic), 
126.59, 127.21, 131.16, 131.38 (CH, C-aromatic), 131.47, 132.59, 133.34, 134.89, 
135.39 (C, C-aromatic), 141.10, 141.32 (CH, C-aromatic), 149.37 (C, C-aromatic), 
150.20, 153.30 (CH, C-aromatic), 154.04, 157.65, 166.83 (C, C-aromatic). 
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N-(3-Methoxy-benzylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (227)31 
(C18H18N4OS; M.W.= 338.4) 
 
 
   193  207   227 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.09 g (57%) 
Melting Point: 199-201°C 
MS (ESI+): 361.0 [M+Na]+ 
Two species observed. Major/minor species ratio: 4/3. 
1H-NMR (CDCl3), : (major species) 1.84-1.92 (m, 4H, CH2), 2.79-2.83 (m, 2H, CH2), 
3.06-3.11 (m, 2H, CH2), 3.88 (s, 3H, H-8’), 6.95-6.99 (m, 1H, H-aromatic), 7.32-7.35 
(m, 3H, H-aromatic, H-2), 7.71 (d, J= 2.8 Hz, 1H, H-aromatic), 8.47 (s, 1H, H-1’),  
10.40 (bs, 1H, NH). 
1H-NMR (CDCl3), : (minor species) 1.94-2.04 (m, 4H, CH2), 2.87-2.91 (m, 2H, CH2), 
3.06-3.11 (m, 2H, CH2), 3.89 (s, 3H, H-8’), 6.95-6.99 (m, 1H, H-aromatic), 7.32-7.35 
(m, 2H, H-aromatic), 7.37-7.39 (m, 1H, H-aromatic), 8.01 (s, 1H, H-1’),  8.62  (bs,  1H,  
NH), 8.64 (s, 1H, H-2). 
13C-NMR (CDCl3), : (major and minor species) 22.43, 22.52, 22.61, 22.90, 25.35, 
25.62, 26.72, 26.96 (CH2), 55.38, 55.47 (CH3, C-8’), 111.45, 112.20, 115.82, 116.77 
(CH, C-aromatic), 119.28 (C, C-aromatic), 120.67, 120.76 (CH, C-aromatic), 124.33, 
124.44, 124.99 (C, C-aromatic), 129.70 (CH, C-aromatic), 131.43, 132.39, 133.74, 
134.89, 136.60 (C, C-aromatic), 141.14, 145.22 (CH, C-aromatic), 149.73 (C, C-
aromatic), 153.14, 154.21 (CH, C-aromatic), 154.00, 157.46, 166.23 (C, C-aromatic). 
 Chapter 6: Experimental 
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N-(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-N'-(3,4,5-
trimethoxy-benzylidene)-hydrazine (228)31 
(C20H22N4O3S; M.W.= 398.4) 
 
 
   193  208   228 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.16 g (91%) 
Melting Point: 224-226°C (lit. 200°C)31 
MS (ESI+): 399.1 [M+H]+ 
Two species observed. Major/minor species ratio: 4/3. 
1H-NMR (CDCl3), : (major species) 1.83-1.92 (m, 4H, CH2), 2.78-2.82 (m, 2H, CH2), 
3.06-3.11 (m, 2H, CH2), 3.91 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 
7.00-7.02 (m, 2H, H-aromatic), 7.68 (s, 1H, H-2), 8.44 (s, 1H, H-1’),   10.43   (bs,   1H,  
NH). 
1H-NMR (CDCl3), : (minor species) 1.93-2.03 (m, 4H, CH2), 2.86-2.90 (m, 2H, CH2), 
3.06-3.11 (m, 2H, CH2), 3.90 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 3.94 (s, 3H, OCH3), 
7.00-7.02 (m, 2H, H-aromatic), 7.98 (s, 1H, H-1’), 8.59 (bs, 1H, NH), 8.62 (s, 1H, H-2). 
13C-NMR (CDCl3), : (major and minor species) 22.43, 22.53, 22.62, 22.90, 25.35, 
25.61, 26.75, 26.97 (CH2), 56.22, 56.32, 60.99 (CH3, C-8’,  9’), 104.66, 104.75 (CH, C-
aromatic), 119.40, 124.37, 124.54, 124.89, 128.99, 130.57, 131.41, 133.91, 135.27, 
136.75 (C, C-aromatic), 141.17, 145.39 (CH, C-aromatic), 148.99 (C, C-aromatic), 
153.06 (CH, C-aromatic), 153.50 (C, C-aromatic), 154.55 (CH, C-aromatic), 154.13, 
157.65, 166.12 (C, C-aromatic). 
 Chapter 6: Experimental 
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N-(3,4-Diethoxy-benzylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (229) 
(C21H24N4O2S; M.W.= 396.5) 
 
 
   193  209   229 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.13 g (77%) 
Melting Point: 237-239°C 
MS (ESI+): 397.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.33-1.39 (m, 6H, H-9’,  11’),  1.74-1.85 (m, 4H, CH2), 2.73-
2.78 (m, 2H, CH2), 2.96-3.01 (m, 2H, CH2), 4.06-4.15 (m, 4H, H-8’,  10’), 7.00 (d, J= 
8.3 Hz, 1H, H-aromatic), 7.35 (d, J= 8.3 Hz, 1H, H-aromatic), 7.62 (s, 1H, H-aromatic), 
7.78 (s, 1H, H-aromatic), 8.31 (s, 1H, H-2), 8.44 (s, 1H, H-1’),  11.69 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 14.66, 14.78 (CH3, C-9’,   11’), 22.00, 22.39, 24.64, 26.55 
(CH2), 63.76, 64.05 (CH2, C-8’,  11’), 111.76, 112.73 (CH, C-aromatic), 118.89 (C, C-
aromatic), 122.27 (CH, C-aromatic), 128.15, 130.85, 132.05 (C, C-aromatic), 143.90 
(CH, C-aromatic), 148.25, 150.08 (C, C-aromatic), 153.15 (CH, C-aromatic), 156.80 
(C, C-aromatic). 
 Chapter 6: Experimental 
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4-[(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazonomethyl]-
phenol (230)31 
(C17H16N4OS; M.W.= 324.4) 
 
 
   193  210   230 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Pale yellow solid; 
Yield: 0.05 g (34%) 
Melting Point: 255-257°C 
MS (ESI+): 325.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.74-1.84 (m, 4H, CH2), 2.70-2.77 (m, 2H, CH2), 2.95-3.02 
(m, 2H, CH2), 6.83 (d, J= 8.3 Hz, 1H, H-aromatic), 7.72-7.80 (m, 3H, H-aromatic,  1’), 
8.29 (s, 1H, H-2), 9.83 (bs, 1H, OH), 11.67 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 22.00, 22.37, 24.64, 26.51 (CH2), 115.39 (CH, C-aromatic), 
118.89, 126.53 (C, C-aromatic), 129.45 (CH, C-aromatic), 131.90, 132.25 (C, C-
aromatic), 143.93 (CH, C-aromatic), 148.99 (C, C-aromatic), 152.95 (CH, C-aromatic), 
156.87, 159.16 (C, C-aromatic). 
 Chapter 6: Experimental 
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N-(4-Bromo-benzylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-
4-yl)-hydrazine (231)31 
(C17H15BrN4S; M.W.= 387.3) 
 
 
   193  211   231 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.06 g (36%) 
Melting Point: 180-182°C 
MS (ESI+): 387.0, 389.0 [M+H]+ 
Two species observed. Major/minor species ratio: 3/2. 
1H-NMR (CDCl3), : major speices- 1.84-1.92 (m, 4H, CH2), 2.79-2.84 (m, 2H, CH2), 
3.04-3.10 (m, 2H, CH2), 7.53-7.57 (m, 2H, H-aromatic), 7.63 (d, J= 8.3 Hz, 2H, H-
aromatic), 7.73 (s, 1H, H-2), 8.43 (s, 1H, H-1’), 10.39 (bs, 1H, NH). 
1H-NMR (CDCl3), : (minor species) 1.94-2.03 (m, 4H, CH2), 2.87-2.91 (m, 2H, CH2), 
3.04-3.10 (m, 2H, CH2), 7.53-7.57 (m, 2H, H-aromatic), 7.66 (d, J= 8.3 Hz, 2H, H-
aromatic), 7.98 (s, 1H, H-1’),  8.64  (s,  1H,  H-2), 8.65 (bs, 1H, NH). 
13C-NMR (CDCl3), : (major and minor species) 22.30, 22.53, 22.88, 25.37, 25.57, 
26.74 (CH2), 119.80, 124.02, 124.30, 124.59 (C, C-aromatic), 128.87, 129.39 (CH, C-
aromatic), 131.39 (C, C-aromatic), 132.03, 132.11 (CH, C-aromatic), 132.49, 133.05, 
134.02, 134.18, 135.49 (C, C-aromatic), 141.14, 143.78 (CH, C-aromatic), 149.57 (C, 
C-aromatic), 153.03 (CH, C-aromatic), 153.86, 157.53 (C, C-aromatic), 161.14 (CH, C-
aromatic). 
 Chapter 6: Experimental 
 
 
353 
 
N-(3-Bromo-benzylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-
4-yl)-hydrazine (232) 
(C17H15BrN4S; M.W.= 387.3) 
 
 
   193  212   232 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.11 g (65%) 
Melting Point: 222-224°C 
MS (ESI+): 387.0, 389.0 [M+H]+ 
Two species observed. Major/minor species ratio: 2/1. 
1H-NMR (CDCl3), : (major species) 1.83-1.92 (m, 4H, CH2), 2.77-2.83 (m, 2H, CH2), 
3.04-3.12 (m, 2H, CH2), 7.26-7.30 (m, 1H, H-aromatic), 7.49-7.54 (m, 1H, H-aromatic), 
7.75 (d, J= 2.6 Hz, 1H, H-3’),  7.97-7.99 (m, 2H, H-aromatic), 8.41 (s, 1H, H-aromatic), 
10.40 (bs, 1H, NH). 
1H-NMR (CDCl3), : (minor species) 1.94-2.05 (m, 4H, CH2), 2.86-2.96 (m, 2H, CH2), 
3.04-3.12 (m, 2H, CH2), 7.26-7.30 (m, 1H, H-aromatic), 7.49-7.54 (m, 1H, H-aromatic), 
7.58-7.61 (m, 2H, H-aromatic), 7.66-7.69 (m, 1H, H-aromatic), 8.65-8.67 (m, 2H, H-
aromatic, NH). 
13C-NMR (CDCl3), : (major and minor species) 22.30, 22.53, 22.88, 25.37, 25.57, 
26.74 (CH2), 119.87, 124.07, 124.41, 124.79 (C, C-aromatic), 126.08, 126.69, 129.68, 
129.94, 130.19, 132.60 (CH, C-aromatic), 132.77 (C, C-aromatic), 132.95 (CH, C-
aromatic), 133.11, 134.23, 134.38, 135.09 (C, C-aromatic), 137.39, 141.06, 143.23 (CH, 
C-aromatic), 149.66 (C, C-aromatic), 152.34 (CH, C-aromatic), 153.75, 157.41 (C, C-
aromatic), 161.07 (CH, C-aromatic). 
 Chapter 6: Experimental 
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N-(4-tert-Butyl-benzylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine 233)31 
(C21H24N4S; M.W.= 364.5) 
 
 
   193  213   233 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.10 g (61%) 
Melting Point: 221-223°C 
MS (ESI+): 365.1 [M+H]+ 
Two species observed. Major/minor species ratio: 3/2. 
1H-NMR (CDCl3), : (major species) 1.36 (s, 9 H, H-9’),   1.85-1.90 (m, 4H, CH2), 
2.78-2.81 (m, 2H, CH2), 3.05-3.12 (m, 2H, CH2), 7.42-7.45 (m, 2H, H-aromatic), 7.63 
(s, 1H, CH), 7.69 (d, J= 8.4 Hz, 2H, H-aromatic), 8.48 (s, 1H, CH), 10.48 (bs, 1H, NH). 
1H-NMR (CDCl3), : (minor species) 1.36 (s, 9 H, H-9’),   1.93-2.02 (m, 4H, CH2), 
2.85-2.89 (m, 2H, CH2), 3.05-3.12 (m, 2H, CH2), 7.42-7.45 (m, 2H, H-aromatic), 7.71 
(d, J= 8.4 Hz, 2H, H-aromatic), 7.99 (s, 1H, CH), 8.58 (bs, 1H, NH), 8.64 (s, 1H, CH). 
13C-NMR (CDCl3), : (major and minor species) 22.43, 22.54, 22.62, 22.92, 25.46, 
25.60, 26.73, 26.95 (CH2), 31.22 (CH3, C-9’),  34.89,  34.91  (C,  C-8’),  115.29,  119.83,  
124.83 (C, C-aromatic), 125.63, 126.45, 127.34, 127.57 (CH, C-aromatic), 130.75, 
131.42, 132.49, 133.69, 135.01 (C, C-aromatic), 141.28, 145.31 (CH, C-aromatic), 
149.18 (C, C-aromatic), 152.19 (CH, C-aromatic), 153.38, 153.63, 154.14 (C, C-
aromatic), 154.28 (CH, C-aromatic), 157.13, 166.98 (C, C-aromatic). 
 Chapter 6: Experimental 
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N-(4-Isopropyl-benzylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (234)31 
(C20H22N4S; M.W.= 350.4) 
 
 
   193  214   234 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.06 g (38%) 
Melting Point: 195-197°C 
MS (ESI+): 373.1 [M+Na]+ 
Two species observed. Major/minor species ratio: 3/2. 
1H-NMR (CDCl3), : (major species) 1.29 (d, J= 5.4 Hz, 6 H, H-9’),  1.84-1.92 (m, 4H, 
CH2), 2.78-2.83 (m, 2H, CH2), 2.93-2.99 (m, 1H, H-8’),  3.06-3.12 (m, 2H, CH2), 7.27-
7.30 (m, 2H, H-aromatic), 7.68-7.74 (m, 3H, H-aromatic), 8.48 (s, 1H, CH), 10.41 (bs, 
1H, NH). 
1H-NMR (CDCl3), : (minor species) 1.29 (d, J= 5.4 Hz,\ 6 H, H-9’),  1.94-2.03 (m, 4H, 
CH2), 2.86-2.89 (m, 2H, CH2), 2.93-2.99 (m, 1H, H-8’),  3.06-3.12 (m, 2H, CH2), 7.27-
7.30 (m, 2H, H-aromatic), 7.68-7.74 (m, 2H, H-aromatic), 8.00 (s, 1H, CH), 8.57 (bs, 
1H, NH), 8.64 (s, 1H, CH). 
13C-NMR (CDCl3), : (major and minor species) 22.44, 22.54, 22.72, 22.92 (CH2), 
23.81 (CH3, C-9’),  25.35, 25.60, 26.72, 26.93 (CH2), 34.13 (CH, C-8’),  115.29,  119.72, 
124.81 (C, C-aromatic), 125.99, 126.80, 127.61, 127.72 (CH, C-aromatic), 130.65, 
131.32, 132.60, 133.75, 135.06 (C, C-aromatic), 141.20, 145.37 (CH, C-aromatic), 
149.10 (C, C-aromatic), 153.21 (CH, C-aromatic), 153.47, 153.60, 154.23 (C, C-
aromatic), 154.37 (CH, C-aromatic), 157.02, 166.96 (C, C-aromatic). 
 Chapter 6: Experimental 
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4-{1-[(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazono]-
ethyl}-phenol (252) 
(C18H18N4OS; M.W.= 338.4) 
 
 
   193  241   252 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Orange solid; 
Yield: 0.10 g (66%) 
Melting Point: 263-265°C 
MS (ESI+): 339.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.74-1.83 (m, 4H, CH2), 2.39 (s, 3H, H-1’),  2.71-2.75 (m, 2H, 
CH2), 2.99-3-03 (m, 2H, CH2), 6.80 (d, J= 8.7 Hz, 2H, H-aromatic), 7.74 (s, 1H, H-2), 
7.90 (d, J= 8.7 Hz, 2H, H-aromatic), 9.68 (bs, 1H, OH), 11.48 (bs, 1H, NH), 
13C-NMR (DMSO-d6), : 14.03 (CH3, C-1’), 22.15, 22.40, 24.65, 26.38 (CH2), 114.84 
(CH, C-aromatic), 119.69 (C, C-aromatic), 128.11 (CH, C-aromatic), 129.71, 130.83, 
131.97 (C, C-aromatic), 144.02 (CH, C-aromatic), 146.70, 156.31, 157.41, 158.51 (C, 
C-aromatic). 
 Chapter 6: Experimental 
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2-[(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazonomethyl]-
benzene-1,4-diol (253) 
(C17H16N4O2S; M.W.= 340.4) 
 
 
   193  237   253 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.09 g (61%) 
Melting Point: 235-237°C 
MS (ESI+): 341.1 [M+H]+ 
Two species observed. Major/minor species ratio: 2/1. 
1H-NMR (DMSO-d6), : (major species) 1.75-1.88 (m, 4H, CH2), 2.71-2.86 (m, 2H, 
CH2), 2.97-3.14 (m, 2H, CH2), 6.71-6.76 (m, 2H, H-aromatic), 7.19 (s, 1H, H-aromatic), 
7.76 (s, 1H, CH), 8.54 (s, 1H, H-aromatic), 8.91 (bs, 1H, OH), 9.60 (bs, 1H, NH), 11.48 
(bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 1.75-1.88 (m, 4H, CH2), 2.71-2.86 (m, 2H, 
CH2), 2.97-3.14 (m, 2H, CH2), 6.71-6.76 (m, 2H, H-aromatic), 6.92 (s, 1H, aromatic), 
8.48 (s, 1H, H-aromatic), 8.54 (s, 1H, H-aromatic), 8.91 (bs, 1H, OH), 10.09 (bs, 1H, 
NH), 10.75 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 21.98, 22.13, 22.35, 24.67, 25.02, 
25.51, 26.59 (CH2), 114.15, 114.47, 116.61, 116.97, 118.30, 118.60 (CH, C-aromatic), 
118.81, 119.42, 120.45, 126.46, 130.86, 132.24, 133.13 (C, C-aromatic), 143.93, 146.48 
(CH, C-aromatic), 147.54, 149.81, 149.94 (C, C-aromatic), 152.55, 153.36 (CH, C-
aromatic ), 156.97 (C, C-aromatic). 
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4-(2-(1-(2,5-dimethoxyphenyl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo 
[4,5]thieno[2,3-d]pyrimidine (254) 
(C20H22N4O2S; M.W.= 382.4) 
 
 
   193  242   254 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Purification: re-crystallisation from DCM/ nhexane; 
Grey solid; 
Yield: 0.07 g (41%) 
Melting Point: 143-145°C 
MS (ESI+): 383.1 [M+H]+ 
Two species observed. Major/minor species ratio: 3/2. 
1H-NMR (DMSO-d6), : (major species) 1.57-1.63 (m, 2H, CH2), 1.68-1.77 (m, 2H, 
CH2), 2.10-2.15 (m, 2H, CH2), 2.29 (s, 3H, H-1’),  2.69-2.75 (m, 2H, CH2), 3.75 (s, 3H, 
OCH3), 3.76 (s, 3H, OCH3), 6.91-6.95 (m, 1H, H-aromatic), 7.06-7.12 (m, 1H, H-
aromatic), 7.18 (d, J= 9.0 Hz, 1H, H-aromatic), 8.38 (s, 1H, H-2), 8.40 (bs, 1H, NH). 
1H-NMR (DMSO-d6), : (minor species) 1.45-1.51 (m, 2H, CH2), 1.68-1.77 (m, 2H, 
CH2), 2.29 (s, 3H, H-1’),  2.32-2.39 (m, 2H, CH2), 2.61-2.65 (m, 2H, CH2), 3.65 (s, 3H, 
OCH3), 3.69 (s, 3H, OCH3), 6.70-6.73 (m, 1H, H-aromatic), 6.83-6.87 (m, 1H, H-
aromatic), 6.91-6.95 (m, 1H, H-aromatic), 7.63 (s, 1H, H-2), 11.43 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : (major and minor species) 21.71, 21.88, 22.34 (CH2), 23.86, 
23.98 (CH3, C-1’),  24.48,  24.74,  24.81,  25.82  (CH2), 55.44, 55.68, 55.86, 56.21 (CH3, 
C-9’,  10’), 112.11, 113.48, 113.57 (CH, C-aromatic), 114.30 (C, C-aromatic), 114.37, 
114.64, 115.97 (CH, C-aromatic), 119.22, 123.49, 125.00, 129.34, 130.84, 131.56, 
133.37 (C, C-aromatic), 143.82 (CH, C-aromatic ), 145.63, 148.89, 149.49, 150.40 (C, 
C-aromatic), 152.58 (CH, C-aromatic), 152.79, 153.28, 153.89, 155.88, 157.89, 165.21 
 Chapter 6: Experimental 
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(C, C-aromatic). 
 
N-[1-(2-Methoxy-phenyl)-ethylidene]-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (255) 
(C19H20N4OS; M.W.= 352.4) 
 
 
   193  243   255 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
T.L.C. System: nhexane -EtOAc 5:5v/v, Rf: 0.61. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
70:30 v/v). 
Yellow solid; 
Yield: 0.08 g (51%) 
Melting Point: 61-63°C 
MS (ESI+): 353.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.76-1.83 (m, 4H, CH2), 2.35 (s, 3H, H-1’),  2.71-2.76 (m, 2H, 
CH2), 2.99-3.04 (m, 2H, CH2), 3.82 (s, 3H, H-9’),  6.96-7.02 (m, 1H, H-aromatic), 7.04-
7.10 (m, 1H, aromatic), 7.34-7.41 (m, 1H, H-aromatic), 7.46-7.52 (m, 1H, H-aromatic), 
7.67 (s, 1H, H-2), 11.46 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 18.60 (CH3, C-1’),  22.15,  22.42,  25.70,  26.35 (CH2), 55.52 
(CH3, C-9’),  111.47 (CH, C-aromatic), 119.52 (C, C-aromatic), 120.25, 129.69, 129.78 
(CH, C-aromatic), 129.84, 130.88, 132.01 (C, C-aromatic), 143.95 (CH, C-aromatic ), 
147.22, 156.58, 157.29, 159.88 (C, C-aromatic). 
 Chapter 6: Experimental 
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N-[1-(3-Methoxy-phenyl)-ethylidene]-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (256) 
(C19H20N4OS; M.W.= 352.4) 
 
 
   193  244   256 
 
General procedure 20; 
Reagent(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Purification: re-crystallisation from EtOH/H2O; 
Yellow solid; 
Yield: 0.05g (35%) 
Melting Point: 137-139°C 
MS (ESI+): 353.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.76-1.83 (m, 4H, CH2), 2.43 (s, 3H, H-1’),  2.73-2.77 (m, 2H, 
CH2), 3.01-3.05 (m, 2H, CH2), 3.83 (s, 3H, H-9’),  6.97-7.00 (m, 1H, H-aromatic), 7.32-
7.36 (m, 1H, aromatic), 7.56-7.60 (m, 2H, H-aromatic), 7.79 (s, 1H, H-2), 11.58 (bs, 
1H, NH). 
13C-NMR (DMSO-d6), : 14.41 (CH3, C-1’),  22.14, 22.37, 24.68, 26.36 (CH2), 55.13 
(CH3, C-9’),  112.35, 114.19, 119.11 (CH, C-aromatic), 119.57 (C, C-aromatic), 128.81 
(CH, C-aromatic), 130.79, 132.29, 140.13 (C, C-aromatic), 143.98 (CH, C-aromatic ), 
147.46, 156.89, 157.41, 159.19 (C, C-aromatic). 
 
 Chapter 6: Experimental 
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N-[1-(2,5-Dichloro-phenyl)-ethylidene]-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno 
[2,3-d]pyrimidin-4-yl)-hydrazine (257) 
(C18H16Cl2N4S; M.W.= 391.3) 
 
 
   193  245   257  
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
T.L.C. System: nhexane -EtOAc 7:3 v/v, Rf: 0.57 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
70:30 v/v). 
Yellow solid; 
Yield: 0.08 g (46%) 
Melting Point: 82-84°C 
MS (ESI+): 391.0, 393.0 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.76-1.84 (m, 4H, CH2), 2.38 (s, 3H, H-1’),  2.74-2.77 (m, 2H, 
CH2), 3.01-3.04 (m, 2H, CH2), 7.49 (dd, J1= 8.6 Hz, J2= 2.5 Hz, 1H, H-6’), 7.55 (d, J= 
8.6 Hz, 1H, H-5’), 7.61 (d, J= 2.5 Hz, 1H, H-8’), 7.71(s, 1H, H-2), 11.58 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 18.48 (CH3, C-1’),  22.13, 22.38, 24.67, 26.35 (CH2), 119.27 
(C, C-aromatic), 129.48 (CH, C-aromatic), 130.07 (C, C-aromatic), 130.30 (CH, C-
aromatic), 130.87 (C, C-aromatic), 131.31 (CH, C-aromatic ), 131.69, 132.45, 141.30 
(C, C-aromatic), 143.77 (CH, C-aromatic), 148.26, 157.29, 157.65 (C, C-aromatic). 
 Chapter 6: Experimental 
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N-[1-(2-Chloro-phenyl)-ethylidene]-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (258) 
(C18H17ClN4S; M.W.= 356.8) 
 
 
   193  246   258 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
T.L.C. System: nhexane -EtOAc 7:3 v/v, Rf: 0.52 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
50:50 v/v). 
Yellow solid; 
Yield: 0.08 g (51%) 
Melting Point: 77-79°C 
MS (ESI+): 357.1, 359.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.76-1.85 (m, 4H, CH2), 2.39 (s, 3H, H-1’),  2.73-2.77 (m, 2H, 
CH2), 3.02-3.05 (m, 2H, CH2), 7.38-7.44 (m, 2H, H-aromatic), 7.48-7.56 (m, 2H, H-
aromatic), 7.68 (s, 1H, H-2), 11.50 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 18.78 (CH3, C-1’),  22.14, 22.40, 24.66, 26.36 (CH2), 119.30 
(C, C-aromatic), 127.04, 129.55, 129.76 (CH, C-aromatic), 130.72 (C, C-aromatic), 
130.88 (CH, C-aromatic), 131.26, 132.29, 139.82 (C, C-aromatic), 143.81 (CH, C-
aromatic ), 147.93, 157.03, 159.00 (C, C-aromatic). 
 Chapter 6: Experimental 
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N-[1-(4-Chloro-phenyl)-ethylidene]-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (259) 
(C18H16ClN4S; M.W.= 356.8) 
 
 
   193  247   259 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.12 g (77%) 
Melting Point: 199-201 °C 
MS (ESI+): 357.1, 359.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.74-1.84 (m, 4H, CH2), 2.42 (s, 3H, H-1’),  2.72-2.76 (m, 2H, 
CH2), 2.99-3.04 (m, 2H, CH2), 7.46 (d, J= 8.3 Hz, 2H, H-aromatic), 7.79 (s, 1H, H-2), 
8.06 (d, J= 8.3 Hz, 2H, H-aromatic), 11.65 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 13.99 (CH3, C-1’),  22.12,  22.36,  24.67,  26.37  (CH2), 119.29 
(C, C-aromatic), 128.02, 128.21 (CH, C-aromatic), 130.82, 132.34, 133.55, 137.44 (C, 
C-aromatic), 143.90 (CH, C-aromatic ), 147.74, 156.23, 157.02 (C, C-aromatic). 
 
N-[1-(2,5-Difluoro-phenyl)-ethylidene]-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (260) 
(C18H17F2N4S; M.W.= 358.4) 
 
 
   193  248   260 
 Chapter 6: Experimental 
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General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Purification: re-crystallisation from EtOH/H2O; 
Yellow solid; 
Yield: 0.07 g (45%) 
Melting Point: 131-133°C 
MS (ESI+): 359.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.74-1.83 (m, 4H, CH2), 2.42 (d, J= 4.1 Hz, 3H, H-1’),  2.72-
2.76 (m, 2H, CH2), 2.99-3.03 (m, 2H, CH2), 7.24-7.32 (m, 2H, H-aromatic), 7.77 (s, 1H, 
H-2), 7.82-7.87 (m, 1H, H-aromatic), 11.64 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 17.36, 17.42 (CH3, C-1’),  22.11, 22.35, 24.66, 26.34 (CH2), 
115.71, 115.74, 115.90, 115.94, 116.81, 116.88, 117.01, 117.08, 117.61, 117.68, 
117.82, 117.89 (CH, C-5’,   6’,   8’), 119.43, 128.83, 128.89, 130.83, 132.49 (C, C-
aromatic), 143.77 (CH, C-2 ), 148.21, 154.29, 155.62, 157.06, 157.32, 157.55, 158.95 
(C, C-aromatic). 
 
N-[1-(2-Fluoro-phenyl)-ethylidene]-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (261) 
(C18H17FN4S; M.W.= 340.4) 
 
 
   193  249   261 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.06 g (42%) 
Melting Point: 65-67°C 
 Chapter 6: Experimental 
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MS (ESI+): 341.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.74-1.85 (m, 4H, CH2), 2.42 (d, J= 3.4 Hz, 3H, H-1’),  2.74-
2.77 (m, 2H, CH2), 3.01-3.04 (m, 2H, CH2), 7.23-7.28 (m, 2H, H-aromatic), 7.42-7.47 
(m, 1H, H-aromatic), 7.42 (s, 1H, H-2), 7.88-7.92 (m, 1H, H-aromatic), 11.54 (bs, 1H, 
NH). 
13C-NMR (DMSO-d6), : 17.84, 17.88 (CH3, C-1’),  22.13, 22.38, 24.66, 26.36 (CH2), 
115.92, 116.10 (CH, C-aromatic), 119.42 (C, C-aromatic), 124.16, 124.18 (CH, C-
aromatic ), 127.62, 127.71 (C, C-aromatic), 130.18 (CH, C-aromatic), 130.21 (C, C-
aromatic), 130.54, 130.61, 130.86 (CH, C-aromatic), 132.36 (C, C-aromatic), 143.87 
(CH, C-2), 147.83, 155.68, 157.03, 159.31, 161.28 (C, C-aromatic). 
 
N-(1-Pyrazin-2-yl-ethylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (262) 
(C16H16N6S; M.W.= 324.4) 
 
 
 193  250   262 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.08 g (55%) 
Melting Point: 201-203°C 
MS (ESI+): 325.1 [M+H]+ 
Microanalysis: Calculated for C16H16N6S (324.4); Theoretical: %C = 59.24, %H = 4.97, 
%N = 25.89; Found: %C = 59.14, %H = 4.79, %N = 25.95. 
Two species observed. Major/minor species ratio: 3/2. 
1H-NMR (DMSO-d6), : (major species) 1.86-191 (m, 4H, CH2), 2.59 (s, 3H, H-1’),  
2.78-2.82 (m, 2H, CH2), 3.10-3.13 (m, 2H, CH2), 7.73 (d, J= 1.6 Hz, 1H, H-6’), 8.46 (d, 
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J= 2.7 Hz, 1H, H-5’), 8.53 (dd, J1= 2.7 Hz, J2= 1.6 Hz, 1H, H-5’), 9.32 (s, 1H, H-
aromatic), 10.56 (bs, 1H, NH). 
1H-NMR (DMSO-d6), : (minor species) 1.93-1.98 (m, 2H, CH2), 1.99-2.05 (m, 2H, 
CH2), 2.49 (s, 3H, H-1’),  2.86-2.90 (m, 2H, CH2), 3.05-3.08 (m, 2H, CH2), 8.50-8.52 
(m, 2H, H-aromatic), 8.66 (s, 1H, H-aromatic), 8.73 (bs, 1H, NH), 9.51 (s, 1H, H-
aromatic). 
13C-NMR (DMSO-d6), : (major and minor species) 10.83, 13.43 (CH3, C-1’),  22.33,  
22.63, 22.70, 22.87, 25.38, 25.60, 26.63, 26.67 (CH2), 116.22, 120.55, 124.38, 131.48, 
134.35, 136.00 (C, C-aromatic), 141.18, 142.82, 142.95, 143.22, 143.34, 143.42, 143.82 
(CH, C-aromatic), 147.68, 149.07, 150.40, 152.02 (C, C-aromatic), 153.08 (CH, C-
aromatic ), 153.74, 157.90, 158.35, 167.34 (C, C-aromatic). 
 
N-(1-Pyridin-2-yl-ethylidene)-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (263) 
(C17H17N5S; M.W.= 323.4) 
 
 
   193  251   263 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Purification: re-crystallisation from EtOH/H2O; 
Orange solid; 
Yield: 0.11 g (81%) 
Melting Point: 195-197°C 
MS (ESI+): 324.1 [M+H]+ 
Two species observed. Major/minor species ratio: 5/2. 
1H-NMR (DMSO-d6), : (major species) 1.75-1.81 (m, 4H, CH2), 2.54 (s, 3H, H-1’),  
2.71-2.74 (m, 2H, CH2), 2.99-3.03 (m, 2H, CH2), 7.36 (dd, J1= 7.5 Hz, J2= 5.1 Hz, 1H, 
H-aromatic), 7.79-7.83 (m, 2H, H-aromatic), 8.53 (d, J= 8.0 Hz, 1H, H-aromatic), 8.57-
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8.61 (m, 1H, H-aromatic), 11.74 (bs, 1H, NH). 
1H-NMR (DMSO-d6), : (minor species) 1.82-1.86 (m, 2H, CH2), 1.91-1.97 (m, 2H, 
CH2), 2.42 (s, 3H, H-1’),  2.75-2.78 (m, 2H, CH2), 3.06-3.09 (m, 2H, CH2), 7.52 (dd, J1= 
7.8 Hz, J2= 5.1 Hz, 1H, H-aromatic), 7.74 (d, J= 8.0 Hz, 1H, H-aromatic), 8.01-8.03 (m, 
1H, H-aromatic), 8.41 (s, 1H, H-aromatic), 8.57-8.61 (m, 1H, H-aromatic), 9.73 (bs, 
1H, NH). 
13C-NMR (DMSO-d6), : (major and minor species) 13.17 (CH3, C-1’),  21.87, 22.10, 
22.25, 22.35, 24.67, 24.95, 26.13, 26.36 (CH2), 119.62 (C, C-aromatic), 120.86, 123.51, 
124.06, 124.37 (CH, C-aromatic), 130.86, 132.47, 132.78 (C, C-aromatic), 135.84, 
143.82, 147.15 (CH, C-aromatic ), 148.08 (C, C-aromatic), 148.40 (CH, C-aromatic), 
156.06, 157.36, 158.65 (C, C-aromatic). 
 
N-[1-(1H-Indol-2-yl)-ethylidene]-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazine (264) 
(C20H19N5S; M.W.= 361.4) 
 
 
  193  235   264 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.08 g (53%) 
Melting Point: 213-215°C 
MS (ESI+): 362.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.77-1.85 (m, 4H, CH2), 2.41 (s, 3H, H-1’),  2.74-2.78 (m, 2H, 
CH2), 3.00-3.06 (m, 2H, CH2), 6.87 (s, 1H, H-10’),   7.01-7.03 (m, 1H, H-aromatic), 
7.18-7.20 (m, 1H, H-aromatic), 7.44 (d, J= 7.9 Hz, 1H, H-aromatic), 7.96 (d, J= 7.9 Hz, 
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1H, H-aromatic), 7.96 (s, 1H, H-2), 11.35 (bs, 1H, NH), 11.98 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 13.58 (CH3, C-1’),  22.13, 22.39, 24.67, 26.30 (CH2), 103.33, 
110.90, 119.15 (CH, C-aromatic), 119.67 (C, C-aromatic), 120.79, 123.03 (CH, C-
aromatic ), 128.15, 130.87, 132.41, 136.83, 137.78 (C, C-aromatic), 143.59 (CH, C-
aromatic), 147.98, 150.37, 156.95 (C, C-aromatic). 
 
N-[1-(1H-Benzoimidazol-2-yl)-ethylidene]-N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno 
[2,3-d]pyrimidin-4-yl)-hydrazine (265) 
(C19H18N6S; M.W.= 362.4) 
 
 
 193  236   265 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Light brown solid; 
Yield: 0.06 g (42%) 
Melting Point: 287-289°C 
MS (ESI+): 363.1 [M+H]+ 
Two species observed. Major/minor species ratio: 5/1. 
1H-NMR (DMSO-d6), : 1.74-1.84 (m, 4H, CH2), 2.72-2.81 (m, 2H, CH2), 3.01-3.08 
(m, 2H, CH2), 3.18 (s, 3H, H-1’),  7.17-7.23 (m, 1H, H-aromatic), 7.25-7.31 (m, 1H, H-
aromatic), 7.54-7.61 (m, 1H, H-aromatic), 7.63-7.73 (m, 1H, H-aromatic), 8.04 (s, 1H, 
H-2), 12.10 (bs, 1H, NH), 12.57 (bs, 1H, NH). 
1H-NMR (DMSO-d6), : 1.91-1.96 (m, 2H, CH2), 2.02-2.10 (m, 2H, CH2), 2.83-2.87 
(m, 2H, CH2), 3.42-3.46 (m, 2H, CH2), 4.08 (s, 3H, H-1’),   7.36-7.43 (m, 2H, H-
aromatic), 7.63-7.73 (m, 2H, H-aromatic), 8.50 (s, 1H, H-2), 13.03 (bs, 1H, NH), 14.31 
(bs, 1H, NH). 
13C-NMR (DMSO-d6), : 13.10 (CH3, C-1’),  22.08, 22.35, 24.68, 26.29 (CH2), 48.57 
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(CH3, C-1’),  111.06,  119.39 (CH, C-aromatic), 119.53 (C, C-aromatic), 121.48, 123.50 
(CH, C-aromatic ), 130.87, 132.92, 133.52 (C, C-aromatic), 143.46 (CH, C-aromatic), 
143.79, 149.20, 149.71, 151.77, 157.94 (C, C-aromatic). 
 
4-(2-(1-(Quinolin-2-yl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno 
[2,3-d]pyrimidine (290) 
(C21H19N5S; M.W.= 373.4) 
 
 
 193   285   290 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Purification: re-crystallisation from EtOH/H2O; 
Orange solid; 
Yield: 0.11 g (71%) 
Melting Point: 121-123°C 
MS (ESI+): 374.0 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.79-1.83 (m, 4H, CH2), 2.62 (s, 3H, H-1’), 2.74-2.78 (m, 2H, 
CH2), 3.05-3.09 (m, 2H, CH2), 7.58-7.61 (m, 1H, H-aromatic), 7.74-7.78 (m, 1H, H-
aromatic), 7.89 (s, 1H, H-2), 7.94 (d, J= 8.3 Hz, 1H, H-aromatic), 8.04 (d, J= 8.3 HZ, 
1H, H-aromatic), 8.34 (d, J= 8.7 Hz, 1H, H-aromatic), 8.77 (d, J= 8.7 Hz, 1H, H-
aromatic), 11.90 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 12.97 (CH3, C-1’),  22.12, 22.35, 24.70, 26.39 (CH2), 119.25 
(CH, C-aromatic), 119.57 (C, C-aromatic), 126.66, 127.67 (CH, C-aromatic ), 127.76 
(C, C-aromatic), 129.08, 129.46 (CH, C-aromatic), 130.91, 132.71 (C, C-aromatic), 
135.23, 143.87 (CH, C-aromatic), 146.97, 148.43, 156.24, 158.04, 159.15 (C, C-
aromatic). 
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4-(2-(1-(Pyridin-3-yl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno 
[2,3-d]pyrimidine (291) 
(C17H17N5S; M.W.= 323.4) 
 
 
 193  286   291 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow crystals; 
Yield: 0.08 g (61%) 
Melting Point: 188-191°C 
MS (ESI+): 324.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.76-1.83 (m, 4H, CH2), 2.46 (s, 3H, H-1’), 2.73-2.76 (m, 2H, 
CH2), 3.01-3.05 (m, 2H, CH2), 7.42-7.45 (m, 1H, H-aromatic), 7.80 (d, J= 3.6 Hz, 1H, 
H-aromatic), 8.33-8.36 (m, 1H, H-aromatic), 8.57 (dd, J1= 4.7 Hz, J2= 1.5 Hz, 1H, H-
aromatic), 9.28 (s, 1H, H-2), 11.74 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 13.84 (CH3, C-1’),  22.12, 22.36, 24.67, 26.38 (CH2), 119.54 
(C, C-aromatic), 123.15 (CH, C-aromatic), 130.83, 132.43 (C, C-aromatic), 133.60 
(CH, C-aromatic), 133.98 (C, C-aromatic), 143.90, 147.87 (CH, C-aromatic), 148.03 
(C, C-aromatic), 149.44 (CH, C-aromatic), 155.41, 157.20 (C, C-aromatic). 
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4-(2-(1-(1H-Pyrrol-2-yl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno 
[2,3-d]pyrimidine (292) 
(C16H17N5S; M.W.= 311.4) 
 
 
   193  287   292 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.08 g (62%) 
Melting Point: 84-89°C 
MS (ESI+): 312.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.76-1.86 (m, 4H, CH2), 2.27 (s, 3H, H-1’), 2.71-2.75 (m, 2H, 
CH2), 2.97-3.01 (m, 2H, CH2), 6.11-6.14 (m, 1H, H-aromatic), 6.47-6.49 (m, 1H, H-
aromatic), 7.00-7.02 (m, 1H, H-aromatic), 7.82 (s, 1H, H-2), 11.31 (bs, 1H, NH), 11.80 
(bs, 1H, NH). 
13C-NMR (DMSO-d6), : 13.48 (CH3, C-1’),  22.14, 22.42, 24.63, 26.26 (CH2), 108.74, 
110.21 (CH, C-aromatic), 119.70 (C, C-aromatic), 120.71 (CH, C-aromatic ), 130.83, 
131.80, 131.91 (C, C-aromatic), 143.61 (CH, C-aromatic), 146.88, 150.42, 156.13 (C, 
C-aromatic). 
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4-(2-(1-(Furan-2-yl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidine (293) 
(C16H16N4OS; M.W.= 312.3) 
 
 
   193  288   293 
 
General procedure 16; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.05 g (36%) 
Melting Point: 134-139°C 
MS (ESI+): 313.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.75-1.82 (m, 4H, CH2), 2.33 (s, 3H, H-1’), 2.72-2.75 (m, 2H, 
CH2), 2.98-3.01 (m, 2H, CH2), 6.63 (dd, J1= 3.4 Hz, J2= 1.7 Hz, 1H, H-aromatic), 7.08 
(d, J= 3.4 Hz, 1H, H-aromatic), 7.76-7.79 (m, 2H, H-aromatic), 11.47 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 13.72 (CH3, C-1’),  22.12, 22.37, 24.65, 26.32 (CH2), 109.99, 
111.96 (CH, C-aromatic), 119.59, 130.81, 132.30 (C, C-aromatic), 143.82, 143.94 (CH, 
C-aromatic), 147.33, 149.57, 153.31, 156.80 (C, C-aromatic). 
 
4-(2-(1-(Thiophen-2-yl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno 
[2,3-d]pyrimidine (294) 
(C16H16N4S2; M.W.= 328.4) 
 
 
   193  289   294 
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General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow crystals; 
Yield: 0.06 g (44%) 
Melting Point: 129-132°C 
MS (ESI+): 329.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.76-1.83 (m, 4H, CH2), 2.42 (s, 3H, H-1’), 2.72-2.75 (m, 2H, 
CH2), 2.98-3.01 (m, 2H, CH2), 7.11 (dd, J1= 5.2 Hz, J2= 3.7 Hz, 1H, H-aromatic), 7.51 
(dd, J1= 3.7 Hz, J2= 0.9 Hz, 1H, H-aromatic), 7.58 (dd, J1= 5.2 Hz, J2= 0.9 Hz, 1H, H-
aromatic), 7.80 (s, 1H, H-2), 11.24 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 14.96 (CH3, C-1’),  22.13, 22.37, 24.66, 26.36 (CH2), 119.59 
(C, C-aromatic), 127.01, 127.50, 127.91 (CH, C-aromatic), 130.80, 132.33 (C, C-
aromatic), 144.07 (CH, C-aromatic), 144.43, 146.80, 153.74, 156.73 (C, C-aromatic). 
 
4-(2-(Thiophen-2-ylmethylene)hydrazinyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidine (457)35 
(C15H14N4S2; M.W.= 314.4) 
 
 
   193  452   457 
 
General procedure 20; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.10 g, 0.4 mmol); 
Yellow solid; 
Yield: 0.04 g (34%) 
Melting Point: 156-161°C (lit. 179-180°C) 
MS (ESI+): 314.9 [M+H]+ 
Two species observed. Major/minor species ratio: 6/1. 
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1H-NMR (DMSO-d6), : (major species) 1.73-1.86 (m, 4H, CH2), 2.72-2.75 (m, 2H, 
CH2), 2.95-2.99 (m, 2H, CH2), 7.13-7.15 (m, 1H, H-aromatic), 7.47-7.48 (m, 1H, H-
aromatic), 7.63-7.66 (m, 1H, H-aromatic), 7.78 (d, J= 3.7 Hz, 1H, H-aromatic), 8.57 (s, 
1H, H-aromatic), 11.49 (bs, 1H, NH). 
1H-NMR (DMSO-d6), : (minor species) 1.73-1.86 (m, 4H, CH2), 2.81-2.84 (m, 2H, 
CH2), 3.05-3.08 (m, 2H, CH2), 7.13-7.15 (m, 1H, H-aromatic), 7.40 (d, J= 3.1 Hz, 1H, 
H-aromatic), 7.63-7.66 (m, 1H, H-aromatic), 8.45 (s, 1H, H-aromatic), 8.57 (s, 1H, H-
aromatic), 10.22 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : (major and minor species) 21.98, 22.19, 22.36, 24.65, 25.19, 
26.47, 26.52 (CH2), 118.82 (C, C-aromatic), 127.74, 127.79, 128.19, 128.61, 129.80, 
130.48 (CH, C-aromatic), 130.80, 132.27, 132.87, 139.19, 140.10 (C, C-aromatic), 
140.58, 144.00, 147.61 (CH, C-aromatic), 148.26 (C, C-aromatic), 152.16 (CH, C-
aromatic), 157.13 (C, C-aromatic). 
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6.4.1.3 2-Pyridinesulfonyl chloride (266)36 
(C5H4ClNO2S; M.W.= 177.6) 
 
 
    270   266 
 
Under ice-cooling, 2-mercaptopyridine (270) (1 g, 9 mmol) was added to sulphuric acid 
(25 mL) and the mixture was stirred at r.t. A sodium hypochlorite solution (63 mL, 
available chlorine 4.00-4.99%) was then added dropwise to the reaction mixture over a 
period of 1.5 h, and the mixture was further stirred at r.t. for 30 min. 
The reaction was then diluted with water (50 mL), and extracted with DCM (2 x 50 
mL). The extract was then washed with brine (100 mL), dried over MgSO4, and 
concentrated at reduced pressure to give the title compound as a colourless oil. 
Yield: 1.23 g (77%) 
1H-NMR (CDCl3), : 7.70-7.74 (m, 1H, H-aromatic), 8.07-8.10 (m, 1H, H-aromatic), 
8.12-8.14 (m, 1H, H-aromatic), 8.83-8.85 (m, 1H, H-aromatic). 
13C-NMR (CDCl3), : 121.94, 129.12, 139.09, 150.71 (CH, C-aromatic), 159.22 (C, C-
1). 
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6.4.1.4 Arylsulfonyl acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-
4-yl)-hydrazides (267-269) 
 
4-tert-Butyl-phenylsulfonyl acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazide (267) 
(C20H24N4O2S2; M.W.= 416.5) 
 
 
    83   267 
 
General procedure 21; 
T.L.C. System: nhexane-EtOAc 4:6 v/v, Rf: 0.66. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
70:30 v/v). 
White solid; 
Yield: 0.11 g (38%) 
Melting Point: 171-173°C 
MS (ESI+): 417.1 [M+H]+ 
1H-NMR (CDCl3), : 1.24 (s, 9H, H-8’),  1.90-2.01 (m, 4H, CH2), 2.83 (t, J= 5.9 Hz, 
2H, CH2), 2.96 (t, J= 5.9 Hz, 2H, CH2), 7.16 (bs, 1H, NH), 7.33 (d, J= 8.5 Hz, 2H, H-
aromatic), 7.80 (d, J= 8.5 Hz, 2H, H-aromatic), 8.00 (s, 1H, H-2), 8.02 (bs, 1H, NH), 
13C-NMR (CDCl3), : 22.35, 22.43, 25.46, 26.17 (CH2), 30.92 (CH3, C-8’),  35.14  (C,  
C-7’),  125.07  (C, C-aromatic), 125.52, 128.60 (CH, C-aromatic), 133.66, 135.81 (C, C-
aromatic), 151.18 (CH, C-2), 154.56, 157.62, 158.18, 166.24 (C, C-aromatic). 
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4-Chlorosulfonyl acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-
yl)-hydrazide (268) 
(C16H15ClN4O2S2; M.W.= 394.8) 
 
 
    13   268 
 
General procedure 21; 
T.L.C. System: nhexane -EtOAc 4:6 v/v, Rf: 0.63. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
50:50 v/v). 
Pale yellow solid; 
Yield: 0.12 g (46%) 
Melting Point: 186-188°C 
MS (ESI+): 395.0, 397.0 [M+H]+ 
1H-NMR (CDCl3), : 1.91-2.01 (m, 4H, CH2), 2.84 (t, J= 5.8 Hz, 2H, CH2), 2.95 (t, J= 
5.8 Hz, 2H, CH2), 7.14 (bs, 1H, NH), 7.34 (d, J= 8.5 Hz, 2H, H-aromatic), 7.85 (d, J= 
8.5 Hz, 2H, H-aromatic), 8.08 (bs, 1H, NH), 8.12 (s, 1H, H-2). 
13C-NMR (DMSO-d6), : 21.84, 22.07, 24.91, 25.15 (CH2), 126.50 (C, C-aromatic), 
128.71, 129.70 (CH, C-aromatic), 133.47, 137.70, 138.45 (C, C-aromatic), 151.31 (CH, 
C-2), 155.98, 161.27, 164.56 (C, C-aromatic). 
 
2-Pyridine sulfonyl acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-
yl)-hydrazide (269) 
(C15H15N5O2S2; M.W.= 361.4) 
 
 
    266   269 
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General procedure 21; 
Purification: re-crystallisation from EtOH. 
White solid; 
Yield: 0.08 g (34%) 
Melting Point: 189-191°C 
MS (ESI+): 362.1 [M+H]+ 
Two species observed. Major/minor species ratio: 3/1. 
1H-NMR (DMSO-d6), : (major species) 1.78-1.84 (m, 4H, CH2), 2.75-2.79 (m, 2H, 
CH2), 2.90-2.94 (m, 2H, CH2), 7.59-7.62 (m, 1H, H-aromatic), 7.90 (d, J= 7.7 Hz, 1H, 
H-aromatic), 7.94-8.00 (m, 1H, H-aromatic), 8.02 (s, 1H, H-2), 8.63-8.67 (m, 1H, H-
aromatic), 8.83 (bs, 1H, NH), 10.10 (bs, 1H, NH). 
1H-NMR (DMSO-d6), : (minor species) 1.50-1.54 (m, 2H, CH2), 1.64-1.68 (m, 2H, 
CH2), 2.26-2.30 (m, 2H, CH2), 2.62-2.66 (m, 2H, CH2), 7.66-7.71 (m, 2H, H-aromatic), 
7.94-8.00 (m, 1H, H-aromatic), 8.08-8.12 (m, 1H, H-aromatic), 8.78 (s, 1H, H-2), 8.83 
(bs, 1H, NH), 9.44 (bs, 1H, NH), 10.10 (bs, 1H, NH), 11.60 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : (major and minor species) 21.86, 22.05, 22.20, 24.49, 24.90, 
25.25, 25.98 (CH2), 115.43 (C, C-aromatic), 122.78, 124.19 (CH, C-aromatic), 126.34 
(C, C-aromatic), 126.98, 127.21 (CH, C-aromatic), 133.38 (C, C-aromatic), 137.69, 
138.24, 143.27, 149.62, 149.75, 151.41 (CH, C-aromatic), 156.30, 156.89, 165.29 (C, 
C-aromatic). 
 Chapter 6: Experimental 
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6.4.1.5 Aryl-carboxylic acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazides (272-273, 278-281, 302-309)  
 
4-tert-Butyl-benzoic acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-
4-yl)-hydrazide (272) 
(C21H24N4OS; M.W.= 380.5) 
  
 
    271   272 
 
General procedure 22a; 
T.L.C. System: nhexane -EtOAc 4:6 v/v, Rf: 0.63. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
40:60 v/v). 
White solid; 
Yield: 0.23 g (86%) 
Melting Point: 137-139°C 
MS (ESI+): 381.2 [M+H]+ 
1H-NMR (CDCl3), : 1.31 (s, 9H, H-9’),   1.87-1.94 (m, 4H, CH2), 2.81-2.85 (m, 2H, 
CH2), 3.07-3.10 (m, 2H, CH2), 7.36 (d, J= 8.4 Hz, 2H, H-aromatic), 7.85 (d, J= 8.4 Hz, 
2H, H-aromatic), 8.35 (bs, 1H, NH), 8.40 (s, 1H, H-2), 10.69 (bs, 1H, NH). 
13C-NMR (CDCl3), : 22.37, 22.40, 25.50, 26.19 (CH2), 31.07 (CH3, C-9’),  34.92  (C,  
C-8’),   116.14   (C,   C-aromatic), 125.42 (CH, C-aromatic), 125.67 (C, C-aromatic), 
127.12 (CH, C-aromatic), 128.24, 135.23 (C, C-aromatic), 151.59 (CH, C-aromatic), 
155.61, 156.23, 165.52 (C, C-aromatic), 166.26 (C, C-1’). 
 Chapter 6: Experimental 
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4-Chloro-benzoic acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-
yl)-hydrazide (273) 
(C17H15ClN4OS; M.W.= 358.8) 
  
 
    119   273 
 
General procedure 22a; 
T.L.C. System: nhexane -EtOAc 4:6 v/v, Rf: 0.50. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
30:70 v/v). 
White solid; 
Yield: 0.09 g (37%) 
Melting Point: 210-212 °C 
MS (ESI+): 359.0, 361.0 [M+H]+ 
1H-NMR (CDCl3), : 1.90-2.01 (m, 4H, CH2), 2.85-2.88 (m, 2H, CH2), 3.07-3.11 (m, 
2H, CH2), 7.42 (d, J= 8.5 Hz, 2H, H-aromatic), 7.68 (d, J= 8.5 Hz, 2H, H-aromatic), 
8.28 (bs, 1H, NH), 8.44 (s, 1H, H-2), 10.14 (bs, 1H, NH). 
13C-NMR (CDCl3), : 22.38, 22.43, 25.51, 26.14 (CH2), 125.44 (C, C-aromatic), 
128.57, 128.99 (CH, C-aromatic), 129.64, 135.71, 138.69 (C, C-aromatic), 151.62 (CH, 
C-2), 156.67, 161.43, 164.89 (C, C-aromatic), 166.39 (C, C-1’). 
 
2,5-Dihydroxy-benzoic acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazide (278) 
(C17H16N4O3S; M.W.= 356.4) 
  
 
   193  274   278 
 Chapter 6: Experimental 
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General procedure 22; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.20 g, 0.9 mmol); 
Purification: re-crystallisation from EtOH. 
Light grey solid; 
Yield: 0.08 g (28%) 
Melting Point: 261-263°C 
MS (ESI+): 357.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.81-1.91 (m, 4H, CH2), 2.80-2.86 (m, 2H, CH2), 2.99-3.08 
(m, 2H, CH2), 6.82 (d, J= 8.7 Hz, 1H, H-aromatic), 6.91 (dd, J1= 8.7 Hz, J2= 1.6 Hz, 1H, 
H-aromatic), 7.37 (d, J= 1.6 Hz, 1H, H-aromatic), 8.36 (s, 1H, H-2), 8.77 (bs, 1H, NH), 
9.09 (bs, 1H, NH), 10.77 (bs 1H, OH), 11.17 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : 21.94, 22.11, 24.95, 25.62 (CH2), 114.00 (CH, C-aromatic), 
115.19, 115.40 (C, C-aromatic), 117.82, 121.48 (CH, C-aromatic), 126.42, 132.99, 
149.61, 151.18 (C, C-aromatic), 152.33 (CH, C-aromatic), 156.42, 165.28 (C, C-
aromatic), 166.48 (C, C-1’). 
 
2-Hydroxy-benzoic acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-
yl)-hydrazide (279)37 
(C17H16N4O2S; M.W.= 340.4) 
  
 
   193  275   279 
 
General procedure 22; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.20 g, 0.9 mmol); 
Purification: re-crystallisation from EtOH/H2O. 
Light orange solid; 
Yield: 0.10 g (35%) 
Melting Point: 327-329°C 
 Chapter 6: Experimental 
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MS (ESI+): 341.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.84-1.88 (m, 4H, CH2), 2.79-2.88 (m, 2H, CH2), 2.98-3.08 
(m, 2H, CH2), 6.94-7.01 (m, 2H, H-aromatic), 7.74 (t, J= 7.7 Hz, 1H, H-aromatic), 8.00 
(d, J= 7.7 Hz, 1H, H-aromatic), 8.37 (s, 1H, H-2), 8.79 (bs, 1H, NH), 10.85 (bs, 1H, 
NH), 10.77 (bs 1H, OH), 11.99 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : 21.94, 22.11, 24.95, 25.66 (CH2), 114.73 (C, C-aromatic), 
117.35, 119.03 (CH, C-aromatic), 126.40, (C, C-aromatic), 128.34 (CH, C-aromatic), 
133.06 (C, C-aromatic), 134.04 (CH, C-aromatic), 149.47, 151.23 (C, C-aromatic), 
152.33 (CH, C-aromatic), 156.65 (C, C-aromatic), 159.20 (C, C-1’). 
 
Pyrazine-2-carboxylic acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazide (280) 
(C15H14N6OS; M.W.= 326.3) 
  
 
   193  276   280 
 
General procedure 22; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.20 g, 0.9 mmol); 
Purification: re-crystallisation from DCM/ nhexane. 
Pale yellow solid; 
Yield: 0.08 g (29%) 
Melting Point: 200-202°C 
MS (ESI+): 327.1 [M+H]+ 
1H-NMR (CDCl3), : 1.90-2.00 (m, 4H, CH2), 2.84-2.87 (m, 2H, CH2), 3.06-3.10 (m, 
2H, CH2), 8.19 (bs, 1H, NH), 8.51 (s, 1H, H-2), 8.61-8.62 (m, 1H, H-aromatic), 8.81 (d, 
J= 2.4 Hz, 1H, H-aromatic), 9.39 (d, J= 1.3 Hz, 1H, H-aromatic), 10.68 (bs, 1H, NH). 
13C-NMR (CDCl3), : 22.40, 22.46, 25.49, 26.08 (CH2), 115.85, 125.22, 135.57 (C, C-
aromatic), 143.07 (CH, C-aromatic), 143.20 (C, C-aromatic), 144.20, 147.91, 152.23 
(CH, C-aromatic), 154.39, 159.25 (C, C-aromatic), 166.39 (C, C-1’). 
 Chapter 6: Experimental 
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Pyridine-2-carboxylic acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)-hydrazide (281) 
(C16H15N5OS; M.W.= 325.3) 
  
 
   193  277   281 
 
General procedure 22; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.20 g, 0.9 mmol); 
Purification: re-crystallisation from EtOH. 
Light green solid; 
Yield: 0.19 g (67%) 
Melting Point: 232-234°C 
MS (ESI+): 326.1 (M+H)+ 
Microanalysis: Calculated for C16H15N5OS (325.3); Theoretical: %C = 59.06, %H = 
4.65, %N = 21.51; Found: %C = 58.99, %H = 4.61, %N = 21.51. 
1H-NMR (CDCl3), : 1.89-2.00 (m, 4H, CH2), 2.83-2.87 (m, 2H, CH2), 3.07-3.11 (m, 
2H, CH2), 7.47-7.51 (m, 1H, H-aromatic), 7.89 (td, J1= 7.7 Hz, J2= 1.6 Hz, 1H, H-
aromatic), 8.15-8.20 (m, 2H, H-aromatic, NH), 8.52 (s, 1H, H-2), 8.65 (d, J= 4.7 Hz, 
1H, H-aromatic), 10.77 (bs, 1H, NH). 
13C-NMR (CDCl3), : 22.43, 22.49, 25.49, 26.11 (CH2), 115.78 (C, C-aromatic), 
122.35 (CH, C-aromatic), 125.31 (C, C-aromatic), 126.74 (CH, C-aromatic), 135.18 (C, 
C-aromatic), 137.41 (CH, C-aromatic), 148.33 (C, C-aromatic), 148.72, 152.48 (CH, C-
aromatic), 154.56, 160.53 (C, C-aromatic), 166.23 (C, C-1’). 
 Chapter 6: Experimental 
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3-Hydroxy-N'-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)benzo 
hydrazide (302) 
(C17H16N4O2S; M.W.= 340.4) 
  
 
   193  295   302 
 
General procedure 22; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.20 g, 0.9 mmol); 
Purification: re-crystallisation from EtOH. 
White solid; 
Yield: 0.09 g (29%) 
Melting Point: 241-243°C 
MS (ESI+): 341.0 [M+H]+ 
1H-NMR (DMSO-d6), : 1.83-1.87 (m, 4H, CH2), 2.81-2.84 (m, 2H, CH2), 3.01-3.04 
(m, 2H, CH2), 6.96-6.99 (m, 1H, H-aromatic), 7.29-7.33 (m, 1H, H-aromatic), 7.34-7.35 
(m, 1H, H-aromatic), 7.40 (dt, J1= 7.7 Hz, J2= 1.2 Hz, 1H, H-aromatic), 8.34 (s, 1H, H-
2), 8.58 (bs, 1H, NH), 9.70 (bs, 1H, OH), 10.48 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 21.98, 22.12, 24.97, 25.79 (CH2), 114.52 (CH, C-aromatic), 
115.18 (C, C-aromatic), 117.98, 118.63 (CH, C-aromatic), 126.43 (C, C-aromatic), 
129.43 (CH, C-aromatic), 132.71, 134.14 (C, C-aromatic), 152.44 (CH, C-aromatic), 
157.35, 157.50, 165.30 (C, C-aromatic), 165.94 (C, C-1’). 
 Chapter 6: Experimental 
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N'-(5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)nicotinohydrazide 
(291) 
(C16H15N5OS; M.W.= 325.3) 
  
 
   193  296   303 
 
General procedure 22; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.20 g, 0.9 mmol); 
Purification: re-crystallisation from EtOH/H2O. 
Pale yellow solid; 
Yield: 0.07 g (23%) 
Melting Point: 137-140 °C 
MS (ESI+): 326.0 [M+H]+ 
1H-NMR (DMSO-d6), : 1.84-1.89 (m, 4H, CH2), 2.81-2.85 (m, 2H, CH2), 3.02-3.06 
(m, 2H, CH2), 7.58 (dd, J1= 8.4 Hz, J2= 4.8 Hz, 1H, H-aromatic), 8.28-8.31 (m, 1H, H-
aromatic), 8.36 (s, 1H, H-2), 8.69- 8.71 (m, 1H, H-aromatic), 8.78-8.80 (m, 1H, H-
aromatic), 9.12 (bs, 1H, NH), 10.80 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 21.97, 22.11, 24.97, 25.76 (CH2), 115.22 (C, C-aromatic), 
123.67 (CH, C-aromatic), 126.40, 128.38, 132.93 (C, C-aromatic), 135.24, 148.49, 
152.43 (CH, C-aromatic), 157.28, 164.56 (C, C-aromatic), 165.40 (C, C-1’). 
 Chapter 6: Experimental 
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N'-(5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-1H-indole-2-carbo 
hydrazide (304) 
(C19H17N5OS; M.W.= 363.4) 
  
 
   193  297   304 
 
General procedure 22; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.20 g, 0.9 mmol); 
Purification: re-crystallisation from EtOH. 
Pale yellow solid; 
Yield: 0.12 g (36%) 
Melting Point: 232-235°C 
MS (ESI+): 364.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.83-1.89 (m, 4H, CH2), 2.81-2.85 (m, 2H, CH2), 3.03-3.08 
(m, 2H, CH2), 7.06-7.09 (m, 1H, H-aromatic), 7.20-7.24 (m, 1H, H-aromatic), 7.34 (s, 
1H, H-3’),  7.47   (d,   J=  8.2  Hz,  1H,  H-aromatic), 7.68 (d, J= 8.0 Hz, 1H, H-aromatic), 
8.35 (s, 1H, H-2), 8.70 (bs, 1H, NH), 10.58 (bs, 1H, NH), 11.69 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 22.00, 22.12, 24.99, 25.80 (CH2), 103.44, 112.34 (CH, C-
aromatic), 115.15 (C, C-aromatic), 119.87, 121.68, 123.61 (CH, C-aromatic), 126.47, 
127.03, 129.76, 132.79, 136.60 (C, C-aromatic), 157.50, 160.99 (C, C-aromatic), 165.37 
(C, C-1’). 
 Chapter 6: Experimental 
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N'-(5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-1H-benzo[d] 
imidazole-2-carbohydrazide (305) 
(C18H16N6OS; M.W.= 364.4) 
  
 
   193  298   305 
 
General procedure 22; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.20 g, 0.9 mmol); 
Purification: re-crystallisation from EtOH. 
Yellow solid; 
Yield: 0.09 g (26%) 
Melting Point: >260°C 
MS (ESI+): 365.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.83-1.86 (m, 4H, CH2), 2.80-2.84 (m, 2H, CH2), 3.00-3.04 
(m, 2H, CH2), 7.31-7.37 (m, 2H, H-aromatic), 7.55-7.61 (m, 1H, H-aromatic), 7.76-7.82 
(m, 1H, H-aromatic), 8.34 (s, 1H, H-2), 8.79 (bs, 1H, NH), 10.89 (bs, 1H, NH), 13.40 
(bs, 1H, NH). 
13C-NMR (DMSO-d6), : 21.97, 22.13, 24.96, 25.76 (CH2), 112.54 (CH, C-aromatic), 
115.23 (C, C-aromatic), 120.06, 122.71, 124.35 (CH, C-aromatic), 126.42, 132.83, 
134.34, 142.59, 144.36 (C, C-aromatic), 152.33 (CH, C-aromatic), 156.92, 158.43 (C, 
C-aromatic), 165.37 (C, C-1’). 
 Chapter 6: Experimental 
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N'-(5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)quinoline-2-
carbohydrazide (306) 
(C20H17N5OS; M.W.= 375.4) 
  
 
  193  282   306 
 
General procedure 22; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.20 g, 0.9 mmol); 
Purification: re-crystallisation from EtOH. 
White solid; 
Yield: 0.23 g (68%) 
Melting Point: 261-263°C 
MS (ESI+): 376.0 [M+H]+ 
1H-NMR (DMSO-d6), : 1.85-1.89 (m, 4H, CH2), 2.82-2.86 (m, 2H, CH2), 3.04-3.08 
(m, 2H, CH2), 7.75-7.78 (m, 1H, H-aromatic), 7.90-7.94 (m, 1H, H-aromatic), 8.12 (d, 
J= 8.1 Hz, 1H, H-aromatic), 8.17 (d, J= 8.4 Hz, 1H, H-aromatic), 8.20 (d, J= 8.4 Hz, 
1H, H-aromatic), 8.34 (s, 1H, H-2), 8.61 (d, J= 8.4 Hz, 1H, H-aromatic), 8.76 (bs, 1H, 
NH), 10.84 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 21.97, 22.13, 24.96, 25.76 (CH2), 115.27 (C, C-aromatic), 
118.80 (CH, C-aromatic), 122.34, 126.52 (C, C-aromatic), 128.14, 128.32 (CH, C-
aromatic), 128.93 (C, C-aromatic), 129.30, 130.65 (CH, C-aromatic), 132.86 (C, C-
aromatic), 137.95 (CH, C-aromatic), 146.08, 149.76 (C, C-aromatic), 152.40 (CH, C-
aromatic), 158.65 (C, C-aromatic), 164.29 (C, C-1’). 
 Chapter 6: Experimental 
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N'-(5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-
carbohydrazide (307) 
(C15H15N5OS; M.W.= 313.3) 
  
 
   193  299   307 
 
General procedure 22; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.20 g, 0.9 mmol); 
Purification: re-crystallisation from MeOH. 
Pale yellow solid; 
Yield: 0.18 g (65%) 
Melting Point: charring > 300°C 
MS (ESI+): 314.0 [M+H]+ 
1H-NMR (DMSO-d6), : 1.83-1.87 (m, 4H, CH2), 2.80-2.84 (m, 2H, CH2), 3.00-3.04 
(m, 2H, CH2), 6.14-6.17 (m, 1H, H-aromatic), 6.93-6.95 (m, 1H, H-aromatic), 6.98-7.00 
(m, 1H, H-aromatic), 8.32 (s, 1H, H-2), 8.52 (bs, 1H, NH), 10.08 (bs, 1H, NH), 11.56 
(bs, 1H, NH). 
13C-NMR (DMSO-d6), : 22.00, 22.11, 24.97, 25.80 (CH2), 108.75, 110.97 (CH, C-
aromatic), 115.07 (C, C-aromatic), 122.04 (CH, C-aromatic), 124.34, 126.47, 132.61 
(C, C-aromatic), 152.43 (CH, C-aromatic), 157.42, 160.43 (C, C-aromatic), 165.25 (C, 
C-1’). 
 Chapter 6: Experimental 
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N'-(5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)furan-2-carbo 
hydrazide (308) 
(C15H14N4O2S; M.W.= 314.3) 
  
 
   193  300   308 
 
General procedure 22; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.20 g, 0.9 mmol); 
Purification: re-crystallisation from MeOH. 
White crystals; 
Yield: 0.10 g (35%) 
Melting Point: 216-219°C 
MS (ESI+): 314.9 [M+H]+ 
1H-NMR (DMSO-d6), : 1.83-1.86 (m, 4H, CH2), 2.80-2.84 (m, 2H, CH2), 2.99-3.03 
(m, 2H, CH2), 6.69 (dd, J1= 3.5 Hz, J2= 1.7 Hz, 1H, H-aromatic), 7.29 (dd, J1= 3.5 Hz, 
J2= 0.4 Hz, 1H, H-aromatic), 7.92-7.93 (m, 1H, H-aromatic), 8.34 (s, 1H, H-2), 8.59 (bs, 
1H, NH), 10.45 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 21.97, 22.11, 24.97, 25.76 (CH2), 111.81, 114.43 (CH, C-
aromatic), 115.13, 126.40, 132.81 (C, C-aromatic), 145.66 (CH, C-aromatic), 146.46 
(C, C-aromatic), 152.39 (CH, C-aromatic), 157.34, 157.53 (C, C-aromatic), 165.35 (C, 
C-1’). 
 Chapter 6: Experimental 
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N'-(5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)thiophene-2-carbo 
hydrazide (309) 
(C15H14N4OS2; M.W.= 330.4) 
  
 
   193  301   309 
 
General procedure 22; 
Reagent: (5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine (193) 
(0.20 g, 0.9 mmol); 
Purification: re-crystallisation from MeOH. 
White solid; 
Yield: 0.04 g (15%) 
Melting Point: 219-221°C 
MS (ESI+): 330.9 [M+H]+ 
1H-NMR (DMSO-d6), : 1.82-1.89 (m, 4H, CH2), 2.80-2.86 (m, 2H, CH2), 2.99-3.05 
(m, 2H, CH2), 7.21-7.25 (m, 1H, H-aromatic), 7.84-7.85 (m, 1H, H-aromatic), 7.94-7.98 
(m, 1H, H-aromatic), 8.35 (s, 1H, H-2), 8.64 (bs, 1H, NH), 10.60 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 21.97, 22.10, 24.97, 25.76 (CH2), 115.12, 126.41 (c, C-
aromatic), 128.12, 128.93, 131.47 (CH, C-aromatic), 132.83, 137.60 (C, C-aromatic), 
152.43 (CH, C-aromatic), 157.34, 160.91 (C, C-aromatic), 165.43 (C, C-1’). 
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6.4.1.6 N-Aryl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (310-
312) 
 
N-(Naphthalen-1-yl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine 
(310) 
(C20H17N3S; M.W.= 331.4) 
  
 
    313   310 
 
General procedure 23; 
T.L.C. System: nhexane -EtOAc 7:3 v/v, Rf: 0.46. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
70:30 v/v). 
Pale yellow solid; 
Yield: 0.06 g (21%) 
Melting Point: 169-172°C 
MS (ESI+): 332.1 [M+H]+ 
1H-NMR (CDCl3), : 1.97-2.02 (m, 2H, CH2), 2.03-2.08 (m, 2H, CH2), 2.91-2.94 (m, 
2H, CH2), 3.20-3.23 (m, 2H, CH2), 7.38 (bs, 1H, NH), 7.52-7.56 (m, 2H, H-aromatic), 
7.57-7.59 (m, 1H, H-aromatic), 7.79 (d, J= 8.1 Hz, 1H, H-aromatic), 7.91-7.95 (m, 2H, 
H-aromatic), 7.99 (d, J= 7.4 Hz, 1H, H-aromatic), 8.43 (s, 1H, H-2). 
13C-NMR (CDCl3), : 22.50, 22.69, 25.60, 26.84 (CH2), 116.78 (C, C-aromatic), 
121.35, 122.20 (CH, C-aromatic), 125.02 (C, C-aromatic), 125.80, 126.11, 126.14, 
126.45 (CH, C-aromatic), 128.70 (C, C-aromatic), 128.88 (CH, C-aromatic), 133.47, 
134.49, 134.65 (C, C-aromatic), 152.94 (CH, C-aromatic), 156.36, 166.54 (C, C-
aromatic). 
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N-(Quinolin-8-yl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine 
(311) 
(C19H16N4S; M.W.= 332.4) 
  
 
    314   311 
 
General procedure 23; 
T.L.C. System: nhexane -EtOAc 7:3 v/v, Rf: 0.59. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
85:15 v/v). 
Pale yellow solid; 
Yield: 0.03 g (14%) 
Melting Point: 193-196 °C 
MS (ESI+): 333.1 [M+H]+ 
1H-NMR (CDCl3), : 1.95-1.99 (m, 2H, CH2), 2.03-2.08 (m, 2H, CH2), 2.86-2.90 (m, 
2H, CH2), 3.32-3.37 (m, 2H, CH2), 7.40-7.44 (m, 2H, H-aromatic), 7.55-7.59 (m, 1H, 
H-aromatic), 8.14 (d, J= 7.8 Hz, 1H, H-aromatic), 8.61 (s, 1H, H-2), 8.78-8.81 (m, 1H, 
H-aromatic), 9.16 (d, J= 7.5 Hz, 1H, H-aromatic), 10.24 (bs, 1H, NH). 
13C-NMR (CDCl3), : 22.53, 22.84, 25.69, 26.54 (CH2), 116.29 (CH, C-aromatic), 
117.97 (C, C-aromatic), 119.93, 121.39 (CH, C-aromatic), 125.88 (C, C-aromatic), 
127.49 (CH, C-aromatic), 128.04, 134.13, 135.74 (C, C-aromatic), 136.29 (CH, C-
aromatic), 138.97 (C, C-aromatic), 147.85, 152.40 (CH, C-aromatic), 154.40, 166.06 
(C, C-aromatic). 
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N-(1H-Benzo[d]imidazol-2-yl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-
4-amine (312) 
(C18H15N5S; M.W.= 321.4) 
 
 
    315   312 
 
General procedure 23; 
T.L.C. System: EtOAc-MeOH 9:1 v/v, Rf: 0.65. 
Purification: flash column chromatography (nhexane:EtOAc 50:50 v/v increasing to 
EtOAc:MeOH 95:5 v/v). 
Pale yellow solid; 
Yield: 0.03 g (12%) 
Melting Point: 122-125°C 
MS (ESI+): 322.1 [M+H]+ 
1H-NMR (CDCl3), : 1.52-1.60 (m, 1H, CH2), 1.61-1.68 (m, 1H, CH2), 1.76-1.84 (m, 
1H, CH2), 1.86-1.93 (m, 1H, CH2), 2.01-2.09 (m, 1H, CH2), 2.28-2.34 (m, 1H, CH2), 
2.89-2.93 (m, 2H, CH2), 5.54 (bs, 2H, NH), 6.79 (d, J= 7.9 Hz, 1H, H-aromatic), 6.99-
7.02 (m, 1H, H-aromatic), 7.16-7.19 (m, 1H, H-aromatic), 7.46 (d, J= 7.9 Hz, 1H, H-
aromatic), 9.01 (s, 1H, H-2). 
13C-NMR (CDCl3), : 21.98, 22.47, 24.33, 26.13 (CH2), 108.85, 116.87, 120.64, 
122.82 (CH, C-aromatic), 126.71, 127.18, 134.98, 141.03, 142.04, 148.05 (C, C-
aromatic), 152.46 (CH, C-aromatic), 153.25, 171.75 (C, C-aromatic). 
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6.4.3 Thieno[2,3-d]pyrimidines 
 
Ethyl 2-aminothienophene-3-carboxylate (318)38 
(C7H9NO2S; M.W.= 171.2) 
 
 
  189  317     318 
 
Triethylamine (1.8 mL, 13.3 mmol) was added dropwise over 10 min. to a mixture of 
ethyl cyanoacetate (189) (3 g, 26.6 mmol) and 1,4-dithiane-2,5-diol (317) (2 g, 13.3 
mmol) in anhydrous DMF (10 mL) at r.t. under N2 atmosphere. After the addition was 
complete the reaction mixture was heated at 45°C for 30 min. The reaction mixture was 
diluted with 0.4 M acetic acid (70 mL) and extracted with EtOAc (4 x 50 mL). The 
combined extracts were washed with water (2 x 100mL), dried over MgSO4, and 
concentrated in vacuo to give a crude brown oil that was purified by flash column 
chromatography (nhexane:EtOAc 100:0 v/v increasing to nhexane-EtOAc 95: 5 v/v) to 
give pure ethyl 2-aminothienophene-3-carboxylate 318 as a colourless oil. 
T.L.C. System: nhexane-EtOAc 4:1 v/v, Rf: 0.55. 
Yield: 2.93 g (64%) 
1H-NMR (CDCl3), : 1.36 (t, J= 7.1 Hz, 3H, H-7), 4.29 (q, J= 7.1 Hz, 2H, H-6), 5.87 
(bs, 2H, NH2), 6.19 (d, J= 5.9 Hz, 1H, H-aromatic), 6.99 (d, J= 5.9 Hz, 1H, H-aromatic),  
13C-NMR (CDCl3), : 14.50 (CH3, C-7), 59.74 (CH2, C-2’),  106.88 (CH, C-aromatic), 
107.20 (C, C-aromatic), 125.92 (CH, C-aromatic), 162.97 (C, C-aromatic), 165.47 (C, 
C-5). 
 
3H-Thieno[2,3-d]pyrimidin-4-one (319)39 
(C6H10N2OS; M.W.= 206.3) 
 
 
    318    319 
 
General procedure 17; 
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Reagent: ethyl 2-aminothienophene-3-carboxylate 318 (2.93 g, 17.1 mmol); 
Purification: re-crystallisation from 40% EtOH/H2O; 
Yellow solid; 
Yield: 1.15 g (44%) 
1H-NMR (DMSO-d6), : 7.39 (d, J= 5.8 Hz, 1H, H-aromatic), 7.57 (d, J= 5.8 Hz, 1H, 
H-aromatic), 8.12 (s, 1H, H-2), 12.47 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 121.58, 123.76 (CH, C-aromatic), 124.58 (C, C-aromatic), 
145.56 (CH, C-2), 157.45 (C, C-aromatic), 164.19 (C, C-1). 
 
4-Chloro-thieno[2,3-d]pyrimidine (320)39 
(C6H3ClN2S; M.W.= 170.6) 
 
 
    319         320 
 
General procedure 18; 
Reagent: 3H-thieno[2,3-d]pyrimidin-4-one (319) (1.15 g, 7.5 mmol); 
T.L.C. System: nhexane-EtOAc 8:2 v/v, Rf: 0.45; 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 90:10 v/v); 
Pale yellow solid; 
Yield: 1.01 g (79%) 
1H-NMR (CDCl3), : 7.45 (d, J= 6.0 Hz, 1H, H-aromatic), 7.64 (d, J= 6.0 Hz, 1H, H-
aromatic), 8.87 (s, 1H, H-2). 
13C-NMR (CDCl3), : 119.90, 128.38 (CH, C-4, 5), 129.55 (C, C-aromatic), 155.09 
(CH, C-2), 168.82 (C, C-aromatic). 
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Thieno[2,3-d]pyrimidin-4-yl-hydrazine (321)41 
(C6H6N4S; M.W.= 166.2) 
 
 
    320   321 
 
General procedure 19; 
Reagent: 4-chloro-thieno[2,3-d]pyrimidine 320 (1.01 g, 5.9 mmol); 
Purification: recrystallization from 40 % EtOH/H2O; 
White crystals; 
Yield: 0.63 g (63%) 
1H-NMR (DMSO-d6), : 4.63 (bs, 2H, NH2), 7.53 (d, J= 5.7 Hz, 2H, H-4, 5), 7.61 (bs, 
1H, NH), 8.37 (s, 1H, H-2), 9.19 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 114.47 (C, C-aromatic), 122.51 (CH, C-4, 5), 153.61 (CH, 
C-2), 158.13, 163.77 (C, C-aromatic). 
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3.4.2.1 N-(1-Aryl-ethylidene)-N'-(thieno[2,3-d]pyrimidin-4-yl)-hydrazines (322-325)  
 
2-[1-(Thieno[2,3-d]pyrimidin-4-yl-hydrazono)-ethyl]-benzene-1,4-diol (322) 
(C14H12N4O2S; M.W.= 300.3) 
 
 
  321  194   322 
 
General procedure 20; 
Reagent: thieno[2,3-d]pyrimidin-4-yl-hydrazine (321) (0.15 g, 0.9 mmol); 
Yellow solid; 
Yield: 0.22 g (81%) 
Melting Point: 267-269°C 
MS (ESI+): 301.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 2.47 (s, 3H, H-2’),  6.75-6.76 (m, 2H, H-aromatic), 6.98-7.00 
(m, 1H, H-aromatic), 7.73 (d, J= 5.8 Hz, 1H, H-aromatic), 7.93 (d, J= 5.8 Hz, 1H, H-
aromatic), 7.93 (bs, 1H, OH), 8.90 (s, 1H, H-2), 10.74 (bs, 1H, NH), 12.10 (bs, 1H, 
OH). 
13C-NMR (DMSO-d6), : 14.33 (CH3, C-2’),  113.47 (CH, C-aromatic), 115.35 (C, C-
aromatic), 117.53, 118.38, 120.82 (CH, C-aromatic), 121.21 (C, C-aromatic), 123.93 
(CH, C-aromatic), 149.20, 150.63, 152.90 (C, C-aromatic), 153.38 (CH, C-aromatic), 
154.48, 167.47 (C, C-aromatic). 
 
2-[1-(Thieno[2,3-d]pyrimidin-4-yl-hydrazono)-ethyl]-phenol (323) 
(C14H12N4OS; M.W.= 284.3) 
 
 
 321  202   323 
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General procedure 20; 
Reagent: thieno[2,3-d]pyrimidin-4-yl-hydrazine (321) (0.15 g, 0.9 mmol); 
Pale yellow crystals; 
Yield: 0.15 g (61%) 
Melting Point: 178-180°C 
MS (ESI+): 285.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 2.54 (s, 3H, H-2’),  6.89-6.94 (m, 2H, H-aromatic), 7.27-7.31 
(m, 1H, H-aromatic), 7.61 (dd, J1= 7.9 Hz, J2= 1.3 Hz, 1H, H-aromatic), 7.72-7.76 (m, 
1H, H-aromatic), 7.91-7.95 (m, 1H, H-aromatic), 8.60 (s, 1H, H-2), 10.79 (bs, 1H, NH), 
12.93 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : 14.21 (CH3, C-2’),  115.41 (C, C-aromatic), 117.08, 118.54, 
120.17 (CH, C-aromatic), 120.58 (C, C-aromatic), 124.03, 128.23, 130.70, 153.35 (CH, 
C-aromatic), 154.24, 154.74, 158.04, 167.38 (C, C-aromatic). 
 
3-[1-(Thieno[2,3-d]pyrimidin-4-yl-hydrazono)-ethyl]-phenol (324) 
(C14H12N4OS; M.W.= 284.3) 
 
 
  321          203    324 
 
General procedure 20; 
Reagent: thieno[2,3-d]pyrimidin-4-yl-hydrazine (321) (0.15 g, 0.9 mmol); 
Yellow solid; 
Yield: 0.09 g (37%) 
Melting Point: 203-205°C 
MS (ESI+): 285.1 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 2.39 (s, 3H, H-2’),  6 84 (d, J= 7.3 Hz, 1H, H-aromatic), 7.22-
7.29 (m, 3H, H-aromatic), 7.68 (d, J= 5.9 Hz, 1H, H-aromatic), 8.08 (d, J= 5.9 Hz, 1H, 
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H-aromatic), 8.52 (s, 1H, H-2), 9.60 (bs, 1H, NH), 10.73 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : 13.96 (CH3, C-2’),  112.57 (CH, C-aromatic), 115.01 (C, C-
aromatic), 116.19, 117.01, 122.85, 123.16, 129.56 (CH, C-aromatic), 139.78, 150.21 (C, 
C-aromatic), 152.72 (CH, C-aromatic), 156.29, 157.48, 169.02 (C, C-aromatic). 
 
3-[1-(Thieno[2,3-d]pyrimidin-4-yl-hydrazono)-ethyl]-phenol (325) 
(C12H10N6S; M.W.= 270.3) 
 
 
           321  250          325 
 
General procedure 20; 
Reagent: thieno[2,3-d]pyrimidin-4-yl-hydrazine (321) (0.15 g, 0.9 mmol); 
White solid; 
Yield: 0.23 g (96%) 
Melting Point: 239-243°C 
MS (ESI+): 271.0 [M+H]+ 
Two species observed.Major/minor species ratio: 5/1. 
1H-NMR (DMSO-d6), : (major species) 2.52 (s, 3H, H-2’),  7.79 (d, J= 5.9 Hz, 1H, H-
aromatic), 8.08 (d, J= 5.9 Hz, 1H, H-aromatic), 8.60 (s, 1H, H-2), 8.64-8.67 (m, 1H, H-
aromatic), 8.69-8.70 (m, 1H, H-aromatic), 9.26 (s, 1H, H-aromatic), 11.21 (bs, 1H, 
NH). 
1H-NMR (DMSO-d6), : (minor species) 2.52 (s, 3H, H-2’),  7.47 (d, J= 5.3 Hz, 1H, H-
aromatic), 7.62 (d, J= 5.3 Hz, 1H, H-aromatic), 7.98-8.00 (m, 1H, H-aromatic), 8.60 (s, 
1H, H-2), 8.64-8.67 (m, 1H, H-aromatic), 9.81 (s, 1H, H-aromatic), 12.06 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : (major and minor species) 11.96, 12.33 (CH3, C-2’),  115.01 
(C, C-aromatic), 121.12, 122.33, 124.25, 141.88, 142.16, 143.30, 143.51, 143.65, 
143.84, 144.61 (CH, C-aromatic), 144.76, 148.35, 150.71 (C, C-aromatic), 152.69 (CH, 
C-aromatic), 156.08 (C, C-aromatic). 
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6.4.2.2 N'-(Thieno[2,3-d]pyrimidin-4-yl)arylcarbohydrazide (326-329) 
 
2,5-Dihydroxy-N'-(thieno[2,3-d]pyrimidin-4-yl)benzohydrazide (326) 
(C13H10N4O3S; M.W.= 302.3) 
  
 
   321  274   326 
 
General procedure 22; 
Reagent: thieno[2,3-d]pyrimidin-4-yl-hydrazine (321) (0.15 g, 0.9 mmol); 
Purification: re-crystallisation from EtOH. 
Light brown solid; 
Yield: 0.05 g (15%) 
Melting Point: >260°C 
MS (ESI+): 303.1 [M+H]+ 
1H-NMR (DMSO-d6), : 6.83 (d, J= 8.8 Hz, 1H, H-4’), 6.93 (dd, J1= 8.8 Hz, J2= 2.8 
Hz, 1H, H-5’), 7.35 (d, J= 2.8 Hz, 1H, H-7’), 7.69-7.72 (m, 2H, H-aromatic), 8.43 (s, 
1H, H-2), 9.11 (bs, 1H, NH), 10.18 (bs, 1H, OH), 10.73 (bs 1H, NH), 11.07 (bs, 1H, 
OH). 
13C-NMR (DMSO-d6), : 113.93 (CH, C-aromatic), 114.78, 115.32 (C, C-aromatic), 
117.90, 119.02, 121.65, 124.11 (CH, C-aromatic), 128.52, 149.45, 149.61, 151.28 (C, 
C-aromatic), 153.41 (CH, C-aromatic), 167.26 (C, C-1’). 
 
2-Hydroxy-N'-(thieno[2,3-d]pyrimidin-4-yl)benzohydrazide (327) 
(C13H10N4O2S; M.W.= 286.3) 
 
 
        321  275   327 
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General procedure 22; 
Reagent: thieno[2,3-d]pyrimidin-4-yl-hydrazine (321) (0.15 g, 0.9 mmol); 
Purification: re-crystallisation from EtOH. 
White solid; 
Yield: 0.05 g (19%) 
Melting Point: 180-183°C 
MS (ESI+): 287.0 [M+H]+ 
1H-NMR (DMSO-d6), : 6.96-7.01 (m, 2H, H-aromatic), 7.46-7.50 (m, 1H, H-
aromatic), 7.68-7.74 (m, 2H, H-aromatic), 7.97 (dd, J1= 7.9 Hz, J2= 1.0 Hz, 1H, H-
aromatic), 8.44 (s, 1H, H-2), 10.18 (bs, 1H, NH), 10.85 (bs 1H, NH), 11.85 (bs, 1H, 
OH). 
13C-NMR (DMSO-d6), : 114.77 (C, C-aromatic), 117.37, 118.97, 119.09 (CH, C-
aromatic), 120.64 (C, C-aromatic), 128.39, 134.15 (CH, C-aromatic), 134.49 (C, C-
aromatic), 153.43 (CH, C-aromatic), 159.12 (C, C-aromatic), 167.99 (C, C-1’). 
 
N'-(Thieno[2,3-d]pyrimidin-4-yl)pyrazine-2-carbohydrazide (328) 
(C11H8N6OS; M.W.= 272.3) 
  
 
       321  276   328 
 
General procedure 22; 
Reagent: thieno[2,3-d]pyrimidin-4-yl-hydrazine (321) (0.15 g, 0.9 mmol); 
Purification: re-crystallisation from EtOH. 
White solid; 
Yield: 0.08 g (31%) 
Melting Point: 193-197°C 
MS (ESI+): 272.9 [M+H]+ 
1H-NMR (DMSO-d6), : 7.68-7.72 (m, 2H, H-aromatic), 8.41 (s, 1H, H-2), 8.83 (dd, 
J1= 2.5 Hz, J2= 1.5 Hz, 1H, H-4’),  8.96  (d,  J=  2.5  Hz,  1H,  H-3’),  9.23  (d,  J=  1.5  Hz,  1H,  
H-5’),  10.14 (bs, 1H, NH), 11.06 (bs 1H, NH). 
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13C-NMR (DMSO-d6), : 114.83 (C, C-aromatic), 119.03, 124.09 (CH, C-aromatic), 
123.14 138.47 (C, C-aromatic), 143.67, 143.77 (CH, C-aromatic), 144.18 (C, C-
aromatic), 148.10, 153.44 (CH, C-aromatic), 162.66 (C, C-1’). 
 
N'-(thieno[2,3-d]pyrimidin-4-yl)picolinohydrazide (329) 
(C12H9N5OS; M.W.= 271.3) 
 
 
   321  277   329 
 
General procedure 22; 
Reagent: thieno[2,3-d]pyrimidin-4-yl-hydrazine (321) (0.15 g, 0.9 mmol); 
Purification: re-crystallisation from EtOH. 
White solid; 
Yield: 0.08 g (30%) 
Melting Point: 191-194°C 
MS (ESI+): 271.9 [M+H]+ 
1H-NMR (DMSO-d6), : 7.67-7.71 (m, 3H, H-aromatic), 8.03-8.09 (m, 2H, H-
aromatic), 8.40 (s, 1H, H-2), 8.74 (d, J= 4.6 Hz, 1H, H-aromatic), 10.09 (bs, 1H, NH), 
10.87 (bs 1H, NH). 
13C-NMR (DMSO-d6), : 114.79 (C, C-aromatic), 119.12 (CH, C-aromatic), 121.12 
(C, C-aromatic), 122.46, 123.90, 127.08, 137.89 (CH, C-aromatic), 138.05 (C, C-
aromatic), 148.74 (CH, C-aromatic), 149.20 (C, C-aromatic), 153.44 (CH, C-aromatic), 
163.50 (C, C-1’). 
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6.4.4 Cyclopentane[b]thienopyrimidines 
 
Ethyl 2-amino-5,6-dihydro-4H-cyclopentane[b]thiophene-3-carboxylate (331) 
(C10H13NO2S; M.W.= 211.2)42 
 
 
         330    331  
 
General procedure 16; 
Reagent: cyclopentanone (330) (1 g, 11.9 mmol); 
T.L.C. System: nhexane-EtOAc 8:2 v/v, Rf: 0.55. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 90:10 v/v); 
White solid; 
Yield: 1.39 g (55%) 
1H-NMR (CDCl3), : 1.34 (t, J= 7.1 Hz, 3H, H-3’),  2.29-2.36 (m, 2H, H-6), 2.71-2.75 
(m, 2H, CH2), 2.82-2.86 (m, 2H, CH2), 4.26 (q, J= 7.1 Hz, 2H, H-2’),   5.88 (bs, 2H, 
NH2). 
13C-NMR (CDCl3), : 14.44 (CH3, C-3’), 27.23, 28.87, 30.78 (CH2, C-5, 6, 7), 59.38 
(CH2, C-2’),  102.89, 121.28, 142.67, 165.78 (C, C-1, 2, 3, 4), 166.39 (C, C-1’). 
 
1,2,3,5-Tetrahydro-8-thia-5,7-diaza-cyclopenta[a]inden-4-one (332)43 
(C9H8N2OS; M.W.= 192.2) 
 
 
    331    332 
 
General procedure 17; 
Reagent: ethyl 2-amino-5,6-dihydro-4H-cyclopentane[b]thiophene-3-carboxylate (331) 
(1.39 g, 6.6 mmol); 
Purification: re-crystallisation from 40% EtOH/H2O; 
Brown solid; 
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Yield: 0.98 g (77%) 
1H-NMR (DMSO-d6), : 2.34-2.41 (m, 2H, H-6), 2.88-2.92 (m, 4H, H-5, 7), 7.99 (s, 
1H, H-2), 12.37 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 27.39, 28.63, 28.90 (CH2, C-5, 6, 7), 120.31, 137.46, 139.56 
(C, C-aromatic), 144.56 (CH, C-2), 157.32 (C, C-aromatic), 167.67 (C, C-1). 
 
4-Chloro-2,3-dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]indene (333)44 
(C9H7ClN2S; M.W.= 210.6) 
 
 
    332            333 
 
General procedure 18; 
Reagent: 1,2,3,5-tetrahydro-8-thia-5,7-diaza-cyclopenta[a]inden-4-one (332) (0.98 g, 
5.1 mmol); 
T.L.C. System: nhexane-EtOAc 1:1 v/v, Rf: 0.66. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 90:10 v/v); 
White solid; 
Yield: 0.73 g (68%) 
1H-NMR (CDCl3), : 2.50-2.58 (m, 2H, H-6), 3.07 (t, J= 7.4 Hz, 2H, CH2), 3.16 (t, J= 
7.4 Hz, 2H, CH2), 8.71 (s, 1H, H-2). 
13C-NMR (CDCl3), : 27.41, 29.42, 30.19 (CH2, C-5, 6, 7), 126.24, 136.32, 144.84 (C, 
C-aromatic), 151.44 (CH, C-2), 152.98, 173.66 (C, C-aromatic). 
 
(2,3-Dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazine (334)45 
(C9H10N4S; M.W.= 206.3) 
 
 
    333            334 
 
 Chapter 6: Experimental 
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General procedure 19; 
Reagent: 4-chloro-2,3-dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]indene (333) (0.73 g, 
3.5 mmol); 
Purification: re-crystallisation from 40% EtOH/H2O; 
White solid; 
Yield: 0.55 g (78%) 
1H-NMR (DMSO-d6), : 2.36-2.43 (m, 2H, H-6), 2.93 (t, J= 7.2 Hz, 2H, CH2), 3.06 (t, 
J= 7.2 Hz, 2H, CH2), 4.65 (bs, 2H, NH2), 8.12 (bs, 1H, NH), 8.32 (s, 1H, H-2). 
13C-NMR (DMSO-d6), : 27.39, 28.97, 29.09 (CH2, C-5, 6, 7), 135.79, 136.94 (C, C-
aromatic), 152.47 (CH, C-2), 157.76 (C, C-aromatic). 
 Chapter 6: Experimental 
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6.4.3.1 N-(2,3-Dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-N'-(1-phenyl-
ethylidene)-hydrazines (335-340) 
 
2-{1-[(2,3-Dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazono]-
ethyl}-benzene-1,4-diol (335) 
(C17H16N4O2S; M.W.= 340.4) 
 
 
   334  194   335 
 
General procedure 20; 
Reagent: (2,3-dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazine (334) 
(0.15 g, 0.7 mmol); 
Yellow solid; 
Yield: 0.18 g (74%) 
Melting Point: 308-310°C 
MS (ESI+): 341.1 [M+H]+ 
Two species observed. Major/minor species ratio: 3/2. 
1H-NMR (DMSO-d6), : (major species) 2.41 (s, 3H, H-2’),  2.44-2.49 (m, 2H, CH2), 
2.98-3.02 (m, 2H, CH2), 3.17-3.21 (m, 2H, CH2), 6.74-6.76 (m, 2H, H-aromatic), 6.98-
7.00 (m, 1H, H-aromatic), 8.52 (s, 1H, H-aromatic), 8.88 (bs, 1H, OH), 9.51 (bs, 1H, 
NH), 12.38 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : 2.41 (s, 3H, H-2’),  2.44-2.49 (m, 2H, CH2), 2.90-2.94 (m, 2H, 
CH2), 3.17-3.21 (m, 2H, CH2), 6.74-6.76 (m, 2H, H-aromatic), 6.98-7.00 (m, 1H, H-
aromatic), 7.73 (s, 1H, H-aromatic), 8.88 (bs, 1H, OH), 11.54 (bs, 1H, NH), 11.79 (bs, 
1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 13.03, 14.45 (CH3, C-2’),  27.32, 
28.67, 29.07, 29.33, 29.59 (CH2, C-5, 6, 7), 112.96 (C, C-aromatic), 113.56, 114.17, 
116.92, 117.61, 118.09, 118.22 (CH, C-aromatic), 119.70, 135.42, 139.20 (C, C-
aromatic), 143.83 (CH, C-aromatic), 144.79, 149.18, 151.02 (C, C-aromatic), 152.53 
(CH, C-aromatic), 153.56, 154.96, 171.33 (C, C-aromatic). 
 Chapter 6: Experimental 
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2-{1-[(2,3-Dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazono]-
ethyl}-phenol (336) 
(C17H16N4OS; M.W.= 324.4) 
 
 
   334  202   336 
 
General procedure 20; 
Reagent: (2,3-dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazine (334) 
(0.15 g, 0.7 mmol); 
Pale yellow solid; 
Yield: 0.17 g (71%) 
Melting Point: 267-269°C 
MS (ESI+): 325.1 [M+H]+ 
Microanalysis: Calculated for C17H16N4OS (324.4); Theoretical: %C = 62.94, %H = 
4.97, %N = 17.26; Found: %C = 62.92, %H = 4.83, %N = 17.36. 
Two species observed. Major/minor species ratio: 2/1. 
1H-NMR (DMSO-d6), : (major species) 2.37 (s, 3H, H-2’),  2.43-2.48 (m, 2H, CH2), 
2.98-3.07 (m, 2H, CH2), 3.18-3.25 (m, 2H, CH2), 6.88-6.92 (m, 2H, H-aromatic), 7.27-
7.32 (m, 1H, H-aromatic), 7.59-7.67 (m, 1H, H-aromatic), 8.54 (s, 1H, H-aromatic), 
9.59 (bs, 1H, NH), 13.16 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 2.37 (s, 3H, H-2’),  2.43-2.48 (m, 2H, CH2), 
2.90-2.94 (m, 2H, CH2), 2.98-3.07 (m, 2H, CH2), 6.88-6.92 (m, 2H, H-aromatic), 7.27-
7.32 (m, 1H, H-aromatic), 7.59-7.67 (m, 1H, H-aromatic), 7.75 (s, 1H, H-aromatic), 
11.49 (bs, 1H, NH), 12.55 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 13.06, 14.48 (CH3, C-2’),  27.36, 
28.69, 29.12, 29.35, 29.57 (CH2, C-5, 6, 7), 112.92 (C, C-aromatic), 116.50, 117.23, 
118.58 (CH, C-aromatic), 119.69, 135.40 (C, C-aromatic), 128.13, 128.72, 130.82 (CH, 
C-aromatic), 135.47, 139.33 (C, C-aromatic), 143.85, 152.57 (CH, C-aromatic), 153.71, 
155.47, 158.31 (C, C-aromatic). 
 Chapter 6: Experimental 
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3-{1-[(2,3-Dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazono]-
ethyl}-phenol (337) 
(C17H16N4OS; M.W.= 324.4) 
 
 
   334         203    337 
 
General procedure 20; 
Reagent: (2,3-dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazine (334) 
(0.15 g, 0.7 mmol); 
Pale pink solid; 
Yield: 0.15 g (64%) 
Melting Point: 320-322°C 
MS (ESI+): 325.1 [M+H]+ 
Two species observed. Major/minor species ratio: 5/2. 
1H-NMR (DMSO-d6), : (major species) 2.41 (s, 3H, H-2’),  2.89-3.02 (m, 6H, CH2), 
6.80-6.83 (m, 1H, H-aromatic), 7.17-7.25 (m, 1H, H-aromatic), 7.38-7.40 (m, 1H, H-
aromatic), 7.47-7.49 (m, 1H, H-aromatic), 7.75 (s, 1H, H-aromatic), 9.39 (bs, 1H, NH), 
11.56 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 2.24-2.30 (m, 2H, CH2), 2.33-2.36 (m, 4H, 
CH2), 2.37 (s, 3H, H-2’),   6.80-6.83 (m, 1H, H-aromatic), 7.17-7.25 (m, 3H, H-
aromatic), 8.45 (s, 1H, H-aromatic), 9.50 (bs, 1H, NH), 9.80 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 13.99, 14.08 (CH3, C-2’),  27.05, 
27.41, 29.07, 29.38, 29.52, 30.98 (CH2, C-5, 6, 7), 112.92 (CH, C-aromatic), 113.03 (C, 
C-aromatic), 113.50, 115.91, 116.17 (CH, C-aromatic), 117.19 (C, C-aromatic), 117.42, 
117.49, 128.86, 129.27 (CH, C-aromatic), 136.89, 137.51, 138.17, 139.40, 139.78, 
140.21 (C, C-aromatic), 143.82 (CH, C-aromatic), 146.70, 151.06 (C, C-aromatic), 
151.65 (CH, C-aromatic), 157.15, 157.26, 157.65, 161.78 (C, C-aromatic). 
 Chapter 6: Experimental 
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4-(2-(1-(Pyrazin-2-yl)ethylidene)hydrazinyl)-6,7-dihydro-5H-cyclopenta[4,5] 
thieno[2,3-d]pyrimidine (338) 
(C15H14N6S; M.W.= 310.3) 
 
 
   334  250   338 
 
General procedure 20; 
Reagent: (2,3-dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazine (334) 
(0.15 g, 0.7 mmol); 
Yellow solid; 
Yield: 0.09 g (42%) 
Melting Point: 182-185°C 
MS (ESI+): 311.1 [M+H]+ 
Two species observed. Major/minor species ratio: 4/1. 
1H-NMR (CDCl3), : (major species) 2.48-2.56 (m, 5H, H-2’,  CH2), 3.05-3.09 (m, 2H, 
CH2), 3.11-3.17 (m, 2H, CH2), 8.53-8.56 (m, 3H, H-aromatic, NH), 8.61 (s, 1H, H-2), 
9.40 (d, J= 1.4 Hz, 1H, H-aromatic). 
1H-NMR (CDCl3), : (minor species) 2.48-2.56 (m, 2H, CH2), 2.61 (s, 3H, CH3), 2.97-
3.01 (m, 2H, CH2), 3.11-3.17 (m, 2H, CH2), 7.75 (s, 1H, H-aromatic), 8.49 (d, J= 2.5 
Hz, 1H, H-aromatic), 8.53-8.56 (m, 1H, H-aromatic), 9.34 (d, J= 1.4 Hz, 1H, H-
aromatic), 10.39 (bs, 1H, NH). 
13C-NMR (CDCl3), : (major and minor species) 10.63, 13.07 (CH3, C-2’),   27.90, 
28.10, 29.70, 29.77, 29.88, 30.95 (CH2, C-5, 6, 7), 113.57, 134.80 (C, C-aromatic), 
140.85 (CH, C-aromatic), 141.18 (C, C-aromatic), 142.95, 143.00, 143.24, 143.34, 
143.45, 143.79 (CH, C-aromatic), 147.34, 150.50 (C, C-aromatic), 152.30 (CH, C-
aromatic), 153.86, 173.68 (C, C-aromatic). 
 Chapter 6: Experimental 
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4-(2-(1-(Pyridin-2-yl)ethylidene)hydrazinyl)-6,7-dihydro-5H-cyclopenta[4,5] 
thieno[2,3-d]pyrimidine (339) 
(C16H15N5S; M.W.= 309.3) 
 
 
   334  251   339 
 
General procedure 20; 
Reagent: (2,3-dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazine (334) 
(0.15 g, 0.7 mmol); 
Orange solid; 
Yield: 0.08 g (36%) 
Melting Point: 153-157°C 
MS (ESI+): 310.1 [M+H]+ 
Two species observed. Major/minor species ratio: 5/2. 
1H-NMR (CDCl3), : (major species) 2.59 (s, 3H, H-2’), 2.60-2.65 (m, 2H, CH2), 3.04-
3.08 (m, 2H, CH2), 3.31-3.35 (m, 2H, CH2), 7.40-7.43 (m, 1H, H-aromatic), 7.62-7.64 
(m, 1H, H-aromatic), 7.91-7.95 (m, 1H, H-aromatic), 8.65 (s, 1H, H-2), 8.68-8.70 (m, 
1H, H-aromatic), 15.07 (bs, 1H, NH). 
1H-NMR (CDCl3), : (minor species) 2.54 (s, 3H, H-2’), 2.49-2.57 (m, 2H, CH2), 3.04-
3.08 (m, 2H, CH2), 3.12-3.16 (m, 2H, CH2), 7.27-7.29 (m, 1H, H-aromatic), 7.71-7.75 
(m, 1H, H-aromatic), 8.20-8.22 (m, 1H, H-aromatic), 8.48 (bs, 1H, NH), 8.61 (s, 1H, H-
2), 8.62-8.63 (m, 1H, H-aromatic). 
13C-NMR (CDCl3), : (major and minor species) 10.91, 22.68 (CH3, C-2’),   27.91, 
27.98, 29.82, 29.87, 30.57 (CH2, C-5, 6, 7), 113.57 (C, C-aromatic), 121.25, 123.63, 
123.73, 123.78 (CH, C-aromatic), 134.91 (C, C-aromatic), 136.24, 137.78 (CH, C-
aromatic), 139.42, 139.87, 140.69 (C, C-aromatic), 146.97, 148.58 (CH, C-aromatic), 
149.70 (C, C-aromatic), 152.66, 153.45 (CH, C-aromatic), 153.63, 153.94, 155.09, 
172.48 (C, C-aromatic). 
 Chapter 6: Experimental 
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4-(2-(1-(1H-Benzo[d]imidazol-2-yl)ethylidene)hydrazinyl)-6,7-dihydro-5H-
cyclopenta[4,5]thieno[2,3-d]pyrimidine (340) 
(C19H14N6S; M.W.= 348.4) 
 
 
 334  298   340 
 
General procedure 20; 
Reagent: (2,3-dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazine (334) 
(0.15 g, 0.7 mmol); 
Light brown solid; 
Yield: 0.14 g (58%) 
Melting Point: charring > 230°C 
MS (ESI+): 349.1 [M+H]+ 
Two species observed. Major/minor species ratio: 5/1. 
1H-NMR (DMSO-d6), : (major species) 2.36-2.42 (m, 2H, CH2), 2.52 (s, 3H, H-2’), 
2.89-2.94 (m, 2H, CH2), 2.99-3.07 (m, 2H, CH2), 7.16-7.24 (m, 2H, H-aromatic), 7.52-
7.60 (m, 1H, H-aromatic), 7.62-7.71 (m, 1H, H-aromatic), 8.04 (s, 1H, H-2), 12.09 (bs, 
1H, NH), 12.54 (bs, 1H, NH). 
1H-NMR (DMSO-d6), : (minor species) 2.29-2.33 (m, 2H, CH2), 2.52 (s, 3H, H-2’), 
2.89-2.94 (m, 2H, CH2), 2.99-3.07 (m, 2H, CH2), 7.35-7.41 (m, 2H, H-aromatic), 7.62-
7.71 (m, 1H, H-aromatic), 7.73-7.76 (m, 1H, H-aromatic), 8.47 (s, 1H, H-2), 13.00 (bs, 
1H, NH), 14.40 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : (major and minor species) 12.65, 18.52 (CH3, C-2’),  27.11, 
27.14, 29.13, 29.39, 29.45, 29.78 (CH2, C-5, 6, 7), 111.06, 111.91, 113.74 (CH, C-
aromatic), 117.24, 118.66 (C, C-aromatic), 119.17, 119.38, 121.45, 123.47, 124.56 (CH, 
C-aromatic), 132.36, 132.92, 134.25, 135.08, 135.47, 136.79, 138.23, 138.95 (C, C-
aromatic), 139.74 (CH, C-aromatic), 141.62, 143.32, 144.35, 146.36, 149.58, 151.82, 
155.20, 172.74 (C, C-aromatic). 
 Chapter 6: Experimental 
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6.4.3.2 N'-(6,7-Dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)arylcarbo 
hydrazides (341-346)  
 
N'-(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-2,5-dihydroxy 
benzohydrazide (341) 
(C16H14N4O3S; M.W.= 342.3) 
 
 
   334  274        341 
 
General procedure 22; 
Reagent: (2,3-dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazine (334) 
(0.2 g, 1.0 mmol); 
Purification: re-crystallisation from EtOH. 
Light grey solid; 
Yield: 0.09 g (26%) 
Melting Point: charring > 248°C 
MS (ESI+): 343.1 [M+H]+ 
1H-NMR (DMSO-d6), : 2.42-2.48 (m, 2H, H-6), 2.99 (t, J=7.1 Hz, 2H, CH2), 3.12 (, 
J=6.9 Hz, 2H, CH2), 6.82 (d, J= 8.8 Hz, 1H, H-4’), 6.92 (dd, J1= 8.8 Hz, J2= 2.8 Hz, 1H, 
H-5’), 7.37 (d, J= 2.8 Hz, 1H, H-7’), 8.35 (s, 1H, H-2), 8.98 (bs, 1H, NH), 9.09 (bs, 1H, 
OH), 10.66 (bs 1H, NH), 11.18 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : 27.45, 29.23 (CH2), 111.91 (C, C-aromatic), 113.85 (CH, C-
aromatic), 115.22 (C, C-aromatic), 117.89, 121.65 (CH, C-aromatic), 135.33, 138.53, 
149.56, 151.47 (C, C-aromatic), 152.26 (CH, C-aromatic), 156.43, 167.37 (C, C-
aromatic), 170.94 (C, C-1’). 
 Chapter 6: Experimental 
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N'-(6,7-Dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-2-hydroxybenzo 
hydrazide (342) 
(C16H14N4O2S; M.W.= 326.3) 
 
 
   334  275   342 
 
General procedure 22; 
Reagent: (2,3-dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazine (334) 
(0.2 g, 1.0 mmol); 
T.L.C. System: 100% EtOAc, Rf: 0.70. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane:EtOAc 0:100 v/v). 
White solid; 
Yield: 0.10 g (30%) 
Melting Point: charring > 230°C 
MS (ESI+): 327.1 [M+H]+ 
1H-NMR (DMSO-d6), : 2.43-2.49 (m, 2H, H-6), 3.00 (t, J=7.1 Hz, 2H, CH2), 3.13 (, 
J=7.1 Hz, 2H, CH2), 6.96-7.00 (m, 2H, H-aromatic), 7.46-7.50 (m, 1H, H-aromatic), 
7.99 (dd, J1= 7.9 Hz, J2= 1.2 Hz, 1H, H-aromatic), 8.36 (s, 1H, H-2), 9.01 (bs, 1H, NH), 
10.79 (bs 1H, NH), 11.98 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 27.44, 29.20, 29.24 (CH2), 111.92, 114.59 (C, C-aromatic), 
117.41, 119.02, 128.21, 134.14 (CH, C-aromatic), 135.31, 138.62 (C, C-aromatic), 
152.28 (CH, C-aromatic), 156.52, 159.39, 168.15 (C, C-aromatic), 171.00 (C, C-1’). 
 Chapter 6: Experimental 
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N'-(6,7-Dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)pyrazine-2-carbo 
hydrazide (343) 
(C14H12N6OS; M.W.= 312.3) 
  
 
   334  276   343 
 
General procedure 22; 
Reagent: (2,3-dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazine (334) 
(0.2 g, 1.0 mmol); 
Purification: re-crystallisation from EtOH. 
Light brown solid; 
Yield: 0.05 g (15%) 
Melting Point: 174-178°C 
MS (ESI+): 313.1 [M+H]+ 
1H-NMR (DMSO-d6), : 2.41-2.47 (m, 2H, H-6), 2.98 (t, J= 7.1 Hz, 2H, CH2), 3.12 (, 
J= 6.7 Hz, 2H, CH2), 8.33 (s, 1H, H-2), 8.82-8.83 (m, 1H, H-4’),  8.95  (d,  J=  2.4  Hz,  1H,  
H-3’),  9.00  (bs, 1H, NH), 9.22 (d, J= 1.2 Hz, 1H, H-5’),  10.93 (bs 1H, NH). 
13C-NMR (DMSO-d6), : 27.46, 29.23, 29.31 (CH2), 111.92, 135.34, 138.46 (C, C-
aromatic), 143.67, 143.69 (CH, C-aromatic), 144.34 (C, C-aromatic), 148.01, 152.26 
(CH, C-aromatic), 156.60, 162.59 (C, C-aromatic), 169.97 (C, C-1’). 
 
N'-(6,7-Dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)picolinohydrazide 
(344) 
(C15H13N5OS; M.W.= 311.3) 
  
 
   334  277   344 
 Chapter 6: Experimental 
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General procedure 22; 
Reagent: (2,3-dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazine (334) 
(0.2 g, 1.0 mmol); 
Purification: re-crystallisation from EtOH. 
Grey solid; 
Yield: 0.09 g (30%) 
Melting Point: 219-222°C 
MS (ESI+): 312.1 [M+H]+ 
1H-NMR (DMSO-d6), : 2.40-2.46 (m, 2H, H-6), 2.98 (t, J= 7.1 Hz, 2H, CH2), 3.12 (, 
J= 6.9 Hz, 2H, CH2), 7.66-7.69 (m, 1H, H-aromatic), 8.02-8.05 (m, 2H, H-aromatic), 
8.31 (s, 1H, H-2), 8.72-8.74 (m, 1H, H-aromatic), 8.96 (bs, 1H, NH), 10.72 (bs 1H, 
NH). 
13C-NMR (DMSO-d6), : 27.46, 29.23, 29.36 (CH2), 111.93, 114.89 (C, C-aromatic), 
122.36, 126.97 (CH, C-aromatic), 135.47 (C, C-aromatic), 137.84 (CH, C-aromatic), 
138.27 (C, C-aromatic), 148.69 (CH, C-aromatic), 149.37 (C, C-aromatic), 152.26 (CH, 
C-aromatic), 156.21 (C, C-aromatic), 169.74 (C, C-1’). 
 
N'-(6,7-Dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-1H-indole-2-carbo 
hydrazide (345) 
(C18H15N5OS; M.W.= 349.4) 
  
 
   334  297   345 
 
General procedure 22; 
Reagent: (2,3-dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazine (334) 
(0.2 g, 1.0 mmol); 
Purification: re-crystallisation from EtOH. 
White solid; 
Yield: 0.13 g (38%) 
 Chapter 6: Experimental 
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Melting Point: 258-260°C 
MS (ESI+): 350.1 [M+H]+ 
1H-NMR (DMSO-d6), : 2.41-2.48 (m, 2H, CH2), 2.97-3.01 (m, 2H, CH2), 3.12-3.16 (, 
m, 2H, CH2), 7.06-7.10 (m, 1H, H-aromatic), 7.20-7.24 (m, 1H, H-aromatic), 7.33 (s, 
1H, H-3’),  7.47   (d,   J=  8.2  Hz,  1H,  H-aromatic), 7.68 (d, J= 7.9 Hz, 1H, H-aromatic), 
8.34 (s, 1H, H-2), 8.96 (bs, 1H, NH), 10.59 (bs 1H, NH), 11.70 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 27.46, 29.23, 29.31 (CH2), 111.92, 135.34, 138.46 (C, C-
aromatic), 143.67, 143.69 (CH, C-aromatic), 144.34 (C, C-aromatic), 148.01, 152.26 
(CH, C-aromatic), 156.60, 162.59 (C, C-aromatic), 169.97 (C, C-1’). 
 
N'-(6,7-Dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-1H-benzo[d] 
imidazole-2-carbohydrazide (346) 
(C17H14N6OS; M.W.= 350.4) 
 
 
   334  298   346 
 
General procedure 22; 
Reagent: (2,3-dihydro-1H-8-thia-5,7-diaza-cyclopenta[a]inden-4-yl)-hydrazine (334) 
(0.2 g, 1.0 mmol); 
Purification: re-crystallisation from EtOH. 
White solid; 
Yield: 0.16 g (47%) 
Melting Point: 230-234°C 
MS (ESI+): 373.1 [M+Na]+ 
1H-NMR (DMSO-d6), : 2.40-2.47 (m, 2H, CH2), 2.96-3.00 (m, 2H, CH2), 3.11-3.14 (, 
m, 2H, CH2), 7.30-7.38 (m, 2H, H-aromatic), 7.56-7.60 (m, 1H, H-aromatic), 7.78-7.82 
(m, 1H, H-aromatic), 8.33 (s, 1H, H-2), 9.04 (bs, 1H, NH), 10.96 (bs 1H, NH), 13.40 
(bs, 1H, NH). 
13C-NMR (DMSO-d6), : 27.47, 29.23, 29.36 (CH2), 111.88 (C, C-aromatic), 112.57, 
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120.09, 122.73, 124.39 (CH, C-aromatic), 135.23, 138.40, 142.25, 144.31 (C, C-
aromatic), 152.23 (CH, C-aromatic), 156.63, 158.72 (C, C-aromatic), 171.01 (C, C-1’). 
 Chapter 6: Experimental 
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6.4.5 Benzo[b]thienopyrimidines 
 
Ethyl 2-aminobenzo[b]thiophene-3-carboxylate (347)46 
(C11H11NO2S; M.W.= 221.2) 
 
 
    190     347 
 
To a mixture of compound 190 (1.8 g, 7.9 mmol) and 10% Pd/C (1.8 g) in toluene (130 
mL) was stirred under reflux for 96 h. The reaction mixture was then cooled to r.t. and 
filtered over celite. The filtrate was concentrated at reduced pressure to afford a yellow 
solid residue, which was purified was by flash column chromatography 
(nhexane:EtOAc 100:0 v/v increasing to nhexane-EtOAc 90:10 v/v) to give pure ethyl 
2-aminobenzo[b]thiophene-3-carboxylate (347) as a white solid. 
T.L.C. System: nhexane-EtOAc 9:1 v/v, Rf: 0.28. 
Yield: 0.72 g (41%) 
1H-NMR (CDCl3), : 1.49 (t, J= 7.1 Hz, 3H, H-3’),  4.44 (q, J= 7.1 Hz, 2H, H-2’),  6.54 
(bs, 2H, NH2), 7.14-7.17 (m, 1H, H-aromatic), 7.32-7.35 (m, 1H, H-aromatic), 7.51-
7.53 (m, 1H, H-aromatic), 8.12-8.14 (m, 1H, H-aromatic). 
13C-NMR (CDCl3), : 14.56 (CH3, C-3’), 59.89 (CH2, C-2’),  99.80 (C, C-aromatic), 
121.29, 122.37, 122.50, 125.46 (CH, C-aromatic), 128.84, 137.41, 164.35 (C, C-
aromatic), 166.31 (C, C-1’). 
 
Benzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (348)46 
(C10H6N2OS; M.W.= 202.2) 
 
 
    347             348 
 
General procedure 17; 
Reagent: ethyl 2-aminobenzo[b]thiophene-3-carboxylate (347) (0.7 g, 3.5 mmol); 
Purification: re-crystallisation from 40% EtOH/H2O. 
 Chapter 6: Experimental 
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Brown solid; 
Yield: 0.57 g (81%) 
1H-NMR (DMSO-d6), : 7.49-7.57 (m, 2H, H-aromatic), 8.07 (d, J= 7.7 Hz, 1H, H-
aromatic), 8.31 (s, 1H, H-2), 12.86 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 117.75 (C, C-aromatic), 122.82, 123.95, 125.73, 126.16 (CH, 
C-aromatic), 133.48, 134.69 (C, C-aromatic), 147.76 (CH, C-2), 157.35 (C, C-
aromatic), 165.87 (C, C-1). 
 
4-Chlorobenzo[4,5]thieno[2,3-d]pyrimidine (349)46 
(C10H5ClN2S; M.W.= 220.6) 
 
 
    348               349 
 
General procedure 18; 
Reagent: benzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (348) (0.7 g, 3.5 mmol); 
T.L.C. System: nhexane-EtOAc 8:2 v/v, Rf: 0.69. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 95:5 v/v). 
White solid; 
Yield: 0.37 g (74%) 
1H-NMR (CDCl3), : 7.61-7.67 (m, 2H, H-aromatic), 7.94- 7.97 (m, 1H, H-aromatic), 
8.76-8.78 (m, 1H, H-aromatic), 8.93 (s, 1H, H-2). 
13C-NMR (CDCl3), : 123.00 (CH, C-aromatic), 125.10 (C, C-aromatic), 125.96, 
126.00, 128.92 (CH, C-aromatic), 130.05, 137.06 (C, C-aromatic), 154.01 (CH, C-
aromatic), 154.50, 171.01 (C, C-aromatic). 
 Chapter 6: Experimental 
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4-Hydrazinylbenzo[4,5]thieno[2,3-d]pyrimidine (350)47 
(C10H8N4S; M.W.= 216.2) 
 
 
    349          350 
 
General procedure 19; 
Reagent: 4-chlorobenzo[4,5]thieno[2,3-d]pyrimidine (349) (0.37 g, 1.7 mmol); 
Purification: re-crystallisation from 40% EtOH/H2O. 
Pale yellow solid; 
Yield: 0.27 g (74%) 
1H-NMR (DMSO-d6), : 4.86 (bs, 2H, NH2), 7.49-7.56 (m, 2H, H-aromatic), 8.06-8.08 
(m, 1H, H-aromatic), 8.45-8.47 (m, 1H, H-aromatic), 8.56 (s, 1H, H-2), 8.83 (bs, 1H, 
NH). 
13C-NMR (DMSO-d6), : 109.24 (C, C-aromatic), 122.95, 123.97, 125.41, 125.96 (CH, 
C-aromatic), 131.66, 134.13 (C, C-aromatic), 154.85 (CH, C-2), 157.99, 166.45 (C, C-
aromatic). 
 Chapter 6: Experimental 
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6.4.4.1 4-(2-(1-Arylethylidene)hydrazinyl)benzo[4,5]thieno[2,3-d]pyrimidines (351-
354)  
 
2-(1-(2-(Benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)hydrazono)ethyl)benzene-1,4-diol 
(351) 
(C18H14N4O2S; M.W.= 350.4) 
 
 
 350  194   351 
 
General procedure 20; 
Reagent: 4-hydrazinylbenzo[4,5]thieno[2,3-d]pyrimidine (350) (0.15 g, 0.7 mmol); 
Yellow solid; 
Yield: 0.18 g (73%) 
Melting Point: 246-249°C 
MS (ESI+): 351.1 [M+H]+ 
Two species observed. Major/minor species ratio: 6/1. 
1H-NMR (DMSO-d6), : (major species) 2.62 (s, 3H, H-2’),   6.77-6.79 (m, 2H, H-
aromatic), 7.04-7.07 (m, 1H, H-aromatic), 7.50-7.52 (m, 1H, H-aromatic), 7.57-7.63 (m, 
1H, H-aromatic), 8.03-8.08 (m, 2H, H-aromatic), 8.74 (d, J= 7.9 Hz, 1H, H-aromatic), 
8.91 (bs, 1H, OH), 11.66 (bs, 1H, NH), 12.06 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 2.62 (s, 3H, H-2’),   6.77-6.79 (m, 2H, H-
aromatic), 7.04-7.07 (m, 1H, H-aromatic), 7.57-7.63 (m, 1H, H-aromatic), 7.66-7.71 (m, 
1H, H-aromatic), 8.15-8.19 (m, 1H, H-aromatic), 8.33-8.37 (m, 1H, H-aromatic), 8.74 
(d, J= 7.9 Hz, 1H, H-aromatic), 8.91 (bs, 1H, OH), 10.42 (bs, 1H, NH), 12.70 (bs, 1H, 
OH). 
13C-NMR (DMSO-d6), : (major and minor species) 15.27 (CH3, C-2’),  114.14 (C, C-
aromatic), 114.39, 117.05, 118.30 (CH, C-aromatic), 121.16 (C, C-aromatic), 122.71, 
125.21, 125.60, 125.70 (CH, C-aromatic), 133.21, 135.19, 145.01 (C, C-aromatic), 
147.01 (CH, C-aromatic), 149.36, 150.84, 160.85, 163.32 (C, C-aromatic). 
 Chapter 6: Experimental 
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2-(1-(2-(Benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)hydrazono)ethyl)phenol (352) 
(C18H14N4OS; M.W.= 334.4) 
 
 
  350  202   352 
 
General procedure 20; 
Reagent: 4-hydrazinylbenzo[4,5]thieno[2,3-d]pyrimidine (350) (0.15 g, 0.7 mmol); 
Yellow solid; 
Yield: 0.19 g (81%) 
Melting Point: 195-199°C 
MS (ESI+): 335.1 [M+H]+ 
Two species observed. Major/minor species ratio: 6/1. 
Microanalysis: Calculated for C18H14N4OS (334.4); Theoretical: %C = 64.65, %H = 
4.22, %N = 16.75; Found: %C = 64.74, %H = 4.10, %N = 16.89. 
1H-NMR (DMSO-d6), : (major species) 2.66 (s, 3H, H-2’),   6.92-6.97 (m, 2H, H-
aromatic), 7.30-7.34 (m, 1H, H-aromatic), 7.50-7.52 (m, 1H, H-aromatic), 7.58-7.60 (m, 
1H, H-aromatic), 7.65-7.70 (m, 1H, H-aromatic), 8.04-8.09 (m, 2H, H-aromatic), 8.73-
8.79 (m, 1H, H-aromatic), 12.04 (bs, 1H, NH), 12.39 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 2.66 (s, 3H, H-2’),   6.92-6.97 (m, 2H, H-
aromatic), 7.30-7.34 (m, 1H, H-aromatic), 7.58-7.60 (m, 1H, H-aromatic), 7.65-7.70 (m, 
2H, H-aromatic), 8.15-8.19 (m, 1H, H-aromatic), 8.34-8.38 (m, 1H, H-aromatic), 8.73-
8.79 (m, 1H, H-aromatic), 10.46 (bs, 1H, NH), 13.46 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 15.17 (CH3, C-2’),  114.16 (C, C-
aromatic), 116.60, 118.75 (CH, C-aromatic), 121.10 (C, C-aromatic), 122.71, 125.23, 
125.61, 125.71, 128.91, 130.88 (CH, C-aromatic), 133.21, 135.20, 145.11 (C, C-
aromatic), 146.94 (CH, C-aromatic), 158.16, 160.93, 163.47 (C, C-aromatic). 
 Chapter 6: Experimental 
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4-(2-(1-(Pyrazin-2-yl)ethylidene)hydrazinyl)benzo[4,5]thieno[2,3-d]pyrimidine 
(353) 
(C16H12N6OS; M.W.= 320.4) 
 
 
   350  250   353 
 
General procedure 20; 
Reagent: 4-hydrazinylbenzo[4,5]thieno[2,3-d]pyrimidine (350) (0.15 g, 0.7 mmol); 
Yellow solid; 
Yield: 0.16 g (73%) 
Melting Point: 218-221°C 
MS (ESI+): 321.1 [M+H]+ 
1H-NMR (DMSO-d6), : 2.62 (s, 3H, H-2’),  7.50-7.54 (m, 1H, H-aromatic), 7.58-7.62 
(m, 1H, H-aromatic), 8.08 (d, J= 7.9 Hz, 1H, H-aromatic), 8.15 (d, J= 3.7 Hz, 1H, H-
aromatic), 8.61 (s, 1H, H-2), 8.65-8.66 (m, 1H, H-aromatic), 8.78 (d, J= 7.9 Hz, 1H, H-
aromatic), 9.87 (d, J= 1.4 Hz, 1H, H-aromatic), 12.44 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 12.82 (CH3, C-2’),  114.42 (C, C-aromatic), 122.71, 125.51, 
125.65, 125.82 (CH, C-aromatic), 133.16, 135.26 (C, C-aromatic), 143.24, 143.43, 
143.69, 146.65 (CH, C-aromatic), 148.23, 151.12, 157.56, 161.84 (C, C-aromatic). 
 
4-(2-(1-(1H-Benzo[d]imidazol-2-yl)ethylidene)hydrazinyl)benzo[4,5]thieno[2,3-d] 
pyrimidine (354) 
(C19H14N6S; M.W.= 358.4) 
 
 
  350   298   354 
 
 Chapter 6: Experimental 
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General procedure 20; 
Reagent: 4-hydrazinylbenzo[4,5]thieno[2,3-d]pyrimidine (350) (0.15 g, 0.7 mmol); 
Yellow solid; 
Yield: 0.16 g (62%) 
Melting Point: charring > 250°C 
MS (ESI+): 359.1 [M+H]+ 
Two species observed. Major/minor species ratio: 5/1. 
1H-NMR (DMSO-d6), : (major species) 2.67 (s, 3H, H-2’),   7.22-7.32 (m, 2H, H-
aromatic), 7.52-7.55 (m, 1H, H-aromatic), 7.61-7.72 (m, 3H, H-aromatic), 8.10 (d, J= 
7.9 Hz, 1H, H-aromatic), 8.36 (s, 1H, H-2), 8.80 (d, J= 7.9 Hz, 1H, H-aromatic), 12.60 
(bs, 1H, NH), 12.68 (bs, 1H, NH). 
1H-NMR (DMSO-d6), : (minor species) 2.63 (s, 3H, H-2’), 7.45-7.48 (m, 2H, H-
aromatic), 7.61-7.72 (m, 2H, H-aromatic), 7.91-8.00 (m, 2H, H-aromatic), 8.22 (d, J= 
7.9 Hz, 1H, H-aromatic), 8.75 (s, 1H, H-2), 9.31 (d, J= 7.9 Hz, 1H, H-aromatic), 13.21 
(bs, 1H, NH), 13.49 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : (major and minor species) 13.30 (CH3, C-2’),  114.38 (C, C-
aromatic), 121.57, 123.25, 124.85, 125.70, 125.79, 125.87, 126.91 (CH, C-aromatic), 
130.40, 133.11, 134.80, 135.26 (C, C-aromatic), 146.36 (CH, C-aromatic), 148.60, 
150.42, 151.66 (C, C-aromatic), 155.23 (CH, C-aromatic), 161.81 (C, C-aromatic). 
 Chapter 6: Experimental 
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6.4.4.2 N'-(Benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)arylcarbohydrazides (355-358) 
 
N'-(Benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-2,5-dihydroxybenzohydrazide (355) 
(C17H12N4O3S; M.W.= 352.4) 
 
 
   350  274   355 
 
General procedure 22; 
Reagent: 4-hydrazinylbenzo[4,5]thieno[2,3-d]pyrimidine (350) (0.2 g, 0.9 mmol); 
T.L.C. System: 100% EtOAc, Rf: 0.65. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane:EtOAc 30:700 v/v). 
Light grey solid; 
Yield: 0.05 g (17%) 
Melting Point: 241-244°C 
MS (ESI+): 353.0 [M+H]+ 
1H-NMR (DMSO-d6), : 6.84 (d, J= 8.8 Hz, 1H, H-4’),  6.93  (dd,  J1= 8.8 Hz, J2= 2.8 
Hz, 1H, H-5’),  7.41  (d,  J=  2.8  Hz,  1H,  H-7’),  7.58-7.66 (m, 2H, H-aromatic), 8.16 (d, J= 
7.6 Hz, 1H, H-aromatic), 8.56-8.61 (m, 2H, H-aromatic), 9.11 (bs, 1H, NH), 9.64 (bs, 
1H, OH), 10.92 (bs, 2H, NH, OH). 
13C-NMR (DMSO-d6), : 110.08, 114.69 (C, C-aromatic), 117.42, 119.06, 123.30, 
124.52, 125.67, 126.64, 128.34 (CH, C-aromatic), 130.55 (C, C-aromatic), 134.16 (CH, 
C-aromatic), 134.56 (C, C-aromatic), 154.90 (CH, C-aromatic), 157.41, 159.36 (C, C-
aromatic), 167.98 (C, C-1’). 
 Chapter 6: Experimental 
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N'-(Benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-2-hydroxybenzohydrazide (356) 
(C17H12N4O2S; M.W.= 336.4) 
  
 
   350  275   356 
 
General procedure 22; 
Reagent: 4-hydrazinylbenzo[4,5]thieno[2,3-d]pyrimidine (350) (0.2 g, 0.9 mmol); 
Purification: recrystallization from EtOH. 
Pale yellow solid; 
Yield: 0.04 g (14%) 
Melting Point: >260°C 
MS (ESI+): 337.0 [M+H]+ 
1H-NMR (DMSO-d6), : 6.98-7.03 (m, 2H, H-aromatic), 7.48-7.52 (m, 1H, H-
aromatic), 7.59-7.67 (m, 2H, H-aromatic), 8.04 (d, J= 7.5 Hz, 1H, H-aromatic), 8.18 (d, 
J= 7.3 Hz, 1H, H-aromatic), 8.59-8.63 (m, 2H, H-aromatic), 9.65 (bs, 1H, NH), 11.00 
(bs, 1H, OH), 12.00 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 110.07, 114.69 (C, C-aromatic), 117.88, 121.58, 123.25, 
124.51, 125.63, 126.65 (CH, C-aromatic), 130.55 (C, C-aromatic), 134.16 (CH, C-
aromatic), 134.56 (C, C-aromatic), 154.90 (CH, C-aromatic), 157.41, 159.36 (C, C-
aromatic), 167.07 (C, C-1’). 
 Chapter 6: Experimental 
 
 
428 
 
N'-(Benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)pyrazine-2-carbohydrazide (357) 
(C15H10N6OS; M.W.= 322.3) 
  
 
   350  276   357 
 
General procedure 22; 
Reagent: 4-hydrazinylbenzo[4,5]thieno[2,3-d]pyrimidine (350) (0.2 g, 0.9 mmol); 
Purification: recrystallization from EtOH/H2O. 
Pale yellow solid; 
Yield: 0.06 g (21%) 
Melting Point: 115-118°C 
MS (ESI+): 323.0 [M+H]+ 
1H-NMR (DMSO-d6), : 7.57-7.65 (m, 2H, H-aromatic), 8.15 (d, J= 7.6 Hz, 1H, H-
aromatic), 8.56 (s, 1H, H-2), 8.63 (d, J= 7.3 Hz, 1H, H-aromatic), 8.84-8.85 (m, 1H, H-
aromatic), 8.96 (d, J= 2.3 Hz, 1H, H-aromatic), 9.26 (d, J= 1.3 Hz, 1H, H-aromatic), 
9.64 (bs, 1H, NH), 11.14 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 110.12 (C, C-aromatic), 123.23, 124.58, 125.61, 125.95 (CH, 
C-aromatic), 126.62, 130.70, 134.48 (C, C-aromatic), 143.67, 143.72 (CH, C-aromatic), 
144.04, 144.38 (C, C-aromatic), 148.02 (CH, C-aromatic), 167.83 (C, C-1’). 
 
N'-(Benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)picolinohydrazide (358) 
(C16H11N5OS; M.W.= 321.4) 
  
 
   350  277   358 
 
General procedure 22; 
 Chapter 6: Experimental 
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Reagent: 4-hydrazinylbenzo[4,5]thieno[2,3-d]pyrimidine (350) (0.2 g, 0.9 mmol); 
Purification: recrystallization from EtOH. 
White solid; 
Yield: 0.08 g (28%) 
Melting Point: 220-223°C 
MS (ESI+): 322.0 [M+H]+ 
1H-NMR (DMSO-d6), : 7.57-7.65 (m, 2H, H-aromatic), 7.68-7.71 (m, 1H, H-
aromatic), 8.04-8.08 (m, 1H, H-aromatic), 8.09-8.12 (m, 1H, H-aromatic), 8.15 (d, J= 
7.6 Hz, 1H, H-aromatic), 8.56 (s, 1H, H-2), 8.63 (d, J= 6.6 Hz, 1H, H-aromatic), 8.76 
(d, J= 4.3 Hz, 1H, H-aromatic), 9.57 (bs, 1H, NH), 10.92 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 110.05 (C, C-aromatic), 122.39, 123.21, 125.58, 126.60, 
126.67, 126.99 (CH, C-aromatic), 130.70, 134.44 (C, C-aromatic), 137.87, 148.70 (CH, 
C-aromatic), 149.38 (C, C-aromatic), 154.88 (CH, C-aromatic), 157.52, 163.27 (C, C-
aromatic), 167.77 (C, C-1’). 
 Chapter 6: Experimental 
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6.4.6 Dimethyl[b]thienopyrimidines 
 
Ethyl 2-amino-4,5-dimethylthiophene-3-carboxylate (363)48 
(C9H13NO2S; M.W.= 180.2) 
 
 
   361          363 
 
General procedure 16; 
Reagent: 2-butanone (361) (1 g, 13.9 mmol); 
T.L.C. System: nhexane -EtOAc 8:2 v/v, Rf: 0.50. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane -EtOAc 85:15 v/v); 
Pale yellow solid; 
Yield: 1.30 g (47%) 
1H-NMR (CDCl3), : 1.37 (t, J= 7.1 Hz, 3H, H-3’),  2.17 (s, 3H, CH3), 2.19 (s, 3H, 
CH3), 4.30 (q, J= 7.1 Hz, 2H, H-2’),  5.92 (bs, 2H, NH2). 
13C-NMR (CDCl3), : 12.29, 14.37, 14.75 (CH3, C-3’, 5, 6), 59.43 (CH2, C-2’), 106.98, 
113.84, 130.35, 160.94 (C, C-1, 2, 3, 4), 166.08 (C, C-1’). 
 
5,6-Dimethylthieno[2,3-d]pyrimidin-4(3H)-one (365)44 
(C8H8N2OS; M.W.= 180.2) 
 
 
    363    365 
 
General procedure 17; 
Reagent: ethyl 2-amino-4,5-dimethylthiophene-3-carboxylate (363) (1.03 g, 5.2 mmol); 
Purification: recrystallization from EtOH/H2O; 
Pale yellow solid; 
Yield: 0.45 g (49%) 
1H-NMR (DMSO-d6), : 2.35 (s, 3H, CH3), 2.38 (s, 3H, CH3), 7.98 (s, 1H, H-2), 12.28 
 Chapter 6: Experimental 
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(bs, 1H, NH). 
13C-NMR (DMSO-d6), : 12.51, 12.81 (CH3, C-5, 6), 123.45, 128.68, 129.23 (C, C-
aromatic), 144.65 (CH, C-2), 157.90 (C, C-aromatic), 161.62 (C, C-1). 
 
4-Chloro-5,6-dimethylthieno[2,3-d]pyrimidine (367)44 
(C8H7ClN2S; M.W.= 198.7) 
 
 
    365           367 
 
General procedure 18; 
Reagent: 5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-one (365) (1.03 g, 5.2 mmol); 
T.L.C. System: nhexane -EtOAc 1:1 v/v, Rf: 0.67. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane -EtOAc 90:10 v/v); 
White solid; 
Yield: 0.34 g (91%) 
1H-NMR (CDCl3), : 2.54 (s, 3H, CH3), 2.57 (s, 3H, CH3), 8.73 (s, 1H, H-2). 
13C-NMR (CDCl3), : 14.08, 14.18 (CH3, C-5, 6), 125.15, 129.43, 136.15 (C, C-
aromatic), 151.48 (CH, C-2), 153.44, 168.30 (C, C-aromatic). 
 
4-Hydrazinyl-5,6-dimethylthieno[2,3-d]pyrimidine (369)49 
(C8H10N4S; M.W.= 194.3) 
 
 
    367           369 
 
General procedure 19; 
Reagent: 4-chloro-5,6-dimethylthieno[2,3-d]pyrimidine (367) (0.34 g, 1.7 mmol); 
Purification: recrystallization from EtOH/H2O; 
Yellow solid; 
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Yield: 0.24 g (73%) 
1H-NMR (DMSO-d6), : 2.38 (s, 3H, CH3), 2.42 (s, 3H, CH3), 4.59 (bs, 2H, NH2), 8.03 
(bs, 1H, NH), 8.33 (s, 1H, H-2). 
13C-NMR (DMSO-d6), : 13.00, 13.83 (CH3, C-5, 6), 115.92, 124.65, 128.34 (C, C-
aromatic), 152.32 (CH, C-2), 158.30, 166.38 (C, C-aromatic). 
 Chapter 6: Experimental 
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6.4.5.1 4-(2-(1-Arylethylidene)hydrazinyl)-5,6-dimethylthieno[2,3-d]pyrimidines 
(371-372) 
 
2-(1-(2-(5,6-Dimethylthieno[2,3-d]pyrimidin-4-yl)hydrazono)ethyl)benzene-1,4-diol 
(371) 
(C16H16N4O2S; M.W.= 328.4) 
 
 
 369  194        371 
 
General procedure 20; 
Reagent: 4-hydrazinyl-5,6-dimethylthieno[2,3-d]pyrimidine (369) (0.15 g, 0.8 mmol); 
Yellow solid; 
Yield: 0.18 g (71%) 
Melting Point: >260°C 
MS (ESI+): 329.1 [M+H]+ 
Two species observed. Major/minor species ratio: 3/1. 
1H-NMR (DMSO-d6), : (major species) 2.36 (s, 3H, CH3), 2.47 (s, 3H, CH3), 2.49 (s, 
3H, CH3), 6.73-6.77 (m, 2H, H-aromatic), 6.97-7.02 (m, 1H, H-aromatic), 7.74 (s, 1H, 
H-2), 8.87 (bs, 1H, OH), 11.36 (bs, 1H, NH), 11.71 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 2.47 (s, 3H, CH3), 2.49 (s, 3H, CH3), 2.61 (s, 
3H, CH3), 6.73-6.77 (m, 2H, H-aromatic), 6.97-7.02 (m, 1H, H-aromatic), 8.52 (s, 1H, 
H-2), 8.87 (bs, 1H, OH), 9.51 (bs, 1H, NH), 12.60 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 12.86, 14.14, 15.02 (CH3, C-5, 6), 
112.55 (C, C-aromatic), 114.23, 116.95, 118.10 (CH, C-aromatic), 121.13, 128.80, 
129.52 (C, C-aromatic), 143.87 (CH, C-aromatic), 144.63, 149.26, 150.87, 155.13, 
163.04 (C, C-aromatic). 
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2-(1-(2-(5,6-Dimethylthieno[2,3-d]pyrimidin-4-yl)hydrazono)ethyl)phenol (372) 
(C16H16N4OS; M.W.= 312.4) 
 
 
   369  202   372 
 
General procedure 20; 
Reagent: 4-hydrazinyl-5,6-dimethylthieno[2,3-d]pyrimidine (369) (0.15 g, 0.8 mmol); 
Pale yellow solid; 
Yield: 0.13 g (54%) 
Melting Point: 222-226°C 
MS (ESI+): 313.1 [M+H]+ 
Two species observed. Major/minor species ratio: 3/1. 
1H-NMR (DMSO-d6), : (major species) 2.36 (s, 3H, CH3), 2.49 (s, 3H, CH3), 2.53 (s, 
3H, CH3), 6.89-6.93 (m, 2H, H-aromatic), 7.27-7.30 (m, 1H, H-aromatic), 7.61 (d, J= 
7.5 Hz, 1H, H-aromatic), 7.75 (s, 1H, H-2), 11.38 (bs, 1H, NH), 12.49 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 2.47 (s, 3H, CH3), 2.53 (s, 3H, CH3), 2.61 (s, 
3H, CH3), 6.89-6.93 (m, 2H, H-aromatic), 7.27-7.30 (m, 1H, H-aromatic), 7.64-7.67 (m, 
1H, H-aromatic), 8.54 (s, 1H, H-2), 9.54 (bs, 1H, NH), 13.37 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 12.87, 13.05, 13.23, 13.55, 14.16, 
14.95 (CH3, C-5, 6, 2’),   116.52, 117.28, 118.50, 118.67 (CH, C-aromatic), 119.48, 
120.10, 121.04, 124.27 (C, C-aromatic), 128.02, 128.74 (CH, C-aromatic), 128.81, 
129.57 (C, C-aromatic), 130.69, 143.85 (CH, C-aromatic), 145.45 (C, C-aromatic), 
152.51 (CH, C-aromatic), 153.97, 155.36, 155.89, 158.18, 158.48, 163.34, 165.11 (C, 
C-aromatic). 
 Chapter 6: Experimental 
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6.4.5.2 N'-(5,6-Dimethylthieno[2,3-d]pyrimidin-4-yl)pyrazine-2-carbohydrazide 
(374) 
(C13H12N6OS; M.W.= 300.3) 
 
 
   369  276   374 
 
General procedure 22; 
Reagent: 4-hydrazinyl-5,6-dimethylthieno[2,3-d]pyrimidine (369) (0.11 g, 0.6 mmol); 
Purification: re-crystallisation from EtOH; 
White solid; 
Yield: 0.06 g (35%) 
Melting Point: 194-197°C 
MS (ESI+): 301.1 [M+H]+ 
1H-NMR (DMSO-d6), : 2.44 (s, 3H, CH3), 2.53 (s, 3H, CH3), 8.31 (s, 1H, H-2), 8.81-
8.81-8.82 (m, 1H, H-aromatic), 8.94 (d, J= 2.3 Hz, 1H, H-aromatic), 8.96(bs, 1H, NH), 
9.22 (d, J= 1.2 Hz, 1H, H-aromatic), 10.90 (bs 1H, NH). 
13C-NMR (DMSO-d6), : 13.14, 14.08 (CH3, C-5, 6), 116.53, 124.60, 127.15, 129.76 
(C, C-aromatic), 143.62 (CH, C-aromatic), 144.42, 146.77 (C, C-aromatic), 147.60, 
147.91, 151.86 (CH, C-aromatic), 161.95 (C, C-1’). 
 Chapter 6: Experimental 
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6.4.7 6-Ethyl-5-methylthieno[2,3-d]pyrimidines 
 
Ethyl 2-amino-5-ethyl-4-methylthiophene-3-carboxylate (364)50 
(C10H15NO2S; M.W.= 213.3) 
 
 
   362     364 
 
General procedure 16; 
Reagent: 2-pentanone (362) (1 g, 11.6 mmol); 
T.L.C. System: nhexane-EtOAc 8:2 v/v, Rf: 0.52; 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane -EtOAc 95:5 v/v); 
Yellow oil; 
Yield: 0.83 g (33%) 
1H-NMR (CDCl3), : 1.17 (t, J= 7.5 Hz, 3H, H-6), 1.37 (t, J= 7.1 Hz, 3H, H-3’),  2.20 
(s, 3H, H-7), 2.60 (q, J= 7.5 Hz, 2H, H-5), 4.30 (q, J= 7.1 Hz, 2H, H-2’),  5.92 (bs, 2H, 
NH2). 
13C-NMR (CDCl3), : 14.44, 14.64, 15.76 (CH3, C-3’, 6, 7), 20.50 (CH2, C-5), 59.43 
(CH2, C-2’), 107.03, 121.79, 129.43, 161.05 (C, C-1, 2, 3, 4), 166.16 (C, C-1’). 
 
6-Ethyl-5-methylthieno[2,3-d]pyrimidin-4(3H)-one (366)51 
(C9H10N2OS; M.W.= 194.3) 
 
 
   364     366 
 
General procedure 17; 
Reagent: ethyl 2-amino-5-ethyl-4-methylthiophene-3-carboxylate (364) (0.83 g, 3.8 
mmol); 
Purification: recrystallisation from 40% EtOH/H2O; 
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Brown solid; 
Yield: 0.61 g (83%) 
1H-NMR (DMSO-d6), : 1.20 (t, J= 7.5 Hz, 3H, H-5), 2.40 (s, 3H, H-7), 2.77 (q, J= 7.5 
Hz, 2H, H-5), 7.99 (s, 1H, H-2), 12.28 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 12.77, 15.36 (CH3, C-6, 7), 20.33 (CH2, C-5), 123.49, 
127.84, 136.67 (C, C-aromatic), 144.67 (CH, C-2), 158.03 (C, C-aromatic), 161.68 (C, 
C-1). 
 
4-Chloro-6-ethyl-5-methylthieno[2,3-d]pyrimidine (368)51 
(C9H9ClN2S; M.W.= 212.7) 
 
 
    366             368 
 
General procedure 18; 
Reagent: 6-ethyl-5-methylthieno[2,3-d]pyrimidin-4(3H)-one (366) (0.61 g, 3.1 mmol); 
T.L.C. System: nhexane-EtOAc 1:1 v/v, Rf: 0.67. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 90:10 v/v); 
White solid; 
Yield: 0.37 g (50%) 
1H-NMR (CDCl3), : 1.36 (t, J= 7.5 Hz, 3H, H-6), 2.59 (s, 3H, H-7), 2.94 (q, J= 7.5 
Hz, 2H, H-5), 8.73 (s, 1H, H-2). 
13C-NMR (CDCl3), : 14.16, 15.20 (CH3, C-6, 7), 21.96 (CH2, C-5), 124.16, 129.55, 
143.66 (C, C-aromatic), 151.43 (CH, C-2), 153.58, 168.31 (C, C-aromatic). 
 
6-Ethyl-4-hydrazinyl-5-methylthieno[2,3-d]pyrimidine (370) 
(C9H12N4S; M.W.= 208.8) 
 
 
    368            370 
 Chapter 6: Experimental 
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General procedure 19; 
Reagent: 4-chloro-6-ethyl-5-methylthieno[2,3-d]pyrimidine (368) (0.34 g, 1.7 mmol); 
Purification: recrystallization from 40% EtOH/H2O; 
Yellow solid; 
Yield: 0.11 g (46%) 
1H-NMR (DMSO-d6), : 1.19 (t, J= 7.5 Hz, 3H, H-6), 2.43 (s, 3H, H-7), 2.79 (q, J= 7.5 
Hz, 2H, H-5), 4.59 (bs, 2H, NH2), 8.07 (bs, 1H, NH), 8.33 (s, 1H, H-2). 
13C-NMR (DMSO-d6), : 13.77, 15.49 (CH3, C-6, 7), 20.65 (CH2, C-5), 115.96, 
123.80, 135.72 (C, C-aromatic), 152.31 (CH, C-2), 158.48, 163.22 (C, C-aromatic). 
 Chapter 6: Experimental 
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6.4.6.1 2-(1-(2-(6-Ethyl-5-methylthieno[2,3-d]pyrimidin-4-yl)hydrazono)ethyl) 
benzene-1,4-diol (373) 
(C17H18N4O2S; M.W.= 342.4) 
 
 
   370  194       373 
 
General procedure 20; 
Reagent: 6-ethyl-4-hydrazinyl-5-methylthieno[2,3-d]pyrimidine (370) (0.09 g, 0.4 
mmol); 
Yellow solid; 
Yield: 0.07 g (53%) 
Melting Point: 235-237°C 
MS (ESI+): 343.1 [M+H]+ 
Two species observed. Major/minor species ratio: 3/1. 
Microanalysis: Calculated for C17H18N4O2S (342.4); Theoretical: %C = 59.63, %H = 
5.30, %N = 16.35; Found: %C = 59.69, %H = 5.31, %N = 16.51. 
1H-NMR (DMSO-d6), : (major species) 1.22 (t, J= 7.4 Hz, 3H, H-6), 2.46 (s, 3H, 
CH3), 2.52 (s, 3H, CH3), 2.78 (q, J= 7.4 Hz, 2H, H-5), 6.73-6.76 (m, 2H, H-aromatic), 
6.97-6.99 (m, 1H, H-aromatic), 7.74 (s, 1H, H-2), 8.87 (bs, 1H, OH), 11.36 (bs, 1H, 
NH), 11.70 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 1.26 (t, J= 7.4 Hz, 3H, H-6), 2.45 (s, 3H, 
CH3), 2.63 (s, 3H, CH3), 2.89 (q, J= 7.4 Hz, 2H, H-5), 6.73-6.76 (m, 2H, H-aromatic), 
7.00-7.02 (m, 1H, H-aromatic), 8.53 (s, 1H, H-2), 8.87 (bs, 1H, OH), 9.53 (bs, 1H, NH), 
12.60 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 14.08, 15.04, 15.39 (CH3, C-6, 7), 
20.62 (CH2, C-5), 114.24, 116.95, 118.09 (CH, C-aromatic), 120.75, 121.12, 127.96, 
137.06 (C, C-aromatic), 143.89 (CH, C-aromatic), 144.75, 149.28, 150.86, 155.24, 
163.07 (C, C-aromatic). 
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6.4.8 6-Chloro-5-methyl-thieno[2,3-d]pyrimidines 
 
Ethyl 2-amino-4-methylthiophene-3-carboxylate (376)55 
(C8H11NO2S; M.W.= 199.3) 
 
 
               375   376 
 
General procedure 16; 
Reagent: acetone (375) (1 g, 17.2 mmol); 
Morpholine used instead of NEt3; 
T.L.C. System: nhexane-EtOAc 8:2 v/v, Rf: 0.46. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 85:15 v/v); 
Pale yellow solid; 
Yield: 1.3 g (41%) 
1H-NMR (CDCl3), : 1.37 (t, J= 7.1 Hz, 3H, H-3’),  2.29 (d, J= 1.2 Hz, 3H, H-5), 4.30 
(q, J= 7.1 Hz, 2H, H-2’),  5.83 (q, J= 1.2 Hz, 1H, H-3), 6.08 (bs, 2H, NH2). 
13C-NMR (CDCl3), : 14.08, 18.44 (CH3, C-3’,  6), 59.54 (CH2, C-2’), 102.81 (CH, C-
3), 106.59, 136.66, 166.13 (C, C-aromatic), 166.63 (C, C-1’). 
 
5-Methylthieno[2,3-d]pyrimidin-4(3H)-one (377)55 
(C7H6N2OS; M.W.= 166.2) 
 
 
         376     377 
 
General procedure 17; 
Reagent: ethyl 2-amino-4-methylthiophene-3-carboxylate (376) (1.3 g, 7 mmol); 
Purification: recrystallization from EtOH/H2O; 
Yellow solid; 
Yield: 0.73 g (62%) 
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1H-NMR (DMSO-d6), : 2.47 (s, 3H, H-6), 7.13 (s, 1H, H-4), 8.04 (s, 1H, H-2), 12.34 
(bs, 1H, NH). 
13C-NMR (DMSO-d6), : 16.10 (CH3, C-6), 118.02 (CH, C-4), 122.83, 133.66 (C, C-
aromatic), 145.52 (CH, C-2), 158.27 (C, C-aromatic), 164.71 (C, C-1). 
 
6-Chloro-5-methylthieno[2,3-d]pyrimidin-4(3H)-one (378)56 
(C7H5ClN2OS; M.W.= 200.6) 
 
 
             377             378 
 
5-Methylthieno[2,3-d]pyrimidin-4(3H)-one (377) (0.76 g, 4.4 mmol) and N-
chlorosuccinimmide (0.7 g, 5.2 mmol) were dissolved in glacial AcOH (23 mL) and 
heated at 95°C for 1.5 h. The reaction mixture was then concentrated in vacuo. The 
residue was stirred with H2O (25 mL), filtered, washed with H2O and MeOH and finally 
dried to give 6-chloro-5-methylthieno[2,3-d]pyrimidin-4(3H)-one (378) as a brown 
solid. 
T.L.C. System: nhexane-EtOAc 2:3 v/v, Rf: 0.65. 
Yield: 0.56 g (63%) 
1H-NMR (DMSO-d6), : 2.42 (s, 3H, H-6), 8.10 (s, 1H, H-2), 12.56 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 12.92 (CH3, C-6), 120.51, 122.55, 130.85 (C, C-aromatic), 
146.38 (CH, C-2), 157.09 (C, C-aromatic), 161.55 (C, C-1). 
 
4,6-Dichloro-5-methylthieno[2,3-d]pyrimidine (379)56 
(C7H4Cl2N2S; M.W.= 219.1) 
 
 
    378          379 
 
General procedure 18; 
Reagent: 6-chloro-5-methylthieno[2,3-d]pyrimidin-4(3H)-one (378) (0.56 g, 2.7 mmol); 
T.L.C. System: nhexane-EtOAc 8:2 v/v, Rf: 0.56. 
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Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 92.5:7.5 v/v); 
White solid; 
Yield: 0.29 g (49%) 
1H-NMR (CDCl3), : 2.66 (s, 3H, H-6), 8.79 (s, 1H, H-2). 
13C-NMR (CDCl3), : 14.43 (CH3, C-6), 127.14, 128.29, 129.58 (C, C-aromatic), 
152.48 (CH, C-2), 153.83, 167.30 (C, C-aromatic). 
 
6-Chloro-4-hydrazinyl-5-methylthieno[2,3-d]pyrimidine (380)56 
(C7H7ClN4S; M.W.= 214.7) 
 
 
    379             380 
 
General procedure 19; 
Reagent: 4,6-dichloro-5-methylthieno[2,3-d]pyrimidine (379) (0.29 g, 1.3 mmol); 
Purification: recrystallization from 40 % EtOH/H2O; 
White crystals; 
Yield: 0.25 g (87%) 
1H-NMR (DMSO-d6), : 2.49 (s, 3H, H-6), 4.66 (bs, 2H, NH2), 8.27 (bs, 1H, NH), 8.39 
(s, 1H, H-2). 
13C-NMR (DMSO-d6), : 13.94 (CH3, C-6), 129.96, 130.41, 131.75 (C, C-aromatic), 
153.59 (CH, C-2), 159.46, 166.78 (C, C-aromatic). 
 Chapter 6: Experimental 
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6.4.8.1 6-Chloro-5-methyl-4-(2-(1-arylethylidene)hydrazinyl)thieno[2,3-d] 
pyrimidines (381-382)  
 
2-(1-(2-(6-Chloro-5-methylthieno[2,3-d]pyrimidin-4-yl)hydrazono)ethyl)phenol 
(381) 
(C15H13ClN4OS; M.W.= 332.8) 
 
 
   380  202   381 
 
General procedure 20; 
Reagent: 6-chloro-4-hydrazinyl-5-methylthieno[2,3-d]pyrimidine (380) (0.05 g, 0.2 
mmol); 
Light green solid; 
Yield: 0.06 g (77%) 
Melting Point: 220-223°C 
MS (ESI+): 332.9 [M+H]+ 
Two species observed. Major/minor species ratio: 5/1. 
1H-NMR (DMSO-d6), : (major species) 2.51 (s, 3H, CH3), 2.54 (s, 3H, CH3), 6.89-
6.94 (m, 2H, H-aromatic), 7.29-7.31 (m, 1H, H-aromatic), 7.60-7.67 (m, 1H, H-
aromatic), 7.82 (s, 1H, H-2), 11.61 (bs, 1H, NH), 12.29 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 2.54 (s, 3H, CH3), 2.69 (s, 3H, CH3), 6.89-
6.94 (m, 2H, H-aromatic), 7.29-7.31 (m, 1H, H-aromatic), 7.60-7.67 (m, 1H, H-
aromatic), 8.63 (s, 1H, H-2), 9.68 (bs, 1H, NH), 13.26 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 14.35, 15.12 (CH3, C-2’,   6), 
116.56, 118.71 (CH, C-aromatic), 119.24, 120.72, 121.02 (C, C-aromatic), 128.89, 
130.91 (CH, C-aromatic), 144.52 (C, C-aromatic), 145.54 (CH, C-aromatic), 155.93, 
158.14, 164.06 (C, C-aromatic). 
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6-Chloro-5-methyl-4-(2-(1-(pyrazin-2-yl)ethylidene)hydrazinyl)thieno[2,3-
d]pyrimidine (382) 
(C13H11ClN6S; M.W.= 318.8) 
 
 
   380            250    382 
 
General procedure 20; 
Reagent: 6-chloro-4-hydrazinyl-5-methylthieno[2,3-d]pyrimidine (380) (0.05 g, 0.2 
mmol); 
Yellow solid; 
Yield: 0.07 g (64%) 
Melting Point: 234-238°C 
MS (ESI+): 318.9 [M+H]+ 
1H-NMR (DMSO-d6), : 2.48 (s, 3H, CH3), 2.58 (s, 3H, CH3), 7.95 (s, 1H, H-
aromatic), 8.61 (d, J= 2.4 Hz, 1H, H-aromatic), 8.64-8.65 (m, 1H, H-aromatic), 9.79 (s, 
1H, H-aromatic), 12.09 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 12.77, 14.27 (CH3, C-6, 2’),  115.78, 120.06 (C, C-aromatic), 
143.27, 143.34, 143.72 (CH, C-aromatic), 144.90, 147.44, 148.74 (C, C-aromatic), 
150.81 (CH, C-aromatic), 155.02, 164.93(C, C-aromatic). 
 Chapter 6: Experimental 
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6.4.8.2 N'-(6-Chloro-5-methylthieno[2,3-d]pyrimidin-4-yl)arylcarbohydrazides 
(383-384) 
 
N'-(6-Ethylthieno[2,3-d]pyrimidin-4-yl)-2-hydroxybenzohydrazide (383) 
(C14H11ClN4O2S; M.W.= 334.8) 
 
 
   380  277   384 
 
General procedure 22; 
Reagent: 6-chloro-4-hydrazinyl-5-methylthieno[2,3-d]pyrimidine (380) (0.07 g, 0.3 
mmol); 
Purification: re-crystallisation from MeOH; 
Light grey solid; 
Yield: 0.02 g (19%) 
Melting Point: 320-324°C 
MS (ESI+): 334.9 [M+H]+ 
Microanalysis: Calculated for C14H11ClN4O2S (334.8); Theoretical: %C = 50.23, %H = 
3.31, %N = 16.73; Found: %C = 50.12, %H = 4.17, %N = 16.36. 
1H-NMR (DMSO-d6), : 2.62 (s, 3H, H-6), 6.96-7.00 (m, 2H, H-aromatic), 7.45-7.50 
(m, 1H, H-aromatic), 8.00 (d, J= 7.7 Hz, 1H, H-aromatic), 8.45 (s, 1H, H-2), 9.17 (bs, 
1H, NH), 10.87 (bs, 1H, NH), 11.93 (bs 1H, OH). 
13C-NMR (DMSO-d6), : 14.17 (CH3, C-6), 114.78, 114.87 (C, C-aromatic), 117.34, 
119.09 (CH, C-aromatic), 123.75, 126.82 (C, C-aromatic), 128.46, 134.09, 153.49 (CH, 
C-aromatic), 159.08 (C, C-aromatic), 168.13 (C, C-1’). 
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N'-(6-Chloro-5-methylthieno[2,3-d]pyrimidin-4-yl)picolinohydrazide (384) 
(C13H10ClN5OS; M.W.= 319.8) 
 
 
   380  277   384 
 
General procedure 17; 
Reagent: 6-chloro-4-hydrazinyl-5-methylthieno[2,3-d]pyrimidine (380) (0.07 g, 0.3 
mmol); 
Purification: re-crystallisation from MeOH; 
Pale yellow solid; 
Yield: 0.07 g (61%) 
Melting Point: 210-212 °C 
MS (ESI+): 319.9 [M+H]+ 
1H-NMR (DMSO-d6), : 2.60 (s, 3H, H-6), 7.66-7.69 (m, 1H, H-aromatic), 8.03-8.09 
(m, 2H, H-aromatic), 8.37 (s, 1H, H-2), 8.72-8.74 (m, 1H, H-aromatic), 9.26 (bs, 1H, 
NH), 10.77 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 14.22 (CH3, C-6), 115.02, 121.46 (C, C-aromatic), 122.34, 
126.98 (CH, C-aromatic), 131.97 (C, C-aromatic), 137.87 (CH, C-aromatic), 144.27 (C, 
C-aromatic), 148.69 (CH, C-aromatic), 149.30 (C, C-aromatic), 162.79 (C, C-1’). 
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6.4.9 6-Methoxy-5-methyl-thieno[2,3-d]pyrimidines 
 
Ethyl 2-amino-5-methoxy-4-methylthiophene-3-carboxylate (386)57 
(C9H13NO3S; M.W.= 215.3) 
 
 
            385          386 
 
General procedure 16; 
Reagent: methoxyacetone (385) (0.5 g, 5.7 mmol); 
Reaction stirred under reflux for 72 h; 
T.L.C. System: nhexane -EtOAc 8:2 v/v, Rf: 0.40. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 95:5 v/v); 
Brown oil; 
Yield: 0.61 g (49%)  
1H-NMR (CDCl3), : 1.35 (t, J= 7.1 Hz, 3H, H-3’),  2.14 (s, 3H, H-6), 3.74 (s, 3H, H-
5), 4.26 (q, J= 7.1 Hz, 2H, H-2’),  5.93 (bs, 2H, NH2). 
13C-NMR (CDCl3), : 12.52, 14.40 (CH3, C-3’, 6), 59.54 (CH2, C-2’), 63.50 (CH3, C-
5), 103.10, 118.11, 142.62, 155.55 (C, C-aromatic), 166.31 (C, C-1’). 
 
6-Methoxy-5-methylthieno[2,3-d]pyrimidin-4(3H)-one (387) 
(C8H8N2O2S; M.W.= 196.2) 
 
 
              386     387 
 
General procedure 17a; 
Reagent: ethyl 2-amino-5-methoxy-4-methylthiophene-3-carboxylate (386) (0.61 g, 2.8 
mmol); 
Brown solid; 
Yield: 0.29 g (52%) 
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1H-NMR (DMSO-d6), : 2.28 (s, 3H, H-8), 3.91 (s, 3H, H-7), 7.97 (s, 1H, H-2), 11.05 
(bs, 1H, NH). 
13C-NMR (DMSO-d6), : 10.72 (CH3, C-8), 62.31 (CH3, C-7), 112.12, 122.35 (C, C-
aromatic), 144.27 (CH, C-2), 154.41, 154.69 (C, C-aromatic), 157.63 (C, C-1). 
 
4-Chloro-6-methoxy-5-methylthieno[2,3-d]pyrimidine (388) 
(C8H7ClN2OS; M.W.= 214.7) 
 
 
    387             388 
 
General procedure 18; 
Reagent: 6-methoxy-5-methylthieno[2,3-d]pyrimidin-4(3H)-one (387) (0.29 g, 1.5 
mmol); 
T.L.C. System: nhexane-EtOAc 8:2 v/v, Rf: 0.59. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 85:15 v/v); 
Light brown solid; 
Yield: 0.25 g (79%) 
1H-NMR (CDCl3), : 2.46 (s, 3H, H-8), 4.06 (s, 3H, H-7), 8.67 (s, 1H, H-2). 
13C-NMR (CDCl3), : 11.56 (CH3, C-8), 61.96 (CH3, C-7), 108.17, 129.31 (C, C-
aromatic), 150.55 (CH, C-2), 152.03, 159.30, 162.29 (C, C-aromatic). 
 
4-Hydrazinyl-6-methoxy-5-methylthieno[2,3-d]pyrimidine (389) 
(C8H10N4OS; M.W.= 210.3) 
 
 
    388              389 
 
General procedure 19; 
Reagent: 4-chloro-6-methoxy-5-methylthieno[2,3-d]pyrimidine (388) (0.25 g, 1.1 
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mmol); 
Purification: recrystallization from 40 % EtOH/H2O; 
Light brown crystals; 
Yield: 0.16 g (66%) 
1H-NMR (DMSO-d6), : 2.33 (s, 3H, H-8), 3.91 (s, 3H, H-7), 4.55 (bs, 2H, NH2), 7.95 
(bs, 1H, NH), 8.31 (s, 1H, H-2). 
13C-NMR (DMSO-d6), : 11.21 (CH3, C-8), 62.24 (CH3, C-7), 100.85, 108.27, 114.63 
(C, C-aromatic), 151.79 (CH, C-2), 153.91, 158.03 (C, C-aromatic). 
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6.4.9.1 6-Methoxy-5-methyl-4-(2-(1-arylethylidene)hydrazinyl)thieno[2,3-d] 
pyrimidines (390-391) 
 
2-(1-(2-(6-Methoxy-5-methylthieno[2,3-d]pyrimidin-4-yl)hydrazono)ethyl)phenol 
(390) 
(C16H16N4O2S; M.W.= 328.4) 
 
 
   389  202   390 
 
General procedure 20; 
Reagent: 4-hydrazinyl-6-methoxy-5-methylthieno[2,3-d]pyrimidine (389) (0.04 g, 0.2 
mmol); 
Yellow crystals; 
Yield: 0.03 g (50%) 
Melting Point: 192-196°C 
MS (ESI+): 329.0 [M+H]+ 
Two species observed. Major/minor species ratio: 3/2. 
1H-NMR (DMSO-d6), : (major species) 2.41 (s, 3H, CH3), 2.53 (s, 3H, CH3), 3.94 (s, 
3H, CH3), 6.89-6.93 (m, 2H, H-aromatic), 7.27-7.31 (m, 1H, H-aromatic), 7.60-7.65 (m, 
1H, H-aromatic), 7.74 (s, 1H, H-2), 11.45 (bs, 1H, NH), 12.52 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 2.41 (s, 3H, CH3), 2.53 (s, 3H, CH3), 3.94 (s, 
3H, CH3), 6.89-6.93 (m, 2H, H-aromatic), 7.27-7.31 (m, 1H, H-aromatic), 7.60-7.65 (m, 
1H, H-aromatic), 8.52 (s, 1H, H-2), 9.50 (bs, 1H, NH), 13.38 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 11.85, 14.82 (CH3, C-2’, 7), 62.25 
(CH3, C-8), 116.58, 118.59 (CH, C-aromatic), 120.84, 121.93, 122.32 (C, C-aromatic), 
128.05, 130.70 (CH, C-aromatic), 144.96 (C, C-aromatic), 144.87 (CH, C-aromatic), 
155.45, 158.28, 163.91 (C, C-aromatic). 
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6-Methoxy-5-methyl-4-(2-(1-(pyrazin-2-yl)ethylidene)hydrazinyl)thieno[2,3-
d]pyrimidine (391) 
(C14H14N6OS; M.W.= 314.4) 
 
 
              389            250        391 
 
General procedure 20; 
Reagent: 4-hydrazinyl-6-methoxy-5-methylthieno[2,3-d]pyrimidine (389) (0.04 g, 0.2 
mmol); 
Yellow solid; 
Yield: 0.02 g (43%) 
Melting Point: 237-240°C 
MS (ESI+): 315.0 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 2.43 (s, 3H, CH3), 2.46 (s, 3H, CH3), 3.93 (s, 3H, H-7), 7.85 
(s, 1H, H-aromatic), 8.57-8.62 (m, 2H, H-aromatic), 9.78 (s, 1H, H-aromatic), 11.93 
(bs, 1H, NH). 
13C-NMR (DMSO-d6), : 11.79, 12.63 (CH3, C-8, 2’),   62.22   (CH3, C-7), 112.52, 
119.19 (C, C-aromatic), 143.22, 143.28, 143.48 (CH, C-aromatic), 148.85, 149.81 (C, 
C-aromatic), 149.96 (CH, C-aromatic), 151.22, 155.58, 156.79 (C, C-aromatic). 
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6.4.9.2 N'-(6-Methoxy-5-methylthieno[2,3-d]pyrimidin-4-yl)arylhydrazides (392-
393) 
 
2-Hydroxy-N'-(6-methoxy-5-methylthieno[2,3-d]pyrimidin-4-yl)benzohydrazide 
(392) 
(C15H14N4O3S; M.W.= 330.4) 
 
 
   389  275     392 
 
General procedure 22; 
Reagent: 4-hydrazinyl-6-methoxy-5-methylthieno[2,3-d]pyrimidine (389) (0.08 g, 0.4 
mmol); 
Purification: re-crystallisation from MeOH/H2O; 
Light grey solid; 
Yield: 0.03 g (26%) 
Melting Point: 199-201°C 
MS (ESI+): 330.9 [M+H]+ 
1H-NMR (DMSO-d6), : 2.44 (s, 3H, H-7), 3.98 (s, 3H, H-6), 6.95-7.00 (m, 2H, H-
aromatic), 7.44-7.49 (m, 1H, H-aromatic), 7.99 (d, J= 7.7 Hz, 1H, H-aromatic), 8.34 (s, 
1H, H-2), 8.86 (bs, 1H, NH), 10.91 (bs, 1H, NH), 11.96 (bs 1H, OH). 
13C-NMR (DMSO-d6), : 11.42 (CH3, C-7), 63.36 (CH3, C-6), 108.13, 114.82, 115.19 
(C, C-aromatic), 117.34, 119.01 (CH, C-aromatic), 126.72 (C, C-aromatic), 128.33, 
133.99, 151.58 (CH, C-aromatic), 154.93, 156.64, 159.19 (C, C-aromatic), 167.49 (C, 
C-1’). 
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N'-(6-Methoxy-5-methylthieno[2,3-d]pyrimidin-4-yl)picolinohydrazide (393) 
(C14H13N5O2S; M.W.= 315.4) 
 
 
              389           277      393 
 
General procedure 22; 
Reagent: 4-hydrazinyl-6-methoxy-5-methylthieno[2,3-d]pyrimidine (389) (0.08 g, 0.4 
mmol); 
Purification: re-crystallisation from MeOH; 
White solid; 
Yield: 0.04 g (38%) 
Melting Point: 169-172°C 
MS (ESI+): 315.9 [M+H]+ 
Microanalysis: Calculated for C14H13N5O2S (315.4); Theoretical: %C = 53.32, %H = 
4.15, %N = 22.20; Found: %C = 53.41, %H = 3.78, %N = 22.23. 
1H-NMR (DMSO-d6), : 2.43 (s, 3H, H-7), 3.97 (s, 3H, H-6), 7.65-7.68 (m, 1H, H-
aromatic), 8.02-8.08 (m, 2H, H-aromatic), 8.30 (s, 1H, H-2), 8.72-8.73 (m, 1H, H-
aromatic), 8.82 (bs, 1H, NH), 10.66 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 11.46 (CH3, C-7), 62.34 (CH3, C-6), 108.25, 115.28, (C, C-
aromatic), 122.26, 126.91 (CH, C-aromatic), 132.06 (C, C-aromatic), 137.83, (CH, C-
aromatic), 144.27 (C, C-aromatic), 148.67 (CH, C-aromatic), 149.38 (C, C-aromatic), 
152.26 (CH, C-aromatic), 154.76 (C, C-aromatic), 163.41 (C, C-1’). 
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6.4.10 Ethyl-5-methyl-thieno[2,3-d]pyrimidine-6-carboxylates 
 
Diethyl 5-amino-3-methylthiophene-2,4-dicarboxylate (395)58 
(C11H15NO4S; M.W.= 257.31) 
 
 
   394     395 
 
General procedure 16; 
Reagent: ethyl acetoacetate (394) (1.5 g, 11.5 mmol); 
T.L.C. System: nhexane-EtOAc 7:3 v/v, Rf: 0.55. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 85:15 v/v); 
Yellow solid; 
Yield: 1.79 g (66%)  
1H-NMR (CDCl3), : 1.34 (t, J= 7.1 Hz, 3H, CH3), 1.39 (t, J= 7.1 Hz, 3H, CH3), 2.71 
(s, 3H, H-8), 4.28 (q, J= 7.1 Hz, 2H, CH2), 4.33 (q, J= 7.1 Hz, 2H, CH2), 6.55 (bs, 2H, 
NH2). 
13C-NMR (CDCl3), : 14.35, 14.41, 16.13 (CH3, C-7,  8,  3’), 60.10, 60.42 (CH2, C-6, 
2’), 108.50, 108.58, 148.05, 162.89 (C, C-aromatic), 166.11, 166.13 (C, C-5, 1’). 
 
Ethyl 5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxylate (396)59 
(C10H10N2O3S; M.W.= 238.3) 
 
 
    395       396 
 
General procedure 17; 
Reagent: diethyl 5-amino-3-methylthiophene-2,4-dicarboxylate (395) (1.86 g, 7.3 
mmol); 
0.5 mL of AcOH added, reaction stirred at 150°C for 5 days; 
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Purification: recrystallization from EtOH/H2O; 
Yellow solid; 
Yield: 1.73 g (71%) 
1H-NMR (DMSO-d6), : 1.31 (t, J= 7.1 Hz, 3H, H-9), 2.28 (s, 3H, H-10), 4.30 (q, J= 
7.1 Hz, 2H, H-8), 8.21 (s, 1H, H-2), 12.65 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 14.10, 14.85 (CH3, C-9, 10), 61.11 (CH2, C-8), 121.41, 
123.76, 143.33 (C, C-aromatic), 148.32 (CH, C-2), 158.28 (C, C-aromatic), 161.80, 
165.73 (C, C-1, 7). 
 
Ethyl 4-chloro-5-methylthieno[2,3-d]pyrimidine-6-carboxylate (397)60 
(C10H9ClN2O2S; M.W.= 256.7) 
 
 
    396    397 
 
To a solution of intermediate ethyl 5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-
6-carboxylate (397) (1.22 g, 5.1 mmol) in toluene (23 mL) were added DIPEA (0.7 mL, 
4.1 mmol) and POCl3 (0.6 mL, 6.1 mmol). The reaction mixture was stirred at 125°C 
o.n., then cooled to r.t., poured into ice-cold saturated NaHCO3-H2O-EtOAc (60 mL-60 
mL-150 mL) and stirred to quence excess POCl3. The organic layer was separated, 
washed with sat. aq. NaHCO3, dried over MgSO4 and concentrated under vacuum. The 
residue was purified by flash column chromatography (nhexane:EtOAc 100:0 v/v 
increasing to nhexane-EtOAc 90:10 v/v) to give pure ethyl 4-chloro-5-
methylthieno[2,3-d]pyrimidine-6-carboxylate (397) as a yellow solid. 
T.L.C. System: nhexane-EtOAc 7:3 v/v, Rf: 0.63. 
Yield: 1.05 g (79%) 
1H-NMR (CDCl3), : 1.44 (t, J= 7.1 Hz, 3H, H-9), 3.07 (s, 3H, H-10), 4.44 (q, J= 7.1 
Hz, 2H, H-8), 8.88 (s, 1H, H-2). 
13C-NMR (CDCl3), : 14.25, 15.87 (CH3, C-9, 10), 62.13 (CH2, C-8), 128.51, 129.01, 
138.94 (C, C-aromatic), 154.23 (CH, C-2), 157.32, 162.13 (C, C-aromatic), 169.24 (C, 
C-7). 
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Ethyl 4-hydrazinyl-5-methylthieno[2,3-d]pyrimidine-6-carboxylate (398) 
(C10H12N4O2S; M.W.= 252.3) 
 
 
    397    398 
 
General procedure 19; 
Reagent: ethyl 4-chloro-5-methylthieno[2,3-d]pyrimidine-6-carboxylate (397) (0.25 g, 
1.1 mmol); 
Purification: recrystallization from 40 % EtOH/H2O; 
Light orange crystals; 
Yield: 0.72 g (69%) 
1H-NMR (DMSO-d6), : 1.31 (t, J= 7.1 Hz, 3H, H-9), 2.86 (s, 3H, H-10), 4.30 (q, J= 
7.1 Hz, 2H, H-8), 4.89 (bs, 2H, NH2), 8.40 (s, 1H, H-2), 8.53 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 14.21, 15.57 (CH3, C-9, 10), 61.05 (CH2, C-8), 116.09, 
120.11, 131.44, 140.00 (C, C-aromatic), 155.26 (CH, C-2), 160.05 (C, C-aromatic), 
162.17 (C, C-7). 
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6.4.10.1 Ethyl-5-methyl-4-(2-(1-phenylethylidene)hydrazinyl)thieno[2,3-d] 
pyrimidine-6-carboxylates (399-400) 
 
Ethyl-4-(2-(1-(2-hydroxyphenyl)ethylidene)hydrazinyl)-5-methylthieno[2,3-
d]pyrimidine-6-carboxylate (399) 
(C18H18N4O3S; M.W.= 370.4) 
 
 
   398  202            399 
 
General procedure 20; 
Reagent: ethyl 4-hydrazinyl-5-methylthieno[2,3-d]pyrimidine-6-carboxylate (398) (0.1 
g, 0.25 mmol); 
Yellow solid; 
Yield: 0.05 g (29%) 
Melting Point: 199-201°C 
MS (ESI+): 371.0 [M+H]+ 
1H-NMR (DMSO-d6), : 1.30 (t, J= 7.1 Hz, 3H, H-9), 2.52 (s, 3H, CH3), 2.92 (s, 3H, 
CH3), 4.29 (s, 2H, CH2), 6.89-6.93 (m, 2H, H-aromatic), 7.28-7.32 (m, 1H, H-aromatic), 
7.63 (d, J= 7.1 Hz, 1H, H-aromatic), 7.88 (s, 1H, H-2), 11.69 (bs, 1H, NH), 12.22 (bs, 
1H, OH). 
13C-NMR (DMSO-d6), : 14.10, 15.27, 16.07 (CH3, C-2’,   9,   10), 60.95 (CH3, C-8), 
116.61, 118.72 (CH, C-aromatic), 120.55, 120.98, 121.33 (C, C-aromatic), 128.96, 
131.03 (CH, C-aromatic), 143.06, 145.07 (C, C-aromatic), 147.36 (CH, C-aromatic), 
158.17, 161.08, 162.23 (C, C-aromatic), 164.59 (C, C-7). 
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Ethyl-5-methyl-4-(2-(1-(pyrazin-2-yl)ethylidene)hydrazinyl)thieno[2,3-d] 
pyrimidine-6-carboxylate (400) 
(C14H14N6OS; M.W.= 314.4) 
 
 
   398  250             400 
 
General procedure 20; 
Reagent: ethyl 4-hydrazinyl-5-methylthieno[2,3-d]pyrimidine-6-carboxylate (398) (0.1 
g, 0.25 mmol); 
Yellow solid; 
Yield: 0.07 g (45%) 
Melting Point: 194-197°C 
MS (ESI+): 357.0 [M+H]+ 
1H-NMR (DMSO-d6), : 1.28 (t, J= 7.1 Hz, 3H, H-9), 2.42 (s, 3H, CH3), 2.88 (s, 3H, 
CH3), 4.23 (q, J= 7.1 Hz, 2H, H-8), 7.95 (s, 1H, H-2), 8.58 (d, J= 2.5 Hz, 1H, H-4’),  
8.60 (dd, J1= 2.5 Hz, J2= 1.5 Hz, 1H, H-5’), 9.75 (d, J= 1.5 Hz, 1H, H-6’), 12.04 (bs, 
1H, NH). 
13C-NMR (DMSO-d6), : 12.84, 14.07, 15.97 (CH3, C-9, 10,   2’),   60.93 (CH2, C-8), 
120.65, 121.53, 143.20 (C, C-aromatic), 143.22, 143.43, 143.85, 147.04 (CH, C-
aromatic), 148.59, 150.81, 158.66, 162.07 (C, C-aromatic), 162.13 (C, C-7). 
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6.4.10.2 Ethyl 5-methyl-4-(2-picolinoylhydrazinyl)thieno[2,3-d]pyrimidine-6-
carboxylate (401) 
(C16H15N5O3S; M.W.= 357.4) 
 
 
   398  277            401 
General procedure 22; 
Reagent: ethyl 4-hydrazinyl-5-methylthieno[2,3-d]pyrimidine-6-carboxylate (398) (0.15 
g, 0.6 mmol); 
Purification: re-crystallisation from MeOH/H2O; 
Yellow solid; 
Yield: 0.1 g (46%) 
Melting Point: 118-122°C 
MS (ESI+): 358.0 [M+H]+ 
1H-NMR (DMSO-d6), : 1.33 (t, J= 7.1 Hz, 3H, H-9), 2.97 (s, 3H, H-10), 4.33 (q, 2H, 
H-8), 7.64-7.67 (m, 1H, H-aromatic), 8.02-8.09 (m, 2H, H-aromatic), 8.31 (s, 1H, H-2), 
8.70-8.73 (m, 1H, H-aromatic), 10.11 (bs, 1H, NH), 11.05 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 14.12, 15.86 (CH3, C-79, 10), 61.12 (CH2, C-8), 116.04, 
121.56 (C, C-aromatic), 122.18, 126.75 (CH, C-aromatic), 135.24 (C, C-aromatic), 
137.85, (CH, C-aromatic), 141.32 (C, C-aromatic), 148.61 (CH, C-aromatic), 149.60 
(C, C-aromatic), 151.97 (CH, C-aromatic), 161.91, 162.06 (C, C-1’). 
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6.4.11 6,7,8,9-Tetrahydro-3H-cyclohepta[4,5]thieno[2,3-d]pyrimidines 
 
Ethyl 2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylate (405)44 
(C12H17NO2S; M.W.= 239.3) 
 
 
    402   405 
General procedure 16; 
Reagent: cycloheptanone (402) (1.5 g, 13.4 mmol); 
Morpholine used instead of NEt3; 
T.L.C. System: nhexane-EtOAc 8:2 v/v, Rf: 0.49. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 95:5 v/v); 
Pale yellow solid; 
Yield: 1.98 g (62%)  
1H-NMR (CDCl3), : 1.37 (t, J= 7.1 Hz, 3H, H-3’),  1.61-1.68 (m, 4H, CH2), 1.80-1.85 
(m, 2H, CH2), 2.58-2.61 (m, 2H, CH2), 2.98-3.01 (m, 2H, CH2), 4.30 (q, J= 7.1 Hz, 2H, 
H-2’),  5.78 (bs, 2H, NH2). 
13C-NMR (CDCl3), : 14.44 (CH3, C-3’), 26.91, 27.84, 28.61, 28.69, 32.10 (CH2, C-5, 
6, 7, 8, 9), 59.53 (CH2, C-2’), 107.62, 121.26, 137.95, 159.85 (C, C-aromatic), 165.97 
(C, C-1’). 
 
6,7,8,9-Tetrahydro-3H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4(5H)-one (408)44 
(C11H12N2OS; M.W.= 220.3) 
 
 
    405    408 
 
General procedure 17; 
Reagent: ethyl 2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylate 
(405) (1.98 g, 8.3 mmol); 
Brown solid; 
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Yield: 1.5 g (82%) 
1H-NMR (DMSO-d6), : 1.54-1.59 (m, 2H, CH2), 1.60-1.65 (m, 2H, CH2), 1.82-1.87 
(m, 2H, CH2), 2.81-2.84 (m, 2H, CH2), 3.24-3.27 (m, 2H, CH2), 7.98 (s, 1H, H-2), 12.27 
(bs, 1H, NH). 
13C-NMR (DMSO-d6), : 26.82, 27.22, 27.27, 28.98, 31.93 (CH2, C-7, 8, 9 10, 11), 
123.20, 136.41, 136.42 (C, C-aromatic), 144.46 (CH, C-2), 158.15 (C, C-aromatic), 
160.82 (C, C-1). 
 
4-Chloro-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidine (411)44 
(C11H11ClN2S; M.W.= 238.7) 
 
 
    408            411 
 
General procedure 18; 
Reagent: 6,7,8,9-tetrahydro-3H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4(5H)-one (408) 
(1.5 g, 6.8 mmol); 
T.L.C. System: nhexane-EtOAc 8:2 v/v, Rf: 0.64. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 95:5 v/v); 
Yellow solid; 
Yield: 1.1 g (67%) 
1H-NMR (CDCl3), : 1.73-1.83 (m, 4H, CH2), 1.94-2.00 (m, 2H, CH2), 2.97-3.01 (m, 
2H, CH2), 3.36-3.39 (m, 2H, CH2), 8.72 (s, 1H, H-2). 
13C-NMR (CDCl3), : 26.43, 26.93, 28.12, 30.13, 31.83 (CH2, C-7, 8, 9 10, 11), 
129.02, 132.44, 143.90 (C, C-aromatic), 151.03 (CH, C-2), 153.11, 167.87 (C, C-
aromatic). 
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4-Hydrazinyl-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidine (414)64 
(C11H14N4S; M.W.= 234.3) 
 
 
    411            414 
 
General procedure 15; 
Reagent: 4-chloro-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidine (411) 
(1.1 g, 4.6 mmol); 
Purification: recrystallization from 40 % EtOH/H2O; 
Yellow solid; 
Yield: 0.84 g (78%) 
1H-NMR (DMSO-d6), : 1.60-1.69 (m, 4H, CH2), 1.80-1.86 (m, 2H, CH2), 2.83-2.87 
(m, 2H, CH2), 3.01-3.05 (m, 2H, CH2), 4.59 (bs, 2H, NH2), 8.20 (bs, 1H, NH), 8.32 (s, 
1H, H-2). 
13C-NMR (DMSO-d6), : 26.61, 26.85, 28.62, 28.73, 30.91 (CH2, C-7, 8, 9 10, 11), 
115.02, 126.72, 135.62 (C, C-aromatic), 151.90 (CH, C-2), 155.98, 163.92 (C, C-
aromatic).
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6.4.11.1 4-(2-(1-Arylethylidene)hydrazinyl)-6,7,8,9-tetrahydro-5H-
cyclohepta[4,5] thieno[2,3-d]pyrimidines (417-418)  
 
2-(1-(2-(6,7,8,9-Tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-yl) 
hydrazono)ethyl)phenol (417) 
(C19H20N4OS; M.W.= 352.5) 
 
   414  202     417 
 
General procedure 20; 
Reagent: 4-hydrazinyl-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidine 
(414) (0.15 g, 0.6 mmol); 
Yellow solid; 
Yield: 0.09 g (39%) 
Melting Point: 170-173°C 
MS (ESI+): 353.0 [M+H]+ 
Two species observed. Major/minor species ratio: 9:1. 
1H-NMR (DMSO-d6), : (major species) 1.59-1.68 (m, 4H, CH2), 1.83-1.89 (m, 2H, 
CH2), 2.49 (s, 3H, H-2’), 2.82-2.85 (m, 2H, CH2), 3.46-3.49 (m, 2H, CH2), 6.89-6.93 
(m, 2H, H-aromatic), 7.26-7.30 (m, 1H, H-aromatic), 7.59-7.62 (m, 1H, H-aromatic), 
7.74 (s, 1H, H-2), 11.37 (bs, 1H, NH), 12.43 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 1.73-1.79 (m, 4H, CH2), 1.83-1.89 (m, 2H, 
CH2), 2.49 (s, 3H, H-2’),  2.93-2.96 (m, 2H, CH2), 3.19-3.23 (m, 2H, CH2), 6.89-6.93 
(m, 2H, H-aromatic), 7.26-7.30 (m, 1H, H-aromatic), 7.64-7.67 (m, 1H, H-aromatic), 
8.54 (s, 1H, H-2), 9.82 (bs, 1H, NH), 13.44 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 15.00 (CH3, C-2’), 26.70, 27.31, 
27.93, 29.03, 31.93 (CH2, C-7, 8, 9 10, 11), 116.53, 118.66 (CH, C-aromatic), 119.72, 
121.09 (C, C-aromatic), 128.73, 130.69 (CH, C-aromatic), 136.58, 136.97 (C, C-
aromatic), 143.60 (CH, C-aromatic), 145.66, 155.21, 158.17, 163.28 (C, C-aromatic). 
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4-(2-(1-(Pyrazin-2-yl)ethylidene)hydrazinyl)-6,7,8,9-tetrahydro-5H-cyclohepta 
[4,5]thieno[2,3-d]pyrimidine (418) 
(C17H18N6S; M.W.= 338.4) 
 
 
   414  250   418 
 
General procedure 20; 
Reagent: 4-hydrazinyl-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidine 
(414) (0.15 g, 0.6 mmol); 
Yellow solid; 
Yield: 0.09 g (43%) 
Melting Point: 201-205°C 
MS (ESI+): 339.0 [M+H]+ 
Microanalysis: Calculated for C17H18N6S (338.4); Theoretical: %C = 60.33, %H = 5.36, 
%N = 24.82; Found: %C = 60.13, %H = 5.29, %N = 24.31. 
Single species observed. 
1H-NMR (DMSO-d6), : 1.59-1.68 (m, 4H, CH2), 1.83-1.89 (m, 4H, CH2), 2.46 (s, 3H, 
H-2’),   2.82-2.86 (m, 2H, CH2), 3.51-3.54 (m, 2H, CH2), 7.86 (d, J= 3.6 Hz, 1H, H-
aromatic), 8.58-8.63 (m, 2H, H-aromatic), 9.80 (d, J= 1.3 Hz, 1H, H-aromatic), 11.94 
(bs, 1H, NH). 
13C-NMR (DMSO-d6), : 12.74 (CH3, C-2’), 26.74, 27.29, 27.86, 29.06, 31.95 (CH2, 
C-7, 8, 9 10, 11), 119.93, 136.69, 137.21 (C, C-aromatic), 143.19, 143.33, 143.41, 
143.51 (CH, C-aromatic), 149.22, 151.18, 156.62, 156.87 (C, C-aromatic). 
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6.4.11.2 N'-(6,7,8,9-Tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-
yl)aryl hydrazides (423-424) 
 
2-Hydroxy-N'-(6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-yl) 
benzohydrazide (423) 
(C18H18N4O2S; M.W.= 354.4) 
 
 
   414  275   423 
 
General procedure 22; 
Reagent: 4-hydrazinyl-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidine 
(414) (0.2 g, 0.9 mmol); 
T.L.C. System: EtOAc 100%, Rf: 0.63. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 50:50 v/v); 
White solid; 
Yield: 0.1 g (38%) 
Melting Point: charring >260°C 
MS (ESI+): 355.0 [M+H]+ 
1H-NMR (DMSO-d6), : 1.67-1.76 (m, 4H, CH2), 1.85-1.92 (m, 2H, CH2), 2.91-2.96 
(m, 2H, CH2), 3.14-3.19 (m, 2H, CH2), 6.95-7.01 (m, 2H, H-aromatic), 7.44-7.49 (m, 
1H, H-aromatic), 7.97-7.01 (m, 1H, H-aromatic), 8.35 (s, 1H, H-2), 8.12 (bs, 1H, NH), 
10.83 (bs, 1H, NH), 11.99 (bs 1H, OH). 
13C-NMR (DMSO-d6), : 26.64, 26.76, 28.73, 28.81, 29.11 (CH2, C-7, 8, 9 10, 11), 
114.83, 116.51 (C, C-aromatic), 117.34, 119.03, 129.25 (CH, C-aromatic), 131.81 (C, 
C-aromatic), 133.99 (CH, C-aromatic), 137.30 (C, C-aromatic), 151.77 (CH, C-
aromatic), 156.66, 159.16, 164.09 (C, C-aromatic), 167.44 (C, C-1’). 
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N'-(6,7,8,9-Tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-yl)picolino 
hydrazide (424) 
(C17H17N5OS; M.W.= 339.4) 
 
 
                414  277       424 
 
General procedure 22; 
Reagent: 4-hydrazinyl-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidine 
(414) (0.2 g, 0.9 mmol); 
Purification: re-crystallisation from EtOH; 
White solid; 
Yield: 0.09 g (30%) 
Melting Point: 147-149°C 
MS (ESI+): 340.4 [M+H]+ 
1H-NMR (DMSO-d6), : 1.69-1.74 (m, 4H, CH2), 1.86-1.91 (m, 2H, CH2), 2.90-2.95 
(m, 2H, CH2), 3.14-3.18 (m, 2H, CH2), 7.66-7.69 (m, 1H, H-aromatic), 8.02-8.09 (m, 
2H, H-aromatic), 8.33 (s, 1H, H-2), 8.71-8.75 (m, 1H, H-aromatic), 9.07 (bs, 1H, NH), 
10.67 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 26.69, 26.78, 28.75, 28.84, 30.92 (CH2, C-7, 8, 9 10, 11), 
116.59 (C, C-aromatic), 122.25, 126.92 (CH, C-aromatic), 131.84, 137.33 (C, C-
aromatic), 137.85, 148.68 (CH, C-aromatic), 149.37 (C, C-aromatic), 151.78 (CH, C-
aromatic), 156.79, 163.17 (C, C-aromatic), 169.21 (C, C-1’). 
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6.4.12 5,6-Dihydro-3H-pyrano[4',3':4,5]thieno [2,3-d]pyrimidines 
 
Ethyl 2-amino-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate (406)65 
(C10H13NO3S; M.W.= 227.3) 
 
 
                403   406 
 
General procedure 16; 
Reagent: tetrahydro-4H-pyran-4-one (403) (1.5 g, 15 mmol); 
Morpholine used instead of NEt3; 
T.L.C. System: nhexane-EtOAc 6:4 v/v, Rf: 0.65. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 85:15 v/v); 
White solid; 
Yield: 3.02 g (89%)  
1H-NMR (CDCl3), : 1.35 (t, J= 7.1 Hz, 3H, H-3’),  2.48 (tt, J1= 5.6 Hz, J2= 2.0 Hz, 2H, 
H-6), 3.92 (t, J= 5.6 Hz, 2H, H-7), 4.29 (q, J= 7.1 Hz, 2H, H-2’),4.57 (t, J= 2.0 Hz, 2H, 
H-5), 6.03 (bs, 2H, NH2). 
13C-NMR (CDCl3), : 14.44 (CH3, C-3’), 27.72, 59.56, 64.60, 65.12 (CH2, C-5, 6, 7, 
2’), 105.47, 114.81, 130.35, 162.21 (C, C-aromatic), 165.84 (C, C-1’). 
 
5,6-Dihydro-3H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4(8H)-one (409)66 
(C9H8N2O2S; M.W.= 208.2) 
 
 
            406     409 
 
General procedure 17; 
Reagent: ethyl 2-amino-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate (406) (3.02 g, 
13.3 mmol); 
Brown solid; 
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Yield: 2.2 g (80%) 
1H-NMR (DMSO-d6), : 2.94 (t, J= 5.5 Hz, 2H, CH2), 3.90 (t, J= 5.5 Hz, 2H, CH2), 
4.75 (s, 2H, H-7), 8.04 (s, 1H, H-2), 12.40 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 26.01, 63.85, 64.23 (CH2, C-7, 8, 9), 122.29, 128.41, 129.93 
(C, C-aromatic), 145.22 (CH, C-2), 157.56 (C, C-aromatic), 163.11(C, C-1). 
 
4-Chloro-6,8-dihydro-5H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidine (412)66 
(C9H7ClN2OS; M.W.= 226.7) 
 
 
    409              412 
 
General procedure 18; 
Reagent: 5,6-dihydro-3H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4(8H)-one (409) (2.2 
g, 10.6 mmol); 
T.L.C. System: nhexane-EtOAc 7:3 v/v, Rf: 0.46. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 80:20 v/v); 
White solid; 
Yield: 2.28 g (95%) 
1H-NMR (CDCl3), : 3.18 (tt, J1= 5.5 Hz, J2= 1.9 Hz, 2H, H-8), 4.05 (t, J= 5.5 Hz, 2H, 
H-9), 4.88 (t, J= 1.9 Hz, 2H, H-7), 8.73 (s, 1H, H-2). 
13C-NMR (CDCl3), : 26.88, 64.66, 65.29 (CH2, C-7, 8, 9), 125.04, 128.20, 137.02 (C, 
C-aromatic), 152.09 (CH, C-2), 153.55, 168.99 (C, C-aromatic). 
 
4-Hydrazinyl-6,8-dihydro-5H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidine (415)66 
(C9H10N4OS; M.W.= 222.3) 
 
 
    412             415 
General procedure 19; 
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Reagent: 4-chloro-6,8-dihydro-5H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidine (415) (2.28 
g, 10 mmol); 
Purification: recrystallization from 40 % EtOH/H2O; 
White solid; 
Yield: 1.24 g (55%) 
1H-NMR (DMSO-d6), : 3.03 (tt, J1= 5.5 Hz, J2= 1.8 Hz, 2H, H-8), 3.92 (t, J= 5.5 Hz, 
2H, H-9), 4.60 (bs, 2H, NH2), 4.77 (t, J= 1.8 Hz, 2H, H-7), 8.01 (bs, 1H, NH), 8.36 (s, 
1H, H-2). 
13C-NMR (DMSO-d6), : 25.97, 63.89, 64.57 (CH2, C-7, 8, 9), 114.17, 124.63, 129.26 
(C, C-aromatic), 152.78 (CH, C-2), 158.46, 164.63 (C, C-aromatic). 
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6.4.12.1 4-(2-(1-Phenylethylidene)hydrazinyl)-6,8-dihydro-5H-
pyrano[4',3':4,5] thieno[2,3-d]pyrimidines (419-420)  
 
2-(1-(2-(6,8-Dihydro-5H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-yl)hydrazono) 
ethyl)phenol (419) 
(C17H16N4O2S; M.W.= 340.4) 
 
 
   415  202      419 
 
General procedure 20; 
Reagent: 4-hydrazinyl-6,8-dihydro-5H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidine (415) 
(0.2 g, 0.9 mmol); 
Yellow solid; 
Yield: 0.29 g (94%) 
Melting Point: 236-239°C 
MS (ESI+): 341.0 [M+H]+ 
Microanalysis: Calculated for C17H16N4O2S (340.4); Theoretical: %C = 59.98, %H = 
4.74, %N = 16.45; Found: %C = 59.96, %H = 4.59, %N = 16.35. 
Two species observed. Major/minor species ratio: 2:1. 
1H-NMR (DMSO-d6), : (major species) 2.49 (s, 3H, H-2’),  3.05-3.09 (m, 2H, CH2), 
3.91-3.95 (m, 2H, CH2), 4.75-4.77 (m, 2H, CH2), 6.89-6.93 (m, 2H, H-aromatic), 7.26-
7.31 (m, 1H, H-aromatic), 7.59-7.67 (m, 1H, H-aromatic), 7.78 (s, 1H, H-2), 11.51 (bs, 
1H, NH), 12.46 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 2.49 (s, 3H, H-2’),  3.25.3.29  (m,  2H,  CH2), 
3.99-4.03 (m, 2H, CH2), 4.84-4.87 (m, 2H, CH2), 6.89-6.93 (m, 2H, H-aromatic), 7.26-
7.31 (m, 1H, H-aromatic), 7.59-7.67 (m, 1H, H-aromatic), 8.59 (s, 1H, H-2), 9.48 (bs, 
1H, NH), 13.30 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 14.84 (CH3, C-2’), 25.54, 27.15, 
64.11, 64.36 (CH2, C-7, 8, 9), 112.85 (C, C-aromatic), 116.53, 117.29, 118.67 (CH, C-
aromatic), 119.42, 120.93 (C, C-aromatic), 128.08 (CH, C-aromatic), 128.36 (C, C-
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aromatic), 128.77 (CH, C-aromatic), 130.71 (C, C-aromatic), 130.43, 130.75 (CH, C-
aromatic), 142.06 (C, C-aromatic), 144.44 (CH, C-aromatic), 145.40, 151.13, 158.22, 
163.56, 168.71 (C, C-aromatic). 
 
4-(2-(1-(Pyrazin-2-yl)ethylidene)hydrazinyl)-6,8-dihydro-5H-pyrano[4',3':4,5] 
thieno[2,3-d]pyrimidine (420) 
(C15H14N6S; M.W.= 326.4) 
 
 
            415          250            420 
 
General procedure 20; 
Reagent: 4-hydrazinyl-6,8-dihydro-5H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidine (415) 
(0.2 g, 0.9 mmol); 
Yellow solid; 
Yield: 0.25 g (86%) 
Melting Point: 219-223°C 
MS (ESI+): 327.0 [M+H]+ 
Two species observed. Major/minor species ratio: 9:1. 
1H-NMR (CDCl3), : (major species) 2.59 (s, 3H, H-2’),  3.21-3.25 (m, 2H, CH2), 4.07 
(t, J= 5.4 Hz, 2H, CH2), 4.93-4.94 (m, 2H, CH2), 7.77-7.78 (m, 1H, H-aromatic), 8.57-
8.60 (m, 1H, H-aromatic), 9.01 (s, 1H, H-aromatic), 9.38 (s, 1H, H-aromatic), 10.45 (bs, 
1H, NH). 
1H-NMR (CDCl3), : (minor species) 2.59 (s, 3H, H-2’),  3.30-3.34 (m, 2H, CH2), 4.18 
(t, J= 5.4 Hz, 2H, CH2), 4.93-4.94 (m, 2H, CH2), 8.57-8.60 (m, 1H, H-aromatic), 8.73-
8.76 (m, 2H, H-aromatic), 9.01 (s, 1H, H-aromatic), 14.36 (bs, 1H, NH). 
13C-NMR (CDCl3), : (major and minor species) 22.19 (CH3, C-2’), 27.06, 27.23, 
64.73, 64.95, 65.21, 65.52 (CH2, C-7, 8, 9), 132.23, 135.11, 139.56 (C, C-aromatic), 
140.89, 142.79, 143.25, 143.78, 144.44 (CH, C-aromatic), 144.96 (C, C-aromatic), 
145.30 (CH, C-aromatic), 147.94, 151.82, 155.57, 157.44 (C, C-aromatic). 
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6.4.12.2 N'-(6,8-Dihydro-5H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-yl)aryl 
hydrazides (425-426) 
 
N'-(6,8-Dihydro-5H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-yl)-2-hydroxybenzo 
hydrazide (425) 
(C16H14N4O3S; M.W.= 342.4) 
 
 
              415            275         425 
 
General procedure 22; 
Reagent: 4-hydrazinyl-6,8-dihydro-5H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidine (415) 
(0.3 g, 1.4 mmol); 
Purification: recrystallization from EtOH/H2O; 
Light brown solid; 
Yield: 0.11 g (23%) 
Melting Point: 132-134°C 
MS (ESI+): 342.9 [M+H]+ 
1H-NMR (DMSO-d6), : 3.12-3.16 (m, 2H, CH2), 4.00 (t, J= 5.2 Hz, 2H, H-9), 4.83-
4.85 (m, 2H, CH2), 6.96-7.00 (m, 2H, H-aromatic), 7.45-7.49 (m, 1H, H-aromatic), 8.00 
(d, J= 7.8 Hz, 1H, H-aromatic), 8.41 (s, 1H, H-2), 8.93 (bs, 1H, NH), 10.87 (bs, 1H, 
NH), 11.95 (bs 1H, OH). 
13C-NMR (DMSO-d6), : 26.24, 63.84, 64.62 (CH2, C-7, 8, 9), 114.59, 114.77 (C, C-
aromatic), 117.35, 119.04 (CH, C-aromatic), 124.27 (C, C-aromatic), 128.37 (CH, C-
aromatic), 130.87 (C, C-aromatic), 134.05, 152.68 (CH, C-aromatic), 156.84, 159.19, 
165.89 (C, C-aromatic), 167.56 (C, C-1’). 
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N'-(6,8-Dihydro-5H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-yl)picolino 
hydrazide (426) 
(C15H13N5O2S; M.W.= 327.4) 
 
 
             415   277         426 
 
General procedure 22; 
Reagent: 4-hydrazinyl-6,8-dihydro-5H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidine (415) 
(0.3 g, 1.4 mmol); 
Purification: re-crystallisation from EtOH; 
White solid; 
Yield: 0.37 g (83%) 
Melting Point: 220-222°C 
MS (ESI+): 327.9 [M+H]+ 
1H-NMR (DMSO-d6), : 3.13 (t, J= 5.4 Hz, 2H, CH2), 3.99 (t, J= 5.4 Hz, 2H, CH2), 
4.84 (s, 2H, H-7), 7.66-7.69 (m, 1H, H-aromatic), 8.03-8.08 (m, 2H, H-aromatic), 8.36 
(s, 1H, H-2), 8.72-8.74 (m, 1H, H-aromatic), 8.88 (bs, 1H, NH), 10.71 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 26.32, 63.86, 64.33 (CH2, C-7, 8, 9), 114.64 (C, C-aromatic), 
122.31 (CH, C-aromatic), 124.35 (C, C-aromatic), 126.95 (CH, C-aromatic), 130.60 (C, 
C-aromatic), 137.85, 148.68 (CH, C-aromatic), 149.34 (C, C-aromatic), 152.65 (CH, C-
aromatic), 157.05, 162.99 (C, C-aromatic), 166.31 (C, C-1’). 
 Chapter 6: Experimental 
 
 
474 
 
6.4.13 7-Methyl-5,6,7,8-Tetrahydropyrido [4',3':4,5]thieno[2,3-d]pyrimidines 
 
Ethyl 2-amino-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate 
(407)67 
(C11H16N2O2S; M.W.= 240.3) 
 
 
               404   407 
 
General procedure 16; 
Reagent: N-methyl-4-piperidone (404) (1.5 g, 13.3 mmol); 
Morpholine used instead of NEt3; 
T.L.C. System: EtOAc-MeOH 9:1 v/v, Rf: 0.44. 
Purification: recrystallization from 60% EtOH/H2O; 
Yellow solid; 
Yield: 2.25 g (71%)  
1H-NMR (CDCl3), : 1.34 (t, J= 7.1 Hz, 3H, H-3’),  2.45 (s, 3H, H-8), 2.67 (t, J= 5.8 
Hz, 2H, H-7),2.85 (dd, J1= 5.8 Hz, J2= 1.9 Hz, 2H, H-6), 3.38 (t, J= 1.9 Hz, 2H, H-5), 
4.27 (q, J= 7.1 Hz, 2H, H-2’), 6.01 (bs, 2H, NH2). 
13C-NMR (CDCl3), : 14.44 (CH3, C-3’), 27.40 (CH2, C-aliphatic), 45.49 (CH3, C-8), 
52.44, 53.32, 59.44 (CH2, C-aliphatic), 105.40, 114.60, 130.72, 162.07 (C, C-aromatic), 
165.95 (C, C-1’). 
 
7-Methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one 
(410)68 
(C10H11N3OS; M.W.= 221.3) 
 
 
              407        410 
 
General procedure 17a; 
 Chapter 6: Experimental 
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Reagent: ethyl 2-amino-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate 
(407) (0.51g, 2.1 mmol); 
After drying under high vacuum, the crude reaction residue was used for the next step 
without further purification. 
Brown oil; 
MS (ESI)+: 221.9 [M+H]+ 
1H-NMR (DMSO-d6), : 2.36 (s, 3H, H-10), 2.65 (t, J= 5.8 Hz, 2H, H-9), 2.93 (tt, J1= 
5.8 Hz, J2= 1.7 Hz, 2H, H-8), 3.54 (t, J= 1.7Hz, 2H, H-7), 8.07 (s, 1H, H-2), 12.28 (bs, 
1H, NH). 
13C-NMR (DMSO-d6), : 25.71 (CH2, C-aliphatic), 44.93 (CH3, C-10), 51.17, 52.88 
(CH2, C-aliphatic), 122.28, 128.89, 129.70 (C, C-aromatic), 145.14 (CH, C-2), 157.63 
(C, C-aromatic), 162.81 (C, C-1). 
 
4-Chloro-7-methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine 
(413)68 
(C10H10ClN3S; M.W.= 239.7) 
 
 
                 410    413 
 
General procedure 14; 
Reagent: 7-methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one 
(410) (0.45 g, 2.1 mmol); 
2 equivalents of NEt3 added; 
T.L.C. System: EtOAc-MeOH 9:1 v/v, Rf: 0.38. 
Purification: flash column chromatography (EtOAc:MeOH 100:0 v/v increasing to 
EtOAc-MeOH 94:6 v/v); 
White solid; 
Yield: 0.25 g (49%) 
MS (ESI)+: 239.9, 241.9 [M+H]+ 
1H-NMR (CDCl3), : 2.55 (s, 3H, H-10), 2.85 (t, J= 5.8 Hz, 2H, H-9), 3.29 (tt, J1= 5.8 
Hz, J2= 1.9 Hz, 2H, H-8), 3.75 (t, J= 1.9 Hz, 2H, H-7), 8.76 (s, 1H, H-2). 
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13C-NMR (CDCl3), : 26.74 (CH2, C-aliphatic), 45.41 (CH3, C-10), 51.75, 54.19 (CH2, 
C-aliphatic), 125.44, 128.26, 136.79 (C, C-aromatic), 151.96 (CH, C-2), 153.46, 168.98 
(C, C-aromatic). 
 
4-Hydrazinyl-7-methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine 
(416) 
(C10H13N5S; M.W.= 235.3) 
 
 
                413    416 
 
General procedure 19; 
Reagent: 4-chloro-7-methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine 
(413) (0.25 g, 1.1 mmol); 
Purification: recrystallization from MeOH; 
Yellow crystals; 
Yield: 1.56 g (62%) 
1H-NMR (DMSO-d6), : 2.37 (s, 3H, H-10), 2.67 (t, J= 5.7 Hz, 2H, CH2), 3.01 (t, J= 
5.7 Hz, 2H, CH2), 3.47 (s, 2H, H-7), 4.57 (bs, 2H, NH2), 7.95 (bs, 1H, NH), 8.35 (s, 1H, 
H-2). 
13C-NMR (DMSO-d6), : 25.75 (CH2, C-aliphatic), 44.84 (CH3, C-10), 51.31, 53.31 
(CH2, C-aliphatic), 114.22, 125.07, 129.12 (C, C-aromatic), 152.70 (CH, C-2), 158.32, 
164.24 (C, C-aromatic). 
 Chapter 6: Experimental 
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6.4.13.1 7-Methyl-4-(2-(1-phenylethylidene)hydrazinyl)-5,6,7,8-
tetrahydropyrido [4',3':4,5]thieno[2,3-d]pyrimidines (421-422)  
 
2-(1-(2-(7-Methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4-yl) 
hydrazono)ethyl)phenol (421) 
(C18H19N5OS; M.W.= 353.4) 
 
 
   416  202           421 
 
General procedure 20; 
Reagent: 4-hydrazinyl-7-methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d] 
pyrimidine (416) (0.08 g, 0.3 mmol); 
Light brown solid; 
Yield: 0.03 g (23%) 
Melting Point: 198-202°C 
MS (ESI+): 354.0 [M+H]+ 
Two species observed. Major/minor species ratio: 3/1. 
1H-NMR (DMSO-d6), : (major species) 2.42 (s, 3H, CH3), 2.52 (s, 3H, CH3), 2.77 (t, 
J= 5.2 Hz, 2H, CH2), 3.10-3.19 (m, 2H, CH2), 3.64-3.67 (m, 2H, CH2), 6.89-6.93 (m, 
1H, H-aromatic), 7.27-7.31 (m, 1H, H-aromatic), 7.63 (d, J= 7.6 Hz, 1H, H-aromatic), 
7.81 (s, 1H, H-2), 8.50 (bs, 1H, NH), 11.97 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 2.42 (s, 3H, CH3), 2.52 (s, 3H, CH3), 2.77 (t, 
J= 5.2 Hz, 2H, CH2), 3.10-3.19 (m, 2H, CH2), 3.64-3.67 (m, 2H, CH2), 6.89-6.93 (m, 
1H, H-aromatic), 7.27-7.31 (m, 1H, H-aromatic), 7.63 (d, J= 7.6 Hz, 1H, H-aromatic), 
7.81 (s, 1H, H-2), 9.48 (bs, 1H, NH), 13.26 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 39.86, 44.70 (CH3, C-10, 2’), 
51.32, 53.05, 55.99 (CH2, C-7, 8, 9), 114.3 (C, C-aromatic), 116.78, 118.61 (CH, C-
aromatic), 120.73, 122.94, 125.62 (C, C-aromatic), 127.21, 128.55, 130.77 (CH, C-
aromatic), 138.34, 143.06, 153.52, 158.30 (C, C-aromatic). 
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7-Methyl-4-(2-(1-(pyrazin-2-yl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydropyrido 
[4',3':4,5]thieno[2,3-d]pyrimidine (422) 
(C16H17N7S; M.W.= 339.4) 
 
 
           416   250             422 
 
General procedure 20; 
Reagent: 4-hydrazinyl-7-methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d] 
pyrimidine (416) (0.08 g, 0.3 mmol); 
Yellow solid; 
Yield: 0.205 g (53%) 
Melting Point: 201-203 °C 
MS (ESI+): 340.0 [M+H]+ 
Single species observed. 
1H-NMR (CDCl3), : 2.38 (s, 3H, CH3), 2.47 (s, 3H, CH3), 2.69 (t, J= 5.7 Hz, 2H, 
CH2), 3.10 (t, J= 5.7 Hz, 2H, CH2), 3.57 (s, 2H, H-7), 7.88 (s, 1H, H-2), 8.58 (d, J= 2.6 
Hz, 1H, H-4’),  8.62  (dd,  J1= 2.6 Hz, J2= 1.5 Hz, 1H, H-5’),  9.79  (d,  J=  1.5  Hz,  1H,  H-
6’),  11.98 (bs, 1H, NH). 
13C-NMR (CDCl3), : 12.61 (CH3, C-aliphatic), 26.76 (CH2, C-aliphatic), 44.96 (CH3, 
C-aliphatic), 51.47, 53.11 (CH2, C-aliphatic), 119.22, 128.95, 130.53 (C, C-aromatic), 
143.21, 143.30, 143.52, 144.11 (CH, C-aromatic), 148.72, 151.21, 157.06, 158.33 (C, 
C-aromatic). 
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6.4.13.2 N'-(7-Methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-
d]pyrimidin-4-yl) benzohydrazide (427-428) 
 
2-Hydroxy-N'-(7-methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-
4-yl)benzohydrazides (427) 
(C17H17N5O2S; M.W.= 355.4) 
 
 
                416  275          427 
 
General procedure 22; 
Reagent: 4-hydrazinyl-7-methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d] 
pyrimidine (416) (0.10 g, 0.4 mmol); 
Purification: recrystallization from MeOH; 
White solid; 
Yield: 0.05 g (30%) 
Melting Point: charring > 240°C 
MS (ESI+): 356.0 [M+H]+ 
1H-NMR (DMSO-d6), : 2.42 (s, 3H, H-10), 2.75-2.79 (m, 2H, CH2), 3.10-3.15 (m, 
2H, CH2), 3.67 (s, 2H, H-7), 6.99-6.99 (m, 2H, H-aromatic), 7.44-7.49 (m, 1H, H-
aromatic), 7.97-8.01 (m, 1H, H-aromatic), 8.38 (s, 1H, H-2), 8.89 (bs, 1H, NH), 11.39 
(bs, 2H, NH, OH). 
13C-NMR (DMSO-d6), : 25.96 (CH2, C-aliphatic), 44.76 (CH3, C-10), 51.18, 53.28 
(CH2, C-aliphatic), 114.88, 114.97 (C, C-aromatic), 117.33, 118.98 (CH, C-aromatic), 
124.48 (C, C-aromatic), 128.33 (CH, C-aromatic), 130.53 (C, C-aromatic), 133.95, 
151.93 (CH, C-aromatic), 156.98, 159.22, 165.96 (C, C-aromatic), 168.02 (C, C-1’). 
 Chapter 6: Experimental 
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N'-(7-Methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4-yl) 
picolinohydrazide (428) 
(C16H16N6OS; M.W.= 340.4) 
 
 
   416  277           428 
 
General procedure 22; 
Reagent: 4-hydrazinyl-7-methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d] 
pyrimidine (416) (0.10 g, 0.4 mmol); 
Purification: re-crystallisation from EtOH; 
Orange solid; 
Yield: 0.06 g (41%) 
Melting Point: charring > 200°C 
MS (ESI+): 341.0 [M+H]+ 
1H-NMR (DMSO-d6), : 2.41 (s, 3H, H-10), 2.75 (t, J= 5.5 Hz, 2H, CH2), 3.10-3.13 
(m, 2H, CH2), 3.64 (s, 2H, H-7), 7.66-7.69 (m, 1H, H-aromatic), 8.02-8.08 (m, 2H, H-
aromatic), 8.33 (s, 1H, H-2), 8.72-8.74 (m, 1H, H-aromatic), 8.85 (bs, 1H, NH), 10.71 
(bs, 1H, NH). 
13C-NMR (DMSO-d6), : 26.06 (CH2, C-aliphatic), 44.81 (CH3, C-10), 51.23, 53.32 
(CH2, C-aliphatic), 114.74 (C, C-aromatic), 122.30 (CH, C-aromatic), 124.83 (C, C-
aromatic), 126.93 (CH, C-aromatic), 130.35 (C, C-aromatic), 137.84, 148.68 (CH, C-
aromatic), 149.37 (C, C-aromatic), 152.46 (CH, C-aromatic), 157.12, 162.91 (C, C-
aromatic), 166.27 (C, C-1’). 
 Chapter 6: Experimental 
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6.4.14 5,6,7,8-Tetrahydropyrido[4',3':4,5]thieno [2,3-d]pyrimidines 
 
tert-Butyl 4-oxopiperidine-1-carboxylate (430)69 
(C10H17NO3; M.W.= 199.3) 
 
 
   429  77           430 
 
To a solution of 4-piperidone hydrate hydrochloride (429) (1 g, 6.5 mmol) in H2O (10 
mL) was added NaOH (0.29 g, 7.2 mmol), di-tert-butyl dicarbonate (77) (1.4 g, 6.5 
mmol) and THF (10 mL). The reaction mixture was stirred at r.t. for 16 h, then 
extracted with diethyl ether (3 x 30 mL). The combined organic layers were washed 
with brine (40 mL), dried over MgSO4 and concentrated under reduced pressure to give 
tert-butyl 4-oxopiperidine-1-carboxylate (430) as a waxy solid. 
Yield: 1.2 g (98%)  
1H-NMR (CDCl3), : 1.51 (s, 9H, H-3’), 2.45 (t, J= 6.2 Hz, 4H, CH2), 3.73 (t, J= 6.2 
Hz, 4H, CH2). 
13C-NMR (CDCl3), : 28.37 (CH3, C-3’), 41.16, 42.99 (CH2, C-aliphatic), 80.46 (C, C-
2’), 154.50 (C, C-2), 207.79 (C, C-1’). 
 
6-tert-Butyl 3-ethyl 2-amino-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-
dicarboxylate (431)30 
(C15H22N2O4S; M.W.= 324.4) 
 
 
       430            431 
 
General procedure 16; 
Reagent: tert-butyl 4-oxopiperidine-1-carboxylate (430) (1.4 g, 7.1 mmol); 
 Chapter 6: Experimental 
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The reaction mixture was cooled to r.t. and the precipitate formed was collected by 
filtration and recrystallized from EtOH. 
Pale yellow solid; 
Yield: 1.4 g (61%)  
1H-NMR (CDCl3), : 1.35 (t, J= 7.1 Hz, 3H, H-3’),  1.50  (s,  9H,  H-10), 2.80-2.84 (m, 
2H, CH2), 3.63 (t, J= 5.7 Hz, 2H, H-7), 4.28 (q, J= 7.1 Hz, 2H, H-2’),  4.36  (s,  2H,  H-5), 
6.04 (bs, 2H, NH2). 
13C-NMR (CDCl3), : 14.14(CH3, C-3’), 27.18 (CH2, C-aliphatic), 28.46 (CH3, C-10), 
40.79, 59.58 (CH2, C-aliphatic), 79.97 (C, C-9), 104.83, 113.71, 131.22, 154.66 (C, C-
aromatic),  162.31, 165.81 (C, C-8, 1’). 
 
tert-Butyl 4-oxo-3,4,5,6-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine-7(8H)-
carboxylate (432)30 
(C14H17N3O3S; M.W.= 307.4) 
 
 
                431                 432 
 
General procedure 17a; 
Reagent: 6-tert-butyl 3-ethyl 2-amino-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-
dicarboxylate (432) (1.4, 4.3 mmol); 
Yellow solid; 
Yield: 1.33 g (83%). 
1H-NMR (DMSO-d6), : 1.43 (s, 9H, H-12), 2.93 (t, J= 5.7 Hz, 2H, CH2), 3.62 (t, J= 
5.7 Hz, 2H, CH2), 4.58 (s, 2H, H-7), 8.04 (s, 1H, H-2), 12.42 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 25.42 (CH2, C-aliphatic), 28.00 (CH3, C-11), 40.55, 42.31 
(CH2, C-aliphatic), 79.38 (C, C-11), 108.46, 122.16, 129.49 (C, C-aromatic), 154.28 
(CH, C-2), 155.86, 157.57 (C, C-aromatic), 165.31 (C, C-1). 
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tert-Butyl 4-chloro-5,6-dihydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine-7(8H)-
carboxylate (433)30 
(C14H16ClN3O2S; M.W.= 325.8) 
 
 
    432             433 
 
To a mixture of POCl3 (3 mL) and NEt3 (3 mL) at 0°C was added intermediate tert-
butyl 4-oxo-3,4,5,6-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine-7(8H)- 
carboxylate (432) (1.1 g, 3.6 mmol). The reaction mixture was heated at 60 °C for 3 h, 
then cooled in an ice-bath and carefully neutralised with sat. Na2CO3 solution. The 
mixture was extracted with DCM (50 mL), the organic layer separated, dried over 
MgSO4 and concentrated under vacuum. The residue was purified by flash column 
chromatography (nhexane -EtOAc: 100:0 v/v increasing to nhexane -EtOAc: 85:15 v/v) 
to give tert-butyl 4-chloro-5,6-dihydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine-7(8H)-
carboxylate (433) as a white solid. 
T.L.C. System: nhexane-EtOAc 7:3 v/v, Rf: 0.48. 
Yield: 1.26 g (96%) 
1H-NMR (CDCl3), : 1.52 (s, 9H, H-11), 3.22 (t, J= 5.7 Hz, 2H, CH2), 3.81 (t, J1= 5.7 
Hz, 2H, ), 4.76 (s, 2H, H-7), 8.78 (s, 1H, H-2). 
13C-NMR (CDCl3), : 26.51 (CH2, C-aliphatic), 28.41 (CH3, C-12), 41.12, 42.55 (CH2, 
C-aliphatic), 78.99 (C, C-11), 125.11, 128.19, 133.24 (C, C-aromatic), 152.17 (CH, C-
2), 155.47, 169.08 (C, C-aromatic). 
 
tert-Butyl 4-hydrazinyl-5,6-dihydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine-7(8H)-
carboxylate (436) 
(C14H19N5O2S; M.W.= 321.4) 
 
 
    433           436 
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General procedure 19; 
Reagent: tert-butyl 4-chloro-5,6-dihydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine-7(8H)-
carboxylate (433) (0.23 g, 0.7 mmol); 
Purification: recrystallization from 40% EtOH/H2O; 
Pale yellow crystals; 
Yield: 0.11 g (46%) 
1H-NMR (DMSO-d6), : 1.44 (s, 3H, H-11), 3.01 (t, J= 5.7 Hz, 2H, CH2), 3.63 (t, J= 
5.7 Hz, 2H, CH2), 4.58-4.62 (bs, 4H, CH2, NH2), 8.03 (bs, 1H, NH), 8.36 (s, 1H, H-2). 
13C-NMR (DMSO-d6), : 25.75 (CH2, C-aliphatic), 28.00 (CH3, C-11), 79.46 (C, C-
10), 114.17, 125.82 (C, C-aromatic), 152.90 (CH, C-2), 158.71, 164.12 (C, C-aromatic). 
 
4-Hydrazinyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine (435) 
(C9H11N5S; M.W.= 221.3) 
 
 
    436         435 
 
To a mixture of intermediate tert-butyl 4-hydrazinyl-5,6-dihydropyrido[4',3':4,5] 
thieno[2,3-d]pyrimidine-7(8H)-carboxylate (436) (0.1 g, 0.3 mmol) in DCM (2 mL) at 
0°C was added TFA (1 mL) and then warmed to r.t. The reaction mixture was stirred for 
2 h, then dried under vacuum. The mixture was neutralised by slow addition of sat. 
NaHCO3 solution, then dried under vacuum. The resulting residue was added of MeOH 
and filtered. The filtrate was finally dried under vacuum to give crude 4-hydrazinyl-
5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine (435) as a brown oil which 
was used for the last reaction step without purification. 
MS (ESI)+: 221.9 [M+H]+ 
 Chapter 6: Experimental 
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6.4.14.1 4-(2-(1-Phenylethylidene)hydrazinyl)-5,6,7,8-
tetrahydropyrido[4',3':4,5] thieno [2,3-d]pyrimidine (437-438)  
 
2-(1-(2-(5,6,7,8-Tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4-yl)hydrazono) 
ethyl)phenol (437) 
(C17H17N5OS; M.W.= 339.4) 
 
 
            435               202           437 
 
General procedure 20; 
Reagent: 4-hydrazinyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine (435) 
(0.07 g, 0.5 mmol); 
Yellow solid; 
Yield: 0.02 g (23%) 
Melting Point: 241-244°C 
MS (ESI+): 340.0 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 2.50 (s, 3H, H-2’), 3.04-3.09 (m, 4H, CH2), 3.10-3.19 (m, 4H, 
CH2), 3.94 (s,2H, H-7), 6.84-7.03 (m, 2H, H-aromatic), 7.26-7.31 (m, 1H, H-aromatic), 
7.61-7.65 (m, 1H, H-aromatic), 8.04 (s, 2H, H-2). 
13C-NMR (DMSO-d6), : 14.13 (CH3, C-7), 26.73, 42.27, 44.07 (CH2, C-7, 8, 9), 
114.37 (C, C-aromatic), 116.80, 118.02 (CH, C-aromatic), 118.52, 123.07, 128.17 (C, 
C-aromatic), 128.42, 130.66 (CH, C-aromatic), 131.99, 143.43 (C, C-aromatic), 152.61 
(CH, C-aromatic), 153.78, 158.42 (C, C-aromatic). 
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4-(2-(1-(Pyrazin-2-yl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydropyrido[4',3':4,5] 
thieno[2,3-d]pyrimidine (438) 
(C15H15N7S; M.W.= 325.4) 
 
 
   435  250        438 
 
General procedure 20; 
Reagent: 4-hydrazinyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine (435) 
(0.07 g, 0.5 mmol); 
Yellow solid; 
Yield: 0.03 g (10%) 
Melting Point: charring > 300°C 
MS (ESI+): 340.0 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 2.48 (s, 3H, CH3), 3.32 (t, J= 6.1 Hz, 2H, CH2), 3.44 (t, J= 6.1 
Hz, 2H, CH2), 34.39 (s, 2H, H-7), 7.96 (ds, 1H, H-2), 8.61 (d, J= 2.5 Hz, 1H, H-4’),  
8.64 (dd, J1= 2.5 Hz, J2= 1.5 Hz, 1H, H-5’),  9.63 (bs, 1H, NH), 9.82 (d, J= 1.5 Hz, 1H, 
H-6’),  12.15 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 12.71 (CH3, C-aliphatic), 23.51, 40.34, 41.40 (CH2, C-
aliphatic), 118.60, 124.76, 128.28 (C, C-aromatic), 143.27, 143.36, 143.75, 145.11 (CH, 
C-aromatic), 148.46, 151.01, 157.69, 159.41 (C, C-aromatic). 
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6.4.15 2-Methyl-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidines 
 
2-Methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (439)61 
(C11H12N2OS; M.W.= 220.3) 
 
 
            190                 439 
 
Intermediate ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (190) 
(0.86 g, 3.8 mmol) and acetonitrile (0.2 mL, 3.8 mmol) were placed in a pressure tube 
and saturated HCl solution in dioxane (8 mL) was added dropwise. The tube was 
carefully sealed and left at r.t. in ultrasonic bath for 4 h, and then heated at 100°C with 
stirring for 16 h. The reaction mixture was then cooled to r.t. and poured into water (70 
mL). The precipitate formed was filtered and washed with water and nhexane to give 2-
methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (439) as a white 
solid. 
Yield: 0.34 g (40%) 
1H-NMR (DMSO-d6), : 1.72-1.77 (m, 2H, CH2), 1.77-1.82 (m, 2H, CH2), 2.31 (s, 3H, 
H-7), 2.70 (t, J= 5.8 Hz, 2H, CH2), 2.84 (t, J= 5.8 Hz, 2H, CH2), 12.18 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 20.78 (CH3, C-7), 21.76, 22.49, 24.32, 25.23 (CH2, C-8, 9, 
10, 11), 120.13, 130.47, 130.69, 154.14, 158.44 (C, C-aromatic), 163.06 (C, C-1). 
 
4-Chloro-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (440)62 
(C11H11ClN2O2S; M.W.= 256.7) 
 
 
    439            440 
 
General procedure 18; 
Reagent: 2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (439) 
(0.4 g, 1.8 mmol); 
T.L.C. System: nhexane-EtOAc 7:3 v/v, Rf: 0.69. 
 Chapter 6: Experimental 
 
 
488 
 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 85:15 v/v); 
Light brown solid; 
Yield: 0.31 g (72%) 
1H-NMR (CDCl3), : 1.91-1.94 (m, 4H, CH2), 2.77 (s, 3H, H-7), 2.85-2.88 (m, 2H, 
CH2), 3.06-3.09 (m, 2H, CH2). 
13C-NMR (CDCl3), : 22.26, 22.53 (CH2, C-aliphatic), 25.26 (CH3, C-7), 25.93, 26.27 
(CH2, C-aliphatic), 126.14, 126.94, 137.90, 152.83, 161.76, 169.50. 
 
4-Hydrazinyl-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine 
(441)63 
(C11H14N4S; M.W.= 234.3) 
 
 
    440           441 
 
General procedure 19; 
Reagent: 4-chloro-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (440) 
(0.23 g, 1 mmol); 
Purification: recrystallization from 40 % EtOH/H2O; 
Yellow crystals; 
Yield: 0.15 g (67%) 
1H-NMR (DMSO-d6), : 1.77-1.80 (m, 4H, CH2), 2.25 (s, 3H, H-7), 2.71-2.74 (m, 2H, 
CH2), 2.87-2.90 (m, 2H, CH2), 4.54 (bs, 2H, NH2), 7.75 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 22.03, 22.19, 24.77 (CH2, C-aliphatic), 25.34 (CH3, C-7), 
25.46 (CH2, C-aliphatic), 112.49, 126.54, 130.06, 158.19, 161.08, 164.61 (C, C-
aromatic). 
 Chapter 6: Experimental 
 
 
489 
 
6.4.15.1 2-Methyl-4-(2-(1-arylethylidene)hydrazinyl)-5,6,7,8-
tetrahydrobenzo[4,5] thieno[2,3-d]pyrimidines (442-443)  
 
2-(1-(2-(2-Methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl) 
hydrazono)ethyl)phenol (442) 
(C19H20N4OS; M.W.= 352.5) 
 
 
              441          202          442 
 
General procedure 20; 
Reagent: 4-hydrazinyl-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine 
(441) (0.05 g, 0.2 mmol); 
Pale yellow solid; 
Yield: 0.06 g (86%) 
Melting Point: 257-260°C 
MS (ESI+): 353.0 [M+H]+ 
Two species observed. Major/minor species ratio: 5/4. 
1H-NMR (DMSO-d6), : (major species) 1.77-1.82 (m, 4H, CH2), 2.33 (s, 3H, CH3), 
2.49 (s, 3H, CH3), 2.72-2.75 (m, 2H, CH2), 2.97-3.01 (m, 2H, CH2), 6.88-6.96 (m, 2H, 
H-aromatic), 7.26-7.31 (m, 1H, H-aromatic), 7.58-7.65 (m, 1H, H-aromatic), 10.96 (bs, 
1H, NH), 12.73 (bs, 1H, OH). 
1H-NMR (DMSO-d6), : (minor species) 1.85-1.89 (m, 4H, CH2), 2.49 (s, 3H, CH3), 
2.56 (s, 3H, CH3), 2.79-2.84 (m, 2H, CH2), 3.12-3.16 (m, 2H, CH2), 6.88-6.96 (m, 2H, 
H-aromatic), 7.26-7.31 (m, 1H, H-aromatic), 7.58-7.65 (m, 1H, H-aromatic), 9.32 (bs, 
1H, NH), 13.35 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : (major and minor species) 12.88, 14.65, 21.21 (CH3, C-
aliphatic), 22.06, 22.13, 22.19, 22.41, 24.62, 24.91 (CH2, C-aliphatic), 25.52 (CH3, C-
aliphatic), 26.46 (CH2, C-aliphatic), 113.66 (C, C-aromatic), 116.58, 117.30 (CH, C-
aromatic), 117.43 (C, C-aromatic), 118.42, 118.53 (CH, C-aromatic), 119.60, 121.08, 
126.11 (C, C-aromatic), 127.93, 128.50, 130.53, 130.70 (CH, C-aromatic), 131.33, 
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132.46, 145.92, 152.88, 153.78, 154.50, 157.00, 158.47, 161.47, 162.68, 166.62 (C, C-
aromatic). 
 
2-Methyl-4-(2-(1-(pyrazin-2-yl)ethylidene)hydrazinyl)-5,6,7,8-tetrahydrobenzo 
[4,5]thieno[2,3-d]pyrimidine (443) 
(C17H18N6S; M.W.= 338.4) 
 
 
   441           250         443 
 
General procedure 20; 
Reagent: 4-hydrazinyl-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine 
(441) (0.05 g, 0.2 mmol); 
Yellow solid; 
Yield: 0.07 g (59%) 
Melting Point: 189-191°C 
MS (ESI+): 339.0 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.76-1.82 (m, 4H, CH2), 2.44 (s, 3H, CH3), 2.46 (s, 3H, CH3), 
2.72-2.74 (m, 2H, CH2), 3.00-3.03 (m, 2H, CH2), 8.58 (d, J= 2.6 Hz, 1H, H-4’),  8.61  
(dd, J1= 2.6 Hz, J2= 1.4 Hz, 1H, H-5’),  9.82   (d,  J=  1.4  Hz, 1H, H-6’),  11.18 (bs, 1H, 
NH). 
13C-NMR (DMSO-d6), : 12.83, 21.51 (CH3, C-7,  2’),  22.14,  22.39,  24.64,  26.40  (CH2, 
C-8, 9, 10, 11), 117.73, 130.61, 131.55 (C, C-aromatic), 143.13, 143.42, 143.66 (CH, C-
aromatic), 148.97, 151.20, 152.79, 157.02, 158.28 (C, C-aromatic). 
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6.4.15.2 N'-(2-Methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-
yl)aryl hydrazides (444-445) 
 
2-Hydroxy-N'-(2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl) 
benzohydrazide (444) 
(C18H18N4O2S; M.W.= 354.4) 
 
 
                441             275        444 
 
General procedure 22; 
Reagent: 4-hydrazinyl-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine 
(441) (0.09 g, 0.4 mmol); 
Purification: re-crystallisation from 70% MeOH/H2O; 
Light orange solid; 
Yield: 0.05 g (36%) 
Melting Point: 209-212°C 
MS (ESI+): 355.0 [M+H]+ 
1H-NMR (DMSO-d6), : 1.82-1.87 (m, 4H, CH2), 2.42 (s, 3H, H-7), 2.77-2.81 (m, 2H, 
CH2), 2.99-3.03 (m, 2H, CH2), 6.95-7.02 (m, 2H, H-aromatic), 7.44-7.48 (m, 1H, H-
aromatic), 7.98 (d, J= 7.0 Hz, 1H, H-aromatic), 8.69 (bs, 1H, NH), 10.92 (bs, 1H, NH), 
11.89 (bs 1H, OH). 
13C-NMR (DMSO-d6), : 21.97, 22.17, 24.87 (CH2, C-aliphatic), 25.41 (CH3, C-7), 
25.62 (CH2, C-aliphatic), 112.87, 115.22 (C, C-aromatic), 117.27, 119.06 (CH, C-
aromatic), 126.16 (C, C-aromatic), 128.46 (CH, C-aromatic), 131.63 (C, C-aromatic), 
133.81 (CH, C-aromatic), 156.30, 158.83, 161.08, 166.11 (C, C-aromatic), 166.88 (C, 
C-1’). 
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N'-(2-Methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)picolino 
hydrazide (445) 
(C17H17N5OS; M.W.= 339.4) 
 
 
         441        277            445 
 
General procedure 22; 
Reagent: 4-hydrazinyl-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine 
(441) (0.08 g, 0.3 mmol); 
Purification: re-crystallisation from MeOH/H2O; 
Pale yellow solid; 
Yield: 0.04 g (38%) 
Melting Point: 99-101°C 
MS (ESI+): 340.0 [M+H]+ 
1H-NMR (DMSO-d6), : 1.83-1.86 (m, 4H, CH2), 2.38 (s, 3H, H-7), 2.78-2.81 (m, 2H, 
CH2), 2.98-3.02 (m, 2H, CH2), 7.65-7.69 (m, 1H, H-aromatic), 8.02-8.08 (m, 2H, H-
aromatic), 8.58 (bs, 1H, NH), 8.72-8.74 (m, 1H, H-aromatic), 10.63 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 22.00, 22.20, 24.88 (CH2, C-aliphatic), 25.45 (CH3, C-7), 
25.69 (CH2, C-aliphatic), 112.96 (C, C-aromatic), 122.25 (CH, C-aromatic), 126.22 (C, 
C-aromatic), 126.92 (CH, C-aromatic), 131.39 (C, C-aromatic), 137.86, 148.71 (CH, C-
aromatic), 149.37, 156.69, 161.08, 162.74 (C, C-aromatic), 166.02 (C, C-1’). 
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6.4.16 6-Ethylthieno[2,3-d]pyrimidines 
 
Ethyl 2-amino-5-ethylthiophene-3-carboxylate (448)52 
(C9H13NO2S; M.W.= 199.3) 
 
 
    447     448 
 
General procedure 16; 
Reagent: butyraldehyde (447) (1 g, 13.9 mmol); 
T.L.C. System: nhexane-EtOAc 8:2 v/v, Rf: 0.52. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane-EtOAc 95:5 v/v); 
White solid; 
Yield: 2.46 g (88%) 
1H-NMR (CDCl3), : 1.24 (t, J= 7.5 Hz, 3H, H-6), 1.35 (t, J= 7.1 Hz, 3H, H-3’),  2.63 
(qd, J1= 7.5 Hz, J2= 1.2 Hz, 2H, H-5), 4.27 (q, J= 7.1 Hz, 2H, H-2’),  5.80 (bs, 2H, NH2), 
6.65 (t, J= 1.2 Hz, 1H, H-3). 
13C-NMR (CDCl3), : 14.54, 15.37 (CH3, C-6,  3’), 23.02, 59.43 (CH2, C-5,  2’), 106.34 
(C, C-aromatic), 120.66 (CH, C-3), 128.46, 161.14 (C, C-aromatic), 165.39 (C, C-1’). 
 
6-Ethylthieno[2,3-d]pyrimidin-4(3H)-one (449)53 
(C8H8N2OS; M.W.= 180.2) 
 
 
              448     449 
 
General procedure 17; 
Reagent: ethyl 2-amino-5-ethylthiophene-3-carboxylate (448) (2.46 g, 12.3 mmol); 
Purification: recrystallization from EtOH/H2O; 
Light brown solid; 
Yield: 1.64 g (73%) 
 Chapter 6: Experimental 
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1H-NMR (DMSO-d6), : 1.27 (t, J= 7.5 Hz, 3H, H-6), 2.85 (qd, J1= 7.5 Hz, J2= 1.1 Hz, 
2H, H-5), 7.11 (t, J= 1.1 Hz, 1H, H-7), 8.05 (s, 1H, H-2), 12.39 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 15.25 (CH3, C-6), 23.12 (CH2, C-5), 117.34 (CH, C-7), 
124.77, 144.23 (C, C-aromatic), 145.00 (CH, C-2), 156.99 (C, C-aromatic), 162.76 (C, 
C-1). 
 
4-Chloro-6-ethylthieno[2,3-d]pyrimidine (450)54 
(C8H7ClN2S; M.W.= 198.7) 
 
 
    449            450 
 
General procedure 18; 
Reagent: 6-ethylthieno[2,3-d]pyrimidin-4(3H)-one (449) (1.64 g, 9.1 mmol); 
T.L.C. System: nhexane-EtOAc 8:2 v/v, Rf: 0.63. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane -EtOAc 95:5 v/v); 
White solid; 
Yield: 1.42 g (78%) 
1H-NMR (CDCl3), : 1.42 (t, J= 7.5 Hz, 3H, H-6), 3.01 (qd, J1= 7.5 Hz, J2= 1.2 Hz, 2H, 
H-5), 7.11 (t, J= 1.2 Hz, 1H, H-7), 8.78 (s, 1H, H-2). 
13C-NMR (CDCl3), : 14.92 (CH3, C-6), 24.59 (CH2, C-5), 115.19 (CH, C-7), 130.49, 
150.86 (C, C-aromatic), 152.02 (CH, C-2), 153.24, 168.45 (C, C-aromatic). 
 
6-Ethyl-4-hydrazinylthieno[2,3-d]pyrimidine (451)53 
(C8H10N4S; M.W.= 194.3) 
 
 
    450             451 
 
General procedure 19; 
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Reagent: 4-chloro-6-ethylthieno[2,3-d]pyrimidine (450) (1.42 g, 7.1 mmol); 
Purification: recrystallization from 40 % EtOH/H2O; 
White crystals; 
Yield: 0.98 g (70%) 
1H-NMR (DMSO-d6), : 1.28 (t, J= 7.5 Hz, 3H, H-6), 2.86 (q, J= 7.5 Hz, 2H, H-5), 
4.56 (bs, 2H, NH2), 7.33 (s, 1H, H-7), 8.30 (s, 1H, H-2), 8.99 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 15.11 (CH3, C-6), 23.47 (CH2, C-5), 114.75 (C, C-aromatic), 
115.97 (CH, C-7), 128.47 (C, C-aromatic), 152.97 (CH, C-2), 158.67, 166.73 (C, C-
aromatic). 
 Chapter 6: Experimental 
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6.4.16.1 6-Ethyl-4-(2-(1-arylethylidene)hydrazinyl)thieno[2,3-d]pyrimidines (446, 
453-454)  
 
6-Ethyl-4-(2-(thiophen-2-ylmethylene)hydrazinyl)thieno[2,3-d]pyrimidine (446)53 
(C13H12N4S2; M.W.= 288.4) 
 
 
 451              452       446 
 
General procedure 20; 
Reagent: 6-ethyl-4-hydrazinylthieno[2,3-d]pyrimidine (451) (0.10 g, 0.5 mmol); 
Pale yellow solid; 
Yield: 0.07 g (46%) 
Melting Point: 164-168°C 
MS (ESI+): 289.0 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.37 (t, J= 7.5 Hz, 3H, H-6), 2.94 (d, J= 7.5 Hz, 2H, H-5), 
7.15 (dd, J1= 5.1 Hz, J2= 3.5 Hz, 1H, H-4’),  7.43  (d,  J=  3.5  Hz,  1H,  H-aromatic), 7.65 
(d, J= 5.1 Hz, 1H, H-aromatic), 7.78 (s, 1H, H-aromatic), 8.40 (s, 2H, H-aromatic), 
11.78 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : 14.60 (CH3, C-6), 23.55 (CH2, C-5), 115.02 (C, C-aromatic), 
117.93, 127.94, 128.05, 129.57, 138.41 (CH, C-aromatic), 139.59, 143.26 (C, C-
aromatic), 152.34 (CH, C-aromatic), 154.26, 162.84 (C, C-aromatic). 
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2-(1-(2-(6-Ethylthieno[2,3-d]pyrimidin-4-yl)hydrazono)ethyl)phenol (453) 
(C16H16N4OS; M.W.= 312.4) 
 
 
   451  202     453 
 
General procedure 20; 
Reagent: 6-ethyl-4-hydrazinylthieno[2,3-d]pyrimidine (451) (0.10 g, 0.5 mmol); 
Pale yellow solid; 
Yield: 0.06 g (44%) 
Melting Point: 123-127°C 
MS (ESI+): 313.0 [M+H]+ 
Single species observed. 
1H-NMR (DMSO-d6), : 1.35 (t, J= 7.5 Hz, 3H, H-6), 2.53 (s, 3H, H-2’), 2.95 (q, J= 
7.5 Hz, 2H, H-5), 6.89-6.94 (m, 2H, H-aromatic), 7.27-7.31 (m, 2H, H-aromatic), 7.62 
(dd, J1= 7.5 Hz, J2= 1.5 Hz, 1H, H-aromatic), 7.66 (s, 1H, H-7), 8.54 (s, 1H, H-2), 10.63 
(bs, 1H, NH), 13.01 (bs, 1H, OH). 
13C-NMR (DMSO-d6), : 14.02, 14.93 (CH3, C-6, 2’),  23.59 (CH2, C-5), 115.61 (CH, 
C-aromatic), 115.79 (C, C-aromatic), 117.13, 118.49 (CH, C-aromatic), 121.24, 124.32 
(C, C-aromatic), 128.12, 130.64 (CH, C-aromatic), 144.33 (C, C-aromatic), 152.82 
(CH, C-aromatic), 154.27, 158.07, 165.25 (C, C-aromatic). 
 
6-Ethyl-4-(2-(1-(pyrazin-2-yl)ethylidene)hydrazinyl)thieno[2,3-d]pyrimidine (454) 
(C14H14N6S; M.W.= 298.4) 
 
 
   451            250         454 
 
General procedure 20; 
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Reagent: 6-ethyl-4-hydrazinylthieno[2,3-d]pyrimidine (451) (0.10 g, 0.5 mmol); 
Pale yellow solid; 
Yield: 0.11 g (71%) 
Melting Point: 149-152°C 
MS (ESI+): 299.0 [M+H]+ 
Two species observed. Major/minor species ratio: 5/1. 
1H-NMR (DMSO-d6), : (major species) 1.33 (t, J= 7.5 Hz, 3H, H-6), 2.47 (s, 3H, H-
2’),   2.93   (q,   J=   7.5  Hz,   2H,  H-5), 7.77-7.78 (m, 1H, H-aromatic), 8.51 (s, 1H, H-2), 
8.61-8.63 (m, 1H, H-aromatic), 8.66 (dd, J1= 2.5 Hz, J2= 1.6 Hz, 1H, H-aromatic), 9.23 
(d, J= 1.6 Hz, 1H, H-aromatic), 10.99 (bs, 1H, NH). 
1H-NMR (DMSO-d6), : (minor species) 1.29 (t, J= 7.5 Hz, 3H, H-6), 2.48 (s, 3H, H-
2’), 2.88 (q, J= 7.5 Hz, 2H, H-5), 7.16-7.17 (m, 1H, H-aromatic), 7.92 (d, J= 3.7 Hz, 
1H, H-aromatic), 8.58 (d, J= 2.5Hz, 1H, H-aromatic), 8.61-8.63 (m, 1H, H-aromatic), 
9.79 (d, J= 1.6 Hz, 1H, H-aromatic), 12.00 (bs, 1H, NH). 
13C-NMR (DMSO-d6), : (major and minor species) 11.75, 12.24, 14.49, 15.35 (CH3, 
C-6, 2’),   23.21, 23.50 (CH2, C-5), 115.69 (C, C-aromatic), 117.04, 117.68, 141.79, 
143.19, 143.27, 143.43, 143.49, 143.66 (CH, C-aromatic), 144.00, 147.56, 150.73 (C, 
C-aromatic), 152.06 (CH, C-aromatic), 155.02, 168.55 (C, C-aromatic). 
 Chapter 6: Experimental 
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6.4.16.2 N'-(6-Ethylthieno[2,3-d]pyrimidin-4-yl)-2-arylcarbohydrazides (455-
456) 
 
N'-(6-Ethylthieno[2,3-d]pyrimidin-4-yl)-2-hydroxybenzohydrazide (455) 
(C15H14N4O2S; M.W.= 314.4) 
 
 
   451  275     455 
 
General procedure 22; 
Reagent: 6-ethyl-4-hydrazinylthieno[2,3-d]pyrimidine (451) (0.2 g, 1 mmol); 
Purification: re-crystallisation from EtOH; 
White solid; 
Yield: 0.10 g (28%) 
Melting Point: 176-179°C 
MS (ESI+): 314.9 [M+H]+ 
1H-NMR (DMSO-d6), : 1.32 (t, J= 7.2 Hz, 3H, H-6), 2.93 (q, J= 7.2 Hz, 2H, H-5), 
6.96-7.01 (m, 2H, H-aromatic), 7.43 (s, 1H, H-7), 7.46-7.50 (m, 1H, H-aromatic), 7.98 
(d, J= 7.9 Hz, 1H, H-aromatic), 8.39 (s, 1H, H-2), 10.09 (bs, 1H, NH), 10.83 (bs, 1H, 
NH), 11.87 (bs 1H, OH). 
13C-NMR (DMSO-d6), : 14.97 (CH3, C-6), 23.53 (CH2, C-5), 114.64 (CH, C-
aromatic), 114.77, 115.23, 116.99 (C, C-aromatic), 117.35, 119.06, 128.39 (CH, C-
aromatic), 132.27 (C, C-aromatic), 134.13 (CH, C-aromatic), 144.57 (C, C-aromatic), 
152.51 (CH, C-aromatic), 159.13 (C, C-aromatic), 168.00 (C, C-1’). 
 Chapter 6: Experimental 
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N'-(6-Ethylthieno[2,3-d]pyrimidin-4-yl)picolinohydrazide (456) 
(C14H13N5OS; M.W.= 299.35) 
 
 
   451  277        456 
 
General procedure 22; 
Reagent: 6-ethyl-4-hydrazinylthieno[2,3-d]pyrimidine (451) (0.2 g, 1 mmol); 
Purification: re-crystallisation from EtOH; 
Pale yellow solid; 
Yield: 0.08 g (26%) 
Melting Point: 149-152°C 
MS (ESI+): 299.9 [M+H]+ 
1H-NMR (DMSO-d6), : 1.30 (t, J= 7.2 Hz, 3H, H-6), 2.91 (q, J= 7.2 Hz, 2H, H-5), 
7.41 (s, 1H, H-7), 7.66-7.71 (m, 1H, H-aromatic), 8.02-8.08 (m, 2H, H-aromatic), 8.33 
(s, 1H, H-2), 8.74 (d, J= 4.2 Hz, 1H, H-aromatic), 9.90 (bs, 1H, NH), 10.83 (bs, 1H, 
NH). 
13C-NMR (DMSO-d6), : 14.95 (CH3, C-6), 23.50 (CH2, C-5), 114.78 (CH, C-
aromatic), 115.19, 116.33 (C, C-aromatic), 122.44, 127.04 (CH, C-aromatic), 132.84 
(C, C-aromatic), 137.87 (CH, C-aromatic), 144.13 (C, C-aromatic), 148.71 (CH, C-
aromatic), 149.26 (C, C-aromatic), 152.81 (CH, C-aromatic), 163.47 (C, C-1’). 
 Chapter 6: Experimental 
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6.5 Synthesis of pyrrolone structures 
 
6.5.1 General procedures 24-25 
 
General procedure 24: synthesis of 3-arylidene-5-phenylfuran-2(3H)-ones 
 
 
 
A stirred solution of 3-benzoyl propanoic acid (460) (1 g, 5.6 mmol), benzaldehyde (6.6 
mmol) and sodium acetate (0.47 g, 5.6 mmol) in 7 mL of acetic anhydride was heated at 
95°C for 2 h under N2 atmosphere . The reaction mixture was then cooled to r.t., diluted 
with MeOH and left in an ice-bath for 2 h. The resulting precipitate was filtered and 
washed with a cold 50% solution of MeOH in water to give 3-arylidene-5-phenylfuran-
2(3H)-ones, that were used for the following step without further purification. 
 
General procedure 25: synthesis of 1-aryl-3-arylidene-5-phenyl-1H-pyrrol-2(3H)-
ones 
 
 
 
A mixture of 3-arylidene-5-phenylfuran-2(3H)-one (2.0 mmol) and differently 
substituted aniline (1.9 mmol) in 18 mL of glacial acetic acid was stirred at r.t. under N2 
atmosphere for 4 h, then heated to reflux for 22 h. The solvent was then evaporated at 
reduced pressure and the crude residue was purified by flash column chromatography to 
afford pure 1-aryl-3-arylidene-5-phenyl-1H-pyrrol-2(3H)-ones. 
 Chapter 6: Experimental 
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6.5.2 Ethyl 4-formylbenzoate (461)70 
(C10H10O3; M.W.= 178.2) 
 
 
    483       461 
 
4-Formyl-benzoic acid (483) (2 g, 13.4 mmol), H2SO4 (0.6 mL) and EtOH (62 mL) 
were mixed and heated under reflux for 18 h. The reaction mixture was then cooled to 
r.t. and the organic solvent was removed under vacuum. The residue was dissolved in 
EtOAc (40 mL), washed with saturated NaHCO3 solution (2 x40 mL), brine (2 x40 
mL), and distilled water (2 x40 mL), and finally dried over MgSO4. The organic solvent 
was then removed under vacuum to afford the title compound as a brown oil, that was 
used for the following step without further purification. 
Yield: 12.0 g (84%) 
1H-NMR (CDCl3), : 1.43 (t, J= 7.1 Hz, 3H, H-2’),  4.43  (q,  J=  7.1  Hz,  2H,  H-1’),  7.96  
(d, J= 8.5 Hz, 2H, H-aromatic), 8.21 (d, J= 8.5 HZ, 2H, H-aromatic), 10.11 (s, 1H, H-8). 
13C-NMR (CDCl3), : 14.26 (CH3, C-2’),  61.38  (CH2, C-1’),  129.46,  130.14  (CH,  C-
aromatic), 135.48, 139.10 (C, C-2, 5), 165.56 (C, C-1), 191.62 (CH, C-8). 
 Chapter 6: Experimental 
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6.5.3 3-Arylidene-5-phenylfuran-2(3H)-ones (466-470) 
 
4-(2-Oxo-5-phenyl-furan-3-ylidenemethyl)-benzoic acid ethyl ester (466) 
(C20H16O4; M.W.= 320.3) 
 
 
    461   466 
 
General procedure 24; 
Yellow solid; 
Yield: 0.55 g (31%) 
1H-NMR (DMSO-d6), : 1.34 (t, J= 7.0 Hz, 3H, H-8’),  4.34  (q,  J=  7.0  Hz,  2H,  H-7’),  
7.40 (s, 1H, H-alkenylic), 7.56-7.60 (m, 3H, H-aromatic), 7.63 (s, 1H, H-alkenylic), 
7.88-7.92 (m, 2H, H-aromatic), 7.97 (d, J= 7.8 Hz, 2H, H-aromatic), 8.01 (d, J= 8.3 Hz, 
2H, H-aromatic). 
13C-NMR (DMSO-d6), : 14.07 (CH3, C-8’), 60.97 (CH2, C-7’), 101.07, 125.47 (CH, 
C-alkenylic, aromatic), 126.57, 127.50 (C, C-aromatic), 129.02, 129.52, 130.58 (CH, C-
aromatic), 130.65 (C, C-aromatic), 130.91, 133.12 (CH, C-aromatic), 138.68, 157.08 
(C, C-aromatic), 165.10, 168.37 (C, C-1,  6’). 
 
3-Benzylidene-5-phenyl-3H-furan-2-one (467)71 
(C17H12O2; M.W.= 248.3) 
 
 
    462   467 
 
General procedure 24; 
Yellow solid; 
Yield: 0.49 g (35%) 
1H-NMR (DMSO-d6), : 7.41 (s, 1H, H-alkenylic), 7.49-7.55 (m, 6H, H-aromatic), 
7.63 (s, 1H, H-alkenylic), 7.88-7.92 (m, 4H, H-aromatic). 
 Chapter 6: Experimental 
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13C-NMR (DMSO-d6), : 101.11 (CH, C-alkenylic), 124.61 (C, C-aromatic), 125.30 
(CH, C-aromatic), 127.74 (C, C-aromatic), 128.86, 129.11, 129.29, 130.55, 130.59 (CH, 
C-aromatic), 134.42 (C, C-aromatic), 135.14 (CH, C-aromatic), 155.99 (C, C-aromatic), 
168.74 (C, C-1). 
 
3-(4-Methoxy-benzylidene)-5-phenyl-3H-furan-2-one (468)72 
(C18H14O3; M.W.= 278.3) 
 
 
    463    468 
 
General procedure 24; 
Yellow solid; 
Yield: 0.51 g (33%) 
1H-NMR (DMSO-d6), : 3.85 (s, 3H, H-6’), 7.06 (d, J= 8.8 Hz, 2H, H-aromatic), 7.36 
(s, 1H, H-3), 7.45-7.53 (m, 3H, H-aromatic), 7.60 (d, J= 0.7 Hz, 1H, H-1’), 7.86-7.89 
(m, 4H, H-aromatic). 
13C-NMR (DMSO-d6), : 55.44 (CH2, C-6’), 101.14, 114.71 (CH, C-alkenylic, 
aromatic), 121.82 (C, C-aromatic), 125.04 (CH, C-aromatic), 127.19, 127.97 (C, C-
aromatic), 128.92, 130.19, 132.82, 135.32 (CH, C-aromatic), 154.84, 161.34 (C, C-
aromatic), 169.08 (C, C-1). 
 
3-(4-Bromo-benzylidene)-5-phenyl-3H-furan-2-one (469) 
(C17H11BrO2; M.W.= 327.2) 
 
 
    464   469 
 
General procedure 24; 
Yellow solid; 
Yield: 0.93 g (51%) 
 Chapter 6: Experimental 
 
 
505 
 
1H-NMR (CDCl3), : 7.28 (s, 1H, H-alkenylic), 7.38 (s, 1H, H-alkenylic), 7.46-7.50 
(m, 3H, H-aromatic), 7.52 (d, J= 8.4 Hz, 2H, H-aromatic), 7.63 (d, J= 7.6 Hz, 2H, H-
aromatic), 7.78-7.83 (m, 2H, H-aromatic). 
13C-NMR (CDCl3), : 99.52 (CH, C-alkenylic), 121.12 (C, C-aromatic), 125.46 (CH, 
C-aromatic), 127.01, 127.54 (C, C-aromatic), 128.95, 130.76, 131.32, 132.41, 133.71 
(CH, C-aromatic), 152.34, 159.53 (C, C-aromatic), 168.89 (C, C-1). 
 
3-(4-Bromo-benzylidene)-5-phenyl-3H-furan-2-one (470) 
(C23H16O2; M.W.= 324.4) 
 
 
    465   470 
 
General procedure 24; 
Yellow solid; 
Yield: 0.74 g (41%) 
1H-NMR (DMSO-d6), : 7.40-7.45 (m, 2H, H-aromatic), 7.47-7.56 (m, 5H, H-
aromatic), 7.67 (s, 1H, H-alkenylic), 7.74-7.79 (m, 2H, H-aromatic), 7.80 (d, J= 8.3 Hz, 
2H, H-aromatic), 7.89-7.93 (m, 2H, H-aromatic), 7.98 (d, J= 8.3 Hz, 2H, H-aromatic). 
13C-NMR (DMSO-d6), : 101.24 (CH, C-alkenylic), 124.35 (C, C-aromatic), 125.30, 
126.74, 127.19 (CH, C-aromatic), 127.77 (C, C-aromatic), 128.16, 128.98, 129.07, 
130.54, 131.34 (CH, C-aromatic), 133.57 (C, C-aromatic), 134.59 (CH, C-aromatic), 
138.98, 141.93, 155.94 (C, C-aromatic), 168.89 (C, C-1). 
 Chapter 6: Experimental 
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6.5.4 1-Aryl-3-arylidene-5-phenyl-1H-pyrrol-2(3H)-ones (459, 475-482) 
 
4-[1-(2-Bromo-4-methyl-phenyl)-2-oxo-5-phenyl-1,2-dihydro-pyrrol-3-ylidene 
methyl]-benzoic acid ethyl ester (459) 
(C27H22BrNO3; M.W.= 488.4) 
 
 
   461     459 
 
General procedure 25; 
Orange solid; 
T.L.C. System: nhexane:EtOAc 8:2 v/v, Rf: 0.36. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane:EtOAc 90:10 v/v). 
Yield: 0.41 g (44%) 
Melting Point: 166-168°C 
MS (ESI+): 488.1, 490.1 [M+H]+ 
Microanalysis: Calculated for C27H22BrNO3 (488.4); Theoretical: %C = 66.40, %H = 
4.54, %N = 2.87; Found: %C = 66.29, %H = 4.25, %N = 2.71. 
1H-NMR (CDCl3), : 1.44 (t, J= 7.1 Hz, 3H, H-3’’),  2.36 (s, 3H, H-12’),  4.43 (q, J= 7.1 
Hz, 2H, H-2’’),  6.50 (d, J= 0.8 Hz, 1H, H-1’), 7.06-7.17 (m, 2H, H-aromatic), 7.27-7.30 
(m, 4H, H-aromatic), 7.30-7.35 (m, 1H, H-aromatic), 7.46-7.47 (m, 1H, H-aromatic), 
7.55 (s, 1H, H-3), 7.76 (d, J= 8.3 Hz, 2H, H-aromatic), 8.13 (d, J= 8.3 Hz, 2H, H-
aromatic). 
13C-NMR (CDCl3), : 14.34 (CH3, C-3’’), 20.90 (CH3, C-12’), 61.19 (CH2, C-2’’),  
100.82 (CH, C-1’), 123.44 (C, C-aromatic), 127.56, 128.41, 129.06, 129.42, 129.97, 
130.01, 130.45 (CH, C-aromatic), 130.63, 130.80, 131.06 (C, C-aromatic), 131.43 (CH, 
C-aromatic), 132.69 (C, C-aromatic), 134.04 (CH, C-aromatic), 140.10, 140.36, 149.85 
(C, C-aromatic), 166.04, 169.38 (C, C-1’’,  1). 
 
 Chapter 6: Experimental 
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3-Benzylidene-1,5-diphenyl-1,3-dihydro-pyrrol-2-one (475)73 
(C23H17NO; M.W.= 323.4) 
 
 
    462    475  
 
General procedure 25; 
Orange solid; 
T.L.C. System: nhexane-EtOAc 8:2 v/v, Rf: 0.53. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane:EtOAc 70:30 v/v). 
Yield: 0.21 g (34%) 
Melting Point: 165-167°C 
MS (ESI+): 324.1 [M+H]+ 
1H-NMR (DMSO-d6), : 6.82 (s, 1H, H-alkenylic), 7.13 (d, J= 7.7 Hz, 2H, H-
aromatic), 7.24-7.35 (m, 6H, H-aromatic), 7.36-7.40 (m, 2H, H-aromatic), 7.42 (s, 1H, 
H-alkenylic), 7.43-7.48 (m, 1H, H-aromatic), 7.48-7.55 (m, 2H, H-aromatic), 7.88 (d, 
J= 7.5 Hz, 2H, H-aromatic). 
13C-NMR (DMSO-d6), : 101.92, 127.20, 127.47, 128.28, 128.63, 128.74 (CH, C-
aromatic), 128.92 (C, C-aromatic), 129.07, 129.13, 129.17 (CH, C-aromatic), 129.93 
(C, C-aromatic), 130.65, 132.28 (CH, C-aromatic), 135.10, 135.66, 147.95 (C, C-
aromatic), 169.03 (C, C-1). 
 
4-(2-Oxo-1,5-diphenyl-1,2-dihydro-pyrrol-3-ylidenemethyl)-benzoic acid ethyl 
ester (476) 
(C26H21NO3; M.W.= 395.5) 
 
 
    461    476 
 
 Chapter 6: Experimental 
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General procedure 25; 
Orange solid; 
T.L.C. System: nhexane:EtOAc 7:3 v/v, Rf: 0.66. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane:EtOAc 80:20 v/v). 
Yield: 0.42 g (57%) 
Melting Point: 133-135°C 
MS (ESI+): 396.1 [M+H]+ 
1H-NMR (DMSO-d6), : 1.34 (t, J= 7.1 Hz, 3H, H-3’’),  4.34  (q,  J=  7.1  Hz,  2H,  H-2’’),  
6.84 (s, 1H, H-alkenylic), 7.12-7.15 (m, 2H, H-aromatic), 7.29-7.35 (m, 6H, H-
aromatic), 7.36-7.43 (m, 3H, H-aromatic), 7.99 (d, J= 8.5 Hz, 2H, H-aromatic), 8.03 (d, 
J= 8.5 Hz, 2H, H-aromatic). 
13C-NMR (DMSO-d6), : 14.10 (CH3, C-3’’),   60.89   (CH2, C-2’’),   101.78, 127.13, 
127.32, 127.72, 128.50, 128.78, 129.44, 129.57 (CH, C-aromatic), 130.16 (C, C-
aromatic), 130.34, 130.54 (CH, C-aromatic), 130.73, 135.49, 139.49, 149.32 (C, C-
aromatic), 165.20, 168.89 (C, C-1’’,  1). 
 
3-(4-Methoxy-benzylidene)-1,5-diphenyl-1,3-dihydro-pyrrol-2-one (477) 
(C24H19NO2; M.W.= 353.4) 
 
 
    463    477 
 
General procedure 25; 
Yellow solid; 
T.L.C. System: nhexane:EtOAc 7:3 v/v, Rf: 0.63. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane:EtOAc 80:20 v/v). 
Yield: 0.26 g (39%) 
Melting Point: 150-152°C 
MS (ESI+): 354.1 [M+H]+ 
 Chapter 6: Experimental 
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1H-NMR (CDCl3), : 6.50 (s, 3H, H-1’’), 6.49 (s, 1H, H-alkenylic), 7.00 (d, J= 8.7 Hz, 
2H, H-aromatic), 7.14-7.17 (m, 2H, H-aromatic), 7.22-7.31 (m, 6H, H-aromatic), 7.32-
7.33 (m, 2H, H-aromatic), 7.53 (s, 1H, H-alkenylic), 7.70 (d, J= 8.7 Hz, 2H, H-
aromatic). 
13C-NMR (CDCl3), : 55.42 (CH3, C-1’’),   102.11, 114.54, 126.71, 127.11 (CH, C-
aromatic), 127.56 (C, C-aromatic), 127.68, 128.28, 128.55, 128.69 (CH, C-aromatic), 
128.84, 131.16 (C, C-aromatic), 132.17, 133.24 (CH, C-aromatic), 135.89, 147.16, 
160.96 (C, C-aromatic), 169.90 (C, C-1). 
 
3-(4-Bromo-benzylidene)-1,5-diphenyl-1,3-dihydro-pyrrol-2-one (478) 
(C23H16BrNO; M.W.= 402.3) 
 
 
  464    478 
 
General procedure 25; 
Orange solid; 
T.L.C. System: nhexane:EtOAc 7:3 v/v, Rf: 0.66. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane:EtOAc 80:20 v/v). 
Yield: 0.22 g (29%) 
Melting Point: 155-157°C 
MS (ESI+): 402.0, 404.0 [M+H]+ 
1H-NMR (CDCl3), : 6.44 (s, 1H, H-alkenylic), 7.13-7.16 (m, 2H, H-aromatic), 7.23-
7.25 (m, 2H, H-aromatic), 7.26-7.30 (m, 3H, H-aromatic), 7.31-7.38 (m, 3H, H-
aromatic), 7.47 (s, 1H, H-alkenylic), 7.56 (d, J= 8.6 Hz, 2H, H-aromatic), 7.60 (d, J= 8.6 
Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 101.60 (CH, C-aromatic), 123.90 (C, C-aromatic), 126.95, 
127.09, 127.29, 127.74, 128.36, 128.78, 129.25 (CH, C-aromatic), 130.16, 130.79 (C, 
C-aromatic), 131.52, 131.55 (CH, C-aromatic), 134.81, 135.59, 148.94 (C, C-aromatic), 
169.57 (C, C-1). 
 Chapter 6: Experimental 
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3-Biphenyl-4-ylmethylene-1,5-diphenyl-1,3-dihydro-pyrrol-2-one (479) 
(C29H21NO; M.W.= 399.5) 
 
 
    465    479 
 
General procedure 25; 
Orange solid; 
T.L.C. System: nhexane:EtOAc 7:3 v/v, Rf: 0.70. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane:EtOAc 80:20 v/v). 
Yield: 0.20 g (27%) 
Melting Point: 187-189°C 
MS (ESI+): 400.1 [M+H]+ 
1H-NMR (CDCl3), : 6.57 (d, J= 0.8 Hz, 1H, H-1’), 7.16-7.19 (m, 2H, H-aromatic), 
7.25-7.34 (m, 6H, H-aromatic), 7.35-7.39 (m, 2H, H-aromatic), 7.42 (tt, J1= 7.3 Hz, J2= 
1.8 Hz, 1H, H-aromatic), 7.49-7.53 (m, 2H, H-aromatic), 7.61 (s, 1H, H-3), 7.66-7.70 
(m, 2H, H-aromatic), 7.72 (d, J= 8.3 Hz, 2H, H-aromatic), 7.81 (d, J= 8.3 Hz, 2H, H-
aromatic). 
13C-NMR (CDCl3), : 101.12 (CH, C-1’), 126.87, 127.07, 127.14, 127.91, 128.10, 
128.34, 128.63, 128.87, 128.96, 129.09 (CH, C-aromatic), 129.55, 130.07 (C, C-
aromatic), 131.22, 132.82 (CH, C-aromatic), 134.91, 135.74, 140.16, 142.34, 148.26 (C, 
C-aromatic), 169.80 (C, C-1). 
 Chapter 6: Experimental 
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4-(2-Oxo-5-phenyl-1-p-tolyl-1,2-dihydro-pyrrol-3-ylidenemethyl)-benzoic acid 
ethyl ester (480) 
(C27H23NO3; M.W.= 409.5) 
 
 
    461    480 
 
General procedure 25; 
Orange solid; 
T.L.C. System: nhexane:EtOAc 8:2 v/v, Rf: 0.43. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane:EtOAc 85:15 v/v). 
Yield: 0.25 g (32%) 
Melting Point: 161-163°C 
MS (ESI+): 410.2[M+H]+ 
1H-NMR (CDCl3), : 1.44 (t, J= 7.1 Hz, 3H, H-3’’),  2.36 (s, 3H, H-12’),  4.43 (q, J= 7.1 
Hz, 2H, H-2’’),  6.47 (d, J= 0.8 Hz, 1H, H-1’), 7.03 (d, J= 8.2 Hz, 2H, H-aromatic), 7.15 
(d, J= 8.2 Hz, 2H, H-aromatic), 7.25-7.35 (m, 5H, H-aromatic), 7.54 (s, 1H, H-3), 7.75 
(d, J= 8.3 Hz, 2H, H-aromatic), 8.13 (d, J= 8.3 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 14.34 (CH3, C-3’’), 21.13 (CH3, C-12’), 61.18 (CH2, C-2’’),  
101.39 (CH, C-1’), 126.92, 127.81, 128.35, 129.32, 129.49, 129.92, 130.01 (CH, C-
aromatic), 130.75 (C, C-aromatic), 131.16 (CH, C-aromatic), 131.42, 132.91, 136.89, 
140.18, 149.79 (C, C-aromatic), 166.04, 169.66 (C, C-1’’,  1). 
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4-[1-(2,3-Dimethyl-phenyl)-2-oxo-5-phenyl-1,2-dihydro-pyrrol-3-ylidenemethyl]-
benzoic acid ethyl ester (481) 
(C28H25NO3; M.W.= 423.5) 
 
 
    461    481 
 
General procedure 25; 
Orange solid; 
T.L.C. System: nhexane:EtOAc 8:2 v/v, Rf: 0.39. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane:EtOAc 85:15 v/v). 
Yield: 0.45 g (56%) 
Melting Point: 64-66°C 
MS (ESI+): 424.2 [M+H]+ 
1H-NMR (CDCl3), : 1.44 (t, J= 7.1 Hz, 3H, H-3’’),  2.13 (s, 3H, CH3), 2.32 (s, 3H, 
CH3), 4.43 (q, J= 7.1 Hz, 2H, H-2’’),  6.52 (d, J= 0.8 Hz, 1H, H-1’), 6.89 (d, J= 7.7 Hz, 
1H, H-aromatic), 7.05-7.09 (m, 1H, H-aromatic), 7.15 (d, J= 7.5 Hz, 1H, H-aromatic), 
7.21-7.27 (m, 4H, H-aromatic), 7.28-7.32 (m, 1H, H-10’),  7.54 (s, 1H, H-3), 7.77 (d, J= 
8.3 Hz, 2H, H-aromatic), 8.13 (d, J= 8.3 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), : 14.34 (CH3, C-3’’), 14.66, 20.42 (CH3, C-12’,  13’), 61.18 (CH2, 
C-2’’),   100.57 (CH, C-1’), 125.95, 126.35, 127.41, 128.36, 129.35, 129.88, 129.94, 
130.02 (CH, C-aromatic), 130.74 (C, C-aromatic), 131.14 (CH, C-aromatic), 131.40, 
134.83, 135.17, 138.26, 140.22, 150.41 (C, C-aromatic), 166.05, 169.59 (C, C-1’’,  1). 
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3-Benzylidene-1-(2-bromo-4-methyl-phenyl)-5-phenyl-1,3-dihydro-pyrrol-2-one 
(482) 
(C24H18BrNO; M.W.= 416.3) 
 
 
    462     482 
 
General procedure 25; 
Yellow solid; 
T.L.C. System: nhexane:EtOAc 8:2 v/v, Rf: 0.38. 
Purification: flash column chromatography (nhexane:EtOAc 100:0 v/v increasing to 
nhexane:EtOAc 85:15 v/v). 
Yield: 0.39 g (50%) 
Melting Point: 175-177°C 
MS (ESI+): 416.0, 418.0 [M+H]+ 
1H-NMR (CDCl3), : 2.36 (s, 3H, H-12’), 6.53 (d, J= 0.8 Hz, 1H, H-1’),  7.11-7.15 (m, 
2H, H-aromatic), 7.25-7.33 (m, 5H, H-aromatic), 7.41 (tt, J1= 7.3 Hz, J2= 2.2 Hz, 1H, 
H-aromatic), 7.45-7.49 (m, 3H, H-aromatic), 7.58 (s, 1H, H-3), 7.72 (d, J= 7.5 Hz, 2H, 
H-aromatic). 
13C-NMR (CDCl3), : 20.90 (CH3, C-12’), 101.10 (CH, C-1’), 123.49 (C, C-aromatic), 
127.52, 128.34, 128.93, 129.02, 129.12, 129.47 (CH, C-aromatic), 129.61 (C, C-
aromatic), 130.31, 130.49 (CH, C-aromatic), 131.78, 132.92 (C, C-aromatic), 133.34, 
134.00 (CH, C-aromatic), 135.90, 140.20, 148.51 (C, C-aromatic), 169.60 (C, 1). 
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Structure and biological evaluation of purchased compounds 
 
All the structures selected with virtual screening studies and purchased from the SPECS 
company were tested for their potential antiviral activity in the subgenomic replicon and 
cytostatic assays. Their structures and biological results are shown in tables 1-3. 
 
Structure-based virtual screening on the enzyme closed conformation (3KQN) 
 
Structure Compound EC50(M) CC50(M) EC90(M) SI 
SHN
O
O
Cl
NN
NHS
O
O
Cl
 
12 8 >90 
89.4% 
inhibition 
at 90 
>6.9 
N
O
OHO
OO
Cl
 
483 30.6 >125.6 - >4.1 
O
Cl
Cl
S
N
OH
O  
484 13.2 33.4 - 2.5 
O
Cl
N O
NH
O
O
 
485 26.4 >121.1 >121.1 >4.5 
N
N
S
O
O
HO
O
O
 
486 41.8 >89.5 >89.5 >2.1 
S
N
N
H
N
SO
HN
O
O
 
487 >113.4 >113.4 >113.4 - 
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O
OH
O
O
O
O
 
488 >101.5 >101.5 >101.5 - 
SHN
O
O
HO
O
 
489 >184.2 >184.2 >184.2 - 
S
N
H
O
N
N
Br
OH  
490 10.4 15.7 - 1.5 
N
N NH
O
O
Br
 
491 81.7 >135.8 - >1.6 
S
H
N N
NO
HO
O O
 
492 126.7 >149 - >1.1 
N
N
S
O
O
HO
O
HO
 
493 35.8 >103.6 - >2.8 
N
H
O
N
O
HO  
494 >224.9 >224.9 >224.9 - 
NN
O
O
OH
O
O
O
H
 
495 57.2 >104.9 - >1.8 
 
Table 1: Antiviral and cytotoxicity data for compounds 12, 483-495 
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Structure-based virtual screening on the enzyme open conformation (3KQH) 
 
Structure Compound EC50(M) CC50(M) EC90(M) SI 
S
N
N
N
HN
HO
OH
 
187 <1 >141 >116 >141 
N
O
O
N
O
N O
O
 
496 32 >106 - >3.3 
N
NH O
OO
O
 
497 10.9 56.2 - 5.2 
NHN
O
OHN
O
N
N
 
498 >149 >149 >149 - 
NH
O
O
O
O
HO
O
O
 
499 36 >101 - >2.8 
N
S
N
HN
O
O
 
500 21 128 - 6.1 
N
N
OH
N
H
O
HO
O  
501 65 >126 - >.19 
O
N
H
N
O
O
OH
HO
 
502 >151 >151 >151 - 
Appendix I 
 
526 
 
N
O
O
S
N
HN
O
O
O
O
 
503 12.8 62.6 - 4.9 
N
S
N
O
NH2
O
 
504 129.5 >141.5 >141.5 >1.1 
N
H
S
HO O
O
O
H
N
O
S
OH
O
O
 
505 >86 >86 >86 - 
O
N
H
O
N
HO OH
 
506 1.9 51.9 - 27.3 
O
O
O
H
N
S
O
O
 
507 1.1 4.7 - 4.3 
S
NN
H
N
S
NHO
O
OH
 
508 42.2 >125.5 - >2.9 
S
N
H
N
SO
O
O
O
O
 
509 >126.8 >126.8 >126.8 - 
S
N
O
O
NO
O
O
 
510 34.5 >116 - >3.4 
N
NH
O
O
O
N
NH2
O
 
511 >144 >144 >144 - 
N
N
N
N S
N
O
 
512 129.5 >139 >139 >1.1 
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NH
N
N
OO
O O
 
513 38.9 61.7 - 1.6 
S
HN
O
O
N
O
NH2
O
 
514 >139.9 >139.9 >139.9 - 
H
N
HN
O
O
OH
 
515 21.5 48.8 - 2.3 
 
Table 2: Antiviral and cytotoxicity data for compounds 187, 596-515 
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Ligand-based virtual screening on triphenylmethane derivative 458 
 
Structure Compound EC50(M) CC50(M) EC90(M) SI 
N
O
OBr
O
 
459 38.3 >204.8 149.1 >5.3 
N
N
N
SO
N
Cl
 
516 146.8 >206.2 >206.2 >1.4 
N
N
N
O
O
O
OH
 
517 >255.4 >255.4 >255.4 - 
N
N S
N
NH
O
O
N
O
O
Cl
 
518 28 150.6 97.6 5.4 
N
NN
N
 
519 7.7 36.9 - 4.8 
NH+
N
N
-O
N
O
 
520 234.6 >264.2 >264.2 - 
 
Table 3: Antiviral and cytotoxicity data for compounds 459, 516-520 
